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Thesis Summary 
 
Breast cancer treatment has been a challenge to date, due in part to cancer cells acquiring 
drug resistance. One of the mechanisms by which resistance can occur is the overexpression 
of drug efflux pumps such as ATP-binding cassette, subfamily C  (ABCC) transporter 1 
(ABCC1) and 4 (ABCC4), which are members of ABC transporters. Recently research has 
shown that these proteins may be implicated in cancer biology independent of cytotoxic drug 
efflux, but so far little is known about this in regards to breast cancer.  
 
ABCC1 and ABCC4 protein levels in MDA-MB231 and MCF-7, human breast cancer derived 
cell lines were measured by Western blot. The role of ABCC1 and ABCC4 in cell proliferation 
and migration were evaluated by colony formation, MTT and scratch assays in the presence 
of various ABCC inhibitors – MK571, Indomethacin, Reversan, Ceefourin 1 and  Ceefourin 2, 
inhibitors of ABCC4. Similarly the effect on proliferation, migration and invasion was monitored 
following knock down of ABCC1 and ABCC4 with ABCC1- and ABCC4- specific siRNAs, or 
overexpression using transfection with pcDNA3.1 plasmids containing the ABCC1 and ABCC4 
genes. The potential correlation between ABCC1 and/or ABCC4 and the expression of G-
protein-coupled receptor 55 (GPR55), or extracellular signal-regulated kinase (ERK), or the 
extracellular efflux of cyclic adenosine monophosphate (cAMP), prostaglandin E2 (PGE2), 
sphingosine-1-phosphate (S1P) and cyteinyl leukotrienes (LTC4, LTD4 and LTE4) were 
investigated by Western blot and enzyme-linked immunosorbent assays. 
 
This thesis demonstrates that the expression levels of ABC transporters varies between breast 
cancer cell lines. Our results suggest that ABCC1 may be more involved in mediating breast 
cancer cell proliferation than ABCC4 and in contrary ABCC4 may be involved in mediating 
breast cancer cell invasion more than ABCC1. There is also an indication that both ABCC1 
and ABCC4 are implicated in breast cancer migration. In addition, potential correlation 
between ABCC1 and/or ABCC4 with cAMP or S1P efflux looks promising but further 
investigation is required. 
 
Taken together this thesis shows that ABCC1 and ABCC4 may be implicated in breast cancer 
development and progression. Further investigations are needed to validate our current 
results, but ABCC1 and ABCC4 could be potential therapeutic targets for breast cancer.  
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Chapter 1 – Introduction 
 
1.1     Nature of Cancer 
  
The term cancer also referred to as malignant tumours and neoplasms is a generic term that 
describes a large group of diseases that can affect any part of the body. One major feature of 
cancer is the uncontrolled growth and reproduction of a cell due to abnormal cell internal 
regulatory mechanisms that can often cause the abnormal cells to grow beyond their usual 
boundaries. Tissues are made up of normal cells that behave in a controlled, specified and 
coordinated unit (World Health Organisation, 2018). However, when normal cells start to 
accumulate genetic and epigenetic changes, they become disorganised among the cell 
population and proliferate in a disorderly manner, forming tumours. Hence the cells break free 
from the tight network of controls that coordinate the homeostasis balance between cell death 
and cell proliferation (Hanahan et al., 2000; Herceg et al., 2007). These tumours can invade 
adjoining parts of the body and spread to other organs. This process is often termed as 
metastasis and is a major cause of death from cancer. There are a wide variety of disorders 
that can occur depending on the type of tissue. Furthermore, some tumours are made up of 
different cells producing different abnormal biological processes (Weinberg, 2013; World 
Health Organisation, 2018). 
 
In 2012, approximately 14 million new cases of cancer were diagnosed making cancer one of 
the leading causes of mortality and morbidity worldwide (World Health Organisation, 2018). In 
2015, cancer was the second leading cause of death globally and was responsible for 8.8 
million deaths (World Health Organisation, 2018). In addition an estimated 9.6 million deaths 
were recorded in 2018 and over the next two decades the number of new cases is expected 
to rise by about 70% (World Health Organisation, 2018). As a result, cancer is one of the major 
research topics among scientists. Although many genes/proteins/pathways have been 
implicated in the development of cancer, the precise process by which cells become malignant 
is still unclear and that further research is required to be able to understand the pattern of 
disease progression and the course of carcinogenesis so as to produce effective actions to 
reduce or eliminate the risk of cancer (Buhle, 2012). 
  
1.1.1     Development of cancer 
 
The regulation of the growth of normal cells is maintained by feedback mechanisms that may 
inhibit or stimulate cell division (Hanahan et al., 2011; Barnum et al., 2014). In tissues, aged 
cells are constantly being replaced with new ones, so as to maintain the health and function 
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of the tissue (Lloyd, 2013). However, some cells such as neurons, lack the ability to form new 
cells or are unable to repair even after tissue damage (Buhle, 2012). 
 
In contrast, when cells lose their ability to divide in an orderly and controlled manner, the 
body’s normal regulatory mechanisms do their best to solve the problem. If they cannot, the 
overall number of cells increases very fast, and as a result a tumour is formed. In addition 
these cells tend to lose the ability to differentiate (Buhle, 2012). Hence, cancer can arise from 
normal cells transforming into tumour cells in a multistage process from a pre-cancerous lesion 
to a malignant tumour (World Health Organisation, 2018). 
 
In some cases, cancer cells originally growing in one part of the body (primary cancer) can 
break away and travel to other parts of the body to form secondary cancer (metastases) 
(DeNittis, et al., 2002). 
 
1.1.2     Types of tumours  
 
A tumour is a lump of cells produced from abnormal cells that divides uncontrollably to produce 
more abnormal cells.  Depending on the degree of aggressive growth, a tumour can be 
classified as either benign or malignant (Weinberg, 2013). 
 
Benign tumours are tumours that keep the cell morphology thus retaining their similarity to the 
tissue of origin and they do not invade new sites of growth. In addition, benign tumours do not 
spread to other parts of the body and usually grow very slowly (Cancer research UK, 2017; 
Buhle, 2012). Furthermore, benign tumours do not cause cancer but may cause problems 
when they put pressure on nearby vital structures such as blood vessels and nerves. On the 
contrary, malignant tumours are cancerous in that they are invasive having the tendency to 
stop differentiating whilst rapidly dividing to produce new cancer cells and they are more likely 
to move to other sites of the body in the bloodstream or through the lymph (Weinberg, 2013). 
A summary of the main differences between benign and malignant tumours is show in table 
1.1. 
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Table 1.1. Summary of the differences between benign and malignant (adapted from 
Buhle, 2012). 
 
 
 
 
1.1.3     Localisation of cancers 
 
The type of tissue involved (histology) and the site of the primary tumour determine the name 
of the cancer.  There are four main groups of normal body tissue namely epithelial, connective 
and muscle, hematopoietic and nerve tissue (Weinberg, 2013). 
 
All the external body surfaces and all internal cavities and spaces are covered and protected 
with epithelial tissue. The epithelial tissues account for the growth of most human tumours. 
Cancers that arise from epithelial tissues are called carcinomas (Table 1.2). In the western 
world, more than 80% of cancer related deaths are due to carcinomas (Buhle, 2012, Weinberg, 
2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benign 
 
  Malignant 
 Encapsulated  
 Non invasive  
 Highly differentiated  
 Mitoses rare  
 Slow growth  
 Little or no anaplasia  
 No metastases  
 Non encapsulated  
 Invasive  
 Tendency toward de-
differentiation  
 Mitoses may be relatively 
common  
 Usually rapid growth  
 Anaplastic to varying degrees  
 May Metastasise 
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Table 1.2. Carcinomas (adapted from Weinberg, 2014). 
(A) Tissue sites of more 
common types of 
adenocarcinoma 
  
(B) Tissue sites of more 
common types of squamous 
cell carcinoma 
(C) Other types of 
carcinomas 
lung 
colon 
breast 
pancreas 
stomach 
oesophagus 
prostate 
endometrium 
ovary 
skin 
nasal cavity 
oropharynx 
larynx 
lung 
oesophagus 
cervix 
small-cell lung carcinoma 
large-cell lung carcinoma 
hepatocellular carcinoma 
renal cell carcinoma 
transitional-cell carcinoma 
(of the urinary bladder) 
  
 
 
The other malignant tumours formed, are from nonepithelial tissues, which, are classified into 
three major groups.  
 
The first group of nonepithelial cancers are formed from various connective tissues with a 
common origin in the mesoderm of the embryo are called the sarcomas (Table 1.3).  A variety 
of mesenchymal cell types account for this type of cancer. The second group of nonepithelial 
cancers are those formed from various cell types that form the blood forming (hematopoietic) 
tissues and cells of the immune system (Table 1.3). The third and last group of nonepithelial 
cancers are formed from cells of various parts of the peripheral and central nervous system 
that consist of two types of cells, glial cells and neurons. These types of nonepithelial cancers 
are called neuroectodermal (Table 1.3). It is of note that some types of tumours do not fall 
under any of the four major groups mentioned above, such as melanomas (Weinberg, 2013). 
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Table 1.3. Various types of more common sarcomas, hematopoietic and 
neuroectodermal malignancies (adapted from Weinberg, 2013). 
Sarcomas 
 
Hematopoietic malignancies Neuroectodermal 
malignancies 
osteosarcoma acute lymphocytic leukaemia glioblastoma multiforme 
liposarcoma acute myelogenous leukaemia astrocytoma 
leiomyosarcoma chronic myelogenous leukaemia meningioma 
rhabdomyosarcoma multiple myeloma neurinoma 
malignant fibrous histiocytoma non-Hodgkin’s lymphoma retinoblastoma 
fibrosarcoma Hodgkin’s disease neuroblastoma 
synovial sarcoma  ependymoma 
angiosarcoma  oligodendroglioma 
chondrosarcoma  medulloblastoma 
 
 
 
1.1.4     Progressive development of cancers 
 
It has been shown that the development of a malignant tumour is a complex and multi-step 
process whereby abnormal cells progressively become more and more invasive and 
aggressive. Some tumours contain a large number of cells that have proliferated 
uncontrollably but look almost similar to those of normal tissue, this type of growth is called 
hyperplastic. On the other hand, there are cases whereby one type of normal cells will replace 
cells of another type at a site not normally found by that type of cell. These type of cells also 
show minimal differences from normal, are termed metaplasia. Cells that are abnormal 
cytologically, no longer look similar to normal cells of the tissue is called dysplastic. Dysplastic 
cells have variable shape and size with increased mitotic activities. They no longer behave as 
normal differentiated cells of the tissue thus causing major changes in the overall tissue 
architecture. Tumour cells that are in the transitional state between completely benign and 
those that are premalignant are considered to be dysplastic. When the growth of abnormal 
cells starts to break through underlying tissues, these cells become malignant cells that can 
be life threatening and such growth are called neoplasms (Weinberg, 2013). 
 
1.1.5     Monoclonal and polyclonal growth 
 
Tumours can be monoclonal as well as polyclonal in origin. Most tumours are monoclonal 
which are made up of cells that have a common genetic marker, indicating they come from a 
single initially mutated cell. However, polyclonal tumours are made up of subpopulation of 
cells that have different genetic markers from each other (Figure 1.1) (Weinberg, 2013). There 
is some debate about whether certain tumours are monoclonal or polyclonal. From the 
evidence acquired so far it is certain that at least 24 different human tumours can have 
polyclonal tumour origin such as tumours of the breast (Going et al., 2001), bladder (Cheng et 
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al., 2002), colon (Ulintz et al., 2018), prostate (van Etten et al., 2016), stomach (Nomura et al., 
1998) and cervix (Guo et al., 2000). However, initial transformed cells through secondary or 
tertiary genetic changes can cause tumours to acquire cytogenetically different clones. 
Therefore, this heterogeneity in tumour of the same diagnostic type contributes to differences 
in response to treatment and clinical behaviour. Together with the initial clone and subclones, 
progenitor cancer cells can also be found in tumours, thus causing the tumour to have a range 
of cells with different genetic states of differentiation and mutation. These populations can 
differ in sensitivity to radiotherapy, chemotherapy and other treatment, thus making clinical 
management difficult (Croce, 2008). In fact, to distinguish whether a tumour is monoclonal or 
polyclonal is very important because for improving cancer risk assessment, for determining a 
more accurate therapeutic approaches, for developing precise mathematical models of tumour 
development and for acquiring a more specific understanding of the initial developments in 
carcinogenesis (Croce, 2008; Parsons, 2008). 
 
 
 
 
Figure 1.1. Schematic representation of the initial events in carcinogenesis. The cells 
are coloured to represent a cell lineage marker independent of the carcinogenic process. 
According to monoclonal tumor origin (A) cells that begin to form tumour originate from a single 
cell displaying initial genetic lesions.  This cell will further be mutated thus producing a clone 
of cells with multiple mutations that favours propagation and may develop into a malignancy. 
Therefore, tumours can be consider as clones of cells with different subsets of genetic lesions 
and may contain additional genetic lesions as well. According to polyclonal tumor origin (B), 
two or more cells or clones of cells with genetic lesions come together to begin the formation 
of tumour. Irrespective of whether the tumour a rise from monoclonal or polyclonal tumour 
origins, the concept regarding the need for the accumulation of mutations, the types of the 
genetic lesions and subsequent clonal selection are equally applicable to both schemes 
(Parsons, 2008; Weinberg, 2013). 
 
 
29 
 
1.1.6     Known or suspected causes of cancers 
 
Reports have established that lung cancer (1.76 million deaths), liver cancer (782,000 deaths), 
colorectal cancer (862,000 deaths), stomach cancer (783,000 deaths) and breast cancer 
(627,000 deaths) are the most common causes of cancer death (World Health Organisation, 
2018). Agents that are able to cause cancers are known as carcinogens. There are many 
factors that have been found and suspected to cause cancers (Weinberg, 2013), often it is an 
interaction between a person’s genetic factors and the external agents including; chemical 
carcinogens such as components of tobacco smoke, arsenic (a drinking water contaminant), 
asbestos and aflatoxin (a food contaminant); physical carcinogens such as ionising and 
ultraviolet radiation; biological carcinogens such as infections from certain bacteria, viruses or 
parasites (Weinberg, 2013). 
 
Furthermore, the risk of development of cancer rises with ageing, most likely due to an 
accumulation of risk over time combined with the tendency for cells to repair themselves 
becoming less effective with ageing (Weinberg, 2013). 
 
1.2     Oncogenes and tumour suppressor genes 
 
Alterations in oncogenes, tumour suppressor genes and microRNA genes can cause cancer 
and usually occur in somatic cells, although mutation can occur in germ-line cells and 
predispose a person to familial or heritable cancer. Moreover, the development of a malignant 
tumour is rarely due to a single genetic change but is due to a multistep process of sequential 
changes in several, tumour suppressor genes, oncogenes or microRNA genes in cancer cells 
(Chow, 2010). 
 
1.2.1     Oncogenes 
 
Certain genes known as oncogenes have the ability to cause cancer, transforming normal 
cells to malignant cells. These genes are often expressed in high levels or mutated in 
abnormal cells (Buhle, 2012). Oncogenes code for proteins that control cellular growth and 
division involved in cell cycle regulation typically causing cells to proceed from G (gap) phases 
to either chromosome segregation (mitosis) or chromosome replication (S phase) (Figure 1.2). 
Examples include signalling molecules that link the receptors to the replication initiator through 
various pathways, proteins that interact with DNA to start replication, receptors at the cell 
surface that binds to growth factors (Croce, 2008; Chow, 2010).  
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Figure 1.2. Cell cycle control by tumour suppressors and oncogenes. Checkpoints are 
represented as thick red bars. The stages of the cell cycle included G1: Gap 1, S: DNA 
synthesis, G2: Gap 2, and M: mitosis. Tumour suppressors such as p53 and pRB act to 
maintain checkpoints (arrows) whereas oncogenes such as Ras and Myc allow for 
checkpoints to be overcome (stop lines) (Chow, 2010). 
 
 
 
In their normal state, the proteins that control these critical processes are coded by genes 
known as proto-oncogenes. However, when proto-oncogenes undergo certain changes, they 
become oncogenes and cause an increase in activity that leads to the formation of tumour. 
Once a tumour starts to form, the tumour cells will progress through all the phases of the cell 
cycle, instead of stopping within a G phase as it should normally do, leading to uncontrolled 
cell growth. Furthermore oncogenes can inhibit cells from programmed cell death (apoptosis) 
(Chow, 2010). 
 
1.2.1.1     Proto-oncogene to oncogene 
 
Proteins that normally interchange between active and inactive states, occasionally, can be 
permanently mutated. Ras proteins are a group of proteins that belong to the large family of 
small GTPases which in response to numerous extracellular stimuli are activated such as in 
response to growth factor stimulation. Activation causes Ras proteins to bind to a number of 
effector proteins, causing the activation of several signalling cascades within the cell that are 
responsible for adhesion, growth, cytoskeletal integrity, differentiation, migration and survival 
(Goodsell, 1999; Rajasekharan et al., 2013). In normal cells, Ras protein signalling is tightly 
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controlled as a small change in Ras signalling may lead to cells becoming malignant 
(Rajalingam et al., 2007; Rajasekharan et al., 2013). It is estimated that about 20% of all 
human tumours have a Ras gene that is mutated (Rajalingam et al., 2007).  
 
The Ras proteins function as binary molecular switches that alternate between active 
guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound 
states. The stimulation of guanine nucleotide exchange-factors (GEFs) promotes conversion 
of the Ras stable, inactive GDP-bound form to active GTP-bound form. The conversion back 
to the inactive form is controlled by GTPase-activating proteins (GAPs). GEFs and GAPs are 
large, multi-domain proteins that can efficiently interact with other proteins, regulatory 
molecules and lipids and control the level of active and inactive Ras to respond to and regulate 
multiple signal inputs (Rajalingham et al., 2007; Simanshu et al., 2017). 
 
Mutation in Ras proteins have been recognised for many years (Simanshu et al., 2017). During 
the ‘on state’, these proto-oncogenes cause a proliferation-stimulating signal that if mutated 
to an oncogene, will permanently keep Ras active, regardless of the signals the cell receives. 
Hence a dysregulated Ras signalling can cause the cell to become cancerous (Chow, 2010; 
Rajasekharan et al., 2013). There are 5 types of Ras oncogenes identified so far (Table 1.4) 
(Rajasekharan et al., 2013).  
 
 
Table 1.4. Classification of Ras oncogenes (adapted from Rajasekharan, et al., 2013). 
Gene Abbreviation Location Common mutation 
H-ras Harvey rat sarcoma 
 
11p15.5 G12V, G12S, G12A, G13D, Q 61R 
K-ras 
 
Kirsten rat sarcoma 
 
12p12.1 
 
G12D,G12S,G12R,G12A,G13D,G12V,G12C 
N-ras 
 
Neuroblastoma Ras 
 
1p13.2 
 
G12D, Q61K 
 
M-ras 
 
Muscle Ras 
 
3q22.3 
 
G22V, Q71L 
R-ras Related Ras 19q13.33 - 
 
 
 
 
One of the key regulators of MAPK pathway is Ras (Figure 1.3). The MAPK pathway is 
activated when growth factors binds to protein tyrosine kinase receptors, which dimerise and 
cross-phosphorylates tyrosine residues in the cytosolic domains.  The tyrosine 
phosphorylation activates son of sevenless (SOS), a set of genes encoding guanine 
nucleotide exchange factors for Ras proteins, which binds to the phosphotyrosine via Growth 
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receptor-bound protein 2 (GRB2) adaptor proteins and also to plasma membrane. 
Consequently when Ras protein is activated, Raf1 kinase is recruited to phosphorylate raf1 
hence causing a downstream signalling. The phosphorylation of Raf1 (a MAP3K) will in turn 
activate and phosphorylate MEK, a duel specific tyrosine/threonine kinase (a MAP2K). 
Phosphorylated MEK, further activates and phosphorylates ERK1 and ERK2 (MAPKs) which 
in turn phosphorylates ELK1 transcription factor causing immediate early response genes 
such as the gene that encode c-Fos and c-Jun protein to transcribe immediately. Hence it is 
well established that mutation in Ras protein is a prognostic factor which constitutively 
activates Ras-MAPK pathway causing cancer to occur. However, due to the complex networks 
of the Ras-MAPK pathway, it is very difficult to target Ras-MAPK pathway. Therefore, 
understanding the mechanism of how Ras promotes the formation of tumours will help to 
discover other therapeutic approaches (Fernandez-Medarde et al., 2011; Rajasekharan et al., 
2013).  
 
 
 
 
Figure 1.3. Normal and mutant Ras circuit connecting MAPK pathway. Epidermal growth 
factor receptor (EGFR) dimerises upon receiving the external signals (EGF/Growth factor 
(GH)) causing autophosphorylation of tyrosine residues that leads to the activation of the 
tyrosine kinase activity. The removal of GDP from Ras is facilitated by Growth factor receptor-
bound protein 2 (GRB2) associates with Son of seven (SOS) and docking protein. Moreover, 
phosphorylation of MEK, ERK and Raf occurs when Ras binds with GTP. Ras is kept at its 
active state due point mutations (G12V) in exon 1 of it gene which is essential in the activation 
of MAPK pathway (Rajasekharan et al., 2013). 
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Interestingly, mutation in oncogenic Ras and other components of Ras mitogen-activated 
protein kinase (Ras-MAPK) signalling pathway have been reported in a number of cancer cells 
and tissues, indicating for tumorigenesis to occur deregulation of Ras-dependent signalling is 
essentially required. In addition, mutation in H-Ras, K-Ras and N-Ras are often detected in 
tumours (Fernandez-Medarde et al., 2011; Rajasekharan et al., 2013). 
 
A chromosomal translocation is another type of genetic alteration that converts a proto-
oncogene to an oncogene. This is where pieces of broken chromosomes reattach randomly, 
causing either a change in the regulation of the protein expression or the production of a fusion 
protein containing the C-terminus from one protein and the N-terminus from another protein 
(Figure 1.4). BCR/ABL is an example of an oncogene that is formed by chromosomal 
translocation. The BCR/ABL oncogene codes for a protein with the N-terminus of Bcr 
(breakpoint cluster region) and the C-terminus of Abl, a tyrosine kinase that relays proliferative 
signals. Hence, when the fusion protein is formed, Abl is switched on permanently, causing 
unregulated cell cycling (Pérez-Caro, et al., 2007; Chow, 2010; Ross, et al., 2014). 
Furthermore, specific breakpoints in the chromosomal translocation generates three forms of 
BCR/ABL protein, p210 BCR/ABL, p230 BCR/ABL and p185 BCR/ABL which is associated 
with chronic myelogenous leukaemia (CML), neutrophilic leukaemia and acute lymphoblastic 
leukaemia, respectively. However, due to lack of an appropriate in vivo model, the signalling 
pathway and the molecular mechanism of BCR/ABL is still unclear, hence targeting the 
BCR/ABL pathway for therapeutic approaches is made difficult. Therefore, better 
understanding of the BCR/ABL pathway, is needed and may open a new path for other 
therapeutic approaches and drug development (Pérez-Caro et al., 2007; Ross et al., 2014). 
 
Another way oncogenes are formed is simply by proto-oncogene existing in multiple copies in 
the cells, leading to an increased expression (Figure 1.4).  The c-MYC, a transcription factor, 
has about 8 to 30 copies of the proto-oncogenes in each HL60 cells, a promyelocytic 
leukaemia cell line. The increased expression of c-MYC will in turn increase expression of its 
transcriptional targets, many of which help to drive the cell cycle forward (Chow, 2010). 
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Figure 1.4. A schematic diagram representing three major types of genetic alterations 
leading to oncogene activation. A horizontal black line and a rectangle in the centre 
represents region of DNA and a proto-oncogene (gene) respectively, and to the left of the 
gene is a regulatory sequence (RS). The activation of the proto-oncogene leads to three 
different genetic alterations. The first alteration is a point mutation, which is shown by a blue 
star and a blue, vertical stripe on the rectangle representing the proto-oncogene. The second 
alteration is a translocation. The translocation of the proto-oncogene altered the sequences of 
both the original RS and part of the proto-oncogene as is represented by one-third of the proto-
oncogene rectangle is shade grey, and the oval-shaped RS is changed with a diamond shape. 
The third alteration is amplification. During amplification both the proto-oncogene and the RS 
has been duplicated within a region of DNA. Three DNA regions with this same duplicated 
pattern are shown, one on top of the other. (Chow, 2010). 
 
 
 
1.2.2     Tumour suppressor genes 
 
In contrast to proto-oncogenes and oncogenes, tumour suppressor genes code for proteins 
that prevent cell proliferation and division or even initiate apoptosis (Giacinti et al., 2006). 
Examples includes proteins that are necessary for apoptosis initiation, inhibitors of cell cycle 
progression and factors required in maintenance of cell cycle checkpoints (Chow, 2010; 
Reisman et al., 2012). Genetic mutations in tumour suppressor genes restrict the regulatory 
protein from inhibiting cell proliferation leading to tumorigenesis. So far there are more than 
100 dominant oncogenes and around 30 tumour suppressor genes (Table 1.5) (Naga Deepthi 
et al., 2011). 
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Table 1.5. Tumour suppressor genes involved in human cancers and diseases (Thomas 
et al., 2012). 
Gene Chromosomal 
location 
Cellular 
location 
Mode of action Example of cancers 
Rb 13 q 14 Nucleus Transcriptional 
regulator 
Retinoblastoma, 
osteosarcoma, 
carcinomas of breast, 
prostate, bladder and 
lung 
p53 17 p 13.1 Nucleus Transcription factor 
/regulator 
Most human cancers,  
breast, brain, sarcomas, 
leukaemia 
APC 5 q 21 Cytoplasm Unknown Carcinomas of colon, 
stomach and pancreas 
WT1 11 p 13 Nucleus Transcription factor Nephroblastoma 
DCC 18 q 21 Membrane Cell adhesion 
molecule 
Carcinomas of colon and 
stomach 
NF-1 17 q 11 Cytoplasm p21, Ras, GTPase 
activator 
Schwannomas 
NF-2 22 q 12 Inner 
membrane 
Cytoskeleton 
membrane link 
Schwannomas, 
meningiomas 
pVHL 3 p 25 Cytoplasm Inhibits transcriptional 
elongation 
Renal cell carcinoma 
Rb, retinoblastoma protein; p53, Tumour protein p53; APC, adenomatous polyposis coli; WT1, 
wilms tumour protein; DCC, deleted in colorectal carcinoma; NF-1, neurofibromatosis type 1; 
NF-2, neurofibromatosis type 2; pVHL, von Hippel-Lindau tumour suppressor. 
 
 
 
The first tumour suppressor gene to be identified and play a critical role in cell cycle regulation 
was the RB1 gene that codes for retinoblastoma protein (pRb). The pRb protein have 16 
potential sites of cyclin dependent kinase (Cdk) phosphorylation and is an important regulator 
of G1 progression. The Rb pathway is shown in figure 1.5. Initially in G1 stage, pRb is tightly 
bound to the E2F transcription factor and is in a hypophosphorylated state. When pRb is 
phosphorylated by Cdk complexes, which is a sequential process initiated by Cdk4 and Cdk6, 
E2F is released and the cell can start DNA synthesis. This causes the formation of active 
Cdk2/cyclin E complexes that help the continuation of pRb phosphorylation, which as a result 
promote pRb-E2F separation so that E2F can be transcriptionally active, an obligation for the 
cell to move from G1 into S phase. Cyclin A is expressed as cells progress into S phase and 
it becomes the main cyclin linked with Cdk2. Moreover, the activity of cdc2 complexed with 
cyclin B phosphorylates proteins regulated during mitosis, thus is a requirement for the cells 
to progress from G2 to mitosis. In addition, pRb phosphorylation is maintained throughout S 
and G2, and during mitosis pRb is rapidly dephosphorylated. Also, during G1 when pRb is 
hypophosphorlated, E2F is again sequestered (Thomas et al., 2012). Therefore, the function 
of pRb is simply to stop the expression of genes needed for progression into the S phase of 
the cell cycle. However, when it is inactivated often due to genetic alterations involving either 
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deletions or frameshift in the RB1 gene, causing defective protein expression and premature 
introduction of stop codon, cells starts to divide uncontrollably. There are some instances 
when other components in the pathway in which pRB functions are defective such as 
activation of the positive component as CDKs and G1 cyclins or inactivation of negative 
components as p53 and CDK inhibitors (Chow, 2010; Di Fiore et al., 2013). 
 
 
 
Figure 1.5. The Rb pathway. In the G1 phase, Rb is linked to E2F transcription factor in a 
hypophosphorylated state. The phosphorylation of Rb by Cdk4 and Cdk6 causes the release 
of E2F from Rb to initiate DNA synthesis. The phosphorylation of Rb continuous due to the 
formation of Cdk2/cyclin E complexes hence causing the cells to move from G1 into S phase. 
As cells moves in the S phase, cyclin A is formed and becomes the main cyclin linked with 
Cdk2. As the cells moves from G2 to mitosis, Cdk1 complexed with cyclin B phosphorylates 
proteins regulated during mitosis. Moreover, throughout S and G2 phases, the 
phosphorylation of Rb is maintained but is rapidly dephosphorylated during mitosis (Thomas 
et al., 2012). 
 
 
 
Another commonly mutated gene in human tumours is the tumour suppressor gene, p53 
(Chow, 2010; Naga Deepthi et al., 2011; Rivlin et al., 2011; Lai et al., 2014). The function of 
the p53 protein is to inhibit proliferation and promote apoptosis in response to DNA damage 
in cells, hence it plays a very important role in managing the cell cycle, the G1 to S cell cycle 
checkpoint. The p53 protein holds the cell long enough for the DNA repair proteins to fix the 
damage and once the damage is fixed the cell is then allowed to continue the cell cycle. On 
the contrary, if the DNA damage proves to be irreparable, the p53 protein will initiate apoptosis 
(Chow, 2010; Naga Deepthi et al., 2011). However, the inactivation of p53 gene due to genetic 
changes will allow a cell to continue to divide even in the presence of DNA damage. 
37 
 
Furthermore, for tumorigenesis to occur both the paternal and maternal copies of a gene 
coding a tumour suppressor must be modified (Chow, 2010; Buhle, 2012).  
 
The mutation of p53 gene codes a stable p53 mutant protein that apart from losing its tumour 
suppressive activities has acquired oncogenic functions that help cells to grow and survive 
without limitations. Interestingly, it was found that when cells become cancerous during the 
multistep process of malignant transformation, at each phase, p53 gene mutation was shown 
to contribute differentially to tumour promotion, initiation, metastasis and aggressiveness 
(Rivlin et al., 2011). 
 
1.2.3     MicroRNA genes 
 
MicroRNA genes consist of a single RNA strand of about 21 to 23 nucleotides that mediate 
gene expression. Although MicroRNA do not encode proteins, they have the ability to cause 
degradation of messenger RNA (mRNA) or block protein translation by annealing to the mRNA 
that has a nucleotide sequence that complements the sequence of the microRNA (Iorio et al., 
2005; MacFarlane et al., 2010). Example of microRNA are miR-15a and miR-16-1 which in 
chronic lymphocytic leukaemia are often down-regulated (Calin et al., 2002). Furthermore, 
depending on their targets in a specific tissue, a microRNA gene can be an oncogene if its 
target is a tumour suppressor gene and vice versa. In addition, the demethylation of CpG 
islands in the promoter regions of the gene or the deregulation and amplification of a 
transcription factor may lead to up regulation of microRNA (Croce, 2008). 
 
1.3     Cancer metastasis  
 
In many physiological events such as embryogenesis, angiogenesis, inflammation, 
neurogenesis and wound healing, cell migration and invasion are important steps but they are 
also implicated in the pathophysiology of many diseases such as cancer (Bozzuto et al., 2010).  
 
Cancer metastasis is a process in which cancer cells disseminate from the primary tumour 
through lymphatic vessels and blood vessels to settle and grow at a different site other than 
the primary tumour site (Guan, 2015). About 10% of deaths due to cancer arise from primary 
tumours, the remaining approximately 90% of death from cancer are due to cancerous growth 
occurring at a distant site from where the primary tumour was originally found (Valastyan et 
al., 2011; Gao et al, 2013; Weinberg, 2014; Orimo, 2014; Guan, 2015;; Pachmayr et al., 2017). 
Most cancer research so far has focused primarily on the development of agents that can 
inhibit tumour growth and on methods that can detect tumours at the early stage. Therefore, 
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if tumours are diagnosed early and before metastasis occurs, most solid tumours can be cured 
or managed. Whereas cancers that are metastatic at diagnosis are usually difficult to manage 
and cure (Guan, 2015; Chambers et al., 2015). Research into the field of metastasis is lagging 
mainly due to the complexity of the metastatic process. 
 
1.3.1     Invasion metastasis cascade 
 
Cancer metastasis is a complex succession of a series of cell-biological processes known as 
the invasion metastasis cascade (Figure 1.6) whereby cells in primary tumours invade locally 
through surrounding extracellular matrix (ECM) and stromal cell layers, intravaste into blood 
and lymphatic vessels, survive and arrest in the circulatory system, extravasate into a new 
microenvironment to form micrometastases and, with enough nutrients and the right 
conditions these micrometastases will colonise the tissue, to form a macroscopic metastasis. 
Colonisation is the most challenging and complex step because the new area (tissue) where 
the cancer cells have landed does not provide them with survival factors and the collection of 
familiar growth factors that their original place of survival has. As a result, the metastasising 
cells may rapidly die or remain as micrometastases that often cannot be clinically detected. 
Furthermore, only a few micrometastases in cancer patient will have the ability to eventually 
grow several millimetres, large enough to be clinically detectable. (Leber et al., 2008; Bozzuto 
et al., 2010; Valastyan, 2011; van Zijl et al., 2011; Weinberg, 2014; Orimo, 2014; Pachmayr 
et al., 2017). 
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Figure 1.6. The invasion metastasis cascade.  A multi-step cell-biological process 
consisting of a series of cellular events including (1) cancer cells invades into surrounding 
tissue (local invasion), (2) enters the blood and lymphatic vessels (intravasation), (3) 
circulating tumour cells (CTCs)  survive and exit from the bloodstream (extravasation), and (4) 
form micro and macroscopic metastases in distant organs (colonisation) (Orimo, 2014). 
 
 
 
1.3.1.1     Local invasion 
 
Local invasion involves the migration of tumour cells from the confined primary tumour into 
the surrounding tumour-associated stroma and thereafter into the adjacent normal tissue. In 
order to invade the underlying connective tissue, tumour cells must invade the basement 
membrane (BM) and the lamina propria and upon doing this, tumour cells change from highly 
differentiated to undifferentiated cells and develop mechanisms to detach from the primary 
tumour. Such transformation enabling tumour cells to accomplish migration and invasion is 
called epithelial-mesenchymal transition (EMT) (Figure 1.7) (Le et al., 2010; van Zijl et al., 
2011; Guan, 2015).  
 
 
 
Figure 1.7. Epithelial-to-mesenchymal transition (EMT). The epithelial cells undergo 
phenotypic changes to take on mesenchymal-like characteristics (Scully et al., 2012). 
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During this process, transcription factors like Twist, Snail, Slug and ZEB-1/-2 downregulate E-
cadherin, a key protein for epithelial cell-cell adhesion, causing the epithelium to be more 
permeable. Certain microRNAs such as those belonging to the miR-200 family have the ability 
to post-transcriptionally suppress expression of the ZEB1 and ZEB2 hence promoting an 
epithelial phenotype. In response, ZEB1 and ZEB2 transcriptionally repress miR-200 
microRNAs, reinforcing the residence of cells in either the epithelial or mesenchymal state. 
Moreover, in response to migratory stimuli, tumour cells are able to migrate as they acquire 
morphological protrusions. These membrane extensions which contain actin serve as a 
traction site for cells (van Zijl et al., 2011; Valastyan et al., 2011; Pachmayr et al., 2017). 
 
Once the tumour cells have detached from the primary tumour, tumour cells undergo 
phenotypic changes to take on mesenchymal-like characteristics allowing them to migrate and 
invade through the basement membrane. Hence, tumour cells can activate the proteolytic 
urokinase-type plasminogen activator system (uPA/uPAR) and secrete proteases like matrix 
metalloproteinase (MMP-1, MMP-2 and MMP-9) (Harlozinska, 2005; Bozzuto et al., 2010) to 
further degrade the BM and the extracellular matrix (ECM). In addition, the MMP-expressing 
cells also help cancer cell proliferation by releasing growth factors (Leber et al., 2008; 
Valastyan et al., 2011; Pachmayr et al., 2017). 
 
The loss of BM allows the tumour cells to enter the stromal compartment where they are 
confronted with various cell types including dendritic cells, macrophages, neutrophils and 
lymphocytes. Furthermore, the stromal cells reacts to tumour invasion with inflammation which 
further increases the aggressive behaviours of tumour cells. For example, the secretion of 
interleukin-6 (IL-6) by adipocytes present in the local microenvironment can stimulate breast 
cancer invasiveness. In addition, breast cancer cells secrete IL-4 which generate cathepsin 
protease activity in tumour-associated macrophages (TAMs) that further increase tumour cell 
invasiveness. The interactions between tumour cells and the nearby stroma is bi-directional 
in that the tumour cells activate the formation of an inflamed stroma which in response 
reinforce the malignant traits of the tumour cells thus setting up a likely self-amplifying positive 
feedback loop. In summary the entry of tumour cells in the stroma, increases the tumour cells 
opportunity to directly enter the systemic circulation to travel to distant sites (Valastyan et al., 
2011; Pachmayr et al., 2017). 
 
1.3.1.2     Intravasation 
 
During intravasation, tumour cells have the ability to cross the endothelial and pericyte barriers 
of the microvessels of the lymphatic or blood vessels due to molecular changes such as during 
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transcriptional programme, cytokine transforming growth factor-β (TGFβ) switches cells from 
cohesive to single cell motility thus facilitating intravasation (Giampieri et al., 2009). Many of 
the mechanisms that help facilitate intravasation, involve stimulation of vascular endothelial 
growth factors (VEGFs) that encourage new blood vessels to form within the local 
microenvironment, a process known as neoangiogenesis (Leber et al., 2008). Furthermore, 
the activation of uPA/uPAR due to the suppression of tumour suppressor programmed cell 
death protein 4 (PDCD4) stimulates intravasation. Urokinase receptor (uPAR) was found to 
be inversely correlated with PDCD4 expression and the activation of uPAR mediated by 
specificity protein 1 (SP1) can be suppressed by PDCD4. In addition the secretion of 
proteases like MMP-1, -2 and -9 also enhance intravasation by promoting angiogenesis 
(Chiang et al., 2015; Pachmayr et al., 2017). It has been reported that epiregulin (EREG) and 
cyclooxygenase-2 (COX-2) facilitate breast cancer cell intravasation due to their ability to 
reduce VEGF, hence causing blood vessels to become more permeable and to stimulate 
neoangiogenesis (Valastyan et al., 2011; Pachmayr et al., 2017). 
 
1.3.1.3     Survival in the circulatory system 
 
Once tumour cells have successfully entered the blood vessels, they can travel throughout 
the circulatory system. However because of their diameter (20 – 30 μm) larger than the 
diameter of capillaries (~ 8 μm), a large number of tumour cells are prone to arrest in various 
capillaries as soon as they enter the circulatory system. Conversely, the circulating tumour 
cells (CTCs) must overcome a number of stresses before they can reach distant organ sites. 
When CTCs are in the circulatory system they lack the integrin-dependent adhesion to ECM 
components which is critical for normal cell survival. In normal cells, the absence of such 
anchorage cause the cells to undergo anoikis (Valastyan et al., 2011; Guan, 2015), a form of 
apoptosis but in CTCs, a number of signalling events such as the control of glucose uptake, 
the pentose phosphate pathway and the tryrosine kinase TrKB are stimulated to suppress 
anoikis responses, and thus help metastatic progression of the CTCs (Valastyan et al., 2011; 
Pachmayr et al., 2017).  
 
Furthermore, apart from withstanding the stresses imposed by matrix, CTCs must overcome 
cells of the immune system especially the natural killer cells and the hemodynamic shear 
forces in the circulatory system (Harlozinska, 2005; Valastyan et al., 2014). Such threats are 
easily overcome in that the CTCs mediate the expression of Tissue-Factor and/or L- and P-
selectin in order to interact with blood platelets to form relatively large emboli, thus protecting 
themselves from immune cells and the shear forces (Guan, 2015). Therefore enabling the 
tumour cells to disseminates and arrest at distant organ sites (Valastyan, et al., 2011). 
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1.3.1.4     Arrest at distant organ site and extravasation 
 
Travelling CTCs in the circulatory system can disseminate to a wide variety of distant target 
organ sites but depending on individual tumour types only form metastatic cells to certain 
organ sites. This theory has been well explained in the Paget’s ‘seed and soil’ theory which 
states that a specific tumour cell (the seed) will only metastasise and be detectable at a 
particular suitable organ or location (the soil) where they can survive and proliferate (Valastyan 
et al., 2011; Jiang et al., 2015; Pachmayr et al., 2017).  Consistent with the ‘seed and soil’ 
theory many cancers have an increased tendency to survive and grow at certain specific organ 
sites.  For example, gastrointestinal cancers appear to frequently metastasise to the liver and 
lung, whereas prostate and breast cancers favour metastasis to the bone. Furthermore, 
certain organs such as the bone, lung, brain and liver have become the main secondary sites 
for most cancer metastasis (Valastyan et al., 2011). One factor which may help tumour cells 
to have specific affinity for certain organs might be the release of chemokines specific for each 
organ and the tumour cells have appropriate chemokine receptors that helps tumour cells to 
target the organ. Chemokine receptor 4 (CXCR4) on tumour cells such as breast cancer cell, 
are attracted to organs expressing high levels of CXCL12 ligand such as the lung, brain, liver 
and bone (Leber et., 2008; Valastyan et al., 2011; Jiang et al., 2015) . Conversely, the 
mechanisms for many cancer types choosing to settle and grow at specific organ sites is still 
widely being investigated by scientists. Such findings could help initiate new strategies to 
combat cancer metastasis (Valastyan et al., 2011; Pachmayr et al., 2017).  
 
Once CTCs arrest in the micro vessels of the distant organs, the formation of a microcolony 
eventually break the vessel wall thereby allowing the CTCs to enter into the new 
microenvironment, a process called extravasation (Valastyan et al., 2011). In order, for the 
CTCs to penetrate in tissues, the CTCs must overcome the low intrinsic microvessel 
permeability by secreting factors to induce vascular hyper-permeability and to change these 
distant microenvironments. Therefore, the facilitation of extravasation of breast cancer cells in 
the lungs to disrupt the pulmonary vascular endothelial cell-cell junctions is from the secretion 
of pleiotropically acting factors COX-2, EREG, MMP-1 and MMP-2 as well as protein 
angiopoietin-like-4 (Angptl4) (Pudua et al., 2008; Valastyan et al., 2011).  Other factors 
secreted by various types of cancer cells to help extravasation in the lung are MMP-3, MMP-
10, angiopoietin2 (Angpt2), VEGF and placental growth factors (Weis, et al., 2004; Huang et 
al., 2009; Valastyan et al., 2011). 
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1.3.1.5     Micrometastasis formation 
 
For metastasis to form, the extravasated cancer cells must survive and adapt to the new 
microenvironment which is usually different from the site of primary tumour formation in terms 
of ECM constituents, types of stromal cells, cytokines, available growth factors and the 
morphology of the tissue itself. Furthermore, for cancer cells to survive in their new 
microenvironments, a series of systemic signals are released by the tumour cells preparing 
and making the metastatic site more receptive to the arrival of the cancer cells (Psaila et al., 
2009). Signals such as those that include lysyl oxidase (LOX) help to upregulate fibronectin in 
specific organs from resident tissue fibroblasts which in turn shift VEGF-receptor-1-positive 
(VEGFR1+) hematopoietic progenitor cells from the bone marrow to the metastatic sites by 
the interaction between the integrin α4β1 receptor found on the hematopoietic progenitor cells 
and the deposited fibronectin (Erler et al., 2009). Furthermore, the secretion of MMP-9 by 
these hematopoietic progenitor cells does not only stimulate various integrins but also activate 
insulated molecules in the ECM such as the stromal cell-derived factor-1 (SDF-1) (Psaila et 
al., 2009). The evidence so far established that in order for tumour cells to initially survive at 
the new microenvironments, tumour cells must use complex mechanisms to change these 
microenvironments (Valastyan et al., 2011).  
 
1.3.1.6     Metastatic colonisation 
 
The initial survival of cancer cells in their new microenvironment often does not indicate that 
the cancer cells will proliferate to form large macrometastases a process known as metastatic 
colonisation. Many persist as micrometastases and eventually become dormant while others 
slowly degrade over periods of weeks and months (Valastyan et al., 2011). Many of the 
micrometastases, lack the ability to activate the Src pathways, integrin β1 and focal adhesion 
kinase (FAK) which are essential to make the foreign microenvironment more hospitable 
(Barkan et al., 2008; Shibue et al., 2009). Alternatively, the micrometastases may continuously 
grow but their growth is suppressed by apoptosis. However, the mechanism to explain such 
high rate of apoptosis is not well understood but it may be due to failure to initiate 
neoangiogenesis by the tumour cells (Valastyan et al., 2011). 
 
A number of genes have been identified whose expression facilitates the metastatic 
colonisation of breast cancer cells to lung (Minn et al., 2005), bone (Kang et al., 2003), liver 
(Tabaries et al., 2011) or brain (Bos et al., 2009). One example is breast cancer cells facilitate 
osteoclastic cytokine IL-11 to form osteolytic bone metastases whereby IL-11 disrupts the 
44 
 
normal physiological signals between osteoclasts and osteoblasts (Kang et al., 2003; 
Valastyan et al., 2011).  
 
Another factor that may determine the success of metastatic colonisation is that metastatic 
cells must possess a high self-renewal capacity. It was found that only a small population of 
cells in a tumour may possess high self-renewal capacity. These cells are known as tumour-
initiating cells (TICs). Therefore, it is those cells, the TICs that must disseminate from the 
tumour to distant organs sites to be able to form macrometastases (Valastyan et al., 2011). 
Furthermore, the promotion of tumour cells to TICs is facilitated by a group of molecules known 
as the EMT-promoting transcriptional factors (TFs), such as Twist, Snail and ZEB1 (Leber et 
al., 2008; Valastyan et al., 2011; Pachmayr et al., 2017). In addition, the metastatic 
colonisation of the lung and breast cancers are also modulated by the homeobox 
transcriptional factor NKx2-1 (Winslow et al., 2011) and the inhibitors of cell differentiation (ID) 
transcriptional factor family, ID1 and ID3 respectively (Gupta et al., 2007). Moreover, there are 
many regulators identified that have a pleiotropic function in the invasion metastasis cascade 
such as the microRNA miR-31 (Le, et., 2010), which inhibits breast cancer metastasis by 
simultaneously slowing metastatic colonisation, local invasion, and one or more early post-
intravasation events (Valastyan et al., 2011). 
 
In conclusion, the continuous change in genetic and/or epigenetic phenotypes as well as the 
interaction of cancer cells with stromal cells, helps cancer cells to complete an intricate cell 
biological process to the formation of macrometastases at distant organ sites which are 
responsible for most cancer deaths (Valastyan et al., 2011). Therefore an in-depth 
understanding of the mechanism underlying the invasion metastases cascade is critical in 
finding new therapeutic strategies to inhibit metastatic growth.  
 
1.4     Breast cancer metastasis 
 
1.4.1     Detection of breast cancer metastasis 
 
One of the most common types of cancer is breast cancer and it accounts for the highest 
cancer mortality in women (Lage, 2003; Scully et al., 2012; Martin et al., 2014; Nounou et al., 
2015). Breast cancer mortality is not only due to primary tumour itself but mainly due to breast 
cancer metastases to distant organ sites (Scully, et al., 2012; Ugenskiene, et al., 2012). 
Currently, there are a number of methods used to detect breast cancer metastasis such as 
radiological evaluations, clinical manifestations of the spread to distant organs, serum tumour 
markers and biopsies of affected organs (Scully, et al., 2012; Nounou et al., 2015). With early 
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diagnosis using mammographic screening, the mortality rate from metastasis has decreased 
but the methods mentioned above are often inefficient at accurately predicting the clinical 
outcome of the disease and at identifying metastasis at the earliest stage. Therefore in order 
to improve the efficiency of diagnosis, the analysis of CTCs to detect metastasis has to be 
used. CTCs are tumour cells found largely circulating in the bloodstream of cancer patients 
and originate from the primary tumour. In addition, CTCs have critical roles in cancer 
metastasis, hence their analysis will help predict metastatic progression and relapse more 
accurately. Furthermore, research also found that CTCs correspond with survival and clinical 
outcome of cancer patients. One study indicated that before treatment, patients with 
metastatic breast cancer with more than five CTCs in 7.5 ml of blood are subject to shorter 
overall survival and progression-free. Moreover, after neoadjuvant chemotherapy, the 
detection of one CTC in 7.5 ml of blood could correlate to metastatic relapse. There are a 
number of methods used to detect CTCs and are showing promising results but in order to 
improve quality and efficacy, a need to normalise the techniques is required (Scully et al., 
2012). 
 
1.4.2     Treatment of breast cancer metastasis 
 
The survival of metastatic breast cancer patients has significantly improved in the recent few 
years but the metastatic disease has proven to be a challenge. Targeted therapy and standard 
chemotherapy are the two types of treatment for breast cancer metastasis (Scully et al., 2012). 
 
Hormone therapy, antiangiogenic therapy and immunological therapy are considered to be 
targeted therapies. In hormone therapy the aim is to inhibit the enzyme aromatase to reduce 
estrogen or simply to block the estrogen receptor (ER). In post-menopausal women the only 
source of endogenous estrogen is from the conversion of adrenal androgen to endogenous 
estrogen by aromatase. In post-menopausal women with metastases the initial hormone 
therapy use is tamoxifen, which is an agent that blocks the ER causing tumour regression. 
Furthermore, aromatase inhibitors used are anastrozole, exemestane and letrozole which 
have a better therapeutic index than tamoxifen, as first-line therapy for post-menopausal 
women with metastases (Scully et al., 2012; American Cancer society, 2017).  
 
In addition, breast cancer patients that show a high expression of human epidermal growth 
factor receptor 2 (HER2) are often treated with trastuzumab (Maughan et al., 2010), a 
monoclonal antibody that selectively binds to the extracellular domains of HER2 to decrease 
tumour growth. More often, trastuzumab is combined in chemotherapy with reports indicating 
an improved response rate, overall survival rate and time-to-regression in metastatic breast 
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cancer patients. Other monoclonal antibodies targeting HER2 include pertuzumab and 
trastuzumab-MCC-DM1 (trastuzumab emtansine), all show encouraging results in metastatic 
breast cancer therapy (Scully et al., 2012; Nounou, 2015). 
 
Furthermore angiogenesis is crucial in the formation of metastases at distant organ thus 
inhibiting new blood vessel growth is necessary to limit the metastases formation. A 
monoclonal antibody derived from murine VEGF known as bevacizumab, is used to limit the 
supply of nutrients and oxygen to the cancer cells, hence inhibiting endothelial growth by 
blocking all VEGF-A isoform only, thus preventing blood vessels from growing to the cancer 
cells. To increase progression-free survival duration, bevacizumab is often used in 
combination with other chemotherapeutic agents but may cause serious side effects such as 
haemorrhage, high blood pressure and heart failure in breast cancer patients (Nielsen et al., 
2010; Sully et al., 2012; Gampenrieder et al., 2017).  
 
On the other hand, in standard chemotherapy, a number of cytotoxic drugs are used, including 
anthracyclines (doxorubicin and epirubicin), taxanes (paclitaxel and docetaxel) and 5-
fluorouracil which are first, second and third lines of therapy respectively (Nicolini et al., 2006). 
However, many of these cytotoxic drugs have severe side effects such as the use of 
anthracycline have been link to cardiac dysfunction (Mitry et al., 2015). Therefore, newer 
cytotoxic agents such as ixabepilone and epothilones (Luu et al., 2011) have been developed 
which show greater efficacy in metastatic breast cancer patients who were originally treated 
with taxanes and anthracyclines (Alvarez, 2010; Scully et al., 2012; American cancer society, 
2017). 
 
Many factors and pathways have rendered breast cancer metastasis to be a very complex 
process where a lot needs to be elucidated to fully understand the process which, at the same 
time could provide new therapeutic strategies. Additionally, more efficient methods are needed 
to predict and detect breast cancer metastasis at the earliest stage possible to increase the 
effectiveness of treatment. 
 
1.5     Drug resistance in cancer cells 
 
In the treatment of diseases, over a period of time, the disease can acquire a phenomenon 
known as drug resistance, a similar concept to bacterial resistant to certain antibiotics. 
Similarly, during chemotherapeutic treatment of cancers, cancer cells can become resistant 
to the drugs (Leonard et al., 2003; Housman et al., 2014). Depending on the response of 
tumour cells to the initial therapy, cancer resistance can be divided in to two categories: 
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primary drug resistance, which exists before any given treatment, and acquired drug 
resistance, which appears after initial treatment (Yasui et al., 2004; Bozzuto et al., 2010; 
Zahreddine et al., 2013). However, regardless of primary or acquired resistance, there are 
many genetic and epigenetic processes taking place inside the cancer cells to give rise to 
cancer drug resistance, hence at certain points during treatment, patients can develop 
resistance (Zahreddine et al., 2013).  There are many mechanisms by which cancer cells can 
become resistant to chemotherapy, namely drug inactivation, drug target alteration, epithelial-
mesenchymal transition (EMT), cell death inhibition, DNA damage repair, drug efflux and 
epigenetics  (Figure 1.8) (Yasui et al., 2004; Housman et al., 2014; Cree et al., 2017). 
  
 
 
 
 
Figure 1.8. Mechanisms through which cancer cells can adopt to promote drug 
resistance. Cancer cells can acquired drug resistance via one or in combination with other 
mechanism that trigger a series of signal transduction pathways (Housman et al., 2014). 
 
 
 
1.5.1     Drug inactivation 
 
Many anticancer drugs need to undergo metabolic activation in order to be clinically effective 
during treatment. Therefore drugs must undergo complex mechanisms of interactions with 
different proteins to either, complex, modify or partially degrade the drugs, all in the aim of 
significantly activating the drugs. However, during cancer treatment, cancer cells can develop 
resistance to anticancer drugs by lowering drug activation (Housman et al., 2014).  For 
instance, cytarabine (AraC), a nucleoside drug, used to treat acute leukaemia (AML) must be 
activated to its active form, AraC-triphosphate through a series of phosphorylation steps that 
involve enzymes such as deoxycytidine kinase. To decrease the activation of AraC, mutation 
or downregulation in this pathway can lead to AraC resistance (Zahreddine et al., 2013; 
Housman et al., 2014; Mansoori et al., 2017). 
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A group of detoxifying enzymes that normally engaged in protecting cellular macromolecules 
from electrophilic compounds known as Glutathione S-transferase (GST), also may promote 
drug resistance by inhibiting the mitogen-activated protein kinase (MAPK) pathway and 
through direct detoxification. In cancer cells these enzymes are overexpressed causing an 
increase in detoxification of the anticancer drugs which leads to less cancer cells toxicity 
(Housman et al., 2014; Mansoori et al., 2017). 
 
Furthermore, platinum-based chemotherapy can be inactivated by thiol glutathione and 
methallothionein which promotes detoxification hence causing cancer cells to acquire 
resistance to platinum based anticancer drugs such as cisplatin, oxaliplatin, and carboplatin 
(Zahreddine, et al., 2013; Housman, et al., 2014). Another way in which cancer cells can 
acquire drug resistance is via changes to apoptosis-related proteins such as the tumour 
suppressor protein p53. In response to chemotherapy, p53 promotes apoptosis but when this 
gene is mutated, cancer cells acquire drug resistance. In addition, inactivation of p53 effectors 
such as caspase-9 and its cofactor, apoptotic protease activating factor 1 (Apaf-1) can also 
develop drug resistance (Housman et al., 2014). 
 
Finally, Uridine 5'-diphospho-glucuronosyltransferase (UGT) is a group of enzymes that 
catalyse the glucuronic acid component of UDP-glucuronic acid to a hydrophobic molecule in 
a reaction known as glucuronidation. This reaction mediates the production of inactive 
hydrophilic glucuronides with substrates such as bile acids, steroids and xenobiotics. UGT 
genes such as UGT1 and UGT2 genes facilitate the first line metabolic defence against 
pathogenic substrates in many tissues such as in the breast, gut and prostate. DNA 
methylation can negatively regulate UGT1A1 expression causing irinotecan, a topoisomerase 
I inhibitor to be functional when the gene is silenced (Gagnon et al., 2013). Unfortunately, 
resistance to irinotecan and other drugs occurs when UGT1A1 expression increases due to 
epigenetic changes (Housman et al., 2014; Takano et al., 2017). In conclusion, drug 
inactivation is an important mechanism through which cancer cells acquire drug resistance 
which needs further investigation. 
 
1.5.2     Drug target alteration 
 
The expression levels of a drug target can be altered due to modification or mutation, hence 
affecting the efficacy of the drug.  Such changes in drug target can lead to drug resistance. 
Topoisomerase II is an enzyme that obstructs super coiled or under-coiled DNA from forming. 
Many anticancer drugs target topoisomerase II by blocking the action of topoisomerase II thus 
leading to inhibition of DNA synthesis and promotion of DNA damage and eventually apoptosis 
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and cell death. However, in certain cancer cell lines, the topoisomerase II gene is mutated 
thus the efficacy of the topoisomerase II inhibitor decreases leading to drug resistance 
(Housman et al., 2014). Moreover, signalling kinases, such as the EGFR family, Ras, Src, Raf 
and Mitogen-activated protein kinase (MAPK) are being targeted by many anticancer drugs. 
However, these drugs lose their efficacy once mutation in these kinases occur leading to 
overexpression of the genes or over activation. One example HER2, receptor tyrosine kinase 
is often targeted in chemotherapy but due to its overexpression in certain breast cancer 
patients, drug resistance is inevitable after long term use of the inhibitors (Housman et al., 
2014; Cree et al., 2017). 
 
Another way which drug response can be altered in cancer cells is through modification of the 
level of enzyme expression. On the other hand, androgen receptor was found to be 
genomically amplified in certain prostate cancers, thus rendering anticancer drugs such as 
bicalutamide and leuprolide ineffective in androgen deprivation therapy (Heinlein et al., 2004; 
Housman et al., 2014). 
 
Changes in signal transduction processes that control drug activation, may alter drug targets 
leading to drug resistance. For example the efficacy of trastuzumab in the treatment of HER2-
postive breast cancers as a single agent is often low, where some patients do not respond to 
treatment and even though the efficacy is a lot higher in combination with other anticancer 
drugs, the continuous use of the drug leads to drug resistance and relapse. Moreover, 
activation of PI3K/Akt pathway, co-expression of growth factor receptors, cell cycle inhibition 
and loss of Phosphatase and tensin homolog (PTEN) function is thought to contribute to the 
mechanism of resistance (Berns, et al., 2007; Pohlmann et al., 2009; Luque-Cabal et al., 
2016). In the trastuzumab-resistant cell line, significant increases in the levels of insulin-like 
growth factor 1 receptor (IGF1R) confirmed that inhibition of IGF1R increases the efficacy of 
trastuzumab.  Therefore, targeting both, IGF1R and HER2 at the same time may enhance 
treatment in HER2-positive breast cancer patients (Browne et al., 2011; Housman et al., 2014; 
Sanabria-Figueroa et al., 2015). 
 
In the treatment of breast cancer, tamoxifen resistance may occur via alterations in signalling 
mechanisms. Tamoxifen is an oestrogen receptor (ER) antagonist that inhibits the effect of 
oestrogen on these receptors. Moreover, interaction of ER signalling with other growth 
signalling pathways may promote drug resistance such as in breast cancer with HER2 
overexpression whereby inhibiting the activity of tamoxifen is reversed to promote tumour 
growth (Shou et al., 2004). Furthermore, in the treatment of ER-positive breast cancer with 
tamoxifen, high expression levels of EGFR and HER2 were detected which continues to 
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increase when tumour became resistant (Massarweh et al., 2008; Chang, 2012; Ali et al., 
2016). Finally, an in-depth understanding of the mechanism of drug target alteration will enable 
the treatment of drug resistant cancers more effective. 
 
1.5.3     DNA damage repair 
 
During chemotherapy, cancer cells trigger a mechanism of DNA damage response to 
counteract the DNA damage done by the anticancer drugs. Cisplatin, a platinum based drug 
promotes apoptosis by producing harmful DNA crosslinks, but cancer cells become resistant 
to platinum based drugs by activating the homologous recombination and nucleotide repair 
mechanisms. Therefore, in order to increase the efficacy of the therapy, inhibitors of the DNA 
repair pathway must be used in combination with anticancer drugs that promotes DNA 
damaging (Housman et al., 2014). 
 
Furthermore, cancer cells intricately have many DNA damage response (DDR) mechanisms 
such as the homologous recombination repair mechanisms (RRM) and the nucleotide excision 
repair system (NER) which can compensate other DDR mechanisms that are either impaired 
or dysregulated by either epigenetic silencing or mutation in certain genes involved in the DDR 
mechanisms. Therefore, for effective chemotherapy, both the over-active and the under-active 
DDR mechanisms must be identified so as to target these DDR mechanisms to leave the 
cancer cells more vulnerable to DNA damaging drugs (Mansoori et al., 2017).   One enzyme 
that has been targeted in the DDR pathway for therapy is the O6-methlguanine DNA 
methyltransferase (MGMT).  The aim of the drugs are to induce guanine O6 alkylation which 
makes the cancer cells undergo cell death. However, targeting the MGMT has proved to be a 
challenge as the drugs on clinical trial such as O6-benzylguanine also affect healthy cells 
(Verbeek et al., 2008; Fan et al., 2013). Therefore, identifying specific proteins in the DDR 
pathways and producing specific drugs to that protein will help to sensitise cancer cells to 
cytotoxic drugs whilst leaving healthy cells unharmed. 
 
1.5.4     Cell death inhibition 
 
Apoptosis and autophagy are two critical mechanisms that promote cell death. Apoptosis 
promotes cell death through either an intrinsic pathway that requires the mitochondria and 
involves proteins such as caspase-9, B-cell lymphoma 2 (BCL-2) family proteins and Akt, and 
an extrinsic pathway that involve death receptors on the cell surface. Furthermore, the 
activation of both pathways activates caspase-3 which causes apoptosis (Housman et al., 
2014; Mansoori et al., 2017).  
51 
 
Drugs targeting the apoptosis pathways are very important in ensuring high efficacy in therapy. 
Proteins such as Akt, BCL-2 family proteins, signal transducer and activator of transcription 
(STAT) proteins and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
are high overexpressed and highly active, making them potential drug targets. Moreover, 
through the activation of caspase-8, recombinant form of tumour necrosis factor related 
apoptosis-inducing ligand (TRAIL) and agonistic antibodies to these receptors can promote 
apoptosis (Mohammad et al., 2015; Rathore et al., 2017). In clinical trials, the use of TRAIL 
with other cytotoxic drugs shows significant results but its use alone is ineffective. In addition, 
several other drugs that may improve the efficacy of therapy includes the histone deacetylase 
inhibitors (HDACi), protease inhibitors, BCL-2 protein inhibitors and kinase inhibitors 
(Housman et al., 2014). 
 
Cell survival can be promoted through a process that involves recycling of damaged or 
unnecessary cellular components and lysosomal degradation known as autophagy, which in 
turn maintains intracellular homeostasis. Therefore in chemotherapy, cancer cells will attempt 
to maintain intracellular balance by eliminating cellular stress and dysfunctional organelles 
triggered by anticancer drugs, hence keeping cancer cells alive (Mohammad et al., 2015).  
Moreover, drugs such as chloroquine and its derivatives causes the pH of the lysosomes to 
increase which result in inactivation of the digestive enzymes in the lysosomes. Chloroquine 
is very effective in rendering cancer cells vulnerable to cytotoxic drugs. Hence, chemotherapy 
is made more effective when fluorouracil is combine with chloroquine (Sasaki et al., 2010). 
Moreover, the inhibition of autophagy in ER-positive cancer cells by hydroxychloroquine, a 
chloroquine derivatives, enhances the sensitivity of ER inhibitors such as tamoxifen (Cook et 
al., 2014). In general, chloroquine is particularly useful in sensitising autophagy drug resistant 
cancers to other anticancer drugs (Manic et al., 2014; Housman et al., 2014). In conclusion, 
targeting the apoptosis and autophagy pathways is crucial in increasing the efficacy of therapy.  
 
1.5.5     Epithelial-Mesenchymal Transition (EMT) 
 
As mentioned above, tumour cells become metastatic by employing a mechanism that 
ensures the transition of epithelial cells to mesenchymal cells known as EMT. During EMT, 
the expression of cell adhesion receptors which help in cell-cell attachment are reduced while 
those that promote cell motility are increased. The release of chemokines and cytokines by 
tumour cells or cells in the microenvironment also mediate cell motility. In addition the MMPs 
help tumour cells to migrate, promoting metastasis. Since, EMT is a very important mechanism 
in cancer metastasis, its involvement in cancer drug resistance may prove to be a critical target 
to reduce drug resistance (Housman et al., 2014). 
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The degree of EMT and the differentiation levels of tumour account for the factors that play an 
important role in the development of drug resistance during EMT. For example, tumours that 
express high levels of β1 integrins in HER2-positive breast cancer are more resistant to 
inhibitors such as trastuzumab (Lesniak et al., 2009; Hou et al., 2016). Moreover, during the 
differentiation processes of cancer cells to facilitate EMT, drug resistance may occur. For 
example, the highly expressed αvβ1 integrin in colon cancer interacts with stromal cell 
adhesion molecules to positively mediate the expression of transforming growth factor β 
(TGFβ), which is essential for EMT (Bates et al., 2005). Other factors such as β3 integrin, src 
(Galliher et al., 2006), FAK (Shibue et al., 2009), VEGF, Flt-1 (Bates et al., 2005), and selectin 
(Bendas et al., 2012) play an important role in mediating the process of EMT and cell survival 
in cancer. Furthermore, research suggest that stromal cells may play a crucial role in causing 
drug resistance in cancer. Such finding was observed when inhibitors of B-Raf, an 
intermediate kinase initiated by receptor tyrosine kinases, were used in melanoma cells which 
develop drug resistance when co-cultured with fibroblast (Straussman et al., 2012; Du et al., 
2016).  
 
Although there are various factors that are involved in cancer metastasis and EMT, cell 
differentiation in metastasis cancer is not uniform due to a heterogeneous cell population 
(Heerboth et al., 2015). Hence, this account for some patients to be more responsive to 
treatment than the others. Furthermore, EMT may bring about drug resistance in some or all 
the cells in the tumour by producing signals that increase survival (Housman et al., 2014). 
Since, EMT is a very complex mechanism, a thorough investigation is necessary to 
understand its involvement in drug resistance so that factors which play a critical role in 
promoting drug resistance can be targeted to improve cancer treatments. 
 
1.5.6     Drug efflux 
 
The efflux of drugs from cancer cells is one of the most complex mechanisms cancer cells use 
to promote drug resistance. Whereas many other methods of developing resistance can be 
overcome by changing to a different drug regime, drug efflux mechanisms in response to one 
drug can lead to resistance to other drugs. This phenomenon is often known as multidrug 
resistance (MDR) where a cell becomes resistant to mechanistically and structurally unrelated 
drugs, including drugs they have not previously been treated with. Thus MDR in cancer cells 
is almost identical to antibiotic resistance (Leonard et al., 2003; Bozzuto et al., 2010). It was 
found that drug efflux by several membrane proteins within the ATP-binding cassette (ABC) 
transporter family proteins are responsible for the multidrug resistance phenomenon (Bozzuto 
et al., 2010; Zahreddine et al., 2013). The first MDR ABC transporter to be identified was P-
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glycoprotein (P-gp/ABCB1) in 1976 by Juliano and Ling, which is capable of exporting a wide 
range of drugs (Jaramillo et al., 2018). Since then several other members of the ABC 
superfamily have also been found to contribute to drug efflux, such as the multidrug resistance 
protein 1 (MRP1/ABCC1) (Cole et al., 1994) (Cole, 2014) and the breast cancer resistance 
protein (BCRP/ABCG2) (Nakanishi et al., 2012; Sun et al., 2012). Many of the ABC 
transporters efflux a variety of xenobiotics, including anthracyclines, vinca alkaloids, kinase 
inhibitors, epipodophyllotoxins and taxanes and have a wide substrate specificity (Liu et al., 
2010). Thus, during chemotherapy, many of the ABC transporters are activated as an act of 
defence to protect the cancer cells. Therefore, MDR mediated by ABC transporters is one of 
the biggest challenges clinically in overcoming tumour progression. Often, certain ABC 
transporters in cancer cells are highly overexpressed rendering the cancer cells more resistant 
to anticancer drugs such as docetaxel, cisplatin, topotecan and doxorubicin to name a few, 
which correlate with higher patient mortality. Therefore, inhibiting certain ABC transporters 
may help in increasing the efficacy of treatment but at the same time can affect the normal 
functions of cells (Morgan et al., 2012). Moreover, continuous use of maximum dose of 
chemotherapy causes tumour remission but due to selection of ABC transporter 
overexpressing cells may also boost chemotherapy resistance in newly formed metastases 
(Kryczka et al., 2018).  Thus further investigation is required to fully understand the complex 
role ABC transporters play in cancer progression. The ABC transporters is further discussed 
in the ABC transporter sections below. 
 
1.5.7     Epigenetics 
 
The heritable changes in gene expression and phenotype that are not due to change in 
nucleotide sequence are termed epigenetics. Epigenetic mechanisms are important in normal 
development and cell functions including chromosome x inactivation, differentiation, genomic 
imprinting and gene silencing (Lim et al., 2010; Ghasemi et al., 2017). However in cancer cells, 
epigenetic modification through DNA methylation and histone modification are important 
mechanisms that are found to cause drug resistance in cancer treatment (Housman et al., 
2014). DNA methylation is a process in which a methyl group is specifically bound to the base 
cytosine in the dinucleotide 5’-CpG-3’. The CpG is a base cytosine linked to a base guanine 
by a phosphate bond in the DNA nucleotide sequence. Usually, in the human genome, most 
CpG dinucleotides are methylated and the unmethylated CpGs are grouped together in a 
cluster known as CpG islands which are in the promoter region of many important genes. In 
cancer cells, the methylation of CpG islands often leads to silencing of gene expression such 
as the tumour suppressor genes (Lim et al., 2010; Christmann et al., 2017). On the other hand, 
histone modifications through histone acetylation and deacetylation opens or closes the 
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conformation of chromatin respectively. However, the normal regulation of chromatin in cancer 
cells is mutated (Vaissiere et al., 2008; Housman et al., 2014; Christmann et al., 2017). For 
example hypermethylation of tumour suppressor genes (Herman, 1999) and hypomethylation 
of oncogenes (Ehrlich, 2009) are often silenced or overexpressed respectively. Therefore the 
mechanisms of epigenetic are usually reversible which makes them ideal drug targets to 
overcome drug resistance. 
 
The DNA damage repair can be influenced by epigenetic mechanisms. The most common 
method which cancer cells used to silence tumour suppressor genes is through DNA 
hypermethylation. However, transcription factors and DNA repair genes can be affected by 
hypermethylation that may indirectly affect downstream targets causing tumorigenesis and 
genetic error (Lattanzio et al., 2015).  For example during the hypermethylation of the human 
mutL homog 1 (hMLH1) gene promoter, the DNA mismatch repair processes is impaired 
causing cancer development (Fleisher et al., 2001). Furthermore, drug resistance due 
epigenetic mechanisms are also found in breast cancer cells. For example, a lack of reduced 
folate carrier (RFC) expression and an essential change in drug uptake promoted 
methotrexate resistance in MDA-MB231 breast cancer cells (Worm et al., 2001). 
 
Additionally, epigenetics are critical in the cancer progression and formation of cancer stem 
cells which often acquire drug resistance. Moreover, epigenetic modifications may play an 
important role in tumour metastasis and tumour formation hence targeting them would be 
effective in counteracting drug resistance (Housman et al., 2014). Finally, it is very important 
in understanding epigenetics modifications that leads to drug resistance so as to identify 
regulators that trigger the modification and thus target theses regulators to improve cancer 
treatments.  
 
1.5.8     Strategies implemented to overcome drug resistance 
 
New synthetic analogues of existing drugs such as vinca alkaloid derivatives have been 
development to try to circumvent drug resistance. In most cases this approach has been 
successful but other toxicity has been a problem (Cree et al., 2017).   
 
Another approach is combining therapies in the aim of targeting two or more independent 
pathways so as to increase the likelihood of hitting two or more targets on the same pathway. 
Thus, increasing the efficacy of therapy while reducing tumours ability to acquire drug 
resistance (Yardley, 2014; Cree et al., 2017; Kydd et al., 2017). 
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Furthermore, another approach suggested is sequential combinations of drugs to reduce 
toxicity and at the same time increase efficacy (Vijayaraghavalu et al., 2013). However, due 
to a lack of molecular understanding of their efficacy, relatively few sequential combinations 
have entered clinical practice. Additionally, the development of DNA and RNA sequencing 
technologies have now facilitated the prediction of sequential combination of drugs effect 
(Cree et al., 2017). 
 
A mechanistic approach to combination and sequence strategies known as synthetic lethality 
is an important new concept in drug development (Shaheen et al., 2011; Weidle et al., 2011). 
Consequently, sufficient knowledge of the molecular makeup of individual cancers is needed 
to ensure the approaches to synthetic lethality is a success. In addition, companion diagnostic 
development strategies and drug development must be coordinated and that careful testing in 
a variety of preclinical setting is needed before moving on to humans (Cree et al., 2017).   
 
Lastly, another approach to circumvent anticancer drug resistance is to use immunotherapy 
which could benefit in the treatment for certain cancers such as lung cancer and melanoma 
(Keller et al., 2017; Cree et al., 2017).  As mentioned earlier, the activation of certain pathways 
as a result of not only genetic and epigenetic events but also due to extracellular signals, can 
cause cancer cells to acquire drug resistance during treatment. Therefore, identifying 
signalling pathways that might promote drug resistance will inspire more systematic approach 
as well as categorising patients into groups depending on their response to the drugs.  Also 
such approach can help design combination strategies to act simultaneously on resistant 
pathways and on multiple cancer cells (Cree et al., 2017). 
 
1.6     ATP-binding cassette (ABC) transporters 
 
1.6.1     Historical background 
 
ATP-binding cassette (ABC) transporters have a diverse physiological functions and are 
considered to be one of the largest of all protein families. ABC transporters are present in all 
species ranging from microorganism to human, having wide variety of physiological roles and 
are important in economy and medicines. In microorganisms, ABC transporters play a key role 
in antifungal and antibiotic resistance and in humans, may get mutated causing a variety of 
genetic diseases including Tangier disease, cystic fibrosis, obstetric cholestasis and are also 
responsible for drug resistance in cancers (Higgins, 1992 and 2001; Coy, 2012). 
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The study of the ABC transporters all started from the studies on nutrient uptake in bacteria 
particularly Escherichia coli and Salmonella typhimurium in the 1970s. Researchers found that 
bacteria use multiple systems for the uptake of most nutrients including the 
phosphotransferase systems which incorporate transporters that depend on electrochemical 
gradient and the shock-sensitive system which incorporate transporters that uses energy from 
ATP hydrolysis. Furthermore, several genes encoding such transporters lead by the maltose 
permease of Escherichia Coli and histidine permease of Salmonella typhimurium were cloned 
in the early 1980s (Higgins, 2001; Theodoulou et al.,  2015). 
 
It was later found in 1986 that bacterial transporters had ATP binding subunits which grouped 
a large superfamily of proteins and their structures were proposed to have four domains. Most 
of these domains belonged to the active transport system with a few maybe able to couple to 
ATPase activity for other biological processes such as DNA repair. In the same period, the 
gene encoding the human multidrug resistance protein, P-glycoprotein/ABCB1 was 
discovered and was the first example of this family of transporters in eukaryotic cells. Although, 
in 1986 saw the discovery of the large family of proteins that has ATP-binding subunits, the 
name ATP binding cassette (ABC) transporters became apparent in 1990. These discoveries, 
highlighted the importance of the ABC transporters as a diverse family of proteins involved in 
a variety of physiological and biochemical processes (Higgins, 2001; Theodoulou et al., 2015). 
A brief overview of the key events in ABC transporter research is shown in figure 1.9. 
  
 
 
 
Figure 1.9. Timeline showing some of the past key events in ABC transporter research 
(Theodoulou et al., 2015). 
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1.6.2     Structure of ABC transporters 
 
Although ABC transporters have a diverse transport mechanism, many of them share similar 
domain architectures. The core structure of ABC transporters are made up of a pair of ATP-
binding domains, also known as nucleotide binding domain (NBD) and two sets of 
transmembrane domains (TMDs). Upon, dimerisation of the two TMDs, the translocation 
pathway is formed and the conformation of the TMDs is controlled by the NBDs through 
hydrolysis-induced separation and ATP-induced dimerisation (Dean et al., 2001; Higgins, 
2001; Procko et al., 2009).  
 
So far, based on TMDs folds, there are seven types of ABC transporters discovered (Figure 
1.10), of which three can only transport substrates from outside to inside of the cells known 
as Type I and Type II importers, and energy coupling factor (ECF) transporters (Type III 
importers) (ter Beek et al., 2014; Rice et al., 2014; Lewinson et al., 2017). These ABC 
importers are only found in prokaryotes. While type IV and V ABC transporters are known as 
the ABC exporters which are found in both prokaryotes and eukaryotes (Locher, 2009; ter 
Beek et al., 2014) and type VI and VII are found in bacterial cells (Crow et al., 2017; Greene 
et al., 2018; Hicks et al., 2018). 
 
 
 
Figure 1.10. Schematic diagram showing the available crystal structures of seven types 
of ABC transporters. The protein data bank identifiers are in bracket below the name of the 
transporters. A single colour code present each protein chain. There are three types of 
importers (Type I, II and III (Energy coupling factor (ECF)) (Example: molybdate transporter 
(ModABC), vitamin B12 transporter (BtuCDF), folate importer (ECF-FolT) respectively). two 
types of exporters (Type IV and V) (Example: multidrug exporter (Sav1866) and sterol 
transporter (ABCG5/G8) repectively) and two types of mechanotransducers (Type VI and VII) 
(Example: lipopolysaccharide extractor (LptBFG) and, enterotoxin and macrolide transporter 
(MacB) respectively) (Greene et al., 2018).   
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In prokaryotes, the two TMDs and the two NBDs of the ABC transporters are often assembled 
as separate protein subunits. Therefore, the two TMDs and NBDs can be identical or different 
proteins (Wilkens, 2015). Furthermore, where the TMDs differ to the NBDs, usually the two 
NBDs are similar in structure and in most cases the two TMDs are also similar in structure 
with the exception of the two TMDs in ECF transporters (Xu et al., 2013; ter Beek et al., 2014). 
In other cases, in particular in prokaryotic transporter have two and occasionally three protein 
domains fused together such as the fusion of the two NBDs and the fusion of the TMDs with 
the NBDs (ter Beek et al., 2014; Wilkens, 2015). See figure 1.11 for a schematic diagram of 
the different core structures of ABC transporters. On the other hand, type IV exporters either 
exist as a dimer of two polypeptides, each of which made up of a TMD and an NBD such as 
in the bacterial exporters (Dawson et al., 2006), or one polypeptide chain comprising all 
domains as in eukaryotic exporters (Locher, 2009 ter Beek et al., 2014) and type V exporters 
are known as ‘half transporters’ comprising of one NBD fused to one TMD to form a single 
polypepide chain consisting of six transmembrane helices (Lee et al., 2016; Taylor et al., 
2017). The third group of ABC transporters are the mechanotransducers, type VI and VII.  
 
Moreover, the Type I and II ABC importers require an additional substrate binding proteins 
(SBPs) are to help facilitate the transport of substrate by capturing the substrate on the trans-
side and distributing it to the TMDs (Figure 1.11). The SBPs can either be found as a separate 
protein subunit or fused with a TMD to form a multidomain subunit (Higgins, 2001; Locher, 
2009). Additionally, apart from the core domains many ABC transporters in prokaryotes and 
eukaryotes have additional subunits or domains such as extra TMDs or regulatory domains 
(Figure1.11) (Theodoulou et al., 2015). 
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Figure 1.11. A schematic diagram of the different core structures of ABC transporters. 
The ABC importers in prokaryotes (Example in Gram-negative bacteria) consist of two TMDs 
linked to two NBDs and a SBP subunit. The ECF transporters comprise of a substrate-specific 
integral membrane protein (S) and a transmembrane protein (T). The ABC exporters in all 
bacteria are homodimeric or heterodimeric, in which a TMD is fused with an NBD. In 
eukaryotes, the ABC transporters are divided into eight distinct subfamilies (A-H) (See section 
1.6.4). Each subfamilies, has some representative of different arrangement of core and 
additional domains. However, subfamilies E, F and H are not present in plants, fungi and 
mammals (Theodoulou et al., 2015).  
 
 
 
1.6.2.1     Nucleotide binding domain (NBD) 
 
As mentioned earlier all ABC transporters have two NBDs which bind and hydrolyse ATP. A 
core of about 200 amino acids make each NBD which also consist of two subdomains, the 
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RecA-like domain and the α-helical domain which is exclusive to ABC transporters. The NBDs 
consist of seven highly conserved motifs (Figure 1.12) (ter Beek et al., 2014; Wilkens, 2015). 
 
 
 
Figure 1.12. A view along an axis perpendicular to the membrane plane from the trans-
side onto the NBDs. The TMDs and SBP are not shown. A colour code show the different 
highly conserved sequence motifs and domains: red, A-loop; magenta, Walker A; orange, 
Walker B; cyan, ABC motif; blue, D-loop; green, H-loop; yellow, Q-loop; faded grey, regulatory 
C-terminal domain; light blue, RecA-like domain; green, α-helical domain. The ATP analogue 
Adenylyl-imidodiphosphate (AMP-PNP) is represented in sticks (ter Beek et al., 2014). 
 
 
 
1.6.2.2     Transmembrane domain (TMD) 
 
The TMDs of ABC transporters comprise a translocation pathway which facilitates the 
movement of substrates across the membrane (ter Beek et al., 2014). 
 
Type I ABC importers consist of two TMDs each made up of five transmembrane (TM) helices. 
The TMDs are either homodimers or similar in structure. Furthermore, in many Type I 
importers there is an additional N-terminal helix thus making the total number of TM helices to 
12 or 8 in some cases. The interface between the two TMDs produces the translocation 
pathway (Locher, 2009; ter Beek et al., 2014; Rice et al., 2014). 
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Type II ABC importers consist of two similar TMDs each made up of 10 tightly packed TM 
helices. In addition the helices in one TMD do not cross over to the other TMD, rather the 
helices line up to each other in a TMD. Furthermore, in each TMD has two group of helices 
pack together to found two subdomains which are position in opposite direction with respect 
to the membrane. Thus the two TMDs form a translocation pathway at the interface (Locher, 
2009; ter Beek et al., 2014; Rice et al., 2014). 
 
ECF-type ABC importers, consist of two TMDs, termed the T-component (EcfT subunit) and 
the S-component. Their function and structure are not similar. The T-component has five TM 
helices and in other transporters may have between four to eight TM helices (Eitinger et al., 
2011) while S-component usually has six TM helices and sometimes an additional N-terminal 
helix (Xu et al., 2013).  The S-component has a high binding affinity for transported substrates 
(Berntsson et al., 2012). However, unlike the other ABC importers, the translocation pathway 
in ECF-type ABC importers rely on the S-component that uses another access mechanism 
(ter Beek et al., 2014).  
 
Type IV ABC exporters consist of two TMDs each comprised of six TM helices. The two TMDs 
can either be similar in structure or identical, often the TMDs are fused with the NBDs and 
there is a crossover of two helices from each TMD to the other TMD.  Moreover, both TMDs 
are embedded deep in the cytoplasm causing the NBDs to be located very far from the 
membrane. Therefore the translocation pathway is more likely to be located at the interface of 
the dimerisation of the TMDs (Higgins, 2001; Procko et al., 2009; ter Beek et al., 2014). 
 
As mentioned above, type V ABC exporters are ‘half transporters’ in that they consist of only 
one TMD and one NBD. Example of a protein belonging to this group is ABCG2. The TMD is 
made up of six TM helices. Similar to other nucleotide-free ABC exporters and importers, type 
V ABC exporters have also adopted an inward conformation. Since they are ‘half transporters’ 
their functional form is a homodimer where by the TM helices from one subunit do not cross 
over to the TMD of the other ‘half transporter’. Moreover, the regions between TM helix 5 and 
TM helix 6 form distinct α-helical structures in the extracellular domain (ECD) (Lee et al., 2016; 
Taylor et al., 2017).  
 
Type VI ABC transporters are lipopolysaccharide (LPS) exporters (Hicks et al., 2018). An LPS 
exporter is an oligomeric complex consisting of Lpt protein B, F, G and C subunits which are 
all bound to the inner membrane (IM) and Lpt D/E heterodimer which is bound in the out 
membrane (OM). The subunits in the IM are connected to the subunit in the OM by periplasmic 
LptA subunit thus form a teramer (Botos et al., 2016; Hicks et al., 2018). 
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Type VII ABC transporters such MacB is a macrolide antibiotic-specific transporter in E. Coli. 
MacB consist of four TM helices, an N-terminal NBD and a large periplasmic domain linking 
TM helix 1 to TM helix 2 (Xu et al., 2009; Crow et al., 2017). MacB is a homodimeric protein 
binds MacA adaptor protein and ToIc exit duct to form a tripartite efflux pump to efflux 
antibiotics and heat-stable enterotoxin II (STII) out of the bacterial cell (Xu et al., 2009; Crow 
et al., 2017; Fitzpatrick et al., 2017; Greene et al., 2018) 
 
1.6.3     Mechanism of ABC transporters 
 
The mechanism by which ABC transporters are able to transport substrate across membrane 
is very complicated due partly to structural diversity in ABC transporters. Furthermore, the 
transport mechanism is different between the different types of ABC transporters (Locher, 
2009; Procko et al., 2009). Also to note, that between members of the ABC transporters that 
have similar structures may adopt a different transport mechanism (ter Beek et al., 2014). 
However, as more studies have been done on both prokaryotic and mammalian systems, 
scientists have begun to predict the mechanism of ABC transporters. 
 
Generally, a conformational change in NBDs and TMDs by ATP binding and hydrolysis 
facilitates the movement of substrate across the membrane. Furthermore, there are two 
ATPase active sites at the interface but is still unclear whether one or two ATP molecules are 
required to hydrolyse one substrate at a time. Moreover, whether the binding of ATP molecules 
to the NBDs is sequential or simultaneous is still a debate (Higgins, 2001; Procko et al., 2009). 
 
More recently, scientists has proposed a model for the transport mechanism of ABC 
transporters known as the ATP switch model which, explained that substrate movement 
depends on the low and high affinity states of substrate binding coupled with ATP catalytic 
cycle. In summary, the ATP-switch model proposed four steps to explain the transport 
mechanism of ABC transporter as first substrate binding, followed by ATP binding and 
substrate translocation and finally ATP hydrolysis to return the protein domains to substrate 
binding conformation (Mamo et al., 2017). 
 
1.6.3.1     Type I ABC importers 
 
Without the nucleotides, the two NBDs are apart and the two TMDs are open from the 
cytoplasmic side of the membrane. The binding of the substrate to SBP trigger a 
conformational changes in the NBDs and in the TMDs which allows the NBDs to come close 
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together to facilitate the binding of ATP (pre-translocation state). In the catalytic intermediate 
state, the two TMDs come close together on the cytoplasmic side of the membrane to form an 
outward facing cavity. At the same time the SBP is still attached and prevent other substrate 
from passing through the cavity and the periplasm. After the release of the substrate into the 
cavity, the SBP is in an open conformational state. The substrate binds to a specific site on 
the TMD. To complete the transport cycle, ATP hydrolysis release a phosphate (Pi) and ADP 
which causes the TMDs to return into the inward conformation with the cavity facing the 
cytoplasm, thus release the substrate in to the cytoplasm (Figure 1.13) (Locher, 2009; ter Beek 
et al., 2014; Rice et al., 2014). 
 
 
 
Figure 1.13. Schematic presentation of the transport mechanism of Type I ABC 
importers. Substrate binds to the SBP and move to the transporter. Hence causing the NBDs 
to move closer to each other to allow ATP binding and eventually NBDs closure. As a results, 
the TMDs are force to form an outward facing conformation that lead to SBP opening. Once 
the SBP opens, substrate is release in to the cavity and bind on to the TMD. Finally, ATP 
hydrolysis cause the TMDs to form an inward facing conformation which release the substrate 
in to the cytoplasm (ter Beek et al., 2014). 
 
 
 
1.6.3.2     Type II ABC importers 
 
Depending on the presence of the substrate and nucleotides, different conformations are 
adopted by the NBDs, TMDs and periplasmic SBP. When the SBP and the nucleotide are not 
present, the transporter adopts an outward facing conformation in which the TMDs are open 
toward the periplasmic side of the membrane thus creating an outward facing cavity.  
Furthermore, a transporter complex is formed when ATP together with SBP bind to the 
transporter to give a translocation pathway where by both ends are sealed by the TMDs. The 
substrate binds non-specifically to the cavity (Locher, 2009; ter Beek et al., 2014; Rice et al., 
2014). 
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To release the substrate to the cytoplasm, the binding of ATP causes ATP hydrolysis to 
convert to Pi and ADP, which causes the NBD dimer to open up and the TMDs to adopt an 
inward facing conformational changes via the coupling helices with the cavity facing the 
cytoplasm. Once the substrate is force out of the cavity in to the cytoplasm, the translocation 
pathway is distorted as the complex changes into an asymmetric state. In addition, the tight 
binding of SBP requires ATP binding to release the SBP (Figure 1.14) (Locher, 2009; ter Beek 
et al., 2014; Rice et al., 2014). 
 
 
 
 
Figure 1.14. Schematic representation of the transport mechanism of Type II ABC 
importer. The substrate binds to the SBP which binds to the transporter in an outward 
conformation. The binding of ATP causes a conformational change in the TMDs forming a 
cavity which the substrate binds non-specifically. ATP hydrolysis further causes the TMDs to 
form an inward conformation and the substrate is release in to the cytoplasm. The transporter 
then adopt an asymmetrical state which may be required to prevent leakage of small 
molecules (ter Beek et al., 2014).  
 
 
 
1.6.3.3     ECF-type ABC importers  
             
Due to research in ECF-type ABC importer still being at a relatively early stage, the toppling 
of the S-component and the coupling mechanism between nucleotide binding, hydrolysis and 
release in the NBDs are still not clear. However, the knowledge acquired from the crystal 
structure, has shown that the T-component has two long X-shaped α-helices which interacts 
with NBDs at one side and the S-component at the other side. The orientation of the S-
component may be affected by the scissor-like movement of the helices and during the 
catalytic cycle. After release of substrate in the cytoplasm, the S-component spontaneously 
assume a conformational change where by the substrate binding site is facing outward in the 
periplasm (Figure 1.15) (ter Beek et al., 2014; Rice et al., 2014).  
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Figure 1.15. Schematic representation of the transport mechanism of ECF-type ABC 
importers. Not much is known about the transport mechanism of ECF-type ABC importers as 
the crystal structures obtained so far are limited. However, it is assumed that the S-component 
(orange) with the substrate binding site at one end topple over and rotate into the membrane 
to transport the substrate from the periplasm and release the substrate into the cytoplasm (ter 
Beek et al., 2014). 
 
 
 
1.6.3.4     Type VI ABC transporters 
 
In the inner membrane, the subcomplex of LptF, LptG and dimeric LptB are responsible to 
transport LPS from the inner membrane to the outer membrane along the periplasmic bridge. 
The TptB dimer hydrolyse ATP to form a complex with and change the transmembrane LptF/G 
dimer conformation. Unlike other ABC transporters, the substrate is extracted directly from 
one conformation of the LptBFG complex (Figure 1.16) (Botos et al., 2016; Hicks et al., 2018). 
 
 
 
 
Figure 1.16. The mechanism of LPS transporter complex. In the resting state, the LptB 
nucleotide-binding sites are unoccupied, and the LptF/G subunits have an inward 
conformation. Upon binding of ATP to LptB, a conformational change in LptF/G dimer is 
induced forming an outward facing cavity to receive the LPS substrate that is still attached in 
the inner membrane. Once the substrate is inside the cavity, the hydrolysis of ATP by LptB 
causes the LptF/G cavity to close again. As a result the substrate is forced out of the inner 
membrane into the periplasm (Hicks et al., 2018).  
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1.6.3.5     Type VII ABC transporters 
 
The inner membrane ABC transporter, MacB, operates in assembly with the periplasmic 
adaptor protein MacA and TolC exit duct, to form the MacAB-ToIC ABC-type tripartite 
multidrug efflux pump (Crow et al., 2017; Fitzpatrick et al., 2017). 
 
According to the mechanotransmission mechanism, an opening in MacB located between 
periplasmic domains and stalk may have caused substrates to enter the interior cavity (Figure 
1.17A). Once the substrate is in the interior cavity, ATP binding causes the MacB periplasmic 
domain to close, forcing the substrate under pressure to move through the MacA gate ring 
which acts as a one-way valve (Fitzpatrick et al., 2017). When the substrate has been expelled 
out into the extracellular space, the pressure on either side of the gate equalised thus causing 
the gate ring to return to its closed resting state, which prevent substrates from moving back. 
The system is reset due to ATP hydrolysis to drive more substrates from the periplasm to the 
extracellular space (Crow et al., 2017; Greene et al., 2018) (Figure 1.17B). 
 
 
 
 
Figure 1.17. Mechanotransmission mechanism for the MacAB-ToIC tripartite efflux 
pump. (A) Crystal structures of nucleotide-free MacB (Left) and ATP-bound MacB (Right). 
Blue, TM helices; red, NBD; purple, periplasmic domain. (B) A schematic diagram showing 
the proposed mechanism of MacAB-ToIC efflux pump. Once the substrate enters the interior 
cavity, ATP binding causes the MacB to close. The substrate is then forced out through MacA 
gate ring into the extracellular space under pressure. Once the substrate has expelled out, the 
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gate ring return to its closed resting state. ATP hydrolysis reset the system to drive more 
substrates out of the periplasm (Crow et al., 2017). 
 
 
 
1.6.3.6     ABC exporters 
 
In ABC exporters, the NBDs are connected to the TMDs in a single protein. ABCG2, 1, 4, 5 
and 8 and ABCB2, 3, 5 and 10 all are homo/hetero dimers. However, with limited crystal 
structures of ABC exporters and only two different states which have been identified, outward 
facing and inward facing conformational states. The coupling mechanism between substrate 
binding, TMDs conformational changes and the ATP binding and hydrolysis are still not clear 
(ter Beek et al., 2014). 
 
Generally, in the presence of no nucleotide, the NBDs are apart causing the TMDs to adopt 
an inward facing conformation, forming an inward facing cavity where the substrate is likely to 
bind to. The cavity is relatively large with multiple binding sites of irregular polarity which 
provide a very wide and efficient substrate recognition (Sarkadi et al., 2006).  Furthermore, 
when ATP binds to the NBDs, the TMDs undergo a conformational change and adopt an 
outward facing conformational change where the substrate is expelled outside the cell. Once 
the substrate is released the ATP hydrolysis releases Pi and ADP causing the TMDs to return 
back to the inward facing conformation ready to accept another substrate to be transported 
across the membrane (Figure 1.19) (Higgins, 2001; Procko et al., 2009). 
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Figure 1.18. Schematic representation of the transport mechanism of ABC exporter. The 
NBDs have an inward open conformation. Substrate enter in the cavity formed by the TMDs 
binds to the TMDs. The binding of ATP molecules to the NBDs causes the TMDs to adopt an 
outward facing conformation where by the substrate is move out of the cavity into the 
extracellular space. ATP hydrolysis release Pi and ADP which causes the TMDs to move back 
to the original resting conformation which is an inward facing conformation (Procko et al., 
2009).  
 
 
 
1.6.4     Human ABC transporters 
 
There are at present 49 human ABC genes identified and these are divided into seven 
subfamilies from ABCA to ABCG (Table 1.6) (Vasiliou et al., 2009) based on structural 
organisation of domain, similarity in gene structure and sequence homology in the NBDs and 
TMDs (Lorkowski et al., 2002; Mamo et al., 2017).  A list of human ABC proteins, their 
chromosomal location and function is shown in Table 1.8. (Vasiliou et al., 2009). In addition, 
certain genes of the ABC transporters are mutated causing a variety of genetic diseases. 
Mutations in these genes are linked to nineteen known genetic diseases and the most 
common ones include Stargardt’s macular dystrophy, progressive familial intrahepatic 
cholestasis, cystic fibrosis and adrenoleukodystrophy (Table 1.7) and currently at least 15 
ABC transporters are responsible for multidrug resistance in cancers, particularly multidrug 
resistance protein 1 (MRP1), P-glycoprotein (P-gp, ABCB1) and breast cancer resistance 
protein (BCRP, ABCG2) (Higgins, 2001; Gillet et al., 2011; Coy, 2012; Jaramillo et al., 2018). 
 
69 
 
Table 1.6. Human ABC transporter subfamilies (Adapted from Vasiliou et al., 2009). 
Subfamily name Aliases Number of genes Number of 
pseudogenes 
ABCA ABC1 12 5 
ABCB MDR 11 4 
ABCC MRP 13 2 
ABCD ALD 4 4 
ABCE OABP 1 2 
ABCF GCN20 3 2 
ABCG White 5 2 
Total  49 21 
ABC1, ATP-binding cassette 1; MDR, multi-drug resistance; ALD, adrenoleukodystrophy; 
OABP, organic anion-binding protein. 
 
 
 
Table 1.7. ABC transporters with known genetic disorders and their substrates (Adapted 
from Coy, 2012). 
Name 
 
Tissue 
Location 
Substrate Disease 
ABCA1 
 
Ubiquitous Phospholipid, 
Cholesterol 
Tangier disease 
ABCA4 Retina N-retinylidene 
phosphatidyl- 
ethanolamine 
Stargardt disease, retinitis 
pigmentosa, macular 
degeneration 
ABCB4/ 
MDR3 
Liver 
hepatocytes 
Phosphatidylcholine Progressive Familial 
Intrahepatic Cholestasis 
(PFIC)-3 
ABCB11/ 
BSEP 
Liver 
hepatocytes 
Bile salts PFIC-2 
ABCC2/ 
MRP2 
Liver, intestine, 
kidney 
Bilirubin glucuronides, 
GSH and GSSG, 
glucuronide, GSH, and 
sulphate conjugates 
Dubin-Johnson syndrome 
ABCC6/ 
MRP6 
Kidney, liver small peptides Pesudo-xanthoma elasticum 
 
ABCC7/ 
CTFR 
Lung, 
intestine, 
cholangiocyte, 
sweat glands 
Chloride channel Cystic Fibrosis 
ABCD1 Many Long-chain fatty acids Adrenoleukodystrophy 
ABCG5/ 
ABCG8 
Liver, intestine Cholesterol, plant 
sterols 
Sitosterolemia 
 
 
 
1.6.4.1     Subfamily A of the ABC family (ABCA) 
 
So far there are 12 members of ABCA subfamily of transporters, most of which are involved 
in lipid trafficking in many diverse organs and cell types. Some of the ABCA transporters are 
considered to be among the largest ABC transporters with more than 2100 amino acids in 
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length. Mutations in some of these genes have led to severe genetic disorders such as Tangier 
disease T1 and harlequin ichthyosis. Furthermore, ABCA transporters could be responsible 
for the resistance of several cancers against anticancer drugs (Dean et al., 2001; Albrecht et 
al., 2007; Vasiliou et al., 2009). 
 
1.6.4.2     Subfamily B of the ABC family (ABCB) 
 
There are 11 members of ABCB subfamily of transporters, four of which are full transporters 
in that they have two TMDs and two NBDs within a single polypeptide chain, and seven half 
transporters in that they have only one TMD and one NBD in a single chain, but then form 
dimers. ABCB family transporters are the only ABC subfamily transporters that have both full 
and half transporters. Many ABCB transporters are involved in multidrug resistance in cancer 
cells. ABCB genes can be mutated causing diseases such as lethal neonatal syndrome, 
coeliac disease and ankylosing spondylitis (Dean et al., 2001; Stefkova et al., 2003; Vasiliou 
et al., 2009).  
 
1.6.4.3     Subfamily D of the ABC family (ABCD) 
 
To date, there are four ABCD subfamily transporters often known as the 
Adrenoleukodystrophy (ALD) or peroxisomal transporters. The ABCD transporters are half 
transporters which can either form homodimers or heterodimers to be functional (Stefkova et 
al., 2003; Vasiliou, et al., 2009). Furthermore, ABCD transporters are involved in the transport 
of long and very long chain fatty acids (VLCFA) or their CoA-derivatives into peroxisome and 
bile acid intermediates di- and tri-hydroxycholestanoyl-CoA (DHCA and THCA) and branched 
chain acyl-CoA (Morita et al., 2012; Kawaguchi et al., 2016 ). Moreover, mutation in certain 
ABCD transporters are implicated in disease such as hepatosplenomegaly and X-linked 
adrenoleukodystrophy (X-ALD) (Table 1.7) (Dean et al., 2001; Stefkova et al., 2003; Vasiliou, 
et al., 2009; Morita et al., 2012; Kawaguchi et al., 2016).  
 
1.7.4.4     Subfamily E of the ABC family (ABCE) 
 
There is only one member of the ABCE subfamily of proteins known as the ABCE1 (OABP). 
The structure of archaeal ABCE1 is made up of two ATP-binding domains linked together by 
a hinge region to facilitate orientation, a pivotal point of the ATP-binding domains and an iron-
sulphur binding domain consisting of eight cysteine residues that mediate two diamagnetic 
[4Fe-4S]2+ clusters present at the N-terminal region of ABCE proteins but no transmembrane 
domain (Navarro-Quiles et al., 2018). Hence, ABCE1 is unlikely to function as a transporter. it 
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Furthermore, research found that the inhibition of protein synthesis by the activation of 
ribonuclease L in a critical pathway involving viral interferon action is often interfered by 
ABCE1 which, resist the activity of ribonuclease L hence, ABCE1 helps to promote interferon 
activity. Currently no disease has been associated with ABCE1 transporter (Dean et al., 2001; 
Stefkova et al., 2003; Vasiliou et al., 2009). 
 
1.6.4.5     Subfamily F of the ABC family (ABCF) 
 
ABCF subfamily is similar to ABCE subfamily, all have a pair of ATP-binding domains which 
are not fused to transmembrane domains. Hence, similar to ABCE, ABCF subfamiy are also 
unlikely to be transporters (Kerr, 2004). ABCF subfamily consist of eukaryotic Elongation 
factor 3 (eEF3) protein which is important in Saccharomyces cerevisiae for polypeptide 
elongation (Skogerson et al., 1976; Murina et al., 2018), ribosome-associated protein GCN20 
is associated with uncharged tRNAs on eukaryotic ribosome for sensing starvation (Vazquez 
de Aldana et al., 1995; Murina et al., 2018), ABC50 promotes translation initiation in eukaryotic 
cells (Paytubi et al., 2009) and both New1 and Arb1 have been proposed to be implicated in 
the stimulation of ribosomal biogenesis in eukaryotic cells (Dong et al., 2005; Murina et al., 
2018). Research found that tumour necrosis factor-α (TNF-α) cause the upregulation of ABCF 
genes and thus ABCF transporters may play a role in inflammatory processes. In addition, 
similar to ABCE1 transporter, no disease have been associated with ABCF transporters (Dean 
et al., 2001; Stefkova et al., 2003; Vasiliou et al., 2009). 
 
1.6.4.6     Subfamily G of the ABC family (ABCG) 
 
ABCG subfamily of transporters consist of five members, all of which are reverse half 
transporters in that they have an NBD at the N-terminus and a TMD at the C-terminus (the 
second half of a heterodimer) (Vasiliou et al., 2009).  ABCG1 efflux cholesterol in 
macrophages and its presence in other cells may help to mediate cellular lipid homeostasis 
(Lorkowski et al., 2002). ABCG2 functions as a multidrug resistance transporter (Woodward 
et al., 2011). The highly expressed ABCG3 in the spleen and thymus, may be involved in the 
transport of specific hydrophobic compounds or peptides from lymphocytes (Lorkowski et al., 
2002; Vasiliou et al., 2009). ABCG5 and ABCG8 have shown to encourage biliary excretion 
and reduce intestinal absorption of sterols. Moreover, mutations in either ABCG5 or ABCG8 
can cause sitosterolaemia (Table 1.7) (Dean et al., 2001; Lorkowski et al., 2002; Stefkova et 
al., 2003; Vasiliou et al., 2009; Woodward et al., 2011). 
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Table 1.8. A list of ABC human transporters, their chromosomal location and function 
(Adapted from Dean et al., 2001). 
Symbol Alias Chromosomal 
location 
Expression Function 
ABCA1 
ABCA2 
ABCA3 
ABCA4 
ABCA5 
ABCA6 
ABCA7 
ABCA8 
ABCA9 
ABCA10 
ABCA12 
ABCA13 
 
ABC1 
ABC2 
ABC3, ABCC 
ABCR 
 
 
 
 
 
 
 
 
9q31.1 
9q34 
16p13.3 
1p22.1-p21 
17q24 
17q24 
19p13.3 
17q24 
17q24 
17q24 
2q34 
7p-11-q11 
Ubiquitous 
Brain 
Lung 
Rod 
photoreceptors 
Muscle, heart, 
testes 
Liver 
Spleen, thymus 
Ovary 
Heart 
Muscle, heart 
Stomach 
Low in all 
tissues 
Cholesterol efflux onto 
HDL 
Drug resistance 
 
N-retinylidiene-PE 
efflux 
 
 
 
 
 
 
 
 
ABCB1 
ABCB2 
ABCB3 
ABCB4 
ABCB5 
ABCB6 
ABCB7 
ABCB8 
ABCB9 
ABCB10 
ABCB11 
PGY1, MDR 
TAP1 
TAP2 
TGY3 
 
MTABC3 
ABC7 
MABC1 
 
MTABC2 
SPGP 
7p21 
6p21 
6p21 
7p21.1 
7p14 
2q36 
Xq12-q13 
7q36 
12q24 
1q42 
2q24 
 
Adrenal, kidney, 
brain 
All cells 
All cells 
Liver 
Ubiquitous 
Mitochondria 
Mitochondria 
Mitochondria 
Heart, brain 
Mitochondria 
Liver 
Multidrug resistance 
Peptide transport 
Peptide transport 
PC transport 
 
Iron transport 
Fe / S cluster transport 
 
 
 
Bile salt transport 
ABCC1 
ABCC2 
ABCC3 
ABCC4 
ABCC5 
ABCC6 
CFTR 
ABCC8 
ABCC9 
ABCC10 
ABCC11 
ABCC12 
MRP1 
MRP2 
MRP3 
MRP4 
MRP5 
MRP6 
ABCC7 
SUR 
SUR2 
MRP7 
MRP8 
MRP9 
 
16p13.1 
10q24 
17q21.3 
13q32 
3q27 
16q13.1 
7q31.2 
11p15.1 
12p12.1 
6p21 
16q11-q12 
16q11-q12 
Lung, testes, 
PBMC 
Liver 
Lung, intestine, 
liver 
Prostate 
Ubiquitous 
Kidney, liver 
Exocrine tissues 
Pancreas 
Heart, muscle 
Low in all 
tissues 
Low in all 
tissues 
Low in all 
tissues 
Drug resistance  
Organic anion efflux 
Drug resistance 
Nucleoside transport 
Nucleoside transport 
 
Chloride ion channel 
Sulphonylurea 
receptor 
 
 
 
 
ABCD1 
ABCD2 
ABCD3 
ABCD4 
 
ALD 
ALDL1, ALDR 
PXMP1, 
PMP70 
PMP69, P70R 
Xq28 
12q11-q12 
1p22-p21 
14q24.3 
Peroxisomes 
Peroxisomes 
Peroxisomes 
Peroxisomes 
VLCFA transport 
regulation 
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ABCE1 
 
OABP, RNS4I 4q31 Ovary, testes, 
spleen 
Oligoadenylate binding 
protein 
ABCF1 
ABCF2 
ABCF3 
 
ABC50 
 
 
6p21.33 
7q36 
3q25 
Ubiquitous 
Ubiquitous 
Ubiquitous 
 
 
 
ABCG1 
ABCG2 
ABCG4 
ABCG5 
ABCG8 
 
ABC8, White 
ABCP, MXR, 
BCRP 
White2 
White3 
21q22.3 
4q22 
11q23 
2p21 
2p21 
Ubiquitous 
Placenta, 
intestine 
Liver 
Liver, intestine 
Liver, intestine 
Cholesterol transport? 
Toxin efflux, drug 
resistance 
 
Sterol transport 
Sterol transport 
PBMC, peripheral blood mononuclear cells; VLCFA, very long chain fatty acids. Since the 
project focus on the ABCC subfamily of transporters, all the members of ABCC transporters 
are highlighted in yellow. 
 
 
 
1.6.4.7     Subfamily C of the ABC family (ABCC) 
 
The ABCC subfamily of ABC transporters is one of the largest subfamilies of ABC transporters 
comprising thirteen ABCC subfamily members and nine of these transporters are sometimes 
called the multidrug resistance proteins (MRPs) 1-9 because they have been found to efflux 
chemotherapeutic compounds or their metabolites from cancer cells, at least in vitro, and as 
a result may play a role in mediating tumour cells multidrug resistance (Table 1.9) (Chen et 
al., 2011; Sodani et al., 2012). The remaining members of ABCC subfamily include cystic 
fibrosis transmembrane regulator gene (CFTR / ABCC7) which is a regulated chloride ion 
channel (Sheppard et al., 1999), two cell surface receptors [sulfonylurea 1 and sulfonylurea 2 
(SUR1 / ABCC8 and SUR2 / ABCC9)] which are the ATP-sensing subunits of a potassium ion 
channel complex that regulates the potassium ion permeability (Bienengraeber et al., 2004) 
and are not known to transport any substrates and one truncated protein (pseudogene) that 
does not transport substrates (ABCC13) (Sodani et al., 2012) . The nine MRPs range from 
1325 to 1545 amino acids (Liu et al., 2010) and are further divided into two groups according 
to their structural features. MRP4, MRP5, MRP8 and MRP9 (ABCC4, ABCC5, ABCC8 and 
ABCC9) have a typical type IV ABC efflux transporter structure comprising of two TMDs (TMD1 
and TMD2) each containing six transmembrane α-helices linked to two NBDs (NBD1 and 
NBD2) and are called the short MRPs (Table 1.9 and Figure 1.19). Conversely MRP1, MRP2, 
MRP3, MRP6 and MRP7 (ABCC1, ABCC2, ABCC3, ABCC6 and ABCC7), have an additional 
TMD (TMD0) which contains only five transmembrane α-helices that is attached to the N-
terminal of a typical ABC transporter via a cytoplasmic linker (Lo), thus are known as the long 
MRPs (Table 1.9 and Figure 1.19) (Dallas et al., 2006; Slot et al, et a., 2011; Sodani et al., 
2012; Zhang et al., 2015). In addition, the membrane localisation whether apical or basolateral 
and the tissue distribution of the MRPs are important as they help to distinguish the 
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physiological and pharmacological functions of each MRPs (Figure 1.20) (Chen et al., 2010).   
Furthermore, the elimination of drugs and their metabolites in normal tissues are also 
modulated by some MRPs. Therefore, MRPs can facilitate the transport of a wide variety of 
molecules across membranes (Table 1.9) and play an important role in many physiological 
and pathological functions (Tian et al., 2005; Liu et al., 2010; Chen et al., 2011). Some MRPs 
share substrate specificity by transporting similar substrates. However, the way in which one 
MRP transports a common substrate is significantly different to how another MRP transport 
the same substrate. In addition, one or more of the MRPs also play an important role in cellular 
efflux of physiologically important organic anions such as cAMP and leukotriene C4 (Chen et 
al., 2011; Slot et al., 2011).  
 
Finally, as with other ABC transporters, mutation of several MRPs is linked to human genetic 
diseases such as mutations in ABCC2 / MRP2 can cause Dubin–Johnson syndrome, a 
conjugated hyperbilirubinemia (Lee et al., 2006) and mutations in ABCC6 / MRP6 causes 
Pseudoxanthoma elasticum, a connective tissue disorder (Hu et al., 2003). 
 
 
 
 
 
Figure 1.19. Predicted structures of MRPs. (A) Long MRPs consist of the core structure of 
a typical ABC transport that is two TMDs, each of which contains six transmembrane α-helices 
and two NBDs. On top of the core structure, long MRP have an additional transmembrane 
domain (TMD0) comprise of five transmembrane α-helices, which is attached to the N-terminal 
via a cytoplasmic linker (Lo) (MRP1, MRP2, MRP3 MRP6 and MRP7) and (B) Short MRPs 
consist of only the core structure of a typical ABC transporters (MRP4, MRP5, MRP8 and 
MRP9) (Dallas et al., 2006).   
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Figure 1.20. A schematic diagram showing the cellular localisation of the MRPs. 
Epithelial and endothelial cells can be polarised, forming distinct apical and basolateral 
membranes of different biochemical properties. MRPs are located either on the apical or the 
basolateral membrane of polarised cells depending on the tissues where it is found. MRP1, 3, 
6, 5 and 4 are located on the basolateral membrane whereas MRP 2, 8 and depending on the 
tissue, MRP4 also can be found on the apical membranes of polarised cells. The membrane 
localisation of MRP7 and MRP9 remain to be elucidated (Chen et al., 2011). 
 
 
 
1.7     Substrates and functions of the human ABCCs / MRPs 
 
1.7.1     The Long ABCCs / MRPs 
 
1.7.1.1     ABCC1 / MRP1 
 
ABCC1 was the first ABCC proteins to be cloned in 1992 from a doxorubicin-selected 
multidrug resistant human lung carcinoma cell line H69AR (Tian et al., 2005; Cole, 2014; 
Zhang et al., 2015). In these lung cancer cells, the ABCC1 mRNA is a 1531 amino acids 
protein with a molecular weight of 170 kDa. However, due to phosphorylation and N-
glycosylation, the ABCC1 in mammalian cells exhibit a molecular weight of 190kDa. Therefore, 
the ABCC1 protein band in gels is often quite diffuse as it depends on the cell type in which it 
is expressed in (Slot et al., 2011). In normal cells, ABCC1 plays an important role in the 
disposition of drug and xenobiotics and also helps to protect certain tissues from harmful 
cytotoxic chemicals. Therefore, ABCC1 is widely expressed in various tissues including 
skeletal, testis, cardiac muscles, macrophages, lung, kidney and placenta and is found on the 
basolateral membrane of polarised cells (Figure 1.20). In addition, ABCC1 is also found in 
certain blood-organ interfaces such as the blood brain barrier and the blood-testis barrier 
which helps to reduce the penetration of cytotoxic agents (Chen et al., 2011; Sodani et al., 
2012). ABCC1 is localised on the basolateral membrane of polarised cells except in the 
placenta and blood brain barrier (Jaramillo et al., 2018). 
 
ABCC1 can transport glutathione (GSH), oxidised glutathione (GSSG) and a number of 
glucoronate, GSH and sulphate conjugated drugs (Hammond et al., 2007) (Table 1.9). In 
addition, ABCC1 also transports a wide variety of physiological substrates ranging from 
organic anions conjugates to glucuronates to sulphates such as the GSH-conjugated cysteinyl 
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leukotriene C4 (LTC4), unconjugated bilirubin, 17-β-D-estradiol-glucoronide (E217βG), 
prostaglandin (PG) A GSH conjugates and sulphate bile acids (Leier et al., 1994; Loe et al., 
1996; Jedlitschky et al., 1996; Cole, 2014) (Table 1.9). Moreover, ABCC1 has a high affinity 
for LTC4 which confers the specific role of ABCC1 in immune responses linked with cellular 
excretion of LTC4 (Liu et al., 2010; Cole, 2014). A point to note is that although the amino acid 
sequence of the human ABCC1 is more than 90% similar to all other species, there is a marked 
differences between the substrate specificity. For example, ABCC1 in human confers 
resistance to anthracycline drugs but not in other species (Chen et al., 2011).  
 
GSH is a cellular tripeptide antioxidant that has a critical role in protecting cells from harmful 
effect of oxidative stress. In a number of cases xenobiotic metabolism is conjugated with GSH 
to form GS-X conjugates before exported by ABCC1 (Chen et al., 2011). Therefore, with 
compiling evidences that GSH is a substrate of ABCC1 has confirmed that ABCC1 plays a 
crucial modulatory role in redox homeostasis and cellular oxidative stress (Krause et al., 
2007). A range of xenobiotics and some stimulatory compounds that are not ABCC1 
substrates can stimulate the transport of GSH in ABCC1 (Chen et al., 2011; Slot et al., 2011; 
Cole 2014).  The transport of GSH by ABCC1 can be enhanced by vinca alkaloid vincristine 
and at the same time GSH can stimulates vincristine transport (Loe et al., 1996; Mao et al., 
2000). As a result GSH appear to be co-transported with the drug (Chen et al., 2011; Slot et 
al., 2011).  Finally, ABCC1 has many substrates which are conjugated organic anions and in 
some cases these conjugated organic anions are being transported due to GSH or is 
enhanced by GSH (Cole, 2014). For example, GSH stimulates the transport of estrone 
sulphate (Leslie et al., 2003) and the conjugates 4-(methylnitrosoamino)-1-(3-pyridyl)-1-
butanol-O-glucuronide (Leslie et al., 2001). Furthermore, nonreducing tripeptides, in which the 
cysteine residue is modified with a short chain alkyl moiety (example S-methyl GSH) or has 
been replaced with another amino acids such as leucine can also stimulate drug transport by 
ABCC1 (Loe et al., 1996; Leslie et al., 2003; Chen et al., 2011).  
 
In tumour cells, ABCC1 can confer resistance to many antineoplastic drugs such as 
doxorubicin, daunorubicin etoposide, vincristine, saquinavir, mitoxantrone, vinca alkaloids and 
methotrexate (MTX) (Table 1.9) (Chen et al; 2011; Sodani et al., 2012; Zhang et al 2015). 
ABCC1 can also transport certain tyrosine kinase inhibitors that modulate a number of signal 
transduction pathways (Hegedus et al., 2002). High expression of ABCC1 has been found in 
numerous cancer types such as in non-small cell lung cancer (Fang et al., 2018), leukaemia 
(van der Kolk et al 2000; Beck et al., 2001), oesophageal carcinomas (Nooter et al., 1998), 
prostate cancer (Sullivan et al., 2000) and breast cancer (Filipits et al., 2005), and high 
expression of ABCC1 was related to shorter overall survival and relapse-free survival in breast 
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cancer (Filipits et al., 2005). Additionally, negative correlation between clinical outcome and 
the ABCC1 expression in cancers has been found (Roundhill et al., 2015; Jaramillo et al., 
2018).  
 
1.7.1.2     ABCC2 / MRP2 
 
ABCC2 was first cloned from rat hepatocytes in 1996 using strategies that took advantages of 
its structural similarity to human ABCC1 and was originally named hepatocellular canalicular 
multiple organic anion transporter (cMOAT) (Slot et al., 2011; Zhang et al 2015). The amino 
acids of ABCC2 have 49% similarity with ABCC1 but its expression pattern is different (Tian 
et al., 2005; Chen et al., 2011; Sodani et al., 2012). ABCC2 is expressed in the apical 
membrane of polarised cells from a variety of tissues mainly in hepatocyte, small intestine and 
renal proximal tubules (Fanayte et al., 2004. Nies et al., 2007). In addition, ABCC2 mRNA is 
also present in the gallbladder, peripheral nerves, placental trophoblasts and CD4+ 
lymphocytes (Chen et al., 2011; Sodani et al., 2012; Zhang et al., 2015). 
 
ABCC2 can transport a wide variety of substrates and has very similar substrate specificities 
to ABCC1. Thus, in the presence of GSH, ABCC2 can also mediate transport of some 
hydrophobic compounds but has a lower affinity to GSH conjugates than that of ABCC1 (Tian 
et al., 2005; Chen et al., 2011). For example, LTC4 and N-ethylmaleimide glutathione has a 
significantly lower affinity for ABCC2 than that of ABCC1 (Bakos et al., 2000) but the affinity 
to ABCC2 for both bilirubin mono glucuronide and bilirubin bis glucuronide is higher for ABCC2 
(Konno et al., 2003; Tian et al., 2005). Moreover, ABCC2 has the ability to confer resistance 
to cisplatin most likely in the presence of GSH which ABCC1 cannot (Borst et al., 2000; Sodani 
et al., 2012).  
 
ABCC2 can transport a wide range of conjugated endogenous metabolites such a GSH, LTC4, 
GSSG, bilirubin conjugates, leukotriene E4 (LTE4), leukotriene D4 (LTD4), and the glucuronide 
conjugates of triiodo-L-thyronine and estrodiol (Table 1.9) (Bakos et al., 2000; Tian, et al 
2005). Additionally, ABCC2 can also transport organic anions including glucuronide, sulphate 
and GSH conjugates (Nies et al., 2007: Chen et al., 2011).  
 
ABCC2 appear to have an important physiological role in eliminating endogenous metabolites 
and xenobiotics and their metabolites. Therefore, there has been an extensive amount of 
interest in understanding the role of ABCC2 in drug-drug interactions. Currently, the activity of 
ABCC2 can be inhibited by a wide range of structurally unrelated compounds such as MK571, 
a leukotriene receptor antagonist (Tian et al., 2005; Roy et al., 2009). Moreover, when ABCC2 
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overexpressing cells were treated with montelukast, a drug used to treat asthma, the 
elimination of saquinavir and paclitaxel was reduced (Roy et al., 2009; Chen et al., 2011). In 
addition, indomethacin, cyclosporine A, rifampicin, glibenclamide and antibiotics such as 
fusidate and azithromycin are some other modulators of ABCC2 (Chen et al., 2011). 
 
ABCC2 expression has been reported in several human cancer cell lines of the renal, gastric, 
colorectal and lung as well as from the kidney, lung, ovary, colon and breast (Narasaki et al., 
1997; Sandusky et al., 2002; Roundhill et al., 2015). A variety of anticancer drugs, including 
cisplatin, paclitaxel, MTX, irinotecan and vincristine have been reported to be transported by 
ABCC2 in vitro (Table 1.9) (Borst et al., 2000; Chen et al., 2011; Roundhill et al., 2015).  
Furthermore, overexpression of ABCC2 have been detected in few cisplatin- and doxorubicin-
resistant cell lines and recent reports have shown that the efficacy of cisplatin-based 
chemotherapy in the treatment of patient with hepatocellular carcinoma is dependent upon the 
expression level of ABCC2 (Chen et al., 2011; Sodani et al., 2012). 
 
Mutations in the ABCC2 genes can cause an inherited autosomal recessive disorder known 
as Dubin-Johnson syndrome characterised by impaired secretion of anionic conjugates from 
hepatocytes into the bile, chronic conjugated hyperbilirubinemia and deposition of brown 
pigments in the liver (Tian et al., 2005; Lee et al., 2006; Slot et al., 2011). Several mutations 
including missense, deletion, splice site and nonsense of the ABCC2 genes have severely 
reduced or eliminated the level of ABCC2 protein in the canalicular membrane (Lee et al., 
2006; Nies et al., 2006; Chen et al., 2011). Many of the studies on Dubin-Johnson syndrome 
have been based from well-established animal model of the disease such as the Groninger 
Yellow transporter rat strains model and the Abcc2 deficient Eisai hyperbilirubinuria rat model 
(Hirohashi et at., 1998; Koopen et al., 1998; Gerk et al., 2002). 
 
1.7.1.3     ABCC3 / MRP3 
 
ABCC3 was first detected in human and rat hepatocytes and shared the highest structural 
similarity to ABCC1 (58% amino acid identity) (Tian et al., 2005; Borst et al., 2007; Chen et 
al., 2011; Sodani et al., 2012). Like ABCC1, ABCC3 is also localised on the basolateral 
membranes of polarised cells (Slot et al., 2011; Roundhill et al., 2015; Zhang et al., 2015). 
The expression of ABCC3 is mainly detected in the adrenal glands, small intestine, colon, 
gallbladder, placenta and pancreas, and to a lower extend in the stomach, prostate, liver, 
spleen, brain, tonsils, kidney and lungs (Tian et al., 2005; Dallas et al., 2006; Chen et al., 2011; 
Sodani et al., 2012).  
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Low expression of ABCC3 is detected in the normal human liver and is mainly located to the 
basolateral membranes of the hepatocytes surrounding the portal tracts and bile duct epithelial 
cells (Borst et al., 2007; Chen et al., 2011). However, in Dubin-Johnson syndrome and 
cholestatic patients, the expression of ABCC3 is upregulated often due to downregulation of 
ABCC2 in liver canalicular membranes (Scheffer et al., 2002a; Borst et al., 2007). Therefore, 
the function of ABCC3 may compensate for the downregulation of ABCC2 in the liver (Konig 
et al., 1999). Indirect approaches using in vitro assays such as in the determination of 
substrate specificity, tissue localisation and upregulation in pathological conditions have used 
to study the physiological function of ABCC3 (Chen et al., 2011). In addition, Abcc3 knockout 
mouse model have provided direct investigation of the role of Abcc3 in the transport of 
xenobiotics and endogenous compounds (Belinsky et al., 2005; Zelcer et al., 2006; Chen et 
al., 2011). Therefore, the studies on the physiological function of ABCC3 using the mice 
models have suggested that during toxic accumulation of hepatotoxic bile salts, ABCC3 may 
protect the liver from cholestasis (Dallas et al., 2006; Teng et al., 2007). 
 
A variety of amphipathic anions including monoanionic bile acids and glucoronate conjugates 
are transported by ABCC3, but unlike ABCC1 and ABCC2, ABCC3 have a very low affinity for 
GSH conjugates even though ABCC3 has high structural similarity to ABCC1 (Kool et al., 
1999a; Borst et al., 2007). Furthermore, ABCC3 does not require GSH to transport drug 
substrates (Zelcer et al., 2001; Borst et al., 2007). Additionally, studies using mice models 
have suggested that ABCC3 plays an important role in the basolateral disposition of certain 
glucuronide conjugates and bile acids (Kool et al., 1999a; Lagas et al., 2010). 
 
High expression levels of ABCC3 in primary ovarian cancer (Ohishi et al., 2002; Ween et al., 
2015), human hepatocellular carcinomas (Nies et al., 2001) and adult acute lymphoblastic 
leukaemia (Plasschaert et al., 2005) have been detected. Such overexpression of ABCC3 in 
adult acute myeloid leukaemia (Benderra et al., 2005), and in childhood and adult acute 
lymphoblastic leukaemia (Plasschaert et al., 2005) and pancreatic carcinoma (Konig et al., 
2005) was associated with poor event-free survival and overall survival. Therefore, ABCC3 
expression was predicted to be a prognostic factor. However, high expression level of ABCC3 
in neuroblastoma was associated with improved overall survival (Henderson et al., 2011; 
Roundhill et al., 2015).  Compared to ABCC1 and ABCC2, ABCC3 transport fewer anticancer 
substrates such as teniposide, etoposide and MTX (Zelcer et al., 2001; Borst et al., 2007).  
 
1.7.1.4     ABCC6 / MRP6 
 
The ABCC6 gene is located next to ABCC1 gene on chromosome 16 and encodes a 1503 
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amino acids proteins (Zhang et al., 2015). ABCC6 was initially detected in epirubicin resistant 
human leukemic cells during the amplification of the 3’-end of the ABCC6 gene (Borst et al., 
2000) and has 45% structurally similarity to ABCC1 (Tian et al., 2005; Chen et al., 2011). The 
kidney and liver have the highest level of ABCC6 protein expression whereas other tissues 
such in the small intestine, pancreas, lung, skeletal muscle, eye and skin have low levels of 
ABCC6 protein expression (Kool et al., 1999b; Scheffer et al., 2002b; Beck et al., 2005; 
Matsuzaki et al 2005). In addition, ABCC6 is widely distributed in various epithelial cells of 
endocrine and exocrine tissues, mucosal cells of intestine, acinar cells in the pancreas, 
follicular epithelial cells of the thyroid, and the canalicular and lateral plasma membrane of 
hepatocytes and is localised in the basolateral membrane of polarised cells (Madon et al., 
2000; Beck et al., 2005; Slot et al., 2011; Zhang et al., 2015).  
 
Studies using animal models such as the membrane vesicles prepared from ABCC6-
transfected Chinese hamster ovary cells and from insect cells have shown that the in vitro 
transport of the GSH conjugates such as S-glutathione, N-ethylmaleimide and LTC4 are 
mediated by ABCC6 but failed to transport glucuronide conjugates such as E217βG (Belinsky 
et al., 2002; Ilias et al., 2002; Dallas et al., 2006; Chen et al., 2011). These observation indicate 
that ABCC6 is a lipophilic anionic transporter (Belinsky et al., 2002; Sodani et al., 2012) but 
further studies are necessary to fully understand the physiological and pharmacological 
functions of ABCC6. 
 
ABCC6 can confer low levels of cellular resistance to a variety of anticancer drugs in vitro such 
as doxorubicin, cisplatin, etoposide and daunorubicin (Belinsky et al., 2002; Tian et al 2005; 
Chen et al., 2011), although whether this is relevant in vivo is unclear. The gene expression 
of ABCC6 has been detected in both adult and child acute lymphoblastic leukaemia and may 
be related to overall survival and event free survival (Plasschaert et al., 2005; Roundhill et al., 
2015). However, due to limited studies done to investigate the multidrug resistance profile of 
ABCC6 further studies are needed to fully understand if or how ABCC6 is involved in multidrug 
resistance (Chen et al., 2011; Zhang et al., 2015). 
 
Mutation in ABCC6 gene have been associated with genetic abnormalities of the heritable 
connective tissue disorder that affect the elastic tissues mainly in the eyes, skin and 
cardiovascular system called pseudoxanthoma elasticum (PXE) (Matsuzaki et al., 2005; Tian 
et al., 2005; Sodani et al., 2012). Patient with PXE surfer myocardial infarction, visual 
impairment and blood vessel rupture (Belinsky et al., 2002; Hu et al., 2003; Chen et al., 2011). 
Furthermore, abnormalities of the elastic fibers are due to calcification of elastic structures and 
the accumulation of miniralised elastotic material in the skin causing loss of vision, baggy skin 
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and calcification of the blood vessels (Li et al., 2009; Chen et al., 2011). Research has also 
suggested that supplementation of inorganic pyrophosphate (PPi) may prevent soft tissue 
mineralisation PXE (Jansen et al., 2013; Favre et al., 2017) but the mechanism by which 
ABCC6 uses PPi to prevent abnormal mineralisation in physiological conditions is still 
unknown (Favre et al., 2017).  Since ABCC6 is mainly expressed in the liver and kidney and 
with low expression in other tissues, many theories have been formed to explain the 
unexpected association of ABCC6 gene mutation with PXE (Kool et al., 1999b; Scheffer et al., 
2002b; Beck et al., 2005; Matsuzaki et al 2005).  
 
1.7.2     The short ABCCs / MRPs 
 
1.7.2.1     ABCC4 / MRP4 
 
ABCC4 gene was identified in a T-lymphoid cell line in 1996 and was characterised as a 
transporter of 9-(2-phosphonylmehoxyethly) adenine (PMEA), a nucleoside monophosphate 
antiviral agent (Borst et al., 2000; Chen et al., 2010; Sodani et al., 2012).  Currently, there are 
no genetic diseases associated with ABCC4 gene mutation but ABCC4 gene is highly 
polymorphic (Slot et al., 2011). In addition, selective defect in ADP storage in platelet δ-
granules have been linked to absence of ABCC4 which may cause abnormal bleeding and 
bleeding times (Jedlitschky et al., 2010; Slot et al., 2011). ABCC4 shares a 41% amino acid 
identity with ABCC1 (Chen et al., 2010). ABCC4 is expressed at very high levels in the 
prostate, but is found in all normal tissues (Borst et al., 2007; Chen et al., 2011). Compared to 
other ABCCs that are localised to either the apical or basolateral membranes in polarised 
cells, ABCC4 is localised to the apical membrane in some polarised cells, whereas it is at the 
basolateral membrane in others. For example, ABCC4 is found at the luminal side of brain 
capillary endothelium cells (Nies et al., 2004; Russel et al., 2008) and renal proximal tubule 
cells (Russel et al., 2008), and the basolateral membrane in polarised cells such as in the 
hepatocytes, choroid plexus epithelium cells and prostate tubuloacinar cells (Borst et al., 2007; 
Russel et al., 2008; Chen et al., 2011; Sodani et al., 2012). Moreover, ABCC4 can also be 
localised to both apical and basolateral side of cells such as the colonic epithelial cells (Russel 
et al., 2008). ABCC4 can transport a wide range of endogenous and xenobiotic organic anionic 
compounds and helps protect crucial tissues against the cytotoxic effects and conferring 
resistance to a variety of cytotoxic compounds (Sodani et al., 2012; Zhang et al., 2015). 
 
Apart from ABCC4 mediating the disposition of drugs and their metabolites, ABCC4 also 
regulates the transport of several important endogenous metabolites that are involved in the 
signalling pathways of critical processes such as inflammation, cell differentiation and 
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apoptosis (Chen et al., 2011). Among the first ABCC4 substrates identified were cAMP and 
cGMP (Chen et al., 2001; Sodani et al., 2012). The affinity of ABCC4 for cAMP and cGMP is 
relatively low which questioned whether ABCC4 is sufficient in regulating the intracellular 
levels of these cyclic nucleotides. (Van Aubel et al., 2002; Wielinga et al., 2003; Borst et al., 
2007). However, a large amount of evidence has suggested that the cyclic nucleotide 
signalling is highly compartmentalised meaning that instead of regulating the whole cell 
concentration of cAMP and cGMP, ABCC4 may be more involved in regulating local 
microdomains (Russel et al., 2008; Chen et al., 2010; Sodani et al., 2012). Other substrates 
of ABCC4 include sulphated bile acids, GSH, LTC4 and GSH-conjugated leukotriene B4 (LTB4) 
(Tian et al., 2005; Rius et al., 2008; Chen et al., 2010) and several eicosanoids such as 
prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) which are inflammation and pain 
mediators and also is involved angiogenesis, development of tumour and response to 
cytotoxic chemotherapy (Reid et al., 2003b; Chen et al., 2011; Kochel et al 2015 and 2017). 
 
Additionally, high expression of ABCC4 have been detected in some invasive tumours 
including neuroblastoma (Norris et al., 2005; Henderson et al., 2011; Huynh et al., 2012; 
Roundhill et al., 2015) and epithelial ovarian carcinoma (Bagnoli et al., 2013; Roundhill et al., 
2015) and is associated with poor patient survival. In contrast, a low expression level of 
ABCC4 in prostate tumours is associated with poor event free survival (Ho et al., 2008; Chen 
et al., 2011; Montani et al., 2013). Furthermore, together with PMEA and other antiviral agents, 
ABCC4 can also efflux a wide range of anticancer agents including methotrexate (MTX), 
thiopurine analogs and topotecan (Wielinga et al., 2002; Russel et al., 2008; Chen et al., 2002 
and 2011). Moreover, in order for thiopurine analogs and most nucleotide-based 
chemotherapeutic drugs to exert their pharmacologic activity, they must undergo intracellular 
phosphorylation (Wielinga et al., 2002; Chen et al., 2011; Slot et al. 2011). Therefore, ABCC4 
effluxes the phosphorylated compounds rather than the parent compounds and as a result 
may cause treatment failure (Zhang et al., 2015). Also, studies have shown that an 
upregulation of COX-2 via the PGE2-dependent pathway in lung cancer may cause an 
overexpression of ABCC4 (Maeng et al., 2014; Zhang et al., 2015). With inconclusive 
evidences provided thus far on the role of ABCC4 in clinical drug resistance further studies 
are needed to elucidated the drug resistance profile of ABCC4 (Sodani et al., 2012). 
 
1.7.2.2     ABCC5 / MRP5 
 
ABCC5 was first identified during a database screening of sequence tags (Kool et al., 1997) 
and shared 38% amino acid identity with ABCC1 (Chen et al., 2011). The expression level of 
ABCC5 is relatively low in most normal tissues but highly expressed in tissues such as in 
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heart, skeletal muscle, cornea and brain (Dazert et al., 2003; Nies et al., 2004; Dallas et al., 
2006; Karla et al., 2009; Sodani et al. 2012; Zhang et al., 2015). However, due partly to lack 
of suitable antibodies for definitive immunolocalisation studies, the characterisation of ABCC5 
tissue distribution is partially described (Borst et al., 2007; Slot et al., 2011). Similar to ABCC1, 
ABCC5 is expressed on the pyramidal neurons, subcortical white matter astrocytes, luminal 
side of brain capillary endothelial cells as well as in smooth muscle cells of various tissues in 
the human genitourinary system but the physiological role of ABCC5 in these tissues has not 
been elucidated (Chen et al., 2011; Slot et al., 2011).   Furthermore, ABCC5 is localised in the 
basolateral membrane of polarised cells (Nies; et al., 2004; Borst et al., 2007; Chen et al., 
2011; Slot et al., 2011; Sodani et al., 2012).  
 
ABCC4 and ABCC5 are structurally similar in that they both lack the TMD0 but there is a 
difference between the two proteins in that at the N-terminus, ABCC5 has an extra 95 amino 
acids compare to ABCC4. The exact function of this additional segment is still not yet 
understood (Haimeur et al., 2004; Sodani et al., 2012). 
 
Thus far, the functional studies of ABCC5 using ABCC5 knockout mice model have produced 
limited understanding into the functional activity of the protein (Chen et al., 2011). Like ABCC4, 
ABCC5 can mediate the transport of cAMP and cGMP and it has higher affinity for cGMP than 
for cAMP (Adachi et al., 2002; Wielinga et al., 2003; Tian et al., 2005; Chen et al., 2011; Sodani 
et al., 2012). In addition, the cGMP in pial arteriolar smooth muscle cells (Xu et al., 2003) and 
in anterior pituitary cells (Andric et al., 2006) is selectively transported by ABCC5. 
Consequently, ABCC5 can transport a variety of organic anions, including certain purine 
analogues such as thioguanine and PMEA  (Wielinga et al., 2002; Tian et al., 2005; Chen et 
al., 2011) and certain monophosphate nucleotide metabolites such as cAMP and cGMP 
(Jedlitschky et al., 2000; Chen et al., 2011; Zhang et al., 2015). Hence, like ABCC4, ABCC5 
is a cyclic nucleotide organic anion transporter (Jedlitschky et al., 2000; Reid et al., 2003a; 
Borst et al., 2007). Other substrates of ABCC5 include unmethylated thionucleotides and other 
organic anions such as GSH and S-(2, 4-dinitrophenyl) glutathione (Chen et al., 2011; Slot et 
al., 2011). 
 
Elevation of ABCC5 protein expression has been found in pancreatic, lung, colon and breast 
cancer samples as well as in ischemic heart (Oguri et al., 2000; Dazert et al., 2003; Pratt et 
al., 2005; Nambaru et al., 2011). Further in vitro studies have also detected ABCC5 gene 
expression in doxorubicin and cisplatin treated non-small cell lung cancer (Oguri et al., 2000; 
Pratt et al., 2005; Zhang et al., 2015). Therefore, ABCC5 could efflux a wide variety of 
anticancer drugs, including cisplatin, doxorubicin, pyrimidine analogues such as 5-fluorouracil, 
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gemcitabine, and cytosine arabinoside, purine analogues such as 6-thioguanine and 6-
mercaptopurine, and antifolate drugs such MTX. However, ABCC5 does not provide 
resistance to vinca alkaloids such as vincristine (Borst et al., 2000; Wielinga et al., 2002 and 
2005; Pratt et al., 2005; Chen et al., 2011). The evidences thus far have suggested the role of 
ABCC5, hence further studies are required in elucidating the exact role of ABCC5 (Chen et 
al., 2011; Slot et al., 2011; Zhang et al., 2015). 
 
1.7.2.3     ABCC11 / MRP8 
 
Through expressed sequence tag database mining and a gene prediction program, high 
expression of ABCC11 was first identified in breast cancer (Bera et al., 2001; Chen et al., 
2011; Toyoda et al., 2010; Sodani et al., 2012) and among the members of the ABCC 
subfamily, ABCC11 is unusual in that no orthologous genes have been found in mammals 
except for primates (Slot et al., 2011). The expression level of ABCC11 gene transcript is 
highest in the brain, placenta, liver, testes and breast (Yabuuchi et al., 2001; Chen et al., 2011; 
Sodani et al., 2012). Furthermore, the variation in the level of ABCC11 gene transcript may 
partly be due to the discovery of multiple splice form of the ABCC11 gene transcript (Yabuuchi 
et al., 2001). Hence, no definite correlation have been found between ABCC11 gene transcript 
levels with ABCC11 protein expression levels in tissues (Chen et al., 2011; Sosonkina et al., 
2011). Therefore, to investigate the relation between ABCC11 tissue expression levels and 
the multiple splice form of ABCC11 gene, further protein expression studies are needed. In 
addition, ABCC11 has been suggested to be associated with the efflux of neuromodulatory 
steroids such dehydroepiandrosterone 3-sulphate as it has been detected in axons of the 
human central nervous system (CNS) and peripheral nervous system (PNS) and is localised 
to apical membranes of polarised epithelial cells (Chen et al., 2011; Sodani et al., 2012; Zhang 
et al., 2015). 
 
Through in vitro vesicular transport assay, using membrane vesicles showed that ABCC11 
can transport a wide variety of compounds including lipophilic anions including natural and 
synthetic glutathione conjugates such as S-(2,4-dinitrophenyl) glutathione, estradiol 
glucuronide and LTC4, cyclic nucleotides such as cAMP and cGMP, folic acids, glucuronidated 
steroids and sulphated conjugates such as estrone 3-sulphate and hydroepiandrosterone 3-
sulphate (Table 1.9) (Chen et al., 2005 and 2011; Martin et al., 2010; Baumann et al., 2014). 
 
The ABCC11 drug resistance profile has been determined using ABCC11 transfected pig 
kidney epithelial (LLC-PK1) cells. Thus according to the system, ABCC11 was found to efflux 
antimetabolites such as MTX, 5-fluorouracil, 5-fluoro-5-deoxyuridine, 5-fluro-2-deoxyuridine, 
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PMEA and cytosine arabinoside (Table 1.9) (Guo et al., 2003; Dallas et al., 2006 Oguri et al., 
2007; Chen et al., 2011). Clinically, high expression level of ABCC11 has been detected in 
breast cancer (Bera et al., 2001; Sodani et al., 2012; Yamada et al., 2013) and gastric cancer 
(Matsumoto et al., 2014; Zhang et al., 2015). Furthermore, overexpression of ABCC11 has 
been associated with low overall survival in acute myelogenous leukaemia (AML) patients, 
indicating that ABCC11 may be a potential biomarker for AML treatment outcome (Guo et al., 
2009). Consequently, the distribution, activity and expression of ABCC11 in human tissues 
still need to be elucidated. Therefore, further studies are required to investigate the possibility 
that ABCC11 may have a role in clinical multidrug resistance (Chen et al., 2011; Slot et al., 
2011; Sodani et al., 2012; Zhang et al., 2015; Roundhill et al., 2015). 
 
A physiological function of ABCC11 was revealed from a single nucleotide polymorphism in 
ABCC11 gene, 538G>A (Gly180Arg) that causes the production of either wet or dry ear wax 
(Yoshiura et al., 2006; Nakano et al., 2009; Ohashi et al., 2011). The single nucleotide 
polymorphism, 538G>A, appear to interfere with the stability and glycosylation of ABCC11 by 
causing a non-conservative arginine substitution of Gly180 in the TMD1 of ABCC11 (Ota et 
al., 2010; Slot et al., 2011; Toyoda et al., 2016a and 2016b). Consequently, the ABCC11 
polymorphism does not transport cAMP hence this may account for the production of dry ear 
wax (Chen et al., 2011). Furthermore, the 538A/A genotype is common in East Asian 
population causing dry ear wax whereas the 538G/A and 538G/G genotypes are common in 
European and African population causing wet ear wax (Yoshiura et al.,2006; Ohashi et al., 
2011; Harker et al., 2014; Toyoda et al., 2016b). In addition, individual with 538G/A and 
538G/G genotypes also suffer a condition known as axillary osmidrosis where fetid sweat are 
secreted from the armpit and in other cases individuals may have colostrums secretion and 
may potentially develop breast cancer.  However, such conditions are rarely noticed in 
individual with 538A/A genotype (Nakano et al., 2009; Martin et al., 2010; Ota et al., 2010; 
Toyoda et al., 2010, 2016a and 2016b). Moreover, the ABCC11 protein with 538A/A genotype 
lacks N-linked glycosylation and, due to disruption of plasma membrane trafficking possibly 
because of misfolding, may cause 538A/A genotype ABCC11 polymorphism to undergo 
proteosomal degradation (Chen et al., 2011; Toyoda et al., 2016b).  
 
1.7.2.4     ABCC12 / MRP9 
 
ABCC12 is located just 20 kb apart from ABCC11 on chromosome 16q12.1 in a head-to-tail 
orientation (Yabuuchi et al., 2001; Chen et al., 2011; Slot et al., 2011; Sodani et al., 2012; 
Zhang et al., 2015). ABCC12 shares similar sequence identity (47%) and similarity (56%) to 
that of ABCC11, thus ABCC12 gene may be formed due to a gene duplication event (Yabuuchi 
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et al., 2001; Chen et al., 2011). However, one major difference between ABCC11 and ABCC12 
is that ABCC12 has got two TMDs each with four membrane spanning regions and only one 
NBD. Any standard ABC transporter requires two NBDs for the transporter to be functional but 
ABCC12 does not require the second NBD to be activated instead a premature stop codon 
truncates the protein. Hence producing only one TMDs which is the carboxyl half of the protein 
(Bera et al., 2002). Furthermore, ABCC12 has got 44% amino acid identity and 55% sequence 
protein identity to that of ABCC5 (Bera et al., 2002; Chen et al., 2011). Moreover, ABCC12 is 
an unusual ABCC in that it does not have an N-linked glycosylation (Ono et al., 2007; Sodani 
et al., 2012)  and the expression of ABCC12 is predominantly localised in the endoplasmic 
reticulum rather to the plasma membrane (Ono et al., 2007; Chen et al., 2011; Sodani et al., 
2012).  
 
Moreover, due to multiple ABCC12 gene transcripts that encode different size of proteins, the 
tissue distribution and activity of ABCC12 is not well defined (Yabuuchi et al., 2001). 
Conversely, some studies have reported that one ABCC12 gene transcript of 4.5 kb in length 
is expressed in normal breasts, testis and breast cancer and another ABCC12 gene transcript 
of 1.3 kb in length is expressed in the ovaries, brain and skeletal muscle (Bera et al., 2002; 
Sodani et al., 2012). 
 
However, so far the substrate specificity of ABCC12 is still unknown hence its functional 
characteristics in terms of its physiological role and whether it is implicated in clinical multidrug 
resistance in cancer chemotherapy have not been reported. Therefore, further studies are 
needed to better understand the functional characteristics of ABCC12 (Chen et al., 2011; Slot 
et al., 2011; Sodani et al., 2012; Zhang et al., 2015). 
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Name  
 
Alternate  
name / Symbol 
Amino acids Tissue location Expression level Major drug substrates Physiological 
substrates 
Inhibitors 
MRP1 ABCC1 1531 All major tissues Differs in various 
organs and cell 
lines 
Folate-based antimetabolites (MTX, 
edatrexate, ZD1694), anthracyclines 
(doxorubicin, daunorubicin, epirubicin, 
idarubicin), plant alkaloids (etoposide, 
vincristine, vinblastine, paclitaxel, 
irinotecan, SN-38), antiandrogens 
(flutamide, hydroxyflutamide), 
saquinavir, ritonavir, indinavir, 
ciprofloxacin, difloxacin, grepafloxacin, 
berberine, pirarubicin, sodium 
arsenite, sodium arsenate, potassium 
antimonite, potassium antimony 
tartrate, leucovorin, various conjugates 
LTC4, E217βG, 
sulphated bile acids, folic 
acid, bilirubin, PGA GSH 
conjugate, 
GSH, GSSG, N-acetyl-
Leu-Leu-norleucinal 
Probenecid, sulfinpyrazone, 
indomethacin, verapamil, 
quercetin, genistein, 
biochanin A, kaempferol, 
schisandrin B, cyclosporine, 
PAK-104P, steroid 
analogues, MK-571, ONO-
1078, sulphonylurea, 
glibenclamide, delavirdine, 
efavirenz, nevirapine, 
abacavir, emtricitabine, 
lamivudine, tenofovir, 
LY475776, LY402913 
MRP2 ABCC2 / 
cMOAT 
1545 Liver, kidney, 
intestine, brain 
 Conjugates, cisplatin, etoposide, vinca 
alkaloids, anthracyclines, 
camptothecins, MTX, olmesartan, 
saquinavir, lopinavir, ritonavir, 
indinavir, ezetimibe, temocaprilat, 
atorvastatin, phloridzin, quercetin 4’-β-
glucoside, genistein-7-glucoside, 
fexofenadine, NNAL, cefoperazone, 
cefbuperazone, cefpiramide, 
ceftriaxone, carboxydichlorofluroscein 
LTC4, GSH, GSSG, 
bilirubin conjugates, LTD4, 
LTE4 
MK-571, probenecid, 
furosemide 
MRP3 ABCC3 / 
MOAT-D 
1527 Small intestine, 
pancreas, colon, 
placenta, 
adrenal gland 
Low levels in the 
liver, brain, 
kidney and 
prostate 
Etoposide, teniposide, dinitrophenyl S-
glutathione, acetaminophen 
glucuronide, vincristine, MTX 
LTC4, E217βG, 
cholate, glycocholate, 
taurocholate 
Etoposide, MTX, delavirdine, 
efavirenz, 
nevirapine, emtricitabine, 
lamivudine, and tenofovir 
MRP4 ABCC4 /  
MOAT-B 
1325 Kidneys, 
prostate, testis, 
ovary, lung, 
hepatocytes, 
intestine, 
pancreas 
Low levels in 
other tissues 
MTX, 6-thioguanine, PMEA, 6-
mercaptopurine, topotecan, irinotecan, 
SN-38, cyclophosphamide, ifosfamide, 
ceftizoxime, cefazolin, cefotaxime, 
cefmetazole, azathioprine 
cGMP, cAMP, 
DHEAS, E217βG, 
PGE1, PGE2, GSH and 
GSH conjugated bile acid, 
LTB4 and LTC4 
MK-571, MTX, celecoxib, 
rofecoxib, diclofenac, 
sulfinpyrazone, 
benzbromarone, 
verapamil, indomethacin 
MRP5 ABCC5 /  
MOAT-C 
1437 Most tissues Low levels 6-Mercaptopurine, 6-thioguanine, 
PMEA, heavy metals, 5-fluorouracil, 
MTX, PMEA, daunorubicin, 
gemcitabine, Ara-C, azathioprine, 
doxorubicin 
cGMP, cAMP, S-(2,4 
dinitrophenyl) glutathione 
Probenecid, sulfinpyrazone, 
benzbromarone, MK-571 
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MRP6 ABCC6 /  
MOAT-K / PXE 
1503 Liver, kidneys Low levels in 
other tissues 
N-ethylmaleimide S-glutathione, 
dinitrophenol glutathione, etoposide, 
doxorubicin, cisplatin, daunorubicin, 
teniposide, actinomycin-D 
LTC4, S-(2,4 dinitrophenyl) 
glutathione 
Indomethacin, probenecid, 
benzbromarone 
MRP7 ABCC10 1492 Most tissues Very low levels Docetaxel, paclitaxel, vincristine, 
vinblastine,  gemcitabine, Ara-C, 
epothilone-B 
E217βG, LTC4 MK-571, LTC4, 
glycolithocholate 3-sulphate, 
cyclosporine 
MRP8 ABCC11 1382 Normal breast, 
testis 
Low levels in the 
liver, brain and 
placenta 
5-Fluorouracil, 5’-fluoro-5’-
deoxyuridine, 5’-fluoro-2’- 
deoxyuridine, PMEA, MTX, Ara-C 
cGMP, cAMP, LTC4, 
DHEAS, bile acids, 
estrone 3-sulphate, 
E217βG, folic acids, S-(2,4 
dinitrophenyl) glutathione 
Unknown 
MRP9 ABCC12 1359 Breast cancer, 
normal breast, 
testis, brain, 
skeletal muscle, 
ovary 
Low levels Unknown Unknown Unknown 
Table 1.9. The tissue distribution, substrates and inhibitors of the MRPs (Adapted from Liu et al., 2010 and Chen et al., 2010). 
cMOAT, canalicular multispecific organic anion transporter; DHEAS, dehydroepiandrosterone-3-sulphate; E217βG, 17-β-D-oestradiol glucuronide; GSH, glutathione; 
GSSG, oxidized glutathione; MRP, multidrug resistance protein; LT, leukotriene; MTX, methotrexate; NNAL, 4 (methylnitrosamino)-1-(3-pyridyl)-1-butanol; PG, 
prostaglandin; PMEA, 9-(2-phosphonylmethoxyethyl) adenine; Ara-C, arabinofuranosyl cytidine 
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1.8     ABC transporters and cancer hallmarks 
 
Tumorigenesis in humans is a multistep process that brings about genetic changes causing 
normal cells to progressively transform into highly malignant derivatives. Furthermore, under 
pathological conditions, cells at organ sites may reveal lesions which represent the evolution 
of normal cells into a series of premalignant states to form invasive cancers. In cancer cells, 
the signaling pathways responsible for maintaining normal cell proliferation and homeostasis 
are dysregulated. Moreover, within specific organs more than 100 distinct types of cancer and 
subtypes of tumours can occur (Hanahan et al., 2000). 
 
Subsequently, the malignant growth of cancer cells is governed by six essential alterations in 
cell physiology and, they are sustaining proliferative signaling, resisting cell death, evading 
growth suppressors, inducing angiogenesis, activating invasion and metastasis, and enabling 
replicative immortality (Figure 1.21) (Hanahan et al., 2000 and 2011). 
 
 
 
Figure 1.21. The hallmarks of cancer. The essential capabilities cancers must acquire 
during their development (Hanahan et al., 2011). 
 
 
 
ABC transporters are well known for their role in mediating chemoresistance in cancer cells. 
Recently many studies have suggested that ABC transporters might be implicated in the 
cancer hallmarks (Fletcher et al., 2010 and 2016). To date, little is known about their direct 
contribution to cancer progression and development irrespective of their drug-efflux abilities 
(Fletcher et al., 2010 and 2016; Adamska et al., 2018). In recent years, several studies have 
90 
 
suggested that the biological functions of ABC transporters are more complex than their role 
in drug resistance. Since ABC transporters transport many active signalling molecules and 
hormones as their substrates, it has been suggested that these substrates can activate cancer 
cells as well as regulate the tumour environment so as to help cancer cells to grow and develop 
(Adamska et al., 2018). In addition, signalling lipid molecules such as sphingosine-1-
phosphate (S1P), prostaglandins and leukotrienes have a profound role in tumour biology and 
are known to be substrates of certain ABC transporters. Therefore, mediating the efflux of 
these molecules may also be important in cancer progression and development (Fletcher et 
al., 2010). 
 
1.8.1     The role of ABC transporters in apoptosis and proliferation 
 
In a specific organ site, the number of cells are tightly regulated by proliferation and apoptosis. 
In many cancers, this tight regulation is abolished and cancer cells become resistance to 
apoptosis and grow uncontrollably to form tumours (Hanahan et al., 2000 and 2011). During 
chemotherapy, ABC transporters efflux a number of cytotoxic drugs thus causing cancer cells 
to become resistant to apoptosis. Apart from the drug effluxing ability of ABC transporters, 
several studies have shown that ABC transporters may also help cancer cells to survive 
(Fletcher et al., 2010 and 2016).  For example, as a single agent, valspodar, an ABCB1 
inhibitor can promote apoptosis and cell cycle arrest in human leukaemia cells in vitro (Lehne 
et al., 1999 and 2002). However, another study showed that in some cell lines the cause of 
apoptosis by valspodar is independent of the inhibition of the transporter (Lopes et al., 2003). 
Moreover, the activation of ABCB1 in normal and cancer cells in response to apoptotic stimuli 
have shown to inhibit cell apoptosis (Pallis et al., 2000). 
 
Studies have found that in neuroblastoma, ABCC1 helps cell survival and spontaneous cell 
death was observed both in mouse xenograft model and in human neuroblastoma cell lines in 
vitro when ABCC1 gene was silenced (Peaston et al., 2001; Kuss et al., 2002). Therefore, 
consistent with these observations, the expression level of ABCC1 gene is often used as an 
independent prognostic factor in neuroblastoma (Haber et al., 2006). 
 
Studies found that cancer cell proliferation is directly mediated by bioactive phospholipids and 
it was found that the transport of lysophosphatidylinositol (LPI) by ABCC1 activates GPR55 in 
an autocrine manner to trigger signalling cascade that induce cell proliferation (Begicevic et 
al., 2017; Adamska et al., 2018). 
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The expansion of tumour populations are well attributed to increase in proliferation of tumour 
cells (Hanahan et al., 2000 and 2011; Fletcher 2010). Studies have found that the proliferation 
of vascular smooth muscle cells in vivo and in vitro was significantly reduced when ABCC4 
gene was knocked down (Sassi et al., 2008). Furthermore, the knock down of ABCC1 gene 
inhibited cell proliferation in neuroblastoma cell line xenografts (kuss et al., 2002). In addition, 
the knockdown of ABCB1 gene significantly reduced tumour expansion in colon cancer 
xenograft model and inhibited the proliferation of a colon cancer cell line in vitro (Katoh et al., 
2008). Additionally, ABCB1 together with ABCA5 may regulate the differential state of colon 
tumours, hence suggesting that ABCB1 and ABCA1 may have a role in tumour development 
(Ohtsuki et al., 2007; Dvorak et al., 2017). Retrovirus that encoded ABCG2 gene largely 
increased the proliferation of retinal progenitors but the proliferation was suppressed when the 
ABCG2 gene was silenced by small interfering RNA (siRNA) (Bhattacharya et al., 2007). 
Moreover, the suppression of ABCG2 was found to decrease cell proliferation and G0/G1-
phase cell arrest in cancer cells through the up regulation of p21 and down regulation of cyclin 
D3 (Chen et al., 2010). 
 
ABCC4 is the main transporter for cAMP, which is a very active molecule involved in cell 
differentiation, proliferation and apoptosis. A study found that when ABCC4 was 
pharmacologically inhibited or genetically silenced in acute myeloid leukaemia cells (AML), 
cell proliferation was inhibited, cell differentiation and apoptosis were induced (Cospel et al., 
2011 and 2014). In another study, inhibition of ABCC4 expression in non-small cell lung cancer 
impaired cell proliferation. This suggested that ABCC4 could mediate cell cycle progression 
via phosphorylation of pRB protein hence promote cell proliferation (Zhao et al., 2014). 
Moreover, downregulation of ABCC4 expression in pancreatic cell lines was associated with 
a decrease in cell proliferation in vitro, hence suggesting ABCC4 promotes cell proliferation 
(Zhang et al., 2012). In another study, the knockdown of ABCC4 gene in gastric cancer cell 
lines was linked to a decreased in cell growth and suggested that ABCC4 may mediate gastric 
cancer cell growth by manipulating the S and the G2/M phase cell cycle regulators (Chen et 
al., 2014). 
 
In response to oxidative stress, GSH is activated to maintain redox status of cells in 
homeostasis. However, activation of GSH mediates several signalling processes that 
regulates cell apoptosis, proliferation and immune response. Furthermore, the transport of 
GSH, GSSG and GSH conjugates (GS-X) are mediated by several members of the ABC 
transporters including ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC7, ABCG2 and 
ABCB10. Thus, suggesting that these ABC transporters are involved in regulating oxidative 
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stress and cell detoxification such as in breast and colorectal cancers (Dovarak et al., 2017; 
Begicevic et al., 2017; Adamska et al., 2018).  
 
1.8.2     The Role of ABC transporters in cell migration, invasion and metastasis 
 
The vast majority of cancer death is due to cancer metastasis whereby cancer cells develop 
the ability to disseminate to distant organ sites and start growing to found new tumours (van 
Zijl et al., 2011; Valastyan et al., 2011; Orimo et al., 2014; Chamber et al., 2015; Guan et al., 
2015). Currently little is known about the role of ABC transporters in metastasis but several 
studies have been done to try to understand the role of ABC transporters in cell migration and 
invasion (Fletcher et al., 2010).  
 
In normal cells, several ABC transporters have been found to be implicated in cell migration 
(Fletcher et al., 2010 and 2016). In Abcc1 gene knockout mice, a decrease in peripheral 
dendritic cell migration to lymph nodes was observed and the dendritic cells with Abcc1 gene 
knockdown had restricted chemotactic response in vitro (van de Ven et al., 2006). Moreover, 
the addition of LTC4 and LTD4 exogenously, both are ABCC1 substrates, were found to 
promote cell migration in vivo and in vitro even in the absence of ABCC1. Thus suggesting 
that ABCC1 in mouse dendritic cells may be involved in autocrine signalling which regulates 
dendritic migration to lymph nodes by transporting LTC4 (Robbiani et al., 2000; Fletcher et al., 
2010).  Other studies has found that other ABC transporters such as ABCB1 may be involved 
in dendritic cell migration as one study showed that the migration of dendritic cells from human 
skin explants were inhibited by the inhibitor verapamil and ABCB1-specific neutralising 
antibodies (Randolph et al., 1998; Fletcher et al., 2010). However, the roles of various ABC 
transporters across species is different thus making it very difficult to compare the role of ABC 
transporters across species such as the role of ABCC4 in murine and human dendritic 
migration (van de Ven et al., 2008 and 2009). Consequently, the migration of human dendritic 
cells are more influenced by ABCC4 than ABCC1 as a study conducted showed that inhibition 
of dendritic cell migration by sildenafil or by ABCC4 gene knockdown, attenuated their 
migration from human skin explants (van de Ven et al., 2008 and 2009). 
 
Similarly, the roles of ABC transporters in cell migration was also observed in normal as well 
as in cancer cell lines. A study assessing the migration of MCF-7 breast cancer cells in matrigel 
invasion and transwell migration assays were significantly supressed when ABCB1 gene was 
knockdown by siRNA (Miletti-Gonzalez et al., 2005). Further studies have also shown that 
after suppressing CD147, a major stimulator of metalloproteinases (MMPs) and has been 
proposed to be a poor prognosis marker in some cancers, in MCF-7/ADR breast cancer cells, 
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have led to an increased in chemosensitivity to ABCB1 substrates, while an overexpression 
of CD147 enhanced ABCB1 efflux ability (Li et al., 2007; Buzzoto et al., 2010).  In addition, a 
drug-resistant human melanoma cancer cell line with high expression levels of ABCB1 was 
found to be more invasive than the parental cell line and that the knockdown of ABCB1 gene 
by siRNA consequently decreases cell invasion in vitro (Colone et al., 2008). In the canine 
kidney cell line MDCK and in the rat brain endothelial cell line RBE4, the expression of ABCB1 
also promote increased in cell migration (Barakat et al., 2008). Moreover, another study which 
used wound closure assays to assess the cell migration of neuroblastoma cells in vitro was 
significantly reduced when both ABCC1 and ABCC4 were suppressed (Henderson et al., 
2011; Fletcher et al., 2016).  In a study the suppression of ABCA1 was found to inhibit ovarian 
cancer cell proliferation and migration (Ween et al, 2015). In another study, the suppression 
of ABCE1 by siRNA in small lung cancer cells inhibited cell proliferation, uneasiness and 
induce cell apoptosis, thus suggesting ABCE1 may be involved in small lung cancer 
tumorigenesis (Huang et al., 2010). 
 
Finally, the role of ABC transporters in cancer metastasis remain to be determined but several 
studies has shown that ABC transporters may be involved in cancer metastasis. For example, 
a study on human prostate carcinoma cell line found that the expression levels of mRNA, 
MMP-2, MMP-9, basic fibroblast growth factor (bFGF) and ABCB1 were high in highly 
metastatic cells compared to those in poorly metastatic parental cells line. This suggested that 
ABCB1 mediated both metastasis and drug resistance (Greene et al., 1997; Buzzoto et al., 
2010). Furthermore, another study found that high expression of ABCB1 in human hepatoma 
cells in vitro was correlated with an increase in invasive properties but not in low ABCB1 
expressing human hepatoma cells (Buzzoto et al., 2010).  
 
CD44 is a glycoprotein, a cell surface adhesion receptor, that is highly expressed in several 
cell types and in many cancers. Subsequently, CD44 has been shown to play a critical role in 
cancer development and progression, mediating metastasis, cell adhesion and tumorigenesis 
(Buzzoto et al., 2010; Senbanjo et al., 2017; Chen et al., 2018). Furthermore, a study found 
that the interaction of CD44 and ABCB1 is very important in modulating cancer cell migration, 
invasion along with multidrug resistance (Miletti-Gonzalez et al., 2005). 
 
A study which investigated the role of ABCB1 in the invasion potential of drug-resistant (M14 
ADR, ABCB1-positive) and drug-sensitive (M14 WT, ABCB1-negative) human melanoma 
cells were found to activate ERK1/2 and p38 MAPK pathways that stimulated the interaction 
of ABCB1 with CD44 causing an increased in proteolytic activity and in metalloproteinase 
(MMP-2, MMP-3 and MMP-9) mRNAs. In addition, when ABCB1 gene was knockdown, CD44 
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was not able to promote cell migration and invasion. As a result, ABCB1 was suggested to be 
an important component in cell migration as well as in the activation of ERK1/2 and p38 MAPK 
signalling (Colone et al., 2008). 
 
In addition, ABCC1 and ABCC4 have both been found to have a role in cancer development 
and progression in neuroblastoma. Suppression of both ABCC1 and ABCC4 in human 
neuroblastoma cell line inhibited tumour cell migration and cell proliferation. However, an 
overexpression of ABCC3 inhibits cell migration and proliferation. Therefore, this indicates that 
low levels of both ABCC1 and ABCC4 were correlated with a decrease in cell migration and 
proliferation whilst an increase in differentiation (Porro et al., 2010; Henderson, et al., 2011).  
 
Furthermore, in a breast cancer study, higher ABCC1 expression was detected in metastatic 
lymph nodes compared to the corresponding primary tumour (Fletcher et al., 2010). In another 
study using melanoma cancer cell lines, the cell lines derived from metastases were found to 
have higher expression of ABCC1 and ABCC4 genes compared to those derived from primary 
tumours (Fletcher et al., 2010). Therefore, in order to fully elucidate the role of ABC 
transporters in cancer metastases more direct lines of investigation will be required (Fletcher 
et al., 2010). 
 
1.8.3     The biological role of ABC transporters in cancer stem cells  
 
Pluripotent stem cells also known as the embryonic stem cells have the ability to self-renewal 
and form differentiated cells and tissues (Fletcher et al., 2010; Chagastelles et al., 2011). The 
expression of ABC transporters is significantly higher in both normal and cancer stem cells 
compared with their more differentiated progeny. Hence, this may suggest that stems cells are 
more protected from damage caused by xenobiotic substances and as such may have critical 
therapeutic implications with cancer stem cells, as the pluripotent cells in a tumour population 
may acquire a drug resistant phenotype, as a result may help to re-establish tumour in a similar 
manner to stem cell-driven recovery of normal tissue after chemotherapy (Dean et al., 2005; 
Fletcher et al., 2010; Moitra et al., 2015; Begicevic et al., 2017). However, it is not yet clear 
whether the cancer cell phenotype is influenced by the expression of ABC transporters or by 
other genetic changes during tumorigenesis (Fletcher et al., 2010; Begicevic et al., 2017). 
 
The involvement of ABC transporters in the regulation of stem cell differentiation is still not 
clear as current genetic evidence shows that the maintenance of normal stem cell 
compartment does not require any ABC transporters and that mice models deficient in Abcg2, 
Abcb1 or Abcc1 genes as well as deficient in both Abcb1 and Abcg2 genes did not affect their 
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development. Therefore, the regulation of cellular differentiation or stem cell maintenance may 
not require ABC transporters (Zhou et al., 2002 and 2003). However, because of the high 
expression of a large number of ABC transporters present in stem cells, it is suggested that 
the role of ABC transporters might have an important role in stem cell growth, differentiation, 
survival and maintenance which still needs to be elucidated (Fletcher et al., 2010; Begicevic 
et al., 2017; Adamska et al., 2018). 
 
Subsequently, ABC transporters has been associated with differentiation in several 
overexpression studies. For example, a study has demonstrated that ABCG2 is implicated in 
the efflux of androgens in prostate stem cells (Sabnis et al., 2017; Begicevic et al., 2017). 
Furthermore, under normal conditions ABC transporters are not required to maintain an 
undifferentiated state but may be required when upregulated in cancer (Fletcher et al., 2010). 
For several tumour types a correlation between poor patient outcome and a low degree of 
differentiation with the presence of transcriptional programmes was found to resemble closely 
to those seen in embryonic stem cells. Moreover, the impaired MYC gene expression can also 
induced such transcriptional programmes (Wong et al., 2008; Ben-Porath et al., 2008).  
 
The PI3K/Akt pathway activation is very important for stem cells pluripotency maintenance. 
Hence the viability and maintenance in certain cancer stem cells such as in prostate cancer, 
breast cancer and brain tumour, required the activation of the PI3K/Akt pathway (Zhou et al., 
2007; Hambardzumyan et al., 2008; Dubrovska et al., 2009, Zinzi et al., 2014). Furthermore, 
in a study, LY294002, a PI3K specific inhibitor was used to inhibit osteosarcoma cancer stem 
cells cell cycle inducing apoptosis while at the same time causing the inhibition of ABCG2, 
ABCB1 and ABCC1 in the stem cells. Thus suggesting that ABCG2, ABCB1 and ABCC1 may 
be involved in cancer stem cells differentiation and maintenance (Imai et al., 2012; Zinzi et al., 
2014; Begicevic et al., 2017). In addition, in melanoma stem cells, ABCB5 was found to 
regulate cellular differentiation and a study found that ABCB5 activates pro-inflammatory 
interleukin 1β/ interleukin 8 (IL1β/IL8) and chemokine receptor 1 (CXCR1) signallings to 
control the pro-inflammatory signallings and thus to maintain melanoma stem cells and 
promote tumour growth (Wilson et al., 2014; Begicevic et al., 2017).  
 
Therefore, due to high expression of ABC transporters in tumours, it is very important to 
elucidate their exact role in tumour development apart from their drug efflux abilities or whether 
they are simply present but does not have an effect in tumour development (Fletcher et al., 
2010).  
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1.8.4     Substrates of ABC transporters with relevance to cancer 
 
ABC transporters transport a wide range of physiological substrates, several of these 
substrates are signalling molecules with established roles in tumour biology. For many of these 
substrates, ABC transporters are either the most important or the only known efflux 
mechanism. These substrates include cyclic nucleotides, platelet activating factor (PAF), 
cholesterol metabolites, leukotrienes, prostaglandins and sphingosine-1-phosphate (S1P) 
(Table 1.10) (Fletcher et al., 2010). 
 
Table 1.10. Selected ABC transporters with their cancer-related substrates and their 
expression in cancer stem cell-like populations (Adapted from Fletcher et al., 2010 and 
Begicevic et al., 2017). 
ABC 
transporters 
 
Cancer-related cellular 
substrates 
Expression in cancer stem cell-like 
populations 
ABCA   
ABCA1 S1P and cholesterol Ovarian cancer 
ABCA2 Cholesterol Lung cancer and AML 
ABCA3 
 
Phospholipids Neuroblastoma 
ABCB   
ABCB1 PAF Lung cancer, glioma, ovarian, breast, 
renal and AML 
ABCB5 
 
ND Melanoma 
ABCC   
ABCC1 LTC4, PGA2, 15d-PGJ2, PGE2 
and S1P 
Squamous cell carcinoma lines, lung 
cancer cell 
lines, glioma and AML 
ABCC2 LTC4, PGD2, PGA1 and PGE2 ND 
ABCC3 LTC4 and 15-deoxy-Δ12,14-
prostaglandin J2 
ND 
ABCC4 LTB4, LTC4, PGA1, PGE1, PGE2, 
PGF1α, PGF2α, TXB2, cAMP and 
cGMP 
Osteocarcinoma 
ABCC5 cAMP and cGMP ND 
ABCC6 LTC4 ND 
ABCC10 LTC4 ND 
ABCC11 
 
LTC4, cAMP and cGMP ND 
ABCG   
ABCG2 cGMP Lung cancer, AML, oesophageal 
carcinoma, 
glioma, neuroblastoma, squamous cell 
carcinoma cell lines, melanoma, 
ovarian cancer 
and nasopharyngeal carcinoma cell 
lines 
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ABC, ATP binding cassette; cAMP, cyclic AMP; cGMP, cyclic GMP; LT, leukotriene; ND, not 
determined; PAF, platelet activation factor; PG, prostaglandin; S1P, sphingosine-1-
phosphate. Several substrates for ABCC1–4 are effluxed as either glutathione or glucuronide 
conjugates, or in a glutathione-dependent manner. 
 
 
 
1.8.4.1     Cyclic nucleotides 
 
Cyclic nucleotides are substrates of ABCC4, ABCC5, ABCC11 and ABCG2 and are important 
secondary messengers downstream of G protein-couple receptors (GPCR) that may be 
implicated in cancer biology (Jedlitschky et al., 2000; Wielinga et al., 2003; Guo et al., 2003; 
de Wolf et al. 2007; Russel et al., 2008; Sassi et al. 2008; Fletcher et al., 2010). However, due 
to their low affinities in cells, their biological relevance in the development of cancer is still not 
clear (Borst et al., 2004 and 2007), but recent studies have found that a decrease in 
extracellular and an in increased in intracellular cAMP was noticed when Abcc4 gene was 
downregulated in vitro, therefore the transport of cyclic nucleotide by ABCC4 may be of 
physiological significant in some systems (Lin et al. 2008; Fletcher et al., 2010). 
 
1.8.4.2     Platelet activating factor (PAF) 
 
PAF is a bioactive lipid that has been found to be a substrate of ABCB1 and is involved in 
various tumour-associated signals and functions such as in breast cancer angiogenesis 
(Montrucchio et al., 1998; Ragger et al., 2001). Furthermore a study found that the activation 
of its extracellular GPCR by PAF induced a secondary signalling pathway that caused an 
upregulation of the anti-apoptotic proteins, BCL-2 and BCL-XL in a nuclear factor-kB (NF-kB) 
dependent way leading to the inhibition of tumour cell apoptosis (Heon Seo et al., 2006). In 
addition, PAF has been shown to facilitate metastasis in colorectal cancer (Denizot et al., 
2005) and melanoma (Melnikova et al., 2006) as well as to enhance cell proliferation and 
motility, and contribute to angiogenesis in breast cancer (Bussolati et al. 2000). 
 
1.8.4.3     Cholesterol metabolites 
 
Many ABCA transporters are implicated in the regulation of lipid metabolism and transport 
(Albrecht et al., 2007). Cellular membranes are composed of cholesterol, an essential 
component of the lipid rafts which not only is important in bringing together cooperating 
membrane-bound proteins for optimal activation of phosphorylation cascades but is also 
important in mediating the division and rapid growth of tumour cells. Furthermore, several 
cancers have an impaired cholesterol metabolism. For example, one study found a lack of 
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circulating cholesterol for tumour growth and cell survival in the prostate cancer xenografts in 
immunodeficient mice. Additionally, a reduction in apoptosis, an increased in phosphorylation 
of Akt and tumour growth in prostate cancer were associated with an upregulation of 
cholesterol (Zhuang et al., 2005). Moreover, the rate of low density lipoprotein uptake and the 
availability of intracellular fatty acids, such as arachidonic acids can be influenced by 
intracellular cholesterol levels and cholesterol trafficking respectively (Hughes-Fulford et al., 
2001). Hence activating many important signalling intermediates. However, the direct link 
between the regulation of ABC transporters in effluxing lipid signalling intermediates and 
regulating cholesterol metabolism to its effect on tumour phenotype is unclear and that further 
studies are required (Fletcher et al., 2010). 
 
1.8.4.4     Leukotrienes 
 
Leukotrienes are eicosanoids which are chronic inflammatory mediators synthesised from 
arachidonate 5-lipoxygenase (ALOX5) pathway (Peters-Golden et al., 2007). The binding of 
leukotrienes to extracellular GPCRs activates signalling cascades that cause the activations 
of several signalling molecules including leukocyte invasive behaviour (Perter-Golden et al., 
2007), β-catenin which is essential in promoting cell proliferation and survival (Nielsen et al., 
2005; Mezhybovska et al., 2006; Ihara et al., 2007; Yang et al., 2017), and cause neutrophils 
to secret pro-angiogenic factors (Tazzyman et al., 2009). Furthermore, leukotriene 
biosynthetic enzymes are upregulated in various cancers such as in pancreatic cancer 
(Hennig et al., 2002; Moore et al., 2017) and studies have shown that successful inhibition of 
ALOX5 in animal models of lung cancer (Poczobutt et al., 2016), pancreatic cancer (Henning 
et al., 2002), prostate cancer (Sarveswaran et al., 2014) and chronic myeloid leukaemia 
(CML), and the knockdown of Alox5 gene in mouse model of BCR-ABL-induced CML, 
impaired the function of leukemic stem cells thus preventing the development of leukaemia 
(Chen et al., 2009; Fletcher et al., 2010).  
 
The efflux and release of LTC4 from leukotriene producing cells are greatly mediated by 
ABCC1 (Fletcher et al., 2010; Chen et al., 2010; Cole, 2014). Moreover, the release of LTC4 
was significantly reduced in the bone marrow-derived mast cells from Abcc1 deficient mice, 
thus exhibited a lack of response to leukotriene-inducing inflammatory stimuli (Fletcher et al. 
2010; Cole et al., 2014). Additionally, the mediation of the transport of LTC4 by ABCC1 has 
been found to be important in facilitating dendritic cell and T lymphocyte migration (van de 
Ven et al., 2006). Apart from ABCC1, many other ABCC subfamily of transporters including 
ABCC2, ABCC3, ABCC10 and ABCC11 are able to efflux LTC4 while ABCC4 is able to efflux 
both LTC4 and LTB4 (Cui et al., 1999; Rius et al., 2008; Chen et al., 2002). In a study, LTB4 
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was found to activate cell proliferation and induce ERK1/2 phosphorylation (Knab et al., 2014). 
Currently the therapeutic targets in leukotriene signalling are enzymes involved in leukotriene 
receptors and leukotriene synthesis, but with the implications of ABCC transporters in 
leukotriene signalling could provide additional or alternative therapeutic targets (Fletcher et 
al., 2010). 
 
1.8.4.5     Prostaglandins 
 
Some cancers proliferate and strive better in an inflammatory microenvironment which, also 
helps in promoting angiogenesis and metastasis. Prostanoids are members of eicosanoids 
which are mediators of chronic inflammation produced from arachidonic acid via the 
cyclooxygenase (COX) pathway (Figure 1.22) (Dannenberg et al., 2003; Fletcher et al., 2010).  
 
 
 
 
 
Figure 1.22. Prostaglandin biosynthesis. Arachidonic acid is first produced in a reaction 
catalysed by phospholipase A2. Then molecular oxygen is inserted into arachidonic acid in a 
catalytic reaction involving COX enzymes to produce an unstable intermediate prostaglandin 
G2 (PGG2) which is quickly converted to prostaglandin H2 (PGH2). After, the PGH2 reacts with 
specific isomerases to form different isoforms of prostaglandins (PGD2, PGE2, PGI2 and 
PGF2α) and thromboxane A2 (TxA2) (Dannenberg et al., 2003). 
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The importance of prostaglandin-mediated pathways in cancer has been well established from 
genetic evidence and clinical observation from mouse models of various tumour types 
including lung, colorectal, breast and liver cancers (Knab et al., 2014; Diakos et al., 2014). 
Numerous evidences has shown that COX is a critical enzyme in the production of 
prostaglandin and has two isoforms, COX-1 and COX-2. Both isoforms are equally important 
whereby COX-1 is essentially expressed in many tissues and COX-2 is a major therapeutic 
target as is often expressed in premalignant and malignant tissues (Dannenberg et al., 2003; 
Fulton et al., 2006; Greenhough et al., 2009). A study found that ABCC4 expression and 
function in lung cancer is regulated by COX-2 via the prostaglandin E synthase dependent 
pathway with an elevated PGE2 production (Maeng et al., 2014). Furthermore, other 
components of prostaglandin synthesis including the various prostaglandin receptors and the 
other downstream enzymes may form potential therapeutic targets (Chell et al., 2006; Reader 
et al., 2011; O’Callaghan et al., 2015; Majumder et al, 2018). 
 
The downward signalling of prostaglandin activates extracellular GPCRs in an autocrine or 
paracrine manner which, later activates other signalling pathways including the PI3K/Akt 
pathway (Tessner et al., 2004; Callaghan et al., 2015), which can lead to various responses 
such as the activation of β-catenin signalling and angiogenic factors such as vascular 
endothelial growth factor  (VEGF) to promote a progenitor-like phenotype and to stimulate 
angiogenesis respectively (Castellone et al., 2005; Xie et al., 2018), all to promote cell survival, 
proliferation, motility, angiogenesis and metastasis (Vivanco et al., 2002; Ding et al., 2003; 
Faes et al., 2015). In addition, prostaglandin signalling might promote inflammatory cells and 
impair the differentiation of dendritic cells as a way to stimulate tumour cells to escape 
immunosurveillance (Sombroek et al., 2002; Mantovani et al., 2008). 
 
Subsequently, many studies have concentrated on the receptors and enzymes of 
prostaglandin synthesis but the role of prostaglandin efflux is not well understood, particularly 
in cancers (Fletcher et al., 2010). One way prostaglandin is effluxed out of cells is through 
passive diffusion but such process is very inadequate as prostaglandin transporters (PGTs) 
and other transporters help the re-uptake of prostaglandin which later undergo intracellular 
oxidation by 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (Schuster, 2002; Tai et al., 
2002; Nomura et al., 2004; Majumder et al., 2018). Several ABCC transporters have been 
found to facilitate the efflux of prostaglandin and are a major transport mechanism of 
prostaglandin in cancer cells where often these transporters are highly expressed (Fletcher et 
al., 2010). In addition, PGE2, an isoform of prostaglandin, is a substrate of ABCC4 and is 
implicated in cancer progression such as inhibition of apoptosis and induction of angiogenesis 
and proliferation (Reid et al., 2003b; Knab et al., 2014; Cole, 2014; Kochel et al., 2015 and 
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2016). Studies have found that in human colorectal cancer specimen and cell lines, the 
expression of ABCC4 is high but the expression of prostaglandin transporter (PGT) is low, 
thus suggesting that with an increased prostaglandin efflux and a decreased re-uptake, 
enhanced prostaglandin signalling could occur (Holla et al., 2008). Furthermore, in another 
study found that the suppression of ABCC4 decreases metastases of triple negative breast 
cancer cells and was suggested to be correlated with the accumulation of PGE2 in the tumour 
microenvironment (Kochel et al., 2017). 
 
Additionally, cyclopentenone prostaglandins, a subset of prostaglandin, consisting of 15-
deoxy-12,13-didehydro-14,15-didehydro-PGJ2 (15d-Δ12,14-PGJ2), 12,13-didehydro-PGJ2 
(Δ12-PGJ2) and PGA2, are actively transported into cells and mediate a variety of gene 
expressions. Ultimately, 15d-Δ12,14-PGJ2 and PGA2, have been found to activate intracellular 
nuclear receptors such as peroxisome proliferator-activated receptor-Ƴ (PPARƳ)  but not 
GPCR to trigger various responses to inhibit proliferation as well as tumorigenesis and induce 
apoptosis (Negishi et al., 2002; Piva et al., 2005; Musiek et al., 2005; Koyani et al., 2014). 
However, majority of the efflux of glutathione-conjugated 15d-Δ12,14-PGJ2 and PGA2 is via 
ABCC1 and ABCC3 (Evers et al., 1997; Paumi et al., 2003; Cole et al., 2014) . Moreover, a 
study found that ABCC1 and ABCC3 expressions may influenced the activities of 15d-Δ12,14-
PGJ2 by preventing the cytotoxicity of breast cancer cells. Therefore, ABC transporters are 
very important components in prostaglandin signalling in that they transport pro-tumorigenic 
prostaglandin to activate their extracellular GPCRs and at the same time efflux anti-
tumorigenic cyclopentenone prostaglandins to prevent the intracellular activation of their 
downstream signalling, all in all to help promote tumorigenesis (Fletcher et al., 2010). 
 
1.8.4.6     Sphingosine-1-phosphate (S1P) 
 
S1P together with ceramide (Cer), sphingosine (Sph), and Cer-1-phosphate (C1P) are 
bioactive molecules representing a major class of lipids known as sphingolipids (SLs) that play 
a critical role in regulating cell signal transduction, differentiation, cell growth and apoptosis 
(Lahiri et al., 2007; Bartke et al., 2009; Pralhada Rao et al., 2013). The synthesis of S1P 
involve a series of catalytic reactions whereby ceramide is first converted to sphingosine using 
ceramidase (CDase) and after phosphorylated by sphingosine kinases (SK1 and SK2) to form 
S1P (Figure 1.23) (Lahiri et al., 2007; Bartke et al., 2009; Fletcher et al., 2010). 
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Figure 1.23. The metabolism of sphingolipids. The bioactive sphingolipids metabolites are 
highlighted in red. Ceramide can be produced by the de novo pathway that involve a series of 
catalytic reactions involving serine palmitoyl transferase (SPT), (dihydro) ceramide synthase 
(CerS, or Lass), and dihydroceramide desaturase (DES), or via the hydrolysis of 
sphingomyelin (SM) by sphingomyelinases (SMases). Ceramide can also be a precursor for 
the synthesis of SM catalysed by SM synthase (SMS) and involving the hydrolysis of 
phosphatidylcholine (PC) to diacylglycerol (DAG), the formation of glucosylceramide by 
glucosylceramide synthase (GCS), or galactosylceramide, and ceramide-1- phosphate (C1P) 
by catalystic reactions involving ceramide kinase (CK). Ceramide can be hydrolysed by 
ceramidases (CDases) to form sphingosine, which can be further converted to sphingosine-
1-phosphate (S1P) by sphingosine kinase (SK). S1P can react with S1P lyase to form lipids 
and ethanolamine-1-phosphate. Moreover, dephosphorylation of Cer1P or S1P or C1P 
phosphatase C1PP and Sphphosphate phosphatase SPPase, respectively produce ceramide. 
(Ogretmen, 2006; Bartke et al., 2009). 
 
 
 
Furthermore, S1P can mediate its action intracellularly such as the mediation of pro-apoptotic 
precursor ceramide and SK1 to inhibit apoptosis and the induction of calcium release from 
endoplaspic reticulum but currently little is known about the intracellular targets of S1P (Strub 
et al., 2010; Berdyshev et al., 2011). However, recently evidences found that S1P can bind 
and change the function of certain intracellular proteins including TNF receptor-associated 
factor 2 (TRAF2), histone deacetylases (HDACs), protein kinase C delta (PKCδ), prohibitin 2 
(PHB2) and β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) (Maceyka et 
al., 2011). On the other hand, through five high-affinity GPCRs, S1P has been found to 
mediate important biological actions extracellularly including cell migration, differentiation, 
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proliferation and cytoskeletal organisation (Taha et al., 2004; Ishii et al., 2004; Young et al., 
2006; Strub et al., 2010).  
 
Consequently S1P has also been found to promote angiogenesis by encouraging the 
formation of blood vessels and stimulation of endothelial cells migration, possibly mediated 
through extracellular S1P receptors, Edg-1 and Edg-2 (Kimura et al., 2000). Studies using 
SK1 and SK2 double knockout mice and S1P receptor-knockout mice have shown a deficiency 
in the formation of blood vessel thus emphasising that S1P is important in angiogenesis (Liu 
et al., 2000; Mizugishi et al., 2005; Argraves et al., 2010). Another study has shown that the 
tumour progression in mouse xenograft and allograft was extensively diminished after 
treatment with a S1P-specific monoclonal antibody, possibly by blocking S1P signalling 
pathways that facilitates tumour angiogenesis, proliferation and metastasis. As a result S1P 
is a key component in promoting tumour angiogenesis (Visentin et al., 2006). Apart from 
facilitating angiogenesis, S1P also helps tumour cells to escape apoptosis and encourage 
tumour cell proliferation, invasion, metastasis as well as protecting tumour cells from apoptosis 
(Kimura et al., 2000; Maceyka et al., 2002; Visentin et al., 2006; Huang et al., 2011). In 
addition, S1P has been found to be a key component in mediating the invasiveness of cancer 
cells such as in human glioblastoma cancer cell lines (van Brocklyn et al., 2003; van Brocklyn, 
2007; Mahajan-Thakur et al., 2017). Moreover, the production of PGE2 and the expression of 
COX-2 have been suggested to be mediated by S1P (Pettus et al., 2003; Hsu et al., 2015; 
Rumzhum et al., 2015; Cheng et al., 2016).  
 
Evidence also has pointed that a reduction in S1P efflux was observed in Abca1-deficient 
astrocytes thus confirming that potent S1P efflux may be mediated by ABCA1 (Sato et al., 
2007; Takabe et al., 2008). ABCA1 is also associated in S1P efflux in epithelial ovarian cancer 
and its expression was associated with poor outcome of ovarian cancer. Thus suggesting that 
the transport of S1P by ABCA1 may promote angiogenesis in ovarian cancer (Hedditch et al., 
2014). Additionally, when ABCC1 gene was knockdown in mast cells, the efflux of S1P was 
substantially reduced thus suggesting that ABCC1 is a major transporter for the efflux of S1P 
in mast cells that may influence migration of mast cells to antigen (Mitra et al., 2006; Alvarez 
et al., 2007). ABCG2 has also been implicated in S1P transport. In a study, using MCF-7 
breast cancer cells, it was found that estradiol stimulated the production of S1P whose efflux 
was mediated by ABCC1 and ABCG2. However, the efflux of estradiol-induced S1P was 
suppressed when ABCC1 and ABCG2 genes were inhibited by either gene silencing or 
pharmacological inhibitors (Takabe et al., 2010; Reitsema et al., 2014).  In another study, the 
export of S1P by ABCC1 lead to a decrease in survival of mice and patients with breast cancer 
(Yamada et al., 2018). A study also found that ABCC4 is responsible for the efflux of S1P from 
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platelets (Vogt et al., 2018).   Apart from ABC transporters as the efflux mechanisms for S1P, 
other transporters such as SPNS2 transporter have also been identify to transport S1P. 
Nonetheless the implication of these mechanisms to tumour biology remains to be determined 
(Fletcher et al., 2010; Bradley et al., 2014; Reitsema et al., 2014). 
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1.9     Project aims and objectives 
 
The most common cancer in women is breast cancer, affecting 1.38million women worldwide 
(Martin, et al., 2014). Following the recent research that has shown the role of ABCC1 and 
ABCC4 have in neuroblastoma development and progression (Henderson, et al., 2011) as 
well as the role of ABCC4 in lung cancer and leukaemia progression (Copsel, et al., 2011; 
2014; Zhao, et al., 2014), the aim of the project was to investigate whether ABCC1 and ABCC4 
have an important role in breast cancer development or progression independent of cytotoxic 
efflux. 
 
Several studies of ABCC1 in breast cancers have shown that a high expression level of 
ABCC1 leads to a reductions in both overall survival and time relapse. Furthermore, there is 
a link between patient relapse-free survival and ABCC1 expression. In addition, patients 
treated with anthracycline-based therapy regime show a correlation between ABCC1 and 
progression-free survival but not in patients treated without anthracyclines alone (Lage, 2003). 
Thus for early-stage breast cancer, ABCC1 expression can be used as a negative prognostic 
marker. Studies also have found that ABCC1 may play an important role in breast cancer as 
high level of expression of ABCC1 in breast cancer lymph node metastases were reported. 
Furthermore, certain drugs such as methotrexate used to treat metastatic breast cancer can 
be mediated by ABCC1 (Munoz, et al., 2007). However, more work is needed to elucidate the 
exact role and mechanism of ABCC1 in breast cancer (Lage, 2003). 
 
In the case of ABCC4, substantial studies have been carried out showing high expression 
levels of ABCC4 in certain cancers. One study found that when anticancer and antiviral drugs 
were transported in human cervix cancer cells, ABCC4 was upregulated after COX-1 down 
regulation (Radilova, et al., 2009). Recently, ABCC4 was found to be one of the most 
commonly up regulated transcript in prostate cancer (Montani, et al., 2013). Moreover, there 
are studies showing that ABCC4 is involved in the regulation of gastric cancer and pancreatic 
cancer (Chen, et al. 2014; Carozzo, et al., 2015). Furthermore, Norris, et al., 2005 have 
confirmed that ABCC4 is a marker of poor prognosis in neuroblastoma. Recently, ABCC4 was 
shown to be expressed in breast cancer cells (Kochel, et al., 2015) but there is a limited 
amount of work done on ABCC4 in breast cancer. Therefore, work still needs to be done to 
determine the exact mechanism of ABCC4 in cancers. 
 
Since ABCC1 and ABCC4 transport a wide variety of bioactive substrates that mediates 
various signalling pathways that regulate cell proliferation, migration, metastasis, invasion, 
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differentiation and apoptosis as previously mentioned. This thesis hypothesises that ABCC1 
and ABCC4 are involved in breast cancer proliferation, migration and invasion.  
 
Research was conducted in vitro using breast cancer cell lines MCF-7 and MDA-MB231 cells 
to carry out a series of cellular functional assays such as colony formation assay to determine 
cell proliferation, scratch assay to determine cell migration, MTT assay to determine cell 
viability, transwell invasion assay to determine cell invasion capacity and Western blotting and 
reverse transcription polymerase chain reaction (RT-PCR) to detect RNA expression of ABC 
transporter proteins. 
 
Both MCF-7 and MDA-MB231 breast cancer cells are invasive with MCF-7 considered to be 
luminal-type breast cancer with the presence of progesterone, oestrogen and human 
epidermal growth factor 2 (HER2) receptors. However, MDA-MB231 is considered to be a 
basal-type breast cancer without progesterone, oestrogen and HER2 receptors (Triple 
negative). 
 
The effects of ABCC1 and ABCC4 inhibitors were investigated, as well as the effect of 
knockdown or overexpression of these proteins. Finally preliminary investigations were 
undertaken to investigate possible mechanisms by which these proteins might affect cancer 
progression. 
 
The results obtained will be a starting point to suggest these proteins might have a role in 
breast cancer cell migration and/or proliferation and thus open up new possible therapeutic 
targets for breast cancer.  
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Chapter 2 – Materials and methods 
 
2.1     Cell lines  
 
2.1.1     HeLa cells  
 
The HeLa cells are a human epithelial carcinoma cell line from a fatal cervical carcinoma 
obtained from Henrietta Lacks, in 1951, who was suffering from cervical cancer. HeLa sticks 
to surfaces thus are adherent cells and in vitro they maintain contact inhibition (Fertey et al., 
2011). 
 
2.1.2     MDA-MB231 cells 
 
The MDA-MB231 is a human breast cancer cell line acquired at M.D. Anderson Cancer Centre 
in 1973 from a patient. The MDA-MB231 cells looks like spindle shaped epithelial cells. The 
cell line has an invasive phenotype in vitro and is adherent cells (Kenny et al., 2007). 
 
2.1.3     MCF-7 cells 
 
The MCF-7 is a human breast cancer cell line obtained from malignant adenocarcinoma breast 
tissue that was first isolated from a 69-year old woman in 1970. The MCF-7 cells got their 
name from the institute, Michigan Cancer Foundation-7, in Detroit. The MCF-7 cells are 
adherent cells capable of forming epithelial and domes like cells when grown in vitro (Kenny 
et al., 2007). 
 
2.1.4     HEK293T cells 
 
The HEK293T is a human embryonic kidney cell line first isolated from human embryonic 
kidney and later was used to produce effectively glycosylated human recombinant proteins, 
adenovirus and other viral vectors. As a result, the HEK293T cell line is often transfected to 
express recombinant proteins and used for virology studies (Dalton et al., 2014). The 
HEK293T cells are adherent cells. 
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2.2     Basic cell culture laboratory techniques 
 
All cell culture works were carried out in a sterile environment in a cell culture hood 
(HERAsafe) and cells were incubated in an incubator at temperature of 37oC with 5% CO2. 
The work surfaces, the surrounding area and equipment used were thoroughly disinfected 
with 70% Industrial methylated spirit (IMS) (ThermoFisher) before and after use. Any spillage 
was quickly wiped with 70% IMS. 
 
2.2.1     Cell passaging  
 
2.2.1.1     Buffers and reagents 
 
Prewarmed DMEM (1X) (Dulbecco’s Modified Eagle’s Medium) (Lonza) with 4.5 g/L glucose 
and L-glutamine was supplemented with 10% v/v FBS (Foetal Bovine Serum) (Gibco® by Life 
TechnologiesTM), 100 U/ml Penicilin and 0.1 mg/ml streptomycin (Sterile filtered Penicillin-
Streptomycin solution 100x, Biowest). 
 
Sterile filtered DPBS (Dulbecco’s Phosphate Buffered Saline) (Biowest) (GE Healthcare Life 
Sciences). 
 
0.25% Trypsin-EDTA (1X) (Gibco® by Life TechnologiesTM). 
 
2.2.1.2     Procedure for passaging cells 
 
After prewarming culture medium at 37oC in a water bath, cells in T-75 flask were checked 
under microscope (10X) to confirm at least 80% confluency. Culture medium in the flask was 
discarded into a waste bottle and 5 - 6 ml of DPBS was added in the flask. The flask was 
gently swirled and DPBS was discarded. Cells were then trypsinised with 2 ml of trypsin-EDTA 
placed in an incubator (37oC, 5% CO2) for 1 - 2 minutes or until cells were fully dislodged from 
the surface. 6 ml of fresh culture medium was added in the flask to inhibit trypsin. The cell 
suspension was then centrifuged at 230 x g and resuspended in 10 ml fresh culture medium. 
10 ml of fresh culture medium was added to a new flask. Then 2 ml of suspension cells were 
added to the new flask (1:5 split) and was gently swirled to ensure even spreading of cells in 
the flask. Cells were then incubated at 37oC with 5% CO2. Cells usually took 2 - 3 days to 
reach at least 80% confluency. Different cell line grows at a different rate, therefore cells were 
constantly monitored to ensure cells grow healthily. 
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2.2.2     Freezing cells 
 
2.2.2.1     Buffers and reagents 
 
Cryoprotective Medium (Basal Eagle Medium with Hanks’ BSS and 15% dimethylsulphuroxide 
without L-glutamine) (Lonza). 
 
 2.2.2.2     Cryopreserving cultured cells 
 
After adding culture medium to trypsinised cells, the suspension cells were pipetted in a 
centrifuge tube and centrifuged at 60 x g for 5 minutes. The supernatant was discarded and a 
ratio of 1:1 of fresh cell culture medium and cryoprotective medium were added to the cell and 
mixed thoroughly by pipetting up and down. The cell suspension was then aliquoted into 
cryovials (1 ml) and placed in the cryo-freezing container (“Mr. Frosty”), which was then placed 
at -80oC. After two days the cryovials were removed from the cryo-freezing container and kept 
at -80oC.  
 
2.2.3     Thawing frozen cells 
 
10 ml of prewarmed culture medium was added to a T-75 tissue culture flask. The frozen cells 
were thawed at 37oC and the cell suspension was quickly added to prewarmed culture 
medium, which was then placed in the incubator (37oC, 5% CO2). Since the cryoprotective 
medium contains DMSO that may dissolve the cell membrane, the cell culture medium was 
replaced up to 3 times with fresh culture medium so as to completely remove the DMSO to 
obtain optimum cell recovery. 
 
2.2.4     Cell counting 
 
The cell suspension was mixed with trypan blue (0.2% v/v) at a ratio of 1:4. 10 µl of the cell 
mixture was loaded in a chamber of the hemocytometer under the coverslip and placed under 
the microscope at a magnification of x10. The unstained cells (live cells) in the 4 corner 
squares were counted (those that fall on the top and right edges of the squares were counted). 
Once a total cell count was obtained cell concentration was calculated from the following 
formula (Equation 1). 
 
Total cells per ml = Total cells counted ×
dilution factor
# of squares
 ×10,000 cells per ml  (Equation 1) 
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2.3     Using ABCC inhibitors in cell proliferation and migration assays 
 
2.3.1     Colony formation assay 
 
The colony formation assay is an in vitro cell survival assay that determines the ability of a cell 
to grow in to a colony after being treated with cytotoxic agents or any kind of inhibitors. There 
should be at least 50 cells clustered together to make a colony (Franken et al., 2006). 
 
2.3.1.1     Buffers and reagents 
 
Fixing reagent – 4% w/v paraformaldehyde in DPBS (PFA) (Fisher Scientific). 
Staining reagent – 0.1% w/v crystal violet in water (Acros Organic). 
 
Table 2.1. ABC inhibitors used. 
Inhibitors Inhibits 
ABCC1 
Inhibits 
ABCC4 
Concentration  supplier Reference 
MK571   50 µM and 100 
µM 
Sigma® life 
science 
Tivnan et al., 
2015 
 
Indomethacin X  10 µM and 30 
µM 
Sigma® life 
science 
Bai, et al., 
2004 
 
Reversan  X 10 µM and 30 
µM 
Tocris bioscience Tivnan et al., 
2015 
 
Ceefourin 1 X  10 µM and 30 
µM 
Abcam 
Biochemicals® 
Cheung, et 
al., 2014 
 
Ceefourin 2 X  10 µM and 30 
µM 
Abcam 
Biochemicals® 
Cheung, et 
al., 2014 
 
 
 
 
2.3.1.2     Colony formation assay  
 
After cells were trypsinised with trypsin-EDTA, prewarmed fresh cell culture medium was 
added to the trypsinised cells. The cell suspension was then centrifuged at 230 x g for 5 
minutes and resuspended in fresh cell culture medium. The cell suspension was passed 
through a cell strainer (40 µm nylon mesh) (Fisher Scientific) to ensure cells were single, not 
clumps. The strained cells were then counted and 100 cells were seeded per well of a 6-well 
plate, which contained 3 ml of fresh culture medium per well. The cells were incubated at 37oC 
for 24 hours.  After 24 hours, the cells in each well were treated with each inhibitor at various 
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concentrations (Table 2.1) from a stock solution prepared in DMSO. Each condition was 
repeated at least 3 times. 
 
After 7 days of incubation at 37oC, the culture medium was removed and 1 ml of 4% w/v PFA 
was added to each well and were left at room temperature for 20 minutes. The 4% w/v PFA 
was then removed and 0.5 ml of 0.1% w/v crystal violet was added and left at room 
temperature for 5 minutes.  The crystal violet was then removed and the wells were washed 
thoroughly with water and were left to dry in open air at room temperature. The colonies formed 
were counted manually using a transparent film and a fine marker. 
 
2.3.2     Scratch assay 
 
One assay commonly adapted and modified to study mammalian cell proliferation and 
migration in response to a variety of experimental conditions such as chemical exposure in 
vitro is the scratch assay. The Scratch assay is a straightforward assay whereby a scratch (a 
gap) in the cell monolayer is created and the cell motility and growth are monitored to 
determine the rate of migration of cells towards the centre of the gap. Different experimental 
conditions will alter the rate of cells closing the gap (Liang, et al., 2007). 
 
In our lab, the scratch assay was performed using the Cell-IQ (CM Technologies – Intelligent 
cell analysis). The Cell-IQ is an advanced incubator which has a time lapse imaging system 
where by image positions were set at certain time intervals for a period of time and images 
were automatically taken at that time interval set. A patented cell secure plate lid was used to 
keep cultures from contamination. Furthermore, to avoid CO2 fluctuations when incubator door 
is being opened or closed, CO2 is directly fed into the culture plate. 
 
2.3.2.1     Cell-IQ scratch assay  
 
Cells were seeded in a 24-well plate from 1 x 105 to 6 x 105 cells to determine which cell 
seeding density is best to reach 100% confluency after 24 hours incubation. After identifying 
the cell seeding density of a cell line, that seeding density was used throughout the assay for 
that cell line. 
 
The cells were incubated at 37oC for 24 hours after which a scratch on the monolayer of cells 
was carefully performed using a 10 μl pipette tip. The culture medium was removed from the 
wells and the cells were carefully washed with sterile DPBS as much as possible not to disturb 
the scratch and the monolayer of cells. After washing, fresh prewarmed culture medium was 
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carefully added to the cells. The cells were then treated with inhibitors as detailed in table 2.1. 
Each condition was repeated at least 3 times. 
 
Distilled water was added in between the wells and the plate was sealed with insulation tape 
together with the patented cell secure plate lid, the plate was placed in Cell-IQ as indicated in 
the instruction guide. Three image positions were allocated for each well, with images being 
taken every 1 hour for 24 hours. After 24 hours, imaging was stopped manually and the image 
results were analysed using the Cell-IQ analysis software. 
 
2.3.3     MTT (Thiazolyl blue tetrazolium bromide) Assay 
 
The MTT assay is an in vitro cell proliferation and viability assay used to measure the cell 
proliferation or cell metabolic activities in response to external factors such as exposure to 
chemical reagents. The principle behind MTT assay is that under defined conditions the 
dehydrogenase enzymes, NAD(P)H-dependent cellular oxidoreductase enzymes may reflect 
cell viability. The yellow tetrazolium MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium 
bromide) is reduced by these enzymes to form insoluble formazan, which is purple in colour 
(Figure 2.1). To solubilise the insoluble formazan, DMSO is added and a purple solution is 
produced. Depending on light absorbance of this solution, will indirectly measure how viable 
the cells are (Riss, et al., 2013). 
 
 
 
 
Figure 2.1. Structures of MTT and colored formazan product. MTT is being converted into 
a purple coloured formazan product with an absorbance of 570 nm by the active metabolism 
involving NADH in viable cells. The intensity of the colour is an indication of the amount of 
viable cells present. Cells, which have died, are unable to convert MTT into formazan (Riss, 
et al., 2013). 
 
 
 
2.3.3.1     Buffers and reagents 
 
Thiazolyl Blue Tetrazolium Bromide (Sigma® life science) – 5 mg/ml in DPBS. 
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2.3.3.2     MTT assay  
 
15000 cells (HeLa and MCF-7) or 6000 cells (MDA-MB231) were seeded per well of a 24-well 
plate and for each well, 400 µl of prewarmed fresh culture medium was added. The cells were 
incubated at 37oC for 4 hours after which cells were treated with inhibitors as detailed in table 
2.1. 
 
The cells were then left to incubate for 6, 12, 24, 48 or 72 hours at 37oC. Once incubation time 
was complete, 40 µl of MTT reagent was added to each well. The cells were incubated for 1 
hour at 37oC.  The culture medium was removed from the wells and the wells were left to air 
dry at 37oC for 5 mins. After the wells were dried, 400 µl of DMSO (Fisher Scientific) were 
added to each well and the plate was left to incubate at 37oC for 10 mins. 100 µl of each 
sample were transferred into a 96-well plate in triplicates. The absorbance values were read 
at 570 nm using multiskan Go microplate reader (ThermoScientific). 
 
2.3.4     Determining cell viability and growth by manual counting  
 
In order to distinguish between dead and live cells, trypan blue is often used, as it stains dead 
cells leaving live cells unstained. Such method is often used to determine cell viability. 
However, trypan blue staining does not distinguish the cells that are alive but lost cell function 
to healthy cells. Therefore, in this project trypan blue staining was used as a second cell 
viability assay to MTT assay. 
 
2.3.4.1     Buffers and reagent 
 
Trypan blue solution (0.4% w/v) (Sigma Life Science) was diluted in DPBS at a ratio of 1:1. 
 
2.3.4.2     Trypan Blue cell viability assay  
 
15000 cells (HeLa and MCF-7) or 6000 cells (MDA-MB231) were seeded per well of a 24-well 
plate. Each well contained 400 µl of culture medium. The cells were incubated for 4 hours 
after which the cells were treated in duplicates with a concentration of an inhibitor as detailed 
in table 2.1, and each condition was repeated at least 3 times.  The cells were left to incubate 
at 37oC for 6, 12, 24, 48 or 72 hours. 
 
Once the incubation time was over, the culture medium in each wells was discarded and the 
wells were washed twice with DPBS and the cells were detached with trypsin-EDTA. A cell 
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suspension was created with culture medium after which was centrifuged at 230 x g for 5 
minutes room temperature. The supernatant was discarded and the cells were suspended in 
culture medium and ready to count according to the cell counting protocol (Section 2.2.4). 
 
2.4     Cell transfection 
 
2.4.1     Standard siRNA transfection of mammalian cells 
 
Gene silencing refers to mechanisms other than genetic modification whereby mRNA 
translation or transcription of a target gene, is being suppressed or interrupted. Gene silencing 
can be obtained by small RNA molecules known as miRNA and siRNA (Shah, et al., 2012). 
 
In order to ensure efficient gene silencing and reproducible transfection, INTERFERin, a 
powerful siRNA transfection reagent was used. At 1 nM siRNA, INTERFERin can provide 
more than 90% silencing efficiency in a wide variety of cells, hence reducing off-targets effects 
as stated from the manufacturer’s guide. 
 
The ABCC1 and ABCC4 genes were suppressed through silencing RNA (siRNA) knockdown 
using INTERFERin in vitro siRNA transfection reagent.  
 
2.4.1.1     Buffers and reagents 
 
OptiMEM – reduced serum medium (Gibco® by Life Technologies) 
INTERFERin TM transfection reagent (Polyplus Transfection®)  
ABCC1 siRNA (SASI_Hs01 00155530) (Sigma) 
ABCC1 siRNA (SASI_Hs01 00155531) (Sigma) 
ABCC4 siRNA (SASI_Hs02 00324134) (Sigma) 
ABCC4 siRNA (SASI_Hs02 00324135) (Sigma) 
Sigma-mission siRNA universal negative control (Sigma)  
                  
The stock concentration of the siRNAs were at 100 µM in OpiMEM. 
The working concentration of siRNAs were 1 nM per well of a 24-well plate.             
All dilutions were done in OptiMEM. 
 
2.4.1.2     Gene knockdown using siRNA 
 
On day one, 25000 cells were seeded per well of a 24-well plate according to the INTERFERin 
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manual. The cells were seeded in 1 ml of fresh culture medium and the plate was swirled 
gently for homogenous coverage of cells. The next day, transfection complexes were made 
by adding siRNA to 100 µl of OptiMEM after which 2 µl of INTERFERin was then added and 
the mixture was immediately mixed by vortexing for about 10 secs to achieve a final 
concentration of 1 nM of siRNA in cell culture. The transfection complexes were allowed to 
form on incubation at room temperature for 10 - 15 minutes. After incubation, 100 µl of the 
transfection complexes were added to the wells and the plate was swirl for even dispersing of 
the RNAi complexes. The plate was incubated for 72 hours. Constant monitoring of cells was 
necessary and a change of fresh culture medium was required when high cell death was 
observed. On day five, the transfected cells were harvested and stored at -20oC or were used 
for further experiments. 
 
2.4.2     Amplification of plasmid DNA 
 
Plasmids; pcDNA3.1 empty vector, pcDNA3.1 – ABCC1, pcDNA3.1 – ABCC4 (Kind gift from 
Prosfessor Susan Cole, Queen’s University, Kingston, Ontario, Canada). 
 
2.4.2.1     Bacterial media 
 
Luria-Bertani (LB) broth -  For liquid broth 20 g LB (Melford Bioscience) dissolved in 1 L distilled 
water and autoclaved. For selective media, ampicillin stored at -20oC at a concentration of 100 
mg/ml was added to a final concentration of 100 μg/ml. 
 
For LB agar a packet of E.coli fast-media (X-gal agar) (Invivogen) was dissolved in distilled 
water according to manufacturer’s instructions. Once the LB agar was made, it was 
supplemented with 100 μg/ml ampicillin and equal volume of agar was pipetted into petri 
dishes and left to set. The agar plates were stored upside down at 4oC. 
 
2.4.2.2     E.coli transformation 
 
An aliquot of 500 μl of DH5-alpha E.coli chemically competent cells was thawed on ice and 
mixed gently by flicking and/or inverting tube with 1 μl of desired plasmid. The competent cells 
were then left on ice undisturbed for 20 minutes before heat shock at 42oC for 30 seconds 
without mixing. After heat shock, the competent cells were left on ice for 2 minutes without 
mixing. 500 μl of LB media without antibiotics was added immediately to the competent cells 
and incubated for 1 hour at 37oC with 200 rpm shaking. The mixture was spread on LB-
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ampicillin agar plates and incubated at 37oC for 24 hours after which they were kept for a 
maximum of 3 months at 4oC. 
 
2.4.2.3     Inoculating a liquid bacterial culture 
 
10 ml of LB medium was poured in a universal tube with ampicillin added to a final 
concentration of 100 μg/ml. A colony of the transformed E.coli used to inoculate the culture 
which was then incubated for 8 - 12 hours at 37oC with 200 rpm shaking.  
 
2.4.2.4     Plasmid DNA Mini prep 
 
The plasmid isolation from transformed E.coli cells were obtained by using the GeneJET 
Plasmid Miniprep kit (ThermoFisher Scientific) according to manufacturer’s instructions. 
 
2 ml of overnight culture of E.coli competent cells containing the desired plasmid was subject 
to centrifugation at 6800 x g in a microfuge for 30 seconds. The pellet was then resuspended 
completely in 250 μl of the resuspension solution. 250 μl of the lysis solution was added to the 
resuspended cell pellet and mixed thoroughly by inverting the tube 4 - 6 times until the solution 
becomes viscous and slightly clear. 350 μl of the neutralisation solution was then added to the 
solution and mixed immediately and thoroughly by gently inverting the tube 4 - 6 times. The 
solution was centrifuged for 5 minutes at 14000 x g in a microfuge to pellet chromosomal DNA 
and cell pellet and the supernatant obtained was carefully transferred to the supplied GeneJet 
spin column. The column was centrifuged for 1 minute at 14000 x g and the flow-through was 
discarded and the column was placed back into the same collection tube. 500 μl of the wash 
solution was added into the column and centrifuged for 1 minute. The flow-through was 
discarded and the column was placed back into the same collection tube.  The wash step was 
repeated one more time after which column was centrifuged an additional 1 minute at 14000 
x g to remove residual wash solution. The column was after transferred into a fresh 1.5 ml 
microfuge tube and 50 μl of distilled water was added to the centre of the column. The column 
was then incubated for 2 minutes at room temperature and centrifuged for 2 minutes at 14000 
x g. The eluted plasmid DNA was aliquoted and stored at -20oC. 
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2.4.2.5     Plasmid DNA Max prep 
 
2.4.2.5.1     Buffers and reagents 
 
Solution 1 – 50 mM Tris-hydrochloric (Tris-HCl) pH 8.0 and 10 mM ethylenediaminetetraacetic 
acid (EDTA) were mixed in distilled water and stored at 4oC. Upon use, RNase at final 
concentration of 50 μg/ml was added and the solution was sterile filtered using 0.45 μm syringe 
filters. 
 
Solution 2 – 200 mM sodium hydroxide (NaOH) and 1% w/v SDS were mixed in distilled water 
and stored at room temperature. Upon use, the solution was sterile filtered using 0.45 μm 
syringe filters. 
 
Solution 3 – 3 M potassium acetate was dissolved in distilled water and pH 5.5 was adjusted 
using glacial acetic acid. Upon use, the solution was sterile filtered using 0.45 μm syringe 
filters. 
 
2.4.2.5.2.     Maxi prep procedure 
 
200 µl of an inoculated overnight culture was added to 200 ml of LB medium with ampicillin at 
working concentration of 100 μg/ml was incubated for 18 - 22 hours at 37oC with 200 rpm 
shaking. The cells were centrifuged for 20 minutes at 2550 x g at 4oC. The supernatant was 
discarded and the cell pellet was resuspended in 5 ml of solution 1 by thoroughly vortexing. 
Once the cells were resuspended, 5 ml of solution 2 was added to the cell suspension and 
incubated for 5 minutes at room temperature. After incubation, 5 ml of solution 3 was added 
to the suspension by vortexing, followed by incubation for 30 minutes at 4oC. The suspension 
was then poured into a 50 ml tube and centrifuged for 20 minutes at 4000 rpm in Beckman 
table top centrifuge at 4oC. A sterile forceps was then used to fish off the fat layer swimming 
on top of the supernatant. The supernatant was sterile filtered using 0.45 μm syringe filters 
into a new 50 ml tube. 15 ml of 100% isopropanol was added to the supernatant and mixed 
thoroughly. The tube was then left to incubate on ice for 15 minutes. After incubation on ice, 
the supernatant was centrifuged for 20 minutes at 4000 rpm in Beckman table top centrifuge 
at 4oC.  The supernatant obtained was discarded and the pellet resuspended and washed in 
10 ml of 70% ethanol. The suspended pellet in 70% ethanol was centrifuged for 10 minutes 
at 4000 rpm in Beckman table top centrifuge at 4oC and the supernatant discarded. 
Subsequently the pellet was washed one more time and the pellet was left to dry at 37oC 
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ensuring no ethanol remains. The dry pellet was suspended in 1 ml of distilled water and 
aliquoted and stored at -20oC. 
 
2.4.2.6.    Plasmid DNA quantification 
 
The plasmid DNA obtained from plasmid DNA mini prep and plasmid DNA max prep were 
quantified using the NanodropTM 1000 spectrophometer (ThermoFisher Scientific) according 
to manufacturer’s instructions. The concentration of plasmid DNA obtained were all expressed 
in µg/µl. 
 
2.4.2.7     Creating bacterial glycerol stocks for long term storage of plasmid DNA 
 
500 µl of the overnight culture was mixed gently with 500 µl of 50% v/v glycerol (diluted in 
distilled water and autoclaved) in a 2 ml cryovial. The glycerol stock tube was frozen at -80oC. 
 
2.4.3     Overexpression of gene using Polyethyleneimine (PEI) as a transfection reagent 
in mammalian cells 
  
PEI is a stable polymer with cationic nitrogen atoms that can form polyplexes with anionic 
DNA. PEI forms a protective shell around the DNA molecule. Upon endocytosis by the cells, 
the DNA molecule is released into the cytoplasm. The addition of sodium chloride can help 
DNA delivery as culture osmolality increases (Sou, et al., 2013). 
 
2.4.3.1     Buffers and reagents 
 
Fresh prewarmed DMEM was supplemented with 2.5% (v/v) FBS and 100 U/ml Penicilin and 
0.1 mg/ml streptomycin (Sterile filtered Penicillin-Streptomycin solution 100x, Biowest). 
 
Plasmids; pcDNA3.1 – empty vector, pcDNA3.1 – ABCC1, pcDNA3.1 – ABCC4 
  
The quantity of DNA in the plasmid DNA solutions was measured using NanodropTM 1000 
spectrophotometer (Thermo Scientific) in µg/µl. 
 
PEI – stock concentration 23 mM was made by making a concentration of PEI at 1 mg/ml (23 
mM solution) in 20 ml of water in a 50 ml tube and the pH was adjusted to 7.0 with HCl. The 
solution was then diluted 2.3-folds to a concentration of 10 mM. The 10 mM solution of PEI 
was filter sterilised and aliquoted to store at -20oC. 
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Sterile DPBS/EDTA was made by adding sterile EDTA to DPBS for a final concentration of 2 
mM. 
 
2.4.3.2     Overexpression of genes using PEI as a transfection reagent 
 
Cells were seeded in 6-well plate at a cell seeding density so as to reach 60 - 70% confluency 
at the time of transfection (24 hours) (HEK293T cells: seeding density 300,000 cells). After 24 
hours, culture medium was replaced with culture medium containing 2.5% (v/v) FBS and the 
plate was incubated for 3 hours at 37oC.  
 
A PEI nitrogen to DNA phosphate ratios of 10:1, 15:1 and 20:1 were used in previous studies 
in our lab and found 15:1 to give >70% transfection efficiency. Therefore, 18 µl of PEI (10 mM) 
was added to 80 µl of pcDNA plasmids (4 µg) (Both the PEI and DNA were first diluted in 
sterile water to form the working solution). The transfection complex was mixed with a pipette 
and 100 µl of OptiMEM was then added to the complex. The transfection complex was 
immediately added drop wise to the cells and the plate was gently tilted to ensure evenly 
distribution of transfection complex. The culture medium was replaced with culture medium 
containing 10% (v/v) FBS after 24 hours of incubation at 37oC. Cells were left to incubate for 
48, 72 and 96 hours. After 48, 72 and 96 hours post transfections, cells were harvested and 
stored at -20oC. 
 
2.4.4     Overexpression of genes using Lipofectamine transfection reagent in 
mammalian cells 
 
Lipofectamine is a cationic lipid that can facilitate the delivery of DNA and siRNA into cells. 
Cationic lipids are made up of a positively charged head group and two hydrocarbon chains. 
The positively charged head group is responsible for the facilitation of DNA condensation and 
the interaction between the lipid and the phosphate backbone of the nucleic acid. Often, 
cationic lipids are formed with a helper lipid or neutral co-lipid, followed by microfluidisation or 
extrusion that can form a positive surface charge in a unilamellar liposomal structure when in 
water (ThermoFisher Scientific, 2016). 
 
The interaction of the nucleic acid and the cell membrane is mediated by the positive surface 
charge of the liposomes as a result forming the liposome / nucleic acid transfection complex 
with the negatively charged cell membrane. Hence by endocytosis the transfection complex 
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can enter the cell and once inside the cell, the complex have to diffuse through the cytoplasm 
and enter the nucleus for gene expression (ThermoFisher Scientific, 2016).  
 
2.4.4.1     Buffers and reagents 
 
Lipofectamine 3000 reagent kit consist of the Lipofectamine 3000® reagent and P3000 reagent 
(Invitrogen – ThermoFisher Scientific). 
                   
2.4.4.2     Overexpression of genes using plasmid DNA and the Lipofectamine 3000® 
transfection reagent 
 
The transfection of plasmid DNA using the Lipofectamine 3000® reagent was performed using 
the Lipofectamine 3000® reagent kit (Invitrogen – Thermofisher Scientific). According to the 
manufacturer’s protocol, on day one, cells were seeded in a 24-well plate so that it reached 
70% confluent at transfection.  On day two, DNA / Lipofectamine complex was made. 25 µl of 
optiMEM was added to tube A and tube B. As the transfection efficiency of Lipofectamine 
differs from one cell line to another, an optimisation volume of 0.75 µl and 1.5 µl of 
Lipofectamine 3000 were initially used. Therefore, either 0.75 µl or 1.5 µl of Lipofectamine 
3000 reagent was added to tube A and mixed thoroughly. To tube B, 0.5 µg of plasmid DNA 
and 1 µl of P3000 reagent was added and mixed thoroughly. Once the contents of both tubes 
have been mixed respectively, the mixture of tube B was added and mixed to the mixture of 
tube A. The Lipofectamine plasmid DNA complex mixture was then left to incubate at room 
temperature for 10 - 15 minutes. 
 
In the meantime, the culture medium in the wells were replaced with 500 µl of fresh culture 
medium. After 10 - 15 minutes incubation of the Lipofectamine plasmid DNA complex mixture, 
50 µl of the complex mixture was added to each well. The plate was swirled gently to ensure 
even distribution of complex mixture over cells. The cells were incubated for two days after 
which the cells were either harvested for Western blot analysis or for experiments. 
 
The volume of reagents specified above to form the Lipofectamine plasmid DNA complex 
mixture is for one well of a 24-well plate. 
 
 
 
 
121 
 
2.5     Cell invasion  
 
The movement of cells from one area to another in response to a chemical signal is known as 
cell migration and is responsible for a variety of functions such as cell differentiation, wound 
repair, the metastasis of tumours and embryonic development (Kramer et al., 2013).  
 
On the other hand, cell invasion requires cell to migrate through by enzymatically degrade a 
basement membrane extract (BME) barrier or an extracellular matrix (ECM) and relocate into 
a new location. Cell invasion is common process in normal cells such as in response to 
inflammation and in tumour cells such as in the process of metastasis. Since cell invasion is 
involved in a wide variety of biological systems, it is very important to understand its underlying 
mechanisms (Kramer et al., 2013). 
 
2.5.1     Buffers and reagents 
 
Prewarmed DMEM (1X) (Dulbecco’s Modified Eagle’s Medium) (Lonza) with 4.5 g/L glucose 
and L-glutamine was supplemented with 10% v/v FBS (Fetal Bovine Serum) (Gibco® by Life 
TechnologiesTM) and 100 U/ml Penicilin and 0.1 mg/ml streptomycin (Sterile filtered Penicillin-
Streptomycin solution 100x, Biowest). 
 
Prewarmed DMEM (1X) (Dulbecco’s Modified Eagle’s Medium) (Lonza) with 4.5 g/L glucose 
and L-glutamine was supplemented with 0.5% v/v FBS (Fetal Bovine Serum) (Gibco® by Life 
TechnologiesTM) and 1% v/v P/S (Sterile filtered Penicillin-Streptomycin solution 100x) 
(Biowest). 
 
Serum free cell culture medium - DMEM (1X) (Dulbecco’s Modified Eagle’s Medium) (Lonza) 
with 4.5 g/L glucose and L-glutamine. 
 
Corning Matrigel basement membrane matrix (Corning) (Aliquoted and stored at -20oC). 
 
Differential Quik Stain Kit (Modified Giemsa) – Solution A (fixative), Solution B (Blue) and 
Solution C (Red) (Polysciences, Inc). 
 
2.5.2     Transwell invasion assay 
 
On day one, the Matrigel was thawed overnight at 4oC. On day two, the 24-well plate transwells 
inserts (pore size 8 µm, translucent) (Greiner bio-one) were coated with 30 µl of ice cold 
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Matrigel mixed with cold serum free medium at a ratio of 1:3. The coated transwell inserts 
were left to set at 37oC for 2 hours. It is to note that pipettes, tips and tubes were pre-cooled 
when handling the Matrigel. 
 
Transfected cells were left to reach 70 - 80% confluency before the cells were prepared for 
the invasion assay. 50,000 cells were seeded in each transwell inserts suspended in 300 µl 
of 0.5% v/v FBS culture medium. 800 µl of chemoattractant (10% v/v FBS cell culture medium 
or 0.5% v/v FBS cell culture medium) was added to the wells and the transwell inserts were 
placed in each of the wells that contain a chemoattractant. The transwells inserts were 
incubated for 24 hours at 37oC in an incubator. 
 
After 24 hours, the culture medium in the transwell inserts were discarded and a cotton swab 
moistened with DPBS was used to gently but putting firm pressure to rub the inside of the 
transwell inserts and this process was repeated with a second cotton swab. 
 
The cells that have moved to the lower surface of the membrane of the transwell inserts were 
stained with Differential Quik stain. First, the transwell inserts were placed in solution A for 10-
15 minutes after which were placed in solution C and solution B for 5 - 10 minutes each. The 
transwell inserts were then rinsed twice in water. A cotton swab moistened with DPBS was 
used to gently but putting firm pressure to wipe again the inside of the transwell inserts to rid 
of any cells left. The transwell inserts were left to dry at room temperature. 
 
To determine the percentage cell invasion, the invaded cells were counted under a light 
microscope at a magnification of x40. The invaded cells were counted from randomly selected 
five fields of view for each transwell inserts and the mean number of invaded cells were 
obtained. The % invasion was calculated according to equation 2. 
 
 
% invasion = 
mean number of transfected cells invading through the coated transwell inserts
mean number of untreated cells invading through the coated transwell inserts
 × 100  (Equation 2) 
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2.6     Protein sample preparation and analysis 
 
2.6.1     Cell Membrane preparation 
 
2.6.1.1     Buffers and reagents 
 
Homogenisation buffer (50 mM Tris-HCl pH 7.4, 250 mM Sucrose and 0.25 mM calcium 
chloride (CaCl2)). 
 
Tris sucrose buffer (TSB) comprised 50 mM Tris-HCl pH 7.4 and 0.25 mM sucrose. 
  
100x Protease inhibitor mix contained 15 mg/ml benzamidine, 1 mg/ml leupeptin and 0.1 
mg/ml pepstatin. 
 
2.6.1.2     Cell membrane preparation using nitrogen cell cavitation 
 
Cell pellets harvested and stored at -80oC, were resuspended in 20 ml of homogenisation 
buffer and 200 µl of 100x protease inhibitor. All the subsequent steps were done on ice. The 
cell suspension was then placed in the cell disruption vessel for nitrogen cavitation at 500 psi 
for 15 minutes (Model 4639 Parr Cell Disruption Vessels (Parr®)). The vessel was left on ice. 
Pressure was released and samples were then collected and centrifuged for 10 minutes at 
560 x g at 4oC (centrifuge 5810R (Eppendorf)). The supernatants were collected and the pellet, 
which contained unbroken cells and debris, was discarded. The supernatants were then 
pipetted in ultra-clear centrifuge tubes (14 x 95 mm - Beckman Coulter) and weighed to ensure 
equal weight of supernatant in each tube. The supernatants were centrifuged in i70 motor for 
20 minutes at 38000 x g at 4oC (OptimaTM L-100K Ultracentrifuge (Beckman Coulter)). After 
centrifugation the supernatants were carefully discarded so as not to disturb the pellet, which 
is the membrane proteins. Membrane pellets were resuspended in TSB (0.5 - 1 ml). A needle 
syringe (0.45 mm x 13 mm) was used to resuspend the membrane proteins in TSB. The 
membrane proteins samples were then aliquoted and stored at -80oC. Samples were kept on 
ice during the membrane preparations. 
 
2.6.2     Whole cell lysate  
        
2.6.2.1     Buffers and reagents 
 
Ice-cold lysis buffer (0.15 M sodium Chloride (NaCl), 0.05 M Tris, pH 8.0, 1% (v/v) Triton-X100             
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1 mM EDTA, 1% (v/v) 100x Protease Inhibitors) 
 
2.6.2.2     Whole cell lysis 
 
Cells harvested were placed on ice in tubes. 300 - 400 µl of ice-cold lysis buffer was added to 
the cells. The cells were resuspended by vortexing. The cell suspension obtained was kept 
on ice and vortexed every 10 minutes for 1 hour. Cells suspension were then pipetted in 
eppendorf tubes and centrifuged for 15 minutes at 15600 x g at 4oC (Eppendorf centrifuge 
5415R) and the supernatant which is the whole cell lysate was carefully aliquoted and stored 
at -20oC or was mixed with sample buffer for loading on  sodium dodecyl sulphate (SDS) gels. 
 
2.6.3     BCA (Bicinchoninic acid) protein assay 
 
A BCA protein assay was used to quantify total protein in both membrane preparation and 
whole cell lysates, since this assay is tolerant of detergents (ThermoFisher). 
 
2.6.3.1     Buffers and reagents  
 
Pierce TM BCA Protein Assay Kit (Thermo Scientific) contains; 
BCA Reagent A - Sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1M sodium hydroxide. 
BCA Reagent B - 4% w/v cupric sulphate 
 
Albumin Standard Ampules, 2 mg/ml - Bovine serum albumin (BSA) at 2 mg/ml in 0.9% w/v 
saline and 0.05% w/v sodium azide. 
 
2.6.3.2     Protein quantification 
 
A BCA assay was carried out to determine the amount of protein present in each sample. BSA 
concentrations of 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 1.0, 1.2, 1.5 mg/ml were prepared by 
dilution with distilled water and 10 µl of each concentrations were transferred to each well of 
a 96-well plate in triplicates. Protein samples were diluted 1/3, 1/10 and 1/30 in distilled water.  
10 µl of each protein samples, diluted and undiluted were transferred to each well of the 96-
well plate in triplicates. The BCA reagent A and B were mixed in a ratio of 50:1 and 200 µl of 
mixture was added to all wells. The plate was then incubated for 30 minutes at 37oC and 
absorbance values were measured at 570 nm using multiskanGo microplate reader 
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(ThermoScientific). A BSA protein standard curve was generated to determine the quantity of 
proteins in each sample, expressed in µg/µl according to manufacturer’s protocol. 
 
2.6.4     SDS PAGE - Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
  
2.6.4.1     Buffers and reagents 
  
5x Laemmli sample buffer (LSB) was made using 144 mM Tris pH 6.5, 29% v/v glycerol, 
38% w/v SDS, 4% v/v β-mercaptoethanol and 0.05% v/v bromophenol blue. The solution 
was kept at room temperature. 
 
1x SDS gel running buffer was made by diluting 100 ml of 10x SDS Tris buffer (0.25 M Tris, 
1.92 M glycine and 1% w/v SDS) in 900 ml of distilled water. 
 
2.6.4.2     SDS PAGE gel preparation 
 
The SDS PAGE gel was prepared as detailed in tables 2.2 and 2.3 below. The tables represent 
the different buffers and their volumes that were mixed together to make two 8% separating 
and two 5% stacking mini-gels respectively. 10% w/v ammonium persulphate (APS) and 
tetramethlylenediamine (TEMED) were added last because TEMED with APS catalyses 
acrylamide polymerisation.  
 
 
Table 2.2. Preparation of 8% acrylamide separating gel.  
 8% Separating/ 
Resolving gel Volume 
to prepare for 2 gels  
 
10% Separating/ 
Resolving gel Volume to 
prepare for 2 gels  
Distilled water 
 
5.4 ml 4.9 ml 
Acrylamide : Bis-Acrylamide 
37.5:1  
 
2 ml 2.5 ml 
1.5 M Tris pH 8.8 buffer 
 
2.5 ml 2.5 ml 
10% w/v SDS 
 
100 µl 100 µl 
10% w/v APS 
 
100 µl 100 µl 
TEMED  
 
10 µl 10 µl 
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Table 2.3. Preparation of 4% acrylamide stacking gel. 
4% Stacking gel 
 
Volume to prepare for 2 gels 
Distilled water 
 
2.4 ml 
Acrylamide : Bis-Acrylamide 37.5:1 
 
0.5 ml 
0.5M Tris pH 8.8 buffer 
 
1 ml 
10% w/v SDS 
 
40 µl 
10%  w/v APS 
 
40 µl 
TEMED  
 
5 µl 
 
 
 
Once the separating gel mixture was made, it was poured in between two glass plate in a gel 
casting system and allowed to set. The stacking gel was then added to the top of separating 
gel and a comb was inserted and removed when the gel solidified.  
 
5x LSB sample buffer was added to protein samples and they were loaded into the wells of 
the gels.  4 µl of prestained protein molecular weight marker (20 – 120 kDA) (Thermo 
Scientific) was also loaded in a well of the gel. Using the Bio-Rad PROTEAN 3 cell the SDS 
PAGE was first run at 120 V and once the dye front reached the top of the separating gel, the 
voltage was increased to 180 V for 1 hour or until the dye front reached the bottom of the 
gel. 
 
2.6.5     Western Blotting 
 
2.6.5.1     Buffers and reagents 
 
1x Transfer buffer was made by diluting 100 ml of 10x Transfer buffer (0.25 M Tris and 1.92 
M glycine) with 200 ml of methanol and 700 ml of distilled water. 
    
Tris buffered saline – Tween 20 (TBS-T) washing buffer was made by diluting 50 ml of 20x 
Tris-Buffered Saline (0.5 M Tris and 3 M NaCl) and 1 ml of Tween 20 with 950 ml of distilled 
water. 
 
Blocking buffer was made by dissolving 5% w/v BSA in TBS-T. 0.1% w/v sodium azide was 
added as a preservative. The solution was stored at 4oC. Alternatively (GPR55 analysis) 
blocking buffer comprised 5% w/v skimmed milk in TBS-T, which was used only once. 
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For ABCC1, ABCC4, ABCB1 and ABCG2 analysis, samples were run on 8% acrylamide gel 
and were transferred on to PVDF membrane blots (0.45 µm) (Immobilon® – P). For GPR55 
analysis, samples were run on 10% acrylamide gel and were transferred on to PVDF 
membrane. For ERK and ERK1/2 analysis, samples were run on 8% acrylamide gel and were 
transferred on to nitrocellulose membrane blots (0.45 µm) (ThermoFisher Scientific). 
 
Table 2.4. Primary antibodies used. 
Antibody Type of antibody Working dilution in 
blocking buffer 
Company 
Primary anti-ABCC1 (rat) – (EPR4658(2)) 
– C-terminal 
1:1000 Abcam® 
anti-ABCC4 (rabbit) (M4 I- 10) 1:100 Abcam® 
anti-ABCG2 (mouse) (Bxp21): 
sc-58222 
1:50 Santa Cruz 
Biotechnology Inc. 
anti-ABCB1 (mouse) 1:200 ThermoFisher 
Scientific 
anti-GPR55 (rabbit) 1:100 Abcam® 
anti-p-ERK (mouse) (E-4): sc-
7383 
1:200 Santa Cruz 
Biotechnology Inc. 
anti-ERK1/2 (mouse) (E-4): sc-
514302 
1:100 Santa Cruz 
Biotechnology Inc. 
anti-α-tubulin (mouse) 1:1000 Sigma 
anti-β-actin (mouse) 1:5000 Sigma 
 
 
Table 2.5. Secondary antibodies used.  
Antibody Type of antibody Working dilution in 
TBS-T 
Company 
Secondary anti-rat HRP 1:5000 Sigma 
anti-mouse HRP 1:4000 Cell signalling Technology® 
anti-rabbit HRP 1:3000 Cell signalling Technology® 
 
-SuperSignal TM West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) 
-Li-Cor pen 
 
2.6.5.2     Western blot transfer and detection of proteins 
 
Following SDS PAGE, the separating gel was removed from the stacking gel. Fibre pads, filter 
paper (Bio-Rad) and PVDF membrane (0.45 um) (pre-activated with methanol) were soaked 
in 1x transfer buffer to allow for equilibration.  
 
128 
 
After the cassette was locked, it was placed into a colour-coded electrophoresis blotting cell. 
The blotting cell and an ice pad was placed in the Bio-Rad PROTEAN 3 cell. The cell was 
then filled with 1x transfer buffer to the top and the transfer was run at 100 V for 1 hour. 
 
After blotting, the PVDF membrane was removed from the cassette and transferred to a 
container of 15 ml of blocking buffer. The membrane was blocked on a rocker for 1 hour at 
room temperature after which the membrane in blocking buffer was left to block overnight at 
4oC. The following day, the blocking buffer was replaced and the membrane was incubated in 
blocking buffer containing the desired diluted primary antibody for 1 hour at room temperature 
on a rocker or overnight at 4oC. The primary antibody was removed by washing the membrane 
3 times with 15 ml of TBS-T for 5 minutes each wash. The membrane was then incubated for 
1 hour at room temperature in TBS-T containing the desired diluted HRP conjugated 
secondary antibody. . The secondary antibody was removed by washing the membrane blot 
5 times with 15 ml of TBS-T for 5 minutes each wash. The membrane blot was then incubated 
for 1 to 2 minutes in 1:1 mixture of peroxide to luminol from SuperSignalTM West Pico PLUS 
chemilunescent substrate kit (Thermo Scientific). The membrane blot was placed in the Li-Cor 
C-Digit blot scanner and the acquisition of images were analysis using Image Studio Lite 
software. 
  
2.7     Gene Expression analyses – Reverse transcription polymerase chain reaction 
(RT-PCR) 
 
RT-PCR is a very common technique to study gene expression. First, the RNA molecules has 
to be extracted and isolated from cell culture samples. After the RNA molecules are converted 
to their complementary DNA (cDNA) sequences by reverse transcriptase. Then the newly 
synthesised cDNA is amplified by quantitative polymerase chain reaction (qPCR) procedures. 
 
2.7.1     RNA isolation 
 
RNA was isolated from samples using Bioline ISOLATE RNA mini kit. Following the 
manufacturer’s protocol, cells were resuspended by pipetting in 450 μl lysis Buffer R 
(Supplied). The cell suspension was then incubated for 3 minutes at room temperature. The 
supernatant was transferred to a spin column R1 placed in a collection tube and centrifuged 
at 10,000 x g for 2 minutes. The spin column was discarded and 1 volume of 70% ethanol 
(450 μl) was thoroughly mixed with the filtrate. After, the mixture was transferred to a spin 
column R2 in a new collection tube. 700 μl of wash buffer BR (supplied) was added to the 
mixture which was then centrifuged at 10,000 x g for 1 minute. This time, the collection tube 
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was discarded and the spin column R2 was placed in a new collection tube, centrifuged at 
10,000 x g for 3 minutes. After centrifuged, the collection tube was again discarded and the 
spin column R2 was placed in a 1.5 ml PCR tube. To elute RNA, 50 μl of RNase/DNase-free 
water was added to the spin column R2 and centrifuged at 6000 x g for 1 minute. The quantity 
of the isolated RNA obtained was measured using NanoDropTM 1000 spectrophotometer 
(ThermoFisher Scientific) and samples were stored at -80oC. 
 
2.7.2     Reverse transcription of RNA samples 
 
The RNA samples obtained were reverse transcribed to cDNA using the Precision nanoScript 
TM 2 Reverse Transcription kit (Primerdesign). Following the manufacturer’s protocol, 600 ng 
of all the RNA samples were diluted in a volume of 9 µl with RNase/DNase-free water. All 
samples were kept on ice. After 1 µl of Oligo-dT primer was added to each sample and then 
incubated at 65oC for 5 minutes on a thermostatically controlled hot block. The samples were 
immediately transferred to the ice and 10 µl mixture of 5 µl of nanoScript2 4X buffer, 1 ul of 
dNTP mix 10 mM, 3 µl of RNase/DNase free water was added to each sample. The samples 
were then placed in a thermocycler which was set for 20 minutes at 42oC, 10 minutes at 75oC 
and hold at 4oC. The cDNA samples obtained were diluted 1 in 10 with RNase/DNase-free 
water and stored at -20oC. 
 
2.7.3     Quantitative polymerase chain reaction (qPCR) 
 
The cDNA samples were amplified in qPCR using the Thermo Scientific PiKoReal 96 Real-
Time PCR system. For one reaction, a master mix containing 10 µl of PrecisionPlusTM 2X 
qPCR Mastermix with Sybr green with inert blue dye (Primerdesign), 1 µl of the reverse primer, 
1 µl of the forward primer and 3 µl of RNase/DNase free water was prepared. 5 µl of cDNA 
were first added to each well of a 96-well Piko PCR plate in triplicates followed by 15 µl of the 
master mix ensuring that no bubbles are formed on the samples in the wells. A PCR film is 
then placed on the PCR plate which was then placed in the PikoReal 96 Real-Time PCR 
machine (Thermo Scientific) to determine the expression levels of the targeted genes in the 
samples. The expression levels were normalised to human β-actin and human GAPDH as the 
house keeping genes. The RNase/DNase-free water was used as the negative control. The 
primers used are shown in table 2.6.  
 
The thermal cycling condition were as follows; 
 
1. 10 minutes at 95oC. 
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2. 40 cycles of 15 seconds at 95oC and 1 minute at 60oC. 
3. Melt curve analysis: 5 seconds at 95oC, 60 seconds at 65oC and continuous for 97oC. 
4. Cooling: 40oC for 10 seconds. 
 
The qPCR data were analysed using the double delta Ct analysis. 
 
Table 2.6. Primers used for qPCR. 
Primers Company 
 
Primer sequence 
Human  
β-actin 
Invitrogen, 
Thermo Fisher Scientific 
F: 5′-CTGGAACGGTGAAGGTGACA-3′  
R:  5′-AAGGGACTTCCTGTAACAATGCA-3′ 
 
Human 
GAPDH 
Invitrogen,  
Thermo Fisher Scientific 
F: 5′-TGCACCACCAACTGCTTAGC-3′ 
R: 5′-GGCATGGACTGTGGTCATGAG-3′ 
 
Human 
ABCC1 
Invitrogen,  
Thermo Fisher Scientific 
F: 5′-CGACATGACCGAGGCTACATT-3′ 
R: 5′-AGCAGACGATCCACAGCAAAA-3′ 
 
Human 
ABCC4 
Invitrogen,  
Thermo Fisher Scientific 
F: 5′-TGTGGCTTTGAACACAGCGTA-3′ 
R: 5′-CCAGCACACTGAACGTGATAA-3′ 
 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; F, Forward nucleotide; R, Reverse 
nucleotide. 
 
 
 
2.8     Enzyme-linked immunosorbent assay (ELISA) 
 
ELISA is a plate-based assay technique used for detecting and quantifying proteins, peptides, 
antibodies, antigens and hormones. They can be used to detect the presence of antigens 
antibodies. 
 
2.8.1     Measurement of cyclic AMP (cAMP) in conditioned medium from siRNA 
transfected breast cancer cells by ELISA 
 
After the cells were transfected with siRNAs, the transfected and non-transfected cells were 
stimulated with 100 µM forskolin for 2 hours at 37oC. The cell culture medium was then 
replaced with fresh cell culture medium and 3 wells of non-transfected cells were treated with 
50 µM MK571, the cells were incubated for 18 hours at 37oC. The supernatants (conditioned 
media) were centrifuged at 1000 x g to pellet out any floating cells and collected and stored at 
-80oC or used immediately for determination of cAMP by using the cAMP ELISA kit (Enzo Life 
Sciences Inc).The cells were also harvested for protein quantification. All reagents used were 
brought to room temperature for at least 30 minutes prior to opening. The cAMP standards, 
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non-acetylated format were prepared as shown in table 2.7. Each Standard was vortexed 
thoroughly. 
 
Table 2.7. Dilutions for making cAMP standards, non-acetylated version. 
Standard (Std.) Cell culture medium 
Vol. (µl) 
Vol. added (µl)  cAMP Conc. 
(pmol/ml) 
1 900 100, standard stock 200 
2 750 250, std. 1 50 
3 750 250, std. 2 12.5 
4 750 250, std. 3 3.12 
5 750 250, std. 4 0.78 
 
 
 
To determine the concentration of cAMP efflux from breast cancer cells, the cAMP ELISA was 
performed according to the manufacturer’s instructions. Briefly, 100 µl of cell culture medium 
was added to the non-specific binding (NSB) and the 0 pmol/ml standard (Bo) wells. 50 µl of 
Assay Buffer 2 was then added to the NSB wells.  After 100 µl of the standards and samples 
were added to the appropriate wells in duplicates.  50 µl of the blue conjugate was added to 
each well except the total activity (TA) and the blank wells followed by the addition of 50 µl of 
the yellow antibody into each wells except the blank, TA and NSB wells. The plate was then 
sealed and incubated at room temperature of a plate shaker at 500 rpm for 2 hours. After 
incubation, the contents of the wells were discarded and the wells were washed thoroughly 3 
times with the wash buffer diluted in distilled water (1:20 dilution). To remove any remaining 
wash buffer, the plate was firmly tapped on paper towel and 5 µl of the blue conjugate was 
added to the TA wells followed by 200 µl of the substrate solution to each of the wells. The 
plate was the sealed and incubated for one hour at room temperature without shaking. After 
one hour incubation, 50 µl of the stop solution was added to each well to stop the reaction and 
the absorbance was measured at 405 nm using multiskan Go microplate reader 
(ThermoScientific). 
 
Once the absorbance values were obtained, the mean optical density (OD) of each samples 
was calculated by subtracting the mean OD of the blank from the mean OD of each sample. 
The data was then input on Graphpad Prism (7.0) and the concentration of cAMP was 
obtained from a standard curve generated from a four parameter (4PL) logistic fitting curve as 
detailed by the manufacturer’s instructions. 
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2.8.2     Measurement of prostaglandin E2 (PGE2) in conditioned medium from siRNA 
transfected breast cancer cells by ELISA 
 
After the cells were transfected with siRNAs, the transfected and non-transfected MCF-7 and 
MDA-MB231 cells were stimulated with 10 µg/ml lipopolysaccharides (LPS) for 24 hours at 
37oC and with 80 nM phorbol 12-myristate 13-acetate (PMA) for 1 hour at 37oC respectively. 
The cell culture medium was replaced with fresh cell culture medium and 3 wells of non-
transfected cells were treated with 50 µM MK571, the cells were incubated for 18 hours at 
37oC . The supernatants (conditioned media) were centrifuged at 1000 x g to pellet out any 
floating cells and collected and stored at -80oC or used immediately for determination of PGE2 
by using the PGE2 ELISA kit (Enzo Life Sciences Inc).The cells were also harvested for protein 
quantification. All reagents used were brought to room temperature for at least 30 minutes 
prior to opening. The PGE2 standards were prepared as shown in table 2.8. Each Standard 
was vortexed thoroughly. 
 
Table 2.8. Dilutions for making PGE2 standards. 
Standard (Std.) Cell culture medium 
Vol. (µl) 
Vol. added (µl)  PGE2 Conc. (pg/ml) 
1 980 20, standard stock 1000 
2 500 500, std. 1 500 
3 500 500, std. 2 250 
4 500 500, std. 3 125 
5 500 500, std. 4 62.5 
6 500 500, std. 5 31.25 
7 500 500, std. 6 15.63 
8 500 500, std. 7 7.81 
 
 
 
To determine the concentration of PGE2 efflux from breast cancer cells, the PGE2 ELISA was 
performed according to the manufacturer’s instructions. Briefly, 100 µl of cell culture medium 
was added to the non-specific binding (NSB) and the 0 pmol/ml standard (Bo) wells. 50 µl of 
the Assay Buffer was then added to the NSB wells.  After 100 µl of the standards and samples 
were added to the appropriate wells in duplicates, following which 50 µl of the blue conjugate 
was added to each wells except the total activity (TA) and the blank wells followed by the 
addition of 50 µl of the yellow antibody into each wells except the blank, TA and NSB wells. 
The plate was then sealed and incubated overnight (18 - 24 hours) at 4oC. After incubation, 
the contents of the wells were discarded and the wells were washed thoroughly 3 times with 
the wash buffer diluted in distilled water (1:20 dilution). To remove any remaining wash buffer, 
the plate was firmly tapped on paper towel and 5 µl of the blue conjugate was added to the 
TA wells followed by 200 µl of the para-Nitrophenylphosphate (pNpp) substrate solution to 
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each of the wells. The plate was then sealed and incubated for one hour at 37oC without 
shaking. After one hour incubation, 50 µl of the stop solution was added to each well to stop 
the reaction and the absorbance was measured at 405 nm using multiskan Go microplate 
reader (ThermoScientific). 
 
Once the absorbance values were obtained, the mean optical density (OD) of each sample 
was calculated by subtracting the mean OD of the blank from the mean OD of each sample. 
The data was then input on Graphpad Prism (7.0) and the concentration of PGE2 was obtained 
from a standard curve generated from a four parameter (4PL) logistic fitting curve according 
to the manufacturer’s instructions. 
 
2.8.3     Measurement of sphingosine-1-phosphate (S1P) in conditioned medium from 
siRNA transfected breast cancer cells by ELISA 
 
After the cells were transfected with siRNAs the cell culture medium was replaced with fresh 
cell culture medium and 3 wells of non-transfected cells were treated with 50 µM MK571, the 
cells were incubated for 18 hours at 37oC . The supernatants (conditioned media) were 
centrifuged at 1000 x g to pellet out any floating cells and collected and stored at -80oC or 
used immediately for determination of S1P by using the human S1P ELISA kit (Abbexa 
Ltd.).The cells were also harvested for protein quantification. The standard was reconstituted 
in 1 ml of the Sample/Standard diluent buffer with gentle agitation for about 15 minutes prior 
to carrying out serial dilution to generate the S1P standards as shown in table 2.9. Each 
Standard was vortexed thoroughly. 
 
Table 2.9. Dilutions for making S1P standards. 
Standard (Std.) Sample/Standard 
diluent buffer Vol. (µl) 
Vol. added (µl)  S1P Conc. (ng/ml) 
1 300 300, standard stock 100 
2 300 300, std. 1 50 
3 300 300, std. 2 25 
4 300 300, std. 3 12.5 
5 300 300, std. 4 6.25 
6 300 300, std. 5 3.125 
 
 
 
To determine the concentration of S1P efflux from breast cancer cells, the S1P ELISA was 
performed according to the manufacturer’s instructions. Briefly, the pre-coated ELISA plate 
was washed twice with the wash buffer diluted in distilled water (1:25 dilution). The remaining 
wash buffer was removed from the plate by firmly tapping the plate on paper towel before 
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which 100 µl of the prepared standards, Sample/Standard diluent buffer and samples were 
added into the appropriate wells. The plate was then sealed and incubated for 90 minutes at 
37oC. After incubation, the contents of the wells were discarded and the wells were washed 
thoroughly twice with the diluted wash buffer (1:25 dilution) and tapped firmly on paper towel 
to remove any remaining wash buffer. 100 µl of the biotin conjugated antibody diluted in the 
antibody diluent buffer (1:100 dilution) was added to each well and the plate was again sealed 
and incubated for 60 minutes at 37oC. The plate was then washed 3 times and the wells 
allowed to soak in the diluted wash buffer for 1 - 2 minutes in between washes before which 
100 µl of the streptavidin-HRP conjugate diluted in HRP diluent (1:100 dilution) was added to 
each well. The plate was again sealed and incubated for a further 30 minutes at 37oC. After 
incubation, the plate was washed 5 times with the diluted wash buffer and the wells were 
allowed to soak in the diluted wash buffer for 1 - 2 minutes in between washes. 90 µl of the 
3,3',5,5'-Tetramethylbenzidine (TMB) substrate was added to each well and the plate was 
covered and incubated in the dark for 15 - 20 minutes at 37oC. When an apparent gradient 
can be seen in the standard wells, 50 µl of the stop solution was added to each well to stop 
the reaction and the absorbance was measured at 450 nm using multiskan Go microplate 
reader (ThermoScientific). 
 
Once the absorbance values were obtained, the mean optical density (OD) of each sample 
was calculated by subtracting the mean OD of the blank from the mean OD of each sample. 
The data was then input on Graphpad Prism (7.0) and the concentration of S1P was obtained 
from a standard curve generated from a Log-log fitting curve as recommended by the 
manufacturer’s instructions. 
 
2.8.4     Measurement of cysteinyl (Cys) leukotrienes (LTC4, LTD4 and LTE4) in 
conditioned medium from siRNA transfected breast cancer cells using ELISA 
 
After the cells were transfected with siRNAs, the MCF-7 and MDA-MB231 cells were 
stimulated with 10 mM acetylsalicylic acid (aspirin) for 2 hours at 37oC after which the cell 
culture medium was replaced with fresh cell culture medium and 3 wells of non-transfected 
cells were treated with 50 µM MK571, the cells were incubated for a further 5 hours at 37oC. 
The supernatants (conditioned media) were centrifuged at 1000 x g to pellet out any floating 
cells and collected and stored at -80oC or used immediately for determination of LTC4 by using 
the Cys LTs ELISA kit (Enzo Life Sciences Inc).The cells were also harvested for protein 
quantification. All reagents used were brought to room temperature for at least 30 minutes 
prior to opening. The Cys LTs standards, were prepared as shown in table 2.10. Each 
Standard was vortexed thoroughly. 
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Table 2.10. Dilutions for making Cys LTs standards. 
Standard (Std.) Cell culture medium 
Vol. (µl) 
Vol. added (µl)  Cys LTs Conc. 
(pg/ml) 
1 900 100, standard stock 2500 
2 500 500, std. 1 1250 
3 500 500, std. 2 625 
4 500 500, std. 3 312.5 
5 500 500, std. 4 156.3 
6 500 500, std. 5 78.1 
 
 
 
To determine the concentration of Cys LTs efflux from breast cancer cells, the Cys LTs ELISA 
was performed according to the manufacturer’s instructions. Briefly, 100 µl of cell culture 
medium was added to the non-specific binding (NSB) and the 0 pmol/ml standard (Bo) wells. 
50 µl of the Assay Buffer was then added to the NSB wells.  After 100 µl of the standards and 
samples were added to the appropriate wells in duplicates, following which 50 µl of the blue 
conjugate was added to each wells except the total activity (TA) and the blank wells followed 
by the addition of 50 µl of the yellow antibody into each wells except the blank, TA and NSB 
wells. The plate was then sealed and incubated on a plate shaker (500 rpm) for 2 hours at 
room temperature. After incubation, the contents of the wells were discarded and the wells 
were washed thoroughly 3 times with the wash buffer diluted in distilled water (1:20 dilution). 
To remove any remaining wash buffer, the plate was firmly tapped on paper towel and 5 µl of 
the blue conjugate diluted in the Assay Buffer (1:10 dilution) was added to the TA wells 
followed by 200 µl of the pNpp substrate solution to each of the wells. The plate was then 
sealed and incubated for two hour at 37oC without shaking. After two hours incubation, 50 µl 
of the stop solution was added to each well to stop the reaction and the absorbance was 
measured at 405 nm using multiskan Go microplate reader (ThermoScientific). 
 
Once the absorbance values were obtained, the mean optical density (OD) of each sample 
was calculated by subtracting the mean OD of the blank from the mean OD of each sample. 
The data was then input on Graphpad Prism (7.0) and the concentration of Cys LTs was 
obtained from a standard curve generated from a four parameter (4PL) logistic fitting curve as 
recommended by the manufacturer’s instructions. 
 
2.9     Statistical analysis 
 
Statistical analysis of data was carried out using GraphPad Prism (7.0). For multiple 
comparisons with one independent variables, a one-way ANOVA was used with Dunnett’s 
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post-hoc test. For multiple comparisons with two independent variables, a two-way ANOVA 
was used with Dunnett’s post-hoc test. A value of p < 0.05 was considered significant. 
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Chapter 3 – Analysis of the effects of small molecule ABC inhibitors on breast cancer 
cell lines in vitro 
 
3.1     Objectives 
 
In order to first assess the possible role of ABCC1 and ABCC4 in breast cancer biology in 
terms of cell proliferation and migration, a series of small molecule ABC inhibitors were 
selected as shown in table 3.1. These ABC inhibitors were used to test their effect on cell 
proliferation and migration of the cancer cells. 
 
Table 3.1. Small molecule ABC inhibitors used in this study 
Inhibitors Inhibits 
ABCC1 
Inhibits 
ABCC4 
supplier Reference 
MK571   Sigma® life science Tivnan et al., 2015 
Indomethacin X  Sigma® life science Bai, et al., 2004 
Reversan  X Tocris bioscience Tivnan et al., 2015 
Ceefourin 1 X  Abcam 
Biochemicals® 
Cheung, et al., 
2014 
Ceefourin 2 X  Abcam 
Biochemicals® 
Cheung, et al., 
2014 
 
 
 
The concentrations of each ABC inhibitors where based upon commonly used values in the 
literature (Fujino et al., 2007; Koley et al., 2012; Barrington et al., 2015) and in our lab. The 
ABC inhibitors were first diluted in dimethyl sulfoxide (DMSO) to produce a stock solution and 
after serial diluted with water to the working concentrations so as to obtain a less than 1% 
concentration of DMSO in growth medium so as to ensure no toxic effect attributed from 
DMSO. Therefore, no vehicle (DMSO) control was tested. 
  
The breast cancer cell lines used were MCF-7 and MDA-MB231 breast cancer cells. Both are 
invasive, however, MCF-7 is considered to be luminal-type breast cancer with progesterone, 
oestrogen and human epidermal growth factor 2 (HER2) receptor positive while MDA-MB231 
is consider to be basal-type breast cancer with progesterone, oestrogen and HER2 receptors 
negative. 
 
As a positive control cancer cell line, the HeLa cervical cancer cell line was used as it was the 
first cultured cancer cell line used in laboratories to test the therapeutic efficacy of anticancer 
agents in cancers and to study the biology of cancer. Furthermore, various cancer cell lines 
have been derived from the HeLa cervical cancer cell line (Gillet et al., 2013). It was previously 
established in our lab that HeLa cells expressed both ABCC1 and ABCC4. 
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This chapter described the effect of the various ABC inhibitors on HeLa, MCF-7 and MDA-
MB231 cancer cell lines with respect to cell proliferation and migration. To assess the effect 
of the various ABC inhibitors on cell proliferation we performed the colony formation assay 
and the MTT assay as well as the trypan blue growth assay. The scratch assay was performed 
to assess the cancer cell migration. 
 
3.2     Determining the expression levels of ABC transporters by Western blot 
 
The ABCB1 (P-glycoprotein), ABCC1 (MRP1) and ABCG2 are the most well studied members 
of the ABC transporters and are involved in multidrug resistance in a number of drug 
resistance tumours (Kovalev, et al., 2013; Begicevic et al., 2017). Together with ABCC4, these 
proteins also transport a variety of physiological, active substrates that may be implicated in 
cancer cell biology (Fletcher et al., 2010; Adamska et al., 2017).  
 
Therefore, the expression levels of ABCB1, ABCC1, ABCC4 and ABCG2 were determined in 
HeLa, MCF-7 and MDA-MB231 cells by western blotting. Membrane protein samples were 
obtained by using the nitrogen cell cavitation and differential centrifugation, whereas the whole 
cell lysate samples were extracted in lysis buffer containing detergent. Figures 3.1 and 3.2 
show the expression levels of the proteins in the membrane protein samples and in the whole 
cell lysate samples respectively. 
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Figure 3.1. Western blot analysis of ABCC1, ABCC4, ABCB1 and ABCG2 protein 
expression derived from whole cell lysate samples from HeLa, MCF-7 and MDA-MB231 
cell lines. 80 μg of total protein was loaded in each well and α-tubulin was used as the loading 
control. The molecular weight standards were loaded in the first lane (Thermo Scientific 
Prestained Protein Molecular weight marker, 20 to 120 kDa). The PVDF membrane blots for 
ABCC1, ABCC4, ABCB1 and ABCG2 proteins were blocked in blocking buffer (5% BSA in 
TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in 
rabbit (1:1000 in blocking buffer), anti-ABCC4 derived in rat (1:100 in blocking buffer), anti-
ABCB1 derived in mouse (1:200 in blocking buffer) and anti-ABCG2 derived in mouse (1:50 
in blocking buffer) respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 
in TBS-T), anti-rat HRP (1:5000 in TBS-T) and anti-mouse HRP (1:4000 in TBS-T). The level 
of protein expressions were detected using the Li-Cor C-Digit blot scanner and the images 
were analysed using Image Studio Lite software imaging system. Western blot analysis was 
repeated at least 3 times and similar protein expression levels were obtained. 
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Figure 3.2. Western blot analysis of ABCC1, ABCC4, ABCB1 and ABCG2 protein 
expression derived from membrane protein samples from HeLa, MCF-7 and MDA-
MB231 cell lines. 80 μg of total protein was loaded in each well and α-tubulin used as the 
loading control. The molecular weight standards were loaded in the first lane (Thermo 
Scientific Prestained Protein Molecular weight marker, 20 to 120 kDa). The PVDF membrane 
blots for ABCC1, ABCC4, ABCB1 and ABCG2 proteins were blocked in blocking buffer (5% 
BSA in TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived 
in rabbit (1:1000 in blocking buffer), anti-ABCC4 derived in rat (1:100 in blocking buffer), anti-
ABCB1 derived in mouse (1:200 in blocking buffer) and anti-ABCG2 derived in mouse (1:50 
in blocking buffer) respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 
in TBS-T), anti-rat HRP (1:5000 in TBS-T) and anti-mouse HRP (1:4000 in TBS-T). The level 
of protein expressions were detected using the Li-Cor C-Digit blot scanner and the images 
were analysed using Image Studio Lite software imaging system. Western blot analysis was 
repeated at least 3 times and similar protein expression levels were obtained 
 
 
 
The expression level of ABCC1 and ABCC4 is highest in HeLa cells followed by MDA-MB231 
cells and MCF-7 cells (Figure 3.1 and 3.2). High expression level of ABCB1 was only seen in 
MCF-7 whole cell lysate sample (Figure 3.1). However, no expression of ABCB1 was detected 
in HeLa and MDA-MB231 cells. Moreover, ABCG2 was only detected in MCF-7 cells with high 
expression level found in the MCF-7 membrane protein sample (Figure 3.1 and 3.2).  
 
Since these experiments were looking at native expression levels within cancer cell lines, the 
relative expression of these proteins may be very small and thus hard to detect. However, the 
experiments were repeated at least 3 times and the results obtained were reproducible as 
confirmed by densitometry (Data not shown), it is suggested that different cancer cell lines 
express different levels of ABC transporters. 
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3.3     Effects of small molecule ABC inhibitors on cancer cell colony formation  
      
The colony formation assay, is an in vitro cell survival assay that determines the ability of a 
cell to grow in to a colony after being treated with cytotoxic agents or any kind of inhibitors. 
The cancer cells were exposed to the inhibitors to examine the ability of cells to proliferate 
from a single cell to form at least 50 cells clustered together which was considered to be a 
colony. Various concentrations of ABC inhibitors were used. After 7 days of exposure of cells 
to the ABC inhibitors, the cells were fixed with 4% w/v PFA and after stained with 0.1% w/v 
crystal violet. The plates were then washed thoroughly with water and left at room temperature 
to air dry. Purple spots of colonies could be visually seen with the naked eye and were 
manually counted (Figure 3.3). A graph of number of colonies formed for each cell lines were 
plotted against the ABC inhibitors used as shown in figures 3.4, 3.5 and 3.6. The untreated 
group is referred to cells not exposed to any inhibitors or vehicle (DMSO). 
 
As can be seen in figures 3.4A and 3.6A, the growth of HeLa and MDA-MB231 cells was 
significantly inhibited by 100µM of MK571, an inhibitor of both ABCC1 and ABCC4. However 
MK571 did not inhibit the growth of MCF-7 cells (Figure 3.5A). Furthermore, treatment with 
Reversan, an ABCC1 inhibitor shows a decrease in colony formation in a concentration-
dependent manner in all three cell lines (Figures 3.4C, 3.5C and 3.6C). Although Reversan 
was originally reported as an ABCC1 specific inhibitor (Burkhart et al., 2009, Henderson et al., 
2011) it has since been shown to also inhibit ABCB1 (Tivnan et al., 2015) In contrast, 
indomethacin, Ceefourin 1 and Ceefourin 2 which all are ABCC4 inhibitors did not significantly 
inhibit cell growth in HeLa cancer cell lines (Figure 3.4B, 3.4D and 3.4E), MCF-7 cancer cell 
lines (Figure 3.5B, 3.5D and 3.5E) or MDA-MB231 cancer cell line  (Figures 3.6B, 3.6D and 
3.6E). 
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Figure 3.3. The effect of ABCC1 and ABCC4 inhibitors on the colony formation. 
Representative images of colony formation assay wells for (A) HeLa cells and (B) MDA-MB231 
cells treated with MK571 (50 µM and 100 µM) or Reversan (10 µM and 30 µM) (Scale - each 
well was 34.8 mm diameter).  
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Figure 3.4. The impact of ABCC1 and ABCC4 inhibitors on the number of colonies 
formed in HeLa cancer cell line. The HeLa cells were treated with (A) MK571 (50 μM and 
100 μM), (B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), (D) 
Ceefourin 1 (10 μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were incubated 
at 37oC for 7 days after which were fixed and stained with PFA and crystal violet respectively. 
Stained cell colonies were visible and were counted manually.  Data are expressed as the 
mean ± standard error of the mean from at least three independent experiments. *** P < 0.001 
and **** P < 0.0001. P values were derived from one-way ANOVA vs untreated. 
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Figure 3.5. The impact of ABCC1 and ABCC4 inhibitors on the number of colonies 
formed in MCF-7 cancer cell line. The MCF-7 cells were treated with (A) MK571 (50 μM and 
100 μM), (B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), (D) 
Ceefourin 1 (10 μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were incubated 
at 37oC for 7 days after which were fixed and stained with PFA and crystal violet respectively. 
Stained cell colonies were visible and were counted manually.  Data are expressed as the 
mean ± standard error of the mean from at least three independent experiments. * P < 0.05 
and *** P < 0.001. P values were derived from one-way ANOVA vs untreated. 
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Figure 3.6. The impact of ABCC1 and ABCC4 inhibitors on the number of colonies 
formed in MDA-MB231 cancer cell line. The MDA-MB231 cells were treated with (A) MK571 
(50 μM and 100 μM), (B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), 
(D) Ceefourin 1 (10 μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were 
incubated at 37oC for 7 days after which were fixed and stained with PFA and crystal violet 
respectively. Stained cell colonies were visible and were counted manually.  Data are 
expressed as the mean ± standard error of the mean from at least three independent 
experiments. * P < 0.05 and **** P < 0.0001. P values were derived from one-way ANOVA vs 
untreated. 
 
 
 
In addition, I observed that some ABC inhibitors, in particular, MK571 and Reversan affected 
not just the number of colonies but also the size of colonies formed. Therefore, the size of 
colonies formed was measured by using Image J. Briefly, images of each well were selected 
on Image J and inverted. The size of the bright spots which represented the colonies were 
measured from the inverted images. The results showed a concentration-dependent decrease 
in colony size for HeLa (Figure 3.7A and 3.7C), MCF-7 (Figure 3.8A and 3.8C) and MDA-
MB231 cells (Figure 3.9A and 3.9C) treated with MK571 or Reversan. However, no significant 
reduction in the size of colonies was seen in HeLa (Figure 3.7B, 3.7D and 3.7E), MCF-7 
(Figure 3.8B, 3.8D and 3.8E) and MDA-MB231 (Figure 3.9B, 39.D and 3.9E) cancer cell lines 
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after treatment with indomethacin, Ceefourin 1 or Ceefourin 2 when compared to the untreated 
cells (No inhibitor or vehicle added). 
 
 
Figure 3.7. The impact of ABCC1 and ABCC4 inhibitors on the size of colonies formed 
in HeLa cancer cell line. The HeLa cells were treated with (A) MK571 (50 μM and 100 μM), 
(B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), (d) Ceefourin 1 (10 
μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were incubated at 37oC for 7 
days after which were fixed and stained with PFA and crystal violet respectively. Stained cell 
colonies were visible and images of the wells were taken and the size of colonies were 
analysed using Image J. Data are expressed as the mean ± standard error of the mean from 
at least three independent experiments. **** P < 0.0001. P values were derived from one-way 
ANOVA vs untreated. 
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Figure 3.8. The impact of ABCC1 and ABCC4 inhibitors on the size of colonies formed 
in MCF-7 cancer cell line. The MCF-7 cells were treated with (A) MK571 (50 μM and 100 
μM), (B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), (D) Ceefourin 
1 (10 μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were incubated at 37oC 
for 7 days after which were fixed and stained with PFA and crystal violet respectively. Stained 
cell colonies were visible and images of the wells were taken and the size of colonies were 
analysed using Image J.  Data are expressed as the mean ± standard error of the mean from 
at least three independent experiments. * P < 0.05. P values were derived from one-way 
ANOVA vs untreated. 
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Figure 3.9. The impact of ABCC1 and ABCC4 inhibitors on the size of colonies formed 
in MDA-MB231 cancer cell line. The MDA-MB231 cells were treated with (A) MK571 (50 μM 
and 100 μM), (B) Indomethacin (10 μM and 30 μM), (C) Reversan (10 μM and 30 μM), (D) 
Ceefourin 1 (10 μM and 30 μM) and (E) Ceefourin 2 (10 μM and 30 μM). Cells were incubated 
at 37oC for 7 days after which were fixed and stained with PFA and crystal violet respectively. 
Stained cell colonies were visible and images of the wells were taken and the size of colonies 
were analysed using Image J.  Data are expressed as the mean ± standard error of the mean 
from at least three independent experiments. **** P < 0.0001. P values were derived from one-
way ANOVA vs untreated. 
 
 
  
3.4     Effects of small molecule ABC inhibitors on cell viability using MTT assay 
 
To determine whether ABC inhibitors cause direct cytotoxicity to cells which may eventually 
lead to cell death, the MTT assay was performed. The results are as shown in figures 3.10, 
3.11 and 3.12. 
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Upon addition of MTT reagent to cells, the MTT reagent is converted into a purple coloured 
formazan product by viable cells with active metabolism. Therefore, when cells die, the 
conversion of MTT into formazan is no longer apparent, thus the colour formation serves as a 
convenient and useful indicator of only viable cells. However, the exact cellular mechanism of 
MTT reduction into formazan is still not well understood but may involve the NAD(P)H-
dependent oxidoreductases (Berridge et al., 2005). 
 
 
 
 
Figure 3.10. Cell viability of HeLa cells in the presence of ABC inhibitors. HeLa cells 
were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. The cell viability was 
assessed at 24-hourly intervals for 72 hours after addition of ABC inhibitors. Briefly, was added 
to each well. After each specific time point, 40 µl of MTT reagent (5 mg/ml) was added to the 
cells and left to incubate for a further 1 hour, the cell culture medium was removed from each 
well and 400 µl of DMSO was added. 100 µl of each sample was transferred into a 96-well 
plate in triplicates. The absorbance values were read at 570 nm. (A) MK571 (50 µM and 100 
µM), (B) indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 30 µM), (D) Ceefourin 1 
(10 µM and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared to untreated HeLa cells. 
Data represent the mean ± standard error of the mean from at least three independent 
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experiments. ** P < 0.01, *** P < 0.001, **** P < 0.0001. P values were derived from two-way 
ANOVA vs untreated. 
 
 
 
As can be seen from figure 3.10A, the ability of HeLa cells to reduce MTT was significantly 
decreased when HeLa cells were exposed to 50 µM and 100 µM MK571 for 24, 48 and 72 
hours. This may indicate a reduction in cell viability. For other ABC inhibitors, a reduction in 
cell viability was seen when HeLa cells were exposed to 30 µM indomethacin (figure 3.10B), 
30 µM Reversan (figure 3.10C), 30 μM of ceefourin 1 (Figure 3.10D) and 30 µM ceefourin 2 
(figure 3.10E) for 24, 48 and 72 hours. 
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Figure 3.11. Cell viability of MCF-7 cells in the presence of ABC inhibitors. MCF-7 cells 
were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. The cell viability was 
assessed at 24-hourly intervals for 72 hours after addition of ABC inhibitors. Briefly, was added 
to each well. After each specific time point, 40 µl of MTT reagent (5 mg/ml) was added to the 
cells and left to incubate for a further 1 hour, the cell culture medium was removed from each 
well and 400 µl of DMSO was added. 100 µl of each sample was transferred into a 96-well 
plate in triplicates. The absorbance values were read at 570 nm. (A) MK571 (50 µM and 100 
µM), (B) indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 30 µM), (D) Ceefourin 1 
(10 µM and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared to untreated MCF-7 
cells. Data represent the mean ± standard error of the mean from at least three independent 
experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. P values were derived 
from two-way ANOVA vs untreated. 
 
 
 
In MCF-7 cells, after exposure to 100 µM MK571 for 48 and 72 hours, the cell viability was 
significantly reduced (Figure 3.11A). After exposure of 30 µM indomethacin for 72 hours, a 
significant decrease in cell viability was recorded (Figure 3.11B).  Furthermore, 10 µM and 30 
µM Reversan decreased the ability of MCF-7 cells to reduce MTT, after both 48 and 72 hours 
exposure (Figure 3.11C). 
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Figure 3.12. Cell viability of MDA-MB231 cells in the presence of ABC inhibitors. MDA-
MB231 cells were seeded in 24-well plates at a seeding density of 6 x 103 cell/well. The cell 
viability was assessed at 24-hourly intervals for 72 hours after addition of ABC inhibitors. 
Briefly, was added to each well. After each specific time point, 40 µl of MTT reagent (5 mg/ml) 
was added to the cells and left to incubate for a further 1 hour, the cell culture medium was 
removed from each well and 400 µl of DMSO was added. 100 µl of each sample was 
transferred into a 96-well plate in triplicates. The absorbance values were read at 570 nm. (A) 
MK571 (50 µM and 100 µM), (B) indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 
30 µM), (D) Ceefourin 1 (10 µM and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared 
to untreated MDA-MB231 cells. Data represent the mean ± standard error of the mean from 
at least three independent experiments. **** P < 0.0001. P values were derived from two-way 
ANOVA vs untreated. 
 
 
 
When 1.5 x 104 MDA-MB231 cells were seeded per well of 24-well plate, 100% confluency 
was observed after 24 hours. Therefore, a lower cell seeding density of 6 x 103 cells was 
trialled. 
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Consequently, when MDA-MB231 cells were exposed to 100 µM MK571 and 30 µM Reversan 
for 72 hours, a decrease in cell viability was recorded (Figures 3.12A and 3.12B respectively). 
However, when MDA-MB231 cells were exposed to indomethacin (Figure 2.12B), Ceefourin 
1 (Figure 3.12D) and Ceefourin 2 (Figure 3.12E), the cell viability was not affected when 
compared to the untreated cells.  
 
When comparing the results from all cell lines, exposure to MK571 or Reversan appear to 
affect cell viability for all three cell lines. However exposure to ABCC1 inhibitors, indomethacin, 
Ceefourin 1 and Ceefourin 2 only significantly affected cell viability of HeLa and MCF-7 cells 
at the 72 hour time point and did not affect MDA-MB231 cell at all. The long exposure time 
with the ABC inhibitors may cause cell cytotoxicity. Other possible issues with the longer 
incubation times include, the cells may have passed their log phase growth and the cells reach 
confluency, the cell metabolism may slow down thus may affect the rate of MTT reduction. 
Hence the linearity between absorbance and cell number may no longer exist. Furthermore 
with a longer incubation time, other changes in the culture conditions such as a reduction in 
essential nutrients such as glucose, or a change in pH of the culture medium may affect the 
ability of cells to reduce MTT (Riss et al., 2016). Subsequently, the cells ability to reduce MTT 
after exposure to ABC inhibitors were assessed at lower time points of 6 and 12 hours. The 
results are as shown in figures 3.13, 3.14 and 3.15. 
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Figure 3.13. Cell viability of HeLa cells in the presence of ABC inhibitors for shorter 
periods of time. HeLa cells were seeded in 24-well plates at a seeding density of 1.5 x 104 
cell/well. The cell viability was assessed at 6, 12 and 24 hours after addition of ABC inhibitors. 
After each specific time point, 40 µl of MTT reagent (5 mg/ml) was added to the cells and left 
to incubate for a further 1 hour, the cell culture medium was removed from each well and 400 
µl of DMSO was added. 100 µl of each sample was transferred into a 96-well plate in 
triplicates. The absorbance values were read at 570 nm. (A) MK571 (50 µM and 100 µM), (B) 
indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 30 µM), (D) Ceefourin 1 (10 µM 
and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared to untreated HeLa cells. Data 
represent the mean ± standard error of the mean from at least three independent experiments. 
** P < 0.01, *** P < 0.001 and **** P < 0.0001. P values were derived from two-way ANOVA 
vs untreated. 
 
 
 
As can be seen from figure 3.13A, when HeLa cells were exposed to 100 µM MK571 for 12 
hours, significant reduction in cell viability was observed. Similar effect was seen when HeLa 
cells were exposed to 30 µM indomethacin for 12 hours (Figure 3.13B). Furthermore, 
Reversan at a concentration of 30 µM, affected HeLa cell viability after 6 and 12 hours 
treatment (Figure 3.13C). However, exposure to Ceefourin 1 and Ceefourin 2 for 6 and 12 
hours, did not affect HeLa cell viability (Figures 3.13D and 3.13E respectively). 
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Figure 3.14. Cell viability of MCF-7 cells in the presence of ABC inhibitors for shorter 
periods of time. MCF-7 cells were seeded in 24-well plates at a seeding density of 1.5 x 104 
cell/well. The cell viability was assessed at 6, 12 and 24 hours after addition of ABC inhibitors. 
After each specific time point, 40 µl of MTT reagent (5 mg/ml) was added to the cells and left 
to incubate for a further 1 hour, the cell culture medium was removed from each well and 400 
µl of DMSO was added. 100 µl of each sample was transferred into a 96-well plate in 
triplicates. The absorbance values were read at 570 nm. (A) MK571 (50 µM and 100 µM), (B) 
indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 30 µM), (D) Ceefourin 1 (10 µM 
and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared to untreated MCF-7 cells. Data 
represent the mean ± standard error of the mean from at least three independent experiments. 
* P < 0.05 and **** P < 0.0001. P values were derived from two-way ANOVA vs untreated. 
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Figure 3.15. Cell viability of MDA-MB231 cells in the presence of ABC inhibitors for 
shorter periods of time. MDA-MB231 cells were seeded in 24-well plates at a seeding 
density of 6 x 103 cell/well. The cell viability was assessed at 6, 12 and 24 hours after addition 
of ABC inhibitors. After each specific time point, 40 µl of MTT reagent (5 mg/ml) was added to 
the cells and left to incubate for a further 1 hour, the cell culture medium was removed from 
each well and 400 µl of DMSO was added. 100 µl of each sample was transferred into a 96-
well plate in triplicates. The absorbance values were read at 570 nm. (A) MK571 (50 µM and 
100 µM), (B) indomethacin (10 µM and 30 µM), (C) Reversan (10 µM and 30 µM), (D) 
Ceefourin 1 (10 µM and 30 µM) and (E) Ceefourin 2 (10 µM and 30 µM) compared to untreated 
MDA-MB231 cells.  
 
 
 
Exposure of ABC inhibitors to MCF-7 and MDA-MB231 cells did not affect cell viability either 
at 6 or 12 hour time points as compared to the untreated cells (Figure 3.14 and Figure 3.15). 
Therefore, at a shorter time scale the ABC inhibitors did not restrict the ability of cells to reduce 
MTT thus did not affect cell viability. Hence at a shorter time scale the ABC inhibitors were 
suggested to be nontoxic to these cells. 
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The MTT assay is an enzyme-based colourimetric method used as a measure of cell viability 
which relies on a reductive colouring reagent and dehydrogenase in a viable cell. Therefore 
the MTT assay only account for metabolically active viable cells (Riss et al., 2016). Moreover, 
the reduction of MTT by the viable cells, produce insoluble formazan product that precipitate 
inside as well as near the cell surface and also in the cell culture medium. Therefore, in order 
to solubilise the formazan product to read absorbance on a plate reader, the cell culture 
medium must first be completely removed and DMSO added to dissolve the formazan product 
(Yadav et al., 2014; Riss et al., 2016). However, when pipetting out cell culture medium from 
each well, complete removal of cell culture medium may not be attain and the amount of cell 
culture medium left in the wells may vary from well to well. Moreover, the results of the MTT 
assay only account for viable cells and may not specifically account for cell proliferation as an 
unviable cell may still proliferate (Riss et al., 2016).  Thus the reading obtained may not be 
accurate. Hence, in order to validate the results from the MTT assay, the trypan blue dye 
exclusion assay was carried out.  
 
Basically, trypan blue is a negatively charged molecules that only interacts with cells with 
damaged membranes and not cells with undamaged membranes. Therefore, cells with 
damaged membranes are usually dead cells will take up trypan blue. As a result, trypan blue 
stains dead cells, but is excluded from healthy cells (Tran et al., 2011; Aslanturk, 2018). 
Moreover, when performing the trypan blue dye exclusion assay, certain factors must be 
considered such as some cells that have been damaged by cytotoxic agents may have their 
membrane intact for several days before the membrane is lost, hence within that time interval 
the lethally damaged cell may continue to proliferate. Consequently this is consider to be one 
of the downside of trypan blue staining is that it cannot be used to determine between the 
healthy viable cells from the cells that are alive but lost their cell functions (Aslanturk, 2018). 
Nevertheless, the trypan blue dye exclusion assay is an inexpensive straight forward assay 
and the results confirmed the same pattern of cell growth/viability as shown from the MTT 
assay (Data not shown). 
 
3.5     Effects of small molecule ABC inhibitors on cell migration 
 
One of the straightforward cell migration assays to study cancer cell migration in response to 
a variety of experimental conditions, is the scratch assay (Kramer et al., 2013). Simply cells 
were seeded a day before the assay to obtained 100% confluency. A gap was carefully 
created in the cell monolayer using with a 10 μl pipette tip and the cell motility and growth 
were monitored to determine the rate of migration of cells towards the centre of the gap.  
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The plate was placed in the Cell-IQ, where the selected image positions were taken every 
hour for 24 hours. The data were analysed using the Cell-IQ software and some examples of 
analysed images are as shown in figure 3.16. Graphs showing the percentage wound closure 
at 6, 12 and 24 hours for the HeLa, MCF-7 and MDA-MB231 cells were plotted as shown in 
figures 3.17, 3.18 and 3.19 respectively. 
 
 
 
 
Figure 3.16. Representative images of MDA-MB231 cells migration in the presence of 
MK571. The cell migration assay was performed using the Cell-IQ. Three image positions 
were allocated in each well of a 24 well-plate, with images being taken every 1 hour for 24 
hours. After 24 hours, imaging was stopped manually and the image results were analysed 
using the Cell-IQ analysis software. The control is untreated cells. Images were taken at a 
magnification of x10 objective. 
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Figure 3.17. Average scratch closure of HeLa cells after treatment with ABC inhibitors. 
(A) 6 h, (B) 12 h and (C) 24 h incubation respectively, in the present of MK571 (50 µM and 
100 µM), indomethacin (10 µM and 30 µM), Reversan (10 µM and 30 µM), Ceefourin 1 (10 
µM and 30 µM) and Ceefourin 2 (10 µM and 30 µM). Data are expressed as the mean ± 
standard error of the mean from at least three independent experiments.  
 
 
 
As can be seen from figure 3.17, the ABC inhibitors did not affect cell migration of HeLa cells 
as compared to the untreated HeLa cells. 
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Figure 3.18. Average scratch closure of MCF-7 cells after treatment with ABC inhibitors. 
(A) 6 h, (B) 12 h and (C) 24 h incubation respectively, in the present of MK571 (50 µM and 
100 µM), indomethacin (10 µM and 30 µM), Reversan (10 µM and 30 µM), Ceefourin 1 (10 
µM and 30 µM) and Ceefourin 2 (10 µM and 30 µM). Data are expressed as the mean ± 
standard error of the mean from at least three independent experiments. 
 
 
 
Similarly, the ABC inhibitors did not affect cell migration of MCF-7 cells as compared to the 
untreated MCF-7 cells (Figure 3.18). 
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Figure 3.19. Average scratch closure of MDA-MB231 cells after treatment with ABC 
inhibitors. (A) 6 h, (B) 12 h and (C) 24 h incubation respectively, in the present of MK571 (50 
µM and 100 µM), indomethacin (10 µM and 30 µM), Reversan (10 µM and 30 µM), Ceefourin 
1 (10 µM and 30 µM) and Ceefourin 2 (10 µM and 30 µM). Data are expressed as the mean 
± standard error of the mean from at least three independent experiments. * P < 0.05. P values 
were derived from one-way ANOVA vs untreated. 
 
 
 
In the case of MDA-MB231 cells, 100 μM MK571 was found to significantly inhibit cell 
migration of MDA-MB231 cells (Figures 3.19B and 3.19C). However the significant inhibition 
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by other ABC inhibitors were not apparent especially at a longer incubation period (24 hours 
incubation) (Figure 3.19C). Subsequently, the cells may have adapted to the altered external 
environment and the cells may have activated other ABC transporters to compensate for the 
inhibition of ABCC1 and ABCC4.  
 
Furthermore, the results observed is due to cell migration rather than cell proliferation as the 
results obtained from the MTT assays indicated that at a shorter time scale, the ABC inhibitors 
did not affect cell proliferation as compared to the untreated cells. Hence, these results 
suggested that ABCC1 and ABCC4 may help to promote cell migration of MDA-MB231 cells 
more than in HeLa and MCF-7 cells. However, further investigation is required to confirm the 
statement. 
 
3.6     Summary 
 
 ABCC1 and ABCC4 are most highly expressed in HeLa cells, second highest in MDA-
MB231 cells, and lowest in MCF-7 cells. 
 
 Other ABC multidrug efflux pumps often implicated in cancer, ABCB1 and ABCG2, 
were only expressed at significant levels in MCF-7 cells. 
 
 MK571, which inhibits ABCC1 and ABCC4, has been found to affect cell proliferation 
of HeLa, MCF-7 and MDA-MB231 cells. 
 
 Reversan which inhibits ABCC1 (Burkhart et al., 2009, Henderson et al., 2011) was 
also found to affect cell proliferation of all cell lines tested. 
 
 Inhibition of cell proliferation was larger in HeLa cells, followed by MDA-MB231 cells 
and MCF-7 cells. Since this matches the relative levels of ABCC1 and ABCC4 
expression in these cell lines, the decrease in cell proliferation may be due to inhibition 
of ABCC1 and ABCC4.  
 
 Since only Reversan but not MK571 affected the cell proliferation of MCF-7 cells, it 
might suggest that ABCC1 is more implicated in cell proliferation than ABCC4. 
However, as Reversan has also been shown to inhibit ABCB1 (Tivnan et al., 2015) 
and MCF-7 cells were the only ones expressing relatively high levels of ABCB1, this 
could be an alternative explanation.  
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 Only MK571 affected the cell migration of MDA-MB231 cells.  The other ABCC1 and 
ABCC4 inhibitors did not have significant effect on cell migration. Since MK571 can 
inhibit both ABCC1 and ABCC4 perhaps it is this dual inhibition which has the greatest 
effect on migration. 
o Alternatively, MK571 is also a leukotriene antagonist, inhibiting the binding of 
LTD4 to cysteinyl leukotriene receptor 1 (CysLT1) (Gekeler et al., 1995).  The 
binding of LTD4 to CysLT1 activates β-catenin signalling promoting cancer cell 
survival and inhibiting apoptosis, thus, inducing cell proliferative response 
(Nielsen et al., 2005; Mezhybovska et al., 2006; Perters-Golden et al., 2007).   
 
In conclusion, since none of the inhibitors used are totally specific to ABCC1 and ABCC4 it 
makes it difficult to interpret the results. Therefore, in chapter 4, ABCC1 and ABCC4 
knockdowns were used to test these proteins involvement in breast cancer biology. 
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Chapter 4 – Analysis of the effects of gene knockdown of ABC transporters in breast 
cancer cell lines in vitro 
 
4.1     Objective 
 
Due to the fact that the ABC inhibitors used were not specific as they can inhibit more than 
one ABC transporters in addition to other targets, the results obtained from chapter 3 are not 
conclusive. Therefore, this chapter looks to target each ABC transporter, ABCC1 and ABCC4 
by knocking down their gene expression and carrying out functional cellular assays using the 
gene knockdown cells to investigate if ABCC1 and ABCC4 promote breast cancer cell 
proliferation, cell migration and/or cell invasion. 
 
Gene silencing describe general processes where by the translation or transcription of the 
mRNA of the target gene is being interrupted or supressed by mechanisms other than genetic 
modification often known as RNA interference (RNAi). The RNAi is a post transcriptional 
sequence-specific gene silencing process that occurs in response to the initiation of double-
stranded RNA (dsRNA) into a cell to produce highly specific suppression of gene expression. 
The RNAi is mediated by either the small interfering RNAs (siRNAs) or microRNA (miRNA) 
(Mocellin et al., 2004; Sandy et al., 2005; Shah et al., 2012). 
 
In this project, siRNAs were used to knock down ABCC1 and ABCC4 genes respectively in 
MCF-7 and MDA-MB231 breast cancer cell lines. Furthermore, in order to increase the 
confidence in the experimental results, two different siRNAs for each transporters were used, 
each targeting a different specific sequence within the gene sequence of interest. In addition, 
a negative siRNA was used to determine sequence-specific silencing from non-specific 
effects. Hence to ensure the results obtained from the siRNA knockdown is due to the effect 
of the specific ABC siRNAs and not just the process for carrying out the knockdown. Moreover, 
the untreated cells were used to monitor and compare the baseline cell viability, phenotype 
and target gene level to the siRNA treated cells. 
 
As a mode of transfection, INTERFERin, a siRNA transfection reagent was used. It was 
recommended as according to the manufacturer recommendation, 1 nM siRNA with 
INTERFERin can provide more than 90% silencing efficiency in a wide variety of cells, hence 
reducing off-target effects. 
 
In this chapter, I investigated whether ABCC1 and/or ABCC4 is/are implicated in cell 
proliferation, migration and invasion by first conducting single siRNA knock down of ABCC1 
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and ABCC4 genes in MCF-7 and MDA-MB231 breast cancer cell lines. The siRNA knockdown 
cells were then used in cellular functional assays, including the colony formation assay to 
assess cell growth, MTT assay to assess cell proliferation, scratch assay to assess cell 
migration and transwell invasion assay to assess cell invasion. 
 
Furthermore, since some ABC transporters transport similar active physiological substrates 
thus the inhibition of one ABC transporter is usually compensated by the activation of another 
ABC transporters (Efferth et al., 2006; Samant et al., 2015; Martins et al., 2016). We therefore 
wanted to investigate whether ABCC1 and ABCC4 work together to compensate each other, 
hence both ABCC1 and ABCC4 were knocked down in the breast cancer cell lines. The 
ABCC1 and ABCC4 combination siRNA knockdown breast cancer cells were then used to test 
whether the effect of combination knockdown of ABCC1 and ABCC4 will cause a greater 
decrease in cell proliferation, migration and invasion in breast cancer cells. 
 
4.2     Analysis of the efficiency of single gene knock down of ABC transporter in breast 
cancer cell lines 
 
4.2.1     Protein expression analysis by Western blot 
 
Before starting the cellular functional assays using the siRNA knockdown cells, we tested the 
efficiency of siRNA transfection. All the siRNA transfection of cells were done in 24-well plate. 
 
Cells were seeded the day before transfection to reach 30 - 50% confluency at the time of 
transfection. On the day of transfection, transfection complexes of 1 nM siRNA, INTERFERin 
and OptiMEM were made according to the manufacturer’s protocol. The transfection 
complexes were allowed to form on incubation at room temperature for 10 - 15 minutes. After 
incubation, 100 µl of the transfection complexes were added to the wells and the plate was 
swirl for even dispersing of the RNAi complexes. The plate was incubated for 72 hours after 
which the transfected cells were harvested. The efficiency of siRNA transfection was 
determined by Western blot analysis as shown in figures 4.1 and 4.2. 
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Figure 4.1 Western blot analysis of ABCC1 and ABCC4 protein expression following 
transfection of MCF-7 breast cancer cells with ABCC1- and ABCC4- specific siRNA 
molecules. ABCC1-specific siRNA molecules: siRNA #30, siRNA #31, and ABCC4-specific 
siRNA molecules: siRNA #34, siRNA #35 were compared with a negative siRNA as a negative 
control to offset any non-specific silencing. After treatment of MCF-7 cells with specific siRNA 
molecules, the MCF-7 transfected cells were left to incubate for 72 hours. Protein lysate of the 
MCF-7 transfected cells were obtained and the efficiency of silencing was analysed in Western 
blot analysis. The molecular weight standards were loaded in the first lane (Thermo Scientific 
Prestained Protein Molecular weight marker, 20 to 120 kDa) and 20 µl of samples were loaded 
in each lanes. α-tubulin was used as the loading control. The PVDF membrane blots for 
ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) overnight 
and incubated in appropriate primary antibodies, anti-ABCC1 derived in rabbit (1:1000 in 
blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) respectively. The 
secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-rat HRP (1:5000 
in TBS-T). The level of protein expressions were detected using the Li-Cor C-Digit blot scanner 
and the images were analysed using Image Studio Lite software imaging system. Western 
blot analysis was repeated at least three times and successful silencing of ABCC1 and ABCC4 
protein expression in MCF-7 transfected cells were obtained each time. 
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Figure 4.2. Western blot analysis of ABCC1 and ABCC4 protein expression following 
transfection of MDA-MB231 breast cancer cells with ABCC1- and ABCC4- specific 
siRNA molecules. ABCC1-specific siRNA molecules: siRNA #30, siRNA #31, and ABCC4-
specific siRNA molecules: siRNA #34, siRNA #35 were compared with a negative siRNA as a 
negative control to offset any non-specific silencing. After treatment of MDA-MB231 cells with 
specific siRNA molecules, the MDA-MB231 transfected cells were left to incubate for 72 hours. 
Protein lysate of the MDA-MB231 transfected cells were obtained and the efficiency of 
silencing was analysed in Western blot analysis. The molecular weight standards were loaded 
in the first lane (Thermo Scientific Prestained Protein Molecular weight marker, 20 to 120 kDa) 
and 20 µl of samples were loaded in each lanes. α-tubulin was used as the loading control. 
The PVDF membrane blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer 
(5% BSA in TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 
derived in rabbit (1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking 
buffer) respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) 
and anti-rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the 
Li-Cor C-Digit blot scanner and the images were analysed using Image Studio Lite software 
imaging system. Western blot analysis was repeated at least three times and successful 
silencing of ABCC1 and ABCC4 protein expression in MDA-MB231 transfected cells were 
obtained each time. 
 
 
 
As can be seen from figure 4.1, the Western blot analysis indicate that the protein expression 
levels of ABCC1 and ABCC4 were successfully decreased by siRNA knockdown in MCF-7 
cells when compared to the untreated MCF-7 cells and the MCF-7 cells treated with a negative 
siRNA. Similarly, Western blot analysis indicated that the expression levels of ABCC1 and 
ABCC4 proteins were successfully decreased by siRNA transfection in MDA-MB231 cells 
when compared to the untreated MDA-MB231 cells and the MDA-MB231 cells treated with a 
negative siRNA (Figure 4.2). Furthermore, it seem that both ABCC1-specific siRNA 
molecules, siRNA #30 and siRNA #31 give a similar degree of ABCC1 gene silencing in both 
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MCF-7 and MDA-MB231 cells. In contrast, ABCC4-specific siRNA #34 results in a higher 
degree of ABCC4 gene silencing than ABCC4-specific siRNA #35 in MDA-MB231 cells. 
 
Subsequently, all cells treated with the INTERFERin / siRNA complexes, the culture medium 
were not change during the whole duration of transfection as low cell cytotoxicity was observed 
compared to untreated cells. Hence the cell culture medium containing the INTERFERin / 
siRNA complexes was not changed within 4 to 6 hours after transfection. Moreover, the MCF-
7 and MDA-MB231 breast cancer cell lines are considered to be difficult to transfect cell lines 
but we have successfully managed to knockdown ABCC1 and ABCC4 in MCF-7 and MDA-
MB231 cells using INTERFERin as the transfection reagent. 
 
4.2.2     mRNA expression analysis using RT-PCR 
 
To determine the efficiency of gene silencing by measuring the mRNA levels of ABCC1 and 
ABCC4 in siRNA knockdown breast cancer cells, the reverse transcription polymerase chain 
reaction (RT-PCR) was performed. Briefly, MCF-7 and MDA-MB231 breast cancer cells were 
transfected with ABCC1- and ABCC4-specific siRNAs. After 72 hours incubation, the 
transfected breast cancer cells were harvested and RNA isolation was performed. The RNA 
concentration of purified samples were determined using the NanoDrop spectrophotometer. 
A 600 ng total RNA from each RNA sample was reverse transcribed to cDNA using random 
primers and the Precision nanoScript TM 2 Reverse Transcription kit (Primerdesign) according 
to manufacturer’s protocols and the cDNA samples obtained were diluted 1 in 10 with 
RNase/DNase-free water and stored at -20oC. Subsequently, the cDNA samples were 
amplified in quantitative PCR (qPCR) reactions, which were performed in triplicates using the 
PikoReal 96 Real-Time PCR system. Specific forward and reverse ABCC1 and ABCC4 
primers from Invitrogen, Thermo Fisher Scientific were used and the ABCC1 and ABCC4 
mRNA expression levels were normalised to the level of β-actin and GAPDH mRNAs. The 
relative ABCC1 and ABCC4 mRNA levels were analysed using the double delta CT (2-ΔΔCT) 
method (Livak et al., 2001; Rao et al., 2013). The relative ABCC1 and ABCC4 mRNA 
expression levels in ABCC1 and ABCC4 knockdown MCF-7 and MDA-MB231 breast cancer 
cells are shown in figures 4.3 and 4.4 respectively. 
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Figure 4.3. ABCC1 and ABCC4 mRNA expression levels following siRNA knockdown in 
MCF-7 cells. Briefly, MCF-7 cells were transfected with ABCC1- and ABCC4-specific siRNAs. 
After 72 hours incubation, the transfected breast cancer cells were harvested and RNA 
isolation was performed. cDNA was synthesed from 600 ng total using random primers and 
the Precision nanoScriptTM 2 Reverse Transcription kit (Primerdesign) according to 
manufacturer’s protocols and the cDNA samples obtained were diluted 1 in 10 with 
RNase/DNase-free water and stored at -20oC. Subsequently, quantitative PCR (qPCR) 
reactions were performed in triplicates using the PikoReal 96 Real-Time PCR system. Specific 
forward and reverse ABCC1 and ABCC4 primers were used and the ABCC1 and ABCC4 
mRNA expression levels were normalised to the level of β-actin and GAPDH mRNAs. The 
RNase/DNase-free water was used as a negative control and the untreated MCF-7 cells as 
the control without any siRNA treatment. Data are expressed as the mean ± standard error of 
the mean from at least three independent experiments. * P < 0.05, ** P < 0.01. P values were 
derived from one-way ANOVA vs untreated. 
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Figure 4.4. ABCC1 and ABCC4 mRNA expression levels following siRNA knockdown in 
MDA-MB231 cells. Briefly MDA-MB231 were transfected with ABCC1- and ABCC4-specific 
siRNAs. After 72 hours incubation, the transfected breast cancer cells were harvested and 
RNA isolation was performed. cDNA was synthesed from 600 ng total using random primers 
and the Precision nanoScriptTM 2 Reverse Transcription kit (Primerdesign) according to 
manufacturer’s protocols and the cDNA samples obtained were diluted 1 in 10 with 
RNase/DNase-free water and stored at -20oC. Subsequently, quantitative PCR (qPCR) 
reactions were performed in triplicates using the PikoReal 96 Real-Time PCR system. Specific 
forward and reverse ABCC1 and ABCC4 primers were used and the ABCC1 and ABCC4 
mRNA expression levels were normalised to the level of β-actin and GAPDH mRNAs. The 
RNase/DNase-free water was used as a negative control and the untreated MDA-MB231 cells 
as the control without any siRNA treatment. Data are expressed as the mean ± standard error 
of the mean from at least three independent experiments. * P < 0.05, ** P < 0.01. P values 
were derived from one-way ANOVA vs untreated. 
 
 
 
As can be seen from figures 4.3A and 4.3B the mRNA expression levels of ABCC1 and 
ABCC4 were significantly decreased in MCF-7 cells following specific siRNA knockdowns 
when compared to the negative siRNA or untreated MCF-7 cells. 
 
Similarly, the expression levels of ABCC1 was significantly decreased in MDA-MB231 cells 
treated with ABCC1 siRNA #31. However, whilst MDA-MB231 cells treated with ABCC1 siRNA 
#30 showed a decrease in ABCC1 expression, this was not statistically significant when 
compared to the untreated MDA-MB231 cells (Figure 4.4A). In the case of ABCC4 knockdown 
in MDA-MB231 cells, treatment with both ABCC4 siRNAs, showed a significant decrease in 
ABCC4 expression level when compared to the untreated MDA-MB231 cells (Figure 4.4B). 
 
Consequently, the analysis of the qPCR data which correlated with the Western blot analysis 
suggested that the knockdown of ABCC1 and ABCC4 in MCF-7 and MDA-MB231 breast 
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cancer cells by ABCC1- and ABCC4-specific siRNA molecules was a success. Hence, similar 
siRNA transfection procedure was performed for all future cellular functional experiments. 
 
4.3     Effects of single gene knockdown of ABC transporters on cancer cell colony 
formation 
 
Cells transfected with siRNA following the INTERFERin manufacturers’ protocol were seeded 
for the colony formation assay to assess the ability of a single cell to grow in to a colony after 
ABCC1 and ABCC4 had been knocked down. Graphs showing the number of colonies formed 
from MCF-7 and MDA-MB231 cell lines are shown in figure 4.5. 
 
 
 
Figure 4.5. The impact of suppression of ABCC1 and ABCC4 gene expression on colony 
formation. (A) MCF-7 and (B) MDA-MB231 breast cancer cells were transfected with 1 nM of 
siRNA and the clonogenic capacity of the breast cancer cells upon depletion of ABCC1 and 
ABCC4 was assayed after 7 days. The transfected breast cancer cells were fixed and stained 
with PFA and crystal violet respectively. Stained cell colonies were visible and were counted 
manually.  Data are expressed as the mean ± standard error of the mean from at least three 
independent experiments.  
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As can be seen in figures 4.5A and 4.5B, the ability of MCF-7 and MDA-MB231 cells to form 
colonies did not decrease after ABCC1 and ABCC4 depletion. In fact, ABCC1 and ABCC4 
suppression in MCF-7 cells may have increased the number of colonies formed (Figure 4.5A) 
while only the suppression of ABCC4 in MDA-MB231 cells may have increased the number 
of colonies formed. Furthermore, the suppression of ABCC1 in MDA-MB231 cells did not affect 
the clonogenic capacity of MDA-MB231 cells (Figure 4.5B).   
 
In general, the RNAi mechanism of suppression of gene expression is usually transient and 
lasts for 96 to 120 hours after which the gene expression will start to recover (Mocellin et al., 
2004). Consequently, since the colony formation assay last for 7 days, it is suggested that the 
suppression of ABCC1 and ABCC4 may have recovered. Therefore, a shorter incubation 
period, for example 3 days may be suggested. Moreover, introducing plasmids which express 
the siRNA may produce a stable RNAi transfection. In addition, some labs uses short hairpin 
RNAs (shRNAs) expressed from plasmids or use viral transduction methods including 
lentivirus, adenovirus and retrovirus based vectors (Mocellin et al., 2004; Sandy et al., 2005). 
 
Initially, the ABCC1 and ABCC4 suppression may have overexpressed other ABC 
transporters as a compensatory effect hence causing the transfected cells to overcome the 
impact of ABCC1 and ABCC4 suppression.   
 
4.4     Effects of single gene knockdown of ABC transporters on cancer cell viability 
 
To study the impact of ABCC1 and ABCC4 suppression in breast cancer cells have on cell 
viability and cell cytotoxicity, the MTT assay was performed. Subsequently, transfected cells 
were seeded in 24-well plate and the cell viability was assessed after 6, 12 24, 48 and 72 
hours. Graphs showing the absorbance values of each cell lines are shown in figures 4.6 and 
4.7. 
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Figure 4.6. Cell viability of ABCC1 knockdown MCF-7 cells and ABCC4 knockdown 
MCF-7 cells. (A) ABCC1 knockdown MCF-7 cells and (B) ABCC4 knockdown MCF-7 cells 
were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. An MTT assay was 
performed. The cell viability was assessed after 6, 12, 24, 48, 72 hours. Briefly, 40 µl of MTT 
(5 mg/ml) was added to each well. After an additional one hour of incubation, the cell culture 
medium was removed from each well and 400 µl of DMSO was added. 100 µl of each sample 
was transferred into a 96-well plate in triplicates. The absorbance values were read at 570 
nm. Data are expressed as the mean ± standard error of the mean from at least three 
independent experiments. *** P < 0.001. P values were derived from two-way ANOVA vs 
untreated. 
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Figure 4.7. Cell viability of ABCC1 knockdown MDA-MB231 cells and ABCC4 
knockdown MDA-MB231 cells. (A) ABCC1 knockdown MDA-MB231 cells and (B) ABCC4 
knockdown MDA-MB231 cells were seeded in 24-well plates at a seeding density of 1.5 x 104 
cell/well. An MTT assay was performed. The cell viability was assessed after 6, 12, 24, 48, 72 
hours. Briefly, 40 µl of MTT (5 mg/ml) was added to each well. After an additional one hour of 
incubation, the cell culture medium was removed from each well and 400 µl of DMSO was 
added. 100 µl of each sample was transferred into a 96-well plate in triplicates. The 
absorbance values were read at 570 nm. Data are expressed as the mean ± standard error of 
the mean from at least three independent experiments. **** P < 0.0001. P values were derived 
from two-way ANOVA vs untreated. 
 
 
 
According to the results obtained from the MTT assay, the depletion of ABCC1 and ABCC4 in 
MCF-7 cells did not affect cell viability when compared to the negative siRNA or untreated 
cells (Figures 4.6A and 4.6B). However, the suppression of ABCC1 in MDA-MB231 cells by 
siRNA #30 significantly decreased cell viability only after 24 hours (Figure 4.7A). One 
explanation could be that since the expression level of ABCC1 in MDA-MB231 cells is higher 
than in MCF-7 cells, therefore the knockdown of ABCC1 in MDA-MB231 cells may be more 
apparent usually at a shorter time scale compared to siRNA knockdown in MCF-7 cells. 
 
4.5     Effects of single gene knockdown of ABC transporters on cancer cell migration 
 
Upon depletion of ABCC1 and ABCC4 in MCF-7 and MDA-MB231 breast cancer cells in 24-
well plate that was left for 72 hours incubation according to the manufacturer’s instructions, a 
cell monolayer was formed and a scratch assay was performed. Simply, a gap was carefully 
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created in the cell monolayer usually with a 10 μl pipette tip and the cell motility were monitored 
to determine the rate of migration of cells towards the centre of the gap.  
 
The plate was placed in the Cell-IQ, where the selected image positions were taken every 
hour for 24 hours. The data collected were analysed using the Cell-IQ analysis software. The 
percentage wound closure at 6, 12 and 24 hours for the MCF-7 and MDA-MB231 cells were 
plotted against the siRNAs as shown in figures 4.8 and 4.9 respectively.  
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Figure 4.8. Average scratch closure of ABCC1 knockdown MCF-7 cells and ABCC4 
knockdown MCF-7 cells. MCF-7 cells transfected with ABCC1 and ABCC4 siRNAs were left 
to incubate for 72 hours to ensure efficient transfection, a cell monolayer was formed and a 
scratch with a 10 μl pipette tip was made in the cell monolayer. The plate was placed in the 
Cell-IQ where the selected image positions were captured every hour for 24 hours. The 
transfected cells were incubated for (A) 6, (B) 12 and (C) 24 hours respectively. The captured 
images were analysed in the Cell-IQ analysis software.  Data are expressed as the mean ± 
standard error of the mean from at least three independent experiments. *P < 0.05, *** P < 
0.001 and **** P < 0.0001. P values were derived from one-way ANOVA vs untreated. 
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Figure 4.9 Average scratch closure of ABCC1 knockdown MDA-MB231 cells and ABCC4 
knockdown MDA-MB231 cells. MDA-MB231 cells transfected with ABCC1 and ABCC4 
siRNAs were left to incubate for 72 hours to ensure efficient transfection, a cell monolayer was 
formed and a scratch with a 10 μl pipette tip was made in the cell monolayer. The plate was 
placed in the Cell-IQ where the selected image positions were captured every hour for 24 
hours. The transfected cells were incubated for (A) 6, (B) 12 and (C) 24 hours respectively. 
The captured images were analysed in the Cell-IQ analysis software.  Data are expressed as 
the mean ± standard error of the mean from at least three independent experiments. 
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Upon depletion of ABCC1 and ABCC4 in MCF-7 cells, the cell motility was assessed by 
performing the scratch assay. The suppression of either ABCC1 or ABCC4 gene expression 
levels in MCF-7 cells significantly decreased cell migration when compared to the untreated 
cells after 6 hours incubation (Figure 4.8A). However, it seem that the suppression levels of 
ABCC1 and ABCC4 decreased with time. This could be the fact that the transfection 
mechanism is transient, thus the ABCC1 and ABCC4 genes slowly recovers with time. 
Consequently after 24 hour incubation the decrease in cell migration of ABC siRNA 
knockdown MCF-7 cells were only affected by one ABCC4 siRNA (ABCC4 siRNA #35) (Figure 
4.8C). 
 
Furthermore, the suppression of ABCC1 and ABCC4 gene expression in MDA-MB231 cells 
may be weak as compared to MCF-7 cells. Hence, the depletion of ABCC4 by only one of the 
two ABCC4 siRNAs (ABCC4 siRNA #35) caused a decrease in cell migration of the MDA-
MB231 cells after 6, 12 and 24 hours incubation (Figure 4.9A, 4.9B and 4.9C) but the decrease 
was not significant when compared to the untreated MDA-MB231 cells. These results 
suggested that the knockdown of ABCC1 and ABCC4 decreased cell migration in MCF-7 cells 
but not in MDA-MB231 cells. 
 
4.6     Effects of single gene knockdown of ABC transporters on cancer cell invasion 
 
To determine whether the of suppression of ABCC1 and ABCC4 gene expression levels in 
MCF-7 and MDA-MB231 breast cancer cells have an effect on not just migration but ability to 
invade, a transwell invasion assay was performed, which is an in vitro system often used to 
study cell invasion of malignant and normal cells. First, 24-well plate transwell inserts were 
coated with ice cold Corning Matrigel at a ratio of 1:3 with serum free cell culture medium to 
provide a condition to assess cancer cell invasive capacity in vitro. The Corning Matrigel Matrix 
blocks the pores of the membrane transwells to serve as a reconstituted basement membrane 
in vitro. Hence the only cells that have the ability to penetrate the Corning Matrigel Matrix and 
through the membrane pores are those that secrete proteases that enzymatically degrade the 
Corning Matrigel Matrix and these cells are often termed invasive cells. Non-invasive cells 
should not be able to migrate through the membrane (Kramer et al., 2013). 
 
In an optimisation process to identify the optimum cell seeding density and the thickness of 
the Corning Matrigel Matrix to be used, we found a seeding density of 50,000 cells and a 
volume of 30 μl of Corning Matrigel Matrix were optimal for each transwell insert.  The cells 
were suspended in 0.5% v/v FBS cell culture medium and, 0.5% v/v and 10% v/v FBS cell 
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culture medium were used as the chemoattractant. The cells were incubated for 24 hours after 
which the cells that migrated across the membranes pores were fixed and stained with 
Differential Quik stain according to manufacturer’s protocol. To determine the percentage cell 
invasion, the migrated cells which were stained were counted from five randomly selected 
fields of view under a light microscope at a magnification of x40. Graphs of percentage 
invasion of ABCC1 knockdown and ABCC4 knockdown MCF-7 and MDA-MB231 cells were 
plotted as shown in figures 4.10 and 4.11 respectively. 
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Figure 4.10. Effect of ABCC1 or ABCC4 knockdown on MCF-7 cell invasion. Percentage 
invasion of (A) ABCC1 knockdown MCF-7 cells and (B) ABCC4 knockdown MCF-7 cells 
across a reconstituted basement membrane in vitro. Upon depletion of ABCC1 and ABCC4 in 
MCF-7 cells, the ABCC1 knockdown MCF-7 cells and the ABCC4 knockdown MCF-7 cells 
were seeded for transwell invasion assay. The transwells were first coated with Corning 
Matrigel Matrix and a cell suspension of the ABCC1 knockdown MCF-7 cells and ABCC4 
knockdown MCF-7 cells in 0.5% v/v FBS cell culture medium were seeded in the transwell 
inserts that were then placed in wells of a 24-well plate containing 10% v/v or 0.5% v/v FBS 
cell culture medium. After 24 hours incubation, invasive cells that have crossed the membrane 
were fixed and stained with Differential Quik stain according to manufacturer protocol. Stained 
cells were counted using a light microscope (x40) from five different fields of view. Data are 
expressed as the mean ± standard error of the mean from at least three independent 
experiments. *P < 0.05 and ** P < 0.01. P values were derived from two-way ANOVA vs 10% 
v/v FBS untreated. 
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Figure 4.11. Effect of ABCC1 or ABCC4 knockdown on MDA-MB231 cell invasion. 
Percentage invasion of (A) ABCC1 knockdown MDA-MB231 cells and (B) ABCC4 knockdown 
MDA-MB231 cells across a reconstituted basement membrane in vitro. Upon depletion of 
ABCC1 and ABCC4 in MDA-MB231 cells, the ABCC1 knockdown MDA-MB231 cells and the 
ABCC4 knockdown MDA-MB231 cells were seeded for transwell invasion assay. The 
transwells were first coated with Corning Matrigel Matrix and a cell suspension of the ABCC1 
knockdown MDA-MB231 cells and ABCC4 knockdown MDA-MB231 cells in 0.5% v/v FBS cell 
culture medium were seeded in the transwell inserts that were then placed in wells of a 24-
well plate containing 10% v/v or 0.5% v/v FBS cell culture medium. After 24 hours incubation, 
invasive cells that have crossed the membrane were fixed and stained with Differential Quik 
stain according to manufacturer protocol. Stained cells were counted using a light microscope 
(x40) from five different fields of view. Data are expressed as the mean ± standard error of the 
mean from at least three independent experiments. *P < 0.05 and ** P < 0.01. P values were 
derived from two-way ANOVA vs 10% v/v FBS untreated. 
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In general, Foetal bovine serum (FBS) was used as the chemoattractant and cancer cells 
usually migrate from a low concentration to a high concentration of chemoattractant. 
Consequently, the ABCC1 and ABCC4 knockdown MCF-7 and MDA-MB231 cells were 
suspended in 0.5% v/v FBS cell culture medium and the chemoattractant was either 0.5% v/v 
or 10% v/v FBS cell culture medium. Therefore, higher numbers of cells were expected to 
migrate when the chemoattractant was 10% v/v FBS cell culture medium compared to 0.5% 
v/v cell culture medium. 
 
The invasive ability of ABCC1 knockdown MCF-7 cells (siRNA #30 and #31) were impaired, 
as a lower percentage of cells moved across the membrane pores to the chemoattractant 10% 
v/v FBS cell culture medium when compared to that of the untreated MCF-7 cells. However, 
when the chemoattractant was 0.5% v/v FBS cell culture medium, no significant inhibition of 
cell invasion was observed (Figure 4.10A). 
  
Moreover, the depletion of ABCC4 in MCF-7 cells (siRNA #34 and #35) show no significant 
decrease in migration across the membrane pores to 10% v/v FBS cell culture medium (Figure 
4.10B). Interestingly, the suppression of ABCC4 gene expression in MCF-7 cells by ABCC4 
siRNA #34 and #35 caused an impaired cell invasive ability of ABCC4 knockdown MCF-7 cells 
to migrate to 0.5% v/v FBS cell culture medium relative to 10% v/v FBS untreated MCF-7 cells 
(Figure 4.10B). 
 
In the case of ABCC1 knockdown in MDA-MB231 cells, the depletion of ABCC1 in MDA-
MB231 cells did not inhibit cell migration across the membrane pores to either 10% v/v or 
0.5% v/v FBS cell culture medium (Figure 4.11A). Furthermore, the suppression of ABCC4 
gene expression levels in MDA-MB231 cells by ABCC4 siRNA #35 caused a decrease in cell 
invasion across the membrane pores to either 10% v/v or 0.5% v/v FBS cell culture medium 
(Figure 4.11B). However, the results obtained may not be reliable due to large degree of 
variation in data resulting in large error bars especially for MDA-MB231 cells. 
 
Nevertheless, results may indicate that depletion of ABCC4 in breast cancer cells may affect 
cell invasion more than the depletion of ABCC1 regardless of the chemoattractant used. 
 
4.7     Analysis of the efficiency of ABCC1 and ABCC4 combination knock down in 
breast cancer cell lines  
 
In order to efficiently knockdown both ABCC1 and ABCC4 in breast cancer cells, we 
investigated the efficiency of combination siRNA transfection between sequential siRNA 
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knockdown and simultaneous siRNA knockdown methods. A total of 1 nM of siRNAs (ABCC1 
and ABCC4 siRNAs) were used in each siRNA transfection. Therefore, in sequential siRNA 
knockdown, 1 nM of ABCC1 siRNA were used to transfect the cells and 24 hours later 1 nM 
of ABCC4 siRNA were added. Therefore, transfected cells were exposed to a total of 1 nM of 
siRNAs at any one time.  Hence, before 1 nM of ABCC4 siRNA was added to the cells, the 
cell culture medium was removed and replaced with fresh cell culture so that the cells were 
exposed to 1 nM of siRNA. The transfected cells were incubated for 72 hours after which they 
were harvested. In the case of simultaneous siRNA knockdown, 0.5 nM of each siRNAs 
(ABCC1 and ABCC4 siRNAs) were added to the cells at the same time. Similarly, the 
transfected cells were incubated for 72 hours after which they were harvested. The efficiency 
of sequential and simultaneous siRNA transfections were determined by Western Blot 
analysis (Figure 4.12). The combination of siRNAs were chosen randomly, hence siRNA #30 
was combined with siRNA #34 and siRNA #31 was combined with siRNA #35. 
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Figure 4.12. Western blot analysis of ABCC1 and ABCC4 protein expression following 
combination knockdown experiments. MCF-7 breast cancer cells were transfected with 
ABCC1- and ABCC4-specific siRNA molecules in combination (Combination: ABCC1 siRNA 
#30 and ABCC1 siRNA #34; ABCC1 siRNA #31 and ABCC4 siRNA #35). A negative siRNA 
was used as a negative control to offset any non-specific silencing. In sequential siRNA 
transfection, 1 nM of ABCC1 siRNA was exposed to MCF-7 cells first. After 24 hours 
incubation, the cell culture medium was replaced with fresh cell culture medium and 1nM of 
ABCC4 siRNA was exposed to MCF-7 cells. The transfected MCF-7 cells were incubated for 
72 hours after which the transfected MCF-7 cells were harvested for Western blot analysis. 
For simultaneous siRNA transfection, 0.5 nM of ABCC1 siRNA and 0.5 nM of ABCC4 siRNA 
were exposed to MCF-7 cells at the same time. The transfected MCF-7 cells were incubated 
for 72 hours after which the transfected MCF-7 cells were harvested for Western blot analysis. 
The molecular weight standards were loaded in the first lane (Thermo Scientific Prestained 
Protein Molecular weight marker, 20 to 120 kDa) and 20 µl of samples were loaded in each 
lanes. β-actin was used as the loading control. The PVDF membrane blots for ABCC1 and 
ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) overnight and incubated 
in appropriate primary antibodies, anti-ABCC1 derived in rabbit (1:1000 in blocking buffer) and 
anti-ABCC4 derived in rat (1:100 in blocking buffer) respectively. The secondary antibodies 
used were anti-rabbit HRP (1:3000 in TBS-T) and anti-rat HRP (1:5000 in TBS-T). The level 
of protein expressions were detected using the Li-Cor C-Digit blot scanner and the images 
were analysed using Image Studio Lite software imaging system. Western blot analysis was 
repeated at least three times and successful silencing of ABCC1 and ABCC4 protein 
expression in MCF-7 transfected cells were obtained each time. 
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As can be seen from the ABCC1 Western blot (Figure 4.12 Western blot A), the ABCC1 protein 
expression is reduced in both protein lysates obtained from MCF-7 cells treated in sequential 
and simultaneous siRNA transfections when compared to protein lysate from untreated and 
negative siRNA treated MCF-7 cells. Moreover, it seem that the ABCC1 protein expression 
levels  from the untreated and negative siRNA treated MCF-7 cells under sequential siRNA 
transfection condition were higher than those under simultaneous siRNA transfection 
condition. This may be because the untreated and the negative siRNA treated MCF-7 cells in 
the sequential siRNA condition were left to incubate along side the sequential transfected cells 
and since the cells were exposed to the first siRNA for 24 hours and after the second siRNA, 
the cells were all left to incubate for 96 hours while those in simultaneous siRNA transfection 
condition were altogether incubated for 72 hours. Therefore, the longer incubation time means 
more cell growth thus the higher quantity of protein. In addition, low cell cytotoxicity was also 
observed. 
 
Although the Western blot for ABCC4 (Figure 4.12 Western blot B) may not be clear due to 
high non-specific background, in the lanes for the protein lysates obtained from the untreated 
and negative siRNA treated MCF-7 cells, a dark band (at 150 kDa mark) can be seen 
compared to the lanes for protein lysates obtained from combination siRNA treated MCF-7 
cells. 
 
Consequently, the efficiency of combination siRNA between sequential and simultaneous 
siRNA transfection methods were only tested in MCF-7 cells. Therefore, since both sequential 
and simultaneous siRNA transfection worked, we decided to use simultaneous siRNA 
transfection as the preferred combination siRNA transfection method for experiments as less 
time is need for successful transfection. In addition, since the efficiency of combination siRNA 
using the sequential and simultaneous siRNA transfections methods were only tested in MCF-
7 cells, we suspected that there is a high probability that the combination siRNA transfection 
will work in MDA-MB231 cells.  Therefore, MDA-MB231 cells were exposed to ABCC1- and 
ABCC4-specific siRNA molecules in combination by using simultaneous siRNA transfection 
method for experiments and the Western blot analysis is shown in figure 4.13.  
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Figure 4.13. Western blot analysis of ABCC1 and ABCC4 protein expression following 
combination siRNA knockdown. MDA-MB231 breast cancer cells to ABCC1- and ABCC4-
specific siRNA molecules in simultaneous combination (Combination: ABCC1 siRNA #30 and 
ABCC1 siRNA #34; ABCC1 siRNA #31 and ABCC4 siRNA #35). A negative siRNA was used 
as a negative control to offset any non-specific silencing. 0.5 nM of ABCC1 siRNA and 0.5 nM 
of ABCC4 siRNA were exposed to MDA-MB231 cells at the same time. The transfected MDA-
MB231 cells were incubated for 72 hours after which the transfected MDA-MB231 cells were 
harvested for Western blot analysis. The molecular weight standards were loaded in the first 
lane (Thermo Scientific Prestained Protein Molecular weight marker, 20 to 120 kDa) and 20 
µl of samples were loaded in each lanes. α-tubulin was used as the loading control. The PVDF 
membrane blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in 
TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in 
rabbit (1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. The Western blot analysis was repeated at least three times and similar transfection 
efficiency were obtained each time. 
 
 
 
As can be seen from figure 4.13. Exposure of MDA-MB231 cells to ABCC1 and ABCC4 
siRNAs simultaneously, successfully decrease both ABCC1 (Figure 4.13 Western blot A) and 
ABCC4 (Figure 4.13 Western blot B)  protein expressions in MDA-MB231 transfected cells 
when compared to the untreated MDA-MB231 cells and the MDA-MB231 cells treated with 
negative siRNA. In addition, ABCC4 knockdown was partial when compared to ABCC1 
knockdown. 
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Therefore, the simultaneous siRNA transfection method was adapted as the method to expose 
MCF-7 and MDA-MB231 breast cancer cells to both ABCC1 and ABCC4 siRNAs at the same 
time. The combination siRNA transfected breast cancer cells were used for cellular functional 
experiments. 
 
4.8     Effects of combination gene knockdown of ABC transporters on cancer cell 
colony formation 
 
Upon combined depletion of ABCC1 and ABCC4 in breast cancer cells, the transfected cells 
were seeded for the colony formation assay to assess the ability of a cell to grow in to a colony 
after both ABCC1 and ABCC4 has been knockdown. Graphs of number of colonies formed 
for each cell lines are shown in figures 4.14. 
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Figure 4.14. The impact of combination suppression of ABCC1 and ABCC4 gene 
expression levels on colony formation. (A) MCF-7 and (B) MDA-MB231 breast cancer cells 
were transfected with 1 nM of total siRNAs and the clonogenic capacity of the breast cancer 
cells upon depletion of ABCC1 and ABCC4 was assayed after 7 days. The transfected breast 
cancer cells were fixed and stained with PFA and crystal violet respectively. Stained cell 
colonies were visible and were counted manually.  Data are expressed as the mean ± standard 
error of the mean from at least three independent experiments. *** P < 0.001 and **** P < 
0.0001. P values were derived from one-way ANOVA vs untreated. 
 
 
 
The combination knockdown of ABCC1 and ABCC4 genes in MCF-7 cells inhibited the 
clonogenic capacity of MCF-7 cells to form cell colonies (Figure 4.14A). Moreover, both 
combination siRNA knockdowns (ABCC1 siRNA #30 and ABCC4 siRNA #34; ABCC1 siRNA 
#31 and ABCC4 siRNA #35) in MCF-7 cells significantly reduced the number of colonies 
formed when compared to the untreated MCF-7 cells. Similar effect of reduction in clonogenic 
capacity of MDA-MB231 cells was seen with one combination of siRNA knockdown (ABCC1 
siRNA #30 and ABCC4 siRNA #35). The other combination siRNA knockdown (ABCC1 siRNA 
#31 and ABCC4 siRNA #35) in MDA-MB231 cells did not significantly affect the clonogenic 
capacity of MDA-MB231 cells when compared to the untreated MDA-MB231 cells (Figure 
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4.14B). These results indicate that ABCC1 and ABCC4, together may mediate breast cancer 
cell growth.  
 
4.9     Effects of combination gene knockdown of ABC transporters on cancer cell 
viability 
 
To study the impact of combine suppression of ABCC1 and ABCC4 gene expression levels in 
breast cancer cells have on cell viability and cell cytotoxicity, the MTT assay was performed. 
Graphs showing the absorbance results are as shown in figures 4.15 and 4.16. 
 
 
 
Figure 4.15. Cell viability of combination ABCC1 and ABCC4 knockdown MCF-7 cells. 
The combination ABCC1 and ABCC4 knockdown MCF-7 cells, the untreated MCF-7 cells 
were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. An MTT assay was 
performed. The cell viability was assessed after 6, 12, 24, 48 and 72 hours. Briefly, 40 µl of 
MTT (5 mg/ml) was added to each well. After an additional 1 hour of incubation, the cell culture 
medium was removed from each well and 400 µl of DMSO was added. 100 µl of each sample 
from each well was transferred into a 96-well plate in triplicates. The absorbance values were 
read at 570 nm. Data are expressed as the mean ± standard error of the mean from at least 
three independent experiments. * P < 0.05. P values were derived from two-way ANOVA vs 
untreated.  
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Figure 4.16. Cell viability of combination ABCC1 and ABCC4 knockdown MDA-MB231 
cells. The combination ABCC1 and ABCC4 knockdown MDA-MB231 cells, the untreated 
MDA-MB231 cells were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. An 
MTT assay was performed. The cell viability was assessed after 6, 12, 24, 48 and 72 hours. 
Briefly, 40 µl of MTT (5 mg/ml) was added to each well. After an additional 1 hour of incubation, 
the cell culture medium was removed from each well and 400 µl of DMSO was added. 100 µl 
of each sample from each well was transferred into a 96-well plate in triplicates. The 
absorbance values were read at 570 nm. Data are expressed as the mean ± standard error of 
the mean from at least three independent experiments. 
 
 
 
The combined suppression of ABCC1 and ABCC4 in MCF-7 cells did not affect cell viability 
after 6, 12 and 24 hours incubation but may have an effect after 48 and 72 hours incubation 
as a decrease in cell viability was seen (Figure 4.15). Although decreased growth was 
observed for double knockdowns at 48 and 72 hours, this was also seen for the negative 
control siRNA suggesting a non-specific effect. No significant changes in cell viability were 
observed after combined depletion of ABCC1 and ABCC4 in MDA-MB231 cells (Figures 4.16). 
These results may indicate that combined depletion of ABCC1 and ABCC4 in MCF-7 cells 
have a greater effect on cell viability than the combine depletion of ABCC1 and ABCC4 in 
MDA-MB231 cells. However, it should be noted that transfection efficiency in MDA-MB231 
cells may not be as high as in MCF-7 cells.  
 
4.10     Effects of combination gene knockdown of ABC transporters on cancer cell 
migration 
 
The effect of the double knockdown of ABCC1 and ABCC4 on cell migration were next 
investigated using the scratch assay. The data collected were analysed using the Cell-IQ 
analysis software. The percentage wound closure at 6, 12 and 24 hours for the combination 
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ABCC1 and ABCC4 knockdown MCF-7 and MDA-MB231 cells are as shown in figures 4.17 
and 4.18 respectively. 
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Figure 4.17. Average scratch closure of combination ABCC1 and ABCC4 knockdown 
MCF-7 cells.  The MCF-7 cells transfected with a combination of ABCC1 and ABCC4 siRNAs, 
were left to incubate for 72 hours. A cell monolayer was formed and a scratch was made in 
the cell monolayer with a 10 μl pipette tip. The plate was placed in the Cell-IQ where the 
selected image positions were captured every hour for 24 hours. The captured images were 
analysed using the Cell-IQ analysis software.  Data are expressed as the mean ± standard 
error of the mean from at least three independent experiments.  
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Figure 4.18. Average scratch closure of combination ABCC1 and ABCC4 knockdown 
MDA-MB231 cells. The MDA-MB231 cells transfected with a combination of ABCC1 and 
ABCC4 siRNAs, were left to incubate for 72 hours, according to the INTERFERin transfection 
instructions. A cell monolayer was formed and a scratch was made in the cell monolayer with 
a 10 μl pipette tip. The plate was placed in the Cell-IQ where the selected image positions 
were captured every hour for 24 hours. The captured images were analysed using the Cell-IQ 
analysis software.  Data are expressed as the mean ± standard error of the mean from at least 
three independent experiments.  
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As can be seen from figure 4.17, combined suppression of ABCC1 and ABCC4 gene 
expression levels in MCF-7 cells did not inhibit cell migration. Similarly, the combined depletion 
of ABCC1 and ABCC4 in MDA-MB231 cells did not affect cell migration (Figure 4.18). At 
present, it is not clear why this may be the case, since a single knockdown of either ABCC1 
or ABCC4 in the breast cancer cells significantly inhibited cell migration. In theory the combine 
suppression of ABCC1 and ABCC4 gene expression levels in breast cancer cells would be 
expected to cause significant decrease in cell migration beyond that caused by a single gene 
knock down. Therefore, further investigation may be required. 
 
4.11     Effects of combination gene knockdown of ABC transporters on cancer cell 
invasion 
 
Finally, the invasive ability of MCF-7 and MDA-MB231 breast cancer cells were investigated 
using the cell invasion assay upon combined depletion of ABCC1 and ABCC4 in the breast 
cancer cells. Graphs of percentage invasion following combination ABCC1 and ABCC4 
knockdown in MCF-7 and MDA-MB231 cells are shown in figures 4.19 and 4.20 respectively. 
 
 
Figure 4.19. Effect of double knockdown of ABCC1 and ABCC4 on MCF-7 cell invasion. 
Percentage invasion of combination knockdown ABCC1 and ABCC4 in MCF-7 cells across a 
reconstituted basement membrane in vitro. Upon combined depletion of ABCC1 and ABCC4 
in MCF-7 cells, the transfected MCF-7 cells were seeded for transwell invasion assay. The 
transwells were first coated with Corning Matrigel Matrix and a cell suspension of MCF-7 
transfected cells in 0.5% v/v FBS cell culture medium were seeded in the transwell insert that 
was then placed in wells of plate wells containing 10% v/v or 0.5% v/v FBS cell culture medium. 
After 24 hours incubation, invasive cells that have crossed the membrane were fixed and 
stained with Differential Quik stain according to manufacturer protocol. Stained cells were 
counted using a light microscope (x40) from five randomly selected fields of view.  Data are 
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expressed as the mean ± standard error of the mean from at least three independent 
experiments. 
 
 
 
Figure 4.20. Effect of double knockdown of ABCC1 and ABCC4 on MDA-MB231 cell 
invasion. Percentage invasion of combination knockdown ABCC1 and ABCC4 in MDA-
MB231 cells across a reconstituted basement membrane in vitro. Upon combined depletion 
of ABCC1 and ABCC4 in MDA-MB231 cells, the transfected MDA-MB231 cells were seeded 
for transwell invasion assay. The transwells were first coated with Corning Matrigel Matrix and 
a cell suspension of MDA-MB231 transfected cells in 0.5% v/v FBS cell culture medium were 
seeded in the transwell insert that was then placed in wells of plate wells containing 10% v/v 
or 0.5% v/v FBS cell culture medium. After 24 hours incubation, invasive cells that have 
crossed the membrane were fixed and stained with Differential Quik stain according to 
manufacturer protocol. Stained cells were counted using a light microscope (x40) from five 
randomly selected fields of view.  Data are expressed as the mean ± standard error of the 
mean from at least three independent experiments. * P < 0.05. P values were derived from 
two-way ANOVA vs 10% v/v FBS untreated. 
 
 
 
While there are some trends with both cell lines suggesting the double knockdowns might 
cause decreased invasion in both cells (Figures 4.19 and 4.20), a significant decreased in 
invasion was observed in MDA-MB231 cells after double knocked down with siRNA #31 and 
#35 (Figure 4.20). However the data shows a large degree of variation resulting in large error 
bars.  
 
4.12     Summary 
 
 ABCC1 and ABCC4 expression levels in MCF-7 and MDA-MB231 cells were 
successfully knocked down using ABCC1- and ABCC4-siRNA specific molecules and 
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INTERFERin as the transfection reagent as confirmed by Western blot analysis and 
gene expression analysis using RT-PCR. 
 
 The single knockdown of ABCC1 and ABCC4 genes did not inhibit the ability of cells 
to form colonies as compared to the untreated cells. This could suggest that the 
knockdown of ABCC1 or ABCC4 have no effect on breast cancer cell growth. However, 
the knockdown of ABCC1 or ABCC4 may be compensated for by other transporters. 
 
 A combination knockdown of ABCC1 and ABCC4 did decrease the number of colonies 
formed. Hence suggesting that ABCC1 and ABCC4 affect the clonogenic capacity of 
breast cancer cells synergistically. 
 
 Although there were some suggestions that ABCC1 knockdown has more of an effect 
on proliferation than ABCC4. However, no significant effects were seen in the 
combined knockdown.  
 
 The knockdown of ABCC1 and ABCC4 in MCF-7 cells affected cell migration more 
than the knockdown of ABCC1 and ABCC4 in MDA-MB231 cells. This was especially 
apparent within the first 6 hours. 
 
 ABCC1 knockdown MCF-7 and ABCC4 knockdown MCF-7 cells have an impaired 
invasion ability compared to the untreated MCF-7 cells. In comparison, only the 
knockdown of ABCC4 in MDA-MB231 cells decreased cell invasion.  This could 
suggest that ABCC4 may be involved in cell invasion more than ABCC1. 
 
 Surprisingly, the combination knockdown of ABCC1 and ABCC4 showed no effect on 
either MCF-7 or MDA-MB231 cell migration using the scratch assay. Also although 
there were some apparent differences, a significant decreased in invasion was 
observed in MDA-MB231 cells after double knocked down with siRNA #31 and #35. 
 
 It is important to note that the method of siRNA transfection is transient and it is a 
knockdown not a knockout. 
o Gene expression usually recovers after 96 to 120 hours after transfection. 
o Since the MDA-MB231 cells may have a higher native expression level of both 
ABCC1 and ABCC4, even after knockdown they may still have sufficient levels 
of the proteins. 
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o The efficiency of transfection was not measured in terms of the proportion of 
cells that were knocked down in comparison to those that were unaffected. 
MDA-MB231 cells may be more difficult to transfect than MCF-7 cells, this may 
be an important consideration.  
o Although the double knockdowns did show decreased expression of both 
proteins on Western blot, this is a bulk measurement and does not prove if both 
are knocked down with in the same cell. 
 
 The results obtained are preliminary but do suggest that ABCC1 may be involved in 
cell proliferation, while ABCC4 is implicated in cell migration and invasion. 
o To validate the results obtained a more reliable and efficient method to 
knockdown MCF-7 and MDA-MB231 cells may be required such as the use of 
plasmids which express siRNA, or  short hairpin RNAs (shRNAs) expressed 
from plasmids, which can undergo selection to obtain stable cell lines with 
knockdown of the target protein. Alternatively a more efficient delivery method 
such as lentivirus, retrovirus and adenovirus based vectors could be beneficial. 
Alternatively, CRISPR/Cas9 could be trialled to achieve an effective knockout 
of these genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
Chapter 5 – Analysis of the effects of gene overexpression of ABC transporters on 
breast cancer cell lines in vitro 
 
5.1     Objective 
 
In chapter 4, the main focus was to knock down ABCC1 and ABCC4 genes in breast cancer 
cells and use these knockdown cells to carry out functional cellular assays to determine 
whether ABCC1 and ABCC4 have an impact on breast cancer cell proliferation, cell migration 
and/or cell invasion. In contrast, this chapter, looks to target ABCC1 and ABCC4 in breast 
cancer cells overexpressing the genes by using specific plasmid DNA. Consequently, the 
overexpressed ABCC1 and ABCC4 breast cancer cells were used to investigate whether the 
overexpression of ABCC1 and ABCC4 have an impact in breast cancer cell proliferation, cell 
migration and/or cell invasion. 
 
In general, plasmids are small double-stranded DNA fragments that can carry genes and can 
replicate independently from chromosomal DNA. In the field of recombinant DNA technology, 
plasmids are most commonly used to facilitate the study and manipulation of genes as most 
plasmids are relatively small with 3000 – 6000 base pairs and are easily replicated in E. coli. 
A typical plasmid has a DNA replication region, a region for the insert of exogenous DNA 
fragments and an antibiotic-resistance gene (Addgene, 2018).  
 
Using transfection of cell lines with plasmids encoding ABCC1 and ABCC4, it was investigated 
whether ABCC1 and/or ABCC4 is/are implicated in cell proliferation, migration and invasion 
by first conducting single overexpression of ABCC1 and ABCC4 genes in MCF-7 and MDA-
MB231 breast cancer cell lines. The overexpressed ABCC1 and ABCC4 breast cancer cells 
were then used in cellular functional assays, including the colony formation assay to assess 
cell growth, MTT assay to assess cell proliferation, scratch assay to assess cell migration and 
transwell invasion assay to assess cell invasion. 
 
Furthermore, since some ABC transporters transport similar active physiological substrates 
(Liu et al., 2010; Chen et al., 2010) we hypothesised that the overexpression of ABCC1 and 
ABCC4 in combination in breast cancer cells may cause a greater significant impact in breast 
cancer biology than that caused by the overexpression of ABCC1 or ABCC4 alone when 
compared to the untreated breast cancer cells and those treated with empty vector plasmid. 
We therefore wanted to investigate whether ABCC1 and ABCC4 work together when they are 
both overexpressed in a breast cancer cell lines to affect cell proliferation, migration and 
invasion. 
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5.2     Plasmid DNA verifications 
 
The plasmid DNAs were a kind gift from Professor Susan Cole’s lab. Briefly, the plasmid DNA 
was transformed into competent cells using the protocol for standard heat-shock 
transformation of chemically competent bacteria. The transformed bacteria were then grown 
overnight on agar plate and a colony of bacteria carrying a specific plasmid DNA was selected 
and inoculated in an overnight liquid LB bacterial culture. Subsequently, plasmid DNA isolation 
and purification were performed using Thermo Scientific GeneJET Plasmid Miniprep kit. The 
purified plasmid DNAs were quantified using NanoDrop TM 1000 spectrophotometer 
(ThermoFisher Scientific) and samples were stored at -20oC.  
 
Large quantities of the plasmid DNAs were amplified in E.Coli and isolated and purified using 
100% kit free plasmid maxiprep. Verification of the plasmid DNAs were performed by 
transfecting HEK293T kidney embryonic cells with the plasmid DNAs using polyethylenimine 
(PEI) and running a Western blot analysis on whole cell lysates (Figure 5.1). 
 
 
 
Figure 5.1. Western blot analysis of ABCC1 and ABCC4 protein expression levels 
derived from whole cell lysate samples from ABCC1 and ABCC4 overexpressed 
HEK293T cells. HEK293T cells were transfected using PEI at a ratio of 15:1 to plasmid DNA 
(empty vector plasmid DNA, ABCC1 plasmid DNA and ABCC4 plasmid DNA). The transfected 
HEK293T cells were incubated for specific time points of 48, 72 and 96 hours. The transfected 
HEK293T cells were harvested and Western blot analysis was performed. The the molecular 
weight standards were loaded in lane 1 (Thermo Scientific PageRuler Plus Prestained Protein 
Ladder, 10 to 250 kDa) and 16 µl of samples were loaded in each lanes. The PVDF membrane 
blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) 
overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in rabbit 
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(1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. 
 
 
 
The Western blot analysis indicated that transfection of HEK293T cells with ABCC1 or ABCC4 
plasmid DNA led to a marked overexpression of the target protein (Figure 5.1). The native 
ABCC1 / ABCC4 expression levels in HEK293T cells transfected with empty vector plasmid 
or untreated HEK293T cells are relatively low hence they were not detected with the exposure 
used.  Polyethyleneimine (PEI) was used as it is a relatively cheap transfection reagent that 
can produce high transient transfection efficiency in most cell lines (Sou et al., 2013). 
 
5.3     Optimisation of plasmid DNA transfection conditions using Polyethyleneimine 
(PEI) as a transfection reagent  
 
Polyethyleneimine (PEI) is a cationic polymer that is often used in both small and large-scale 
transient expression in mammalian cells (Longo et al., 2013) as it is a very cost effective 
transfection reagent providing 40 to 90% transfection efficiency (Sou et al., 2013). PEI works 
by forming nucleic acid-polymer complexes which are positively charged. Through 
electrostatic interaction, the positively charged nucleic acid-polymer complexes interact and 
adhere to the negatively charged cell membrane and releases the complexes in to the cells 
via endocytosis (Gibco Life Technologies, 2016). 
 
Therefore, because PEI is a very cost effective transfection reagent that produces highly 
stable complexes and reproducible results as well as high transfection efficiency in most cell 
lines, PEI was used as the transfection reagent to transfect cells with the plasmid DNAs. 
However, different cell lines may require different conditions for optimal transfection. Hence, 
optimisation of plasmid DNA transfection condition using PEI was performed. Briefly, the cell 
seeding density of each cell line was determined so as to obtain 60 – 70% cell confluency at 
the time of transfection. The cells were starved for 3 hours at 37oC and transfection complex 
of PEI nitrogen to DNA phosphate ratios of 10:1, 15:1 and 20:1 were used to transfect the 
cells. After 24 hours of transfection, the low FBS (2.5% v/v) cell culture medium was replaced 
with 10% v/v FBS cell culture medium and cell were left to incubate for 48, 72 and 96 hours. 
After 48, 72 and 96 hours post transfections, cells were harvested. Subsequently, the protein 
expression levels of ABCC1 and ABCC4 in the transfected cells were analysed by Western 
blot analysis (Figure 5.2). All PEI transfections were performed in 6-well plates. 
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Figure 5.2. Protein expression levels of ABCC1 and ABCC4 in HEK293T cells following 
PEI transfection with ABCC1 and ABCC4 plasmid DNA respectively. HEK293T cells were 
transfected with PEI at a ratio of 10:1, 15:1, 20:1 to plasmid DNA (empty vector plasmid, 
ABCC1 plasmid DNA and ABCC4 plasmid DNA). The transfected HEK293T cells were 
incubated at specific time points of 48, 72 and 96 hours. At each specific time point, transfected 
HEK293T cells were harvested and Western blot analysis was performed. The molecular 
weight standards were loaded in the first lane (Thermo Scientific Prestained Protein Molecular 
weight marker, 20 to 120 kDa) and 12 µl of samples were loaded in each lanes. The PVDF 
membrane blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in 
TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in 
rabbit (1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. 
 
 
 
As an expression tool for recombinant protein in many experimental set up, HEK293T cell line 
was used. Moreover, HEK293T cells are quick and easy to grow in the lab and produce high 
transfection efficiency and large amount of protein (Thomas et al., 2005). Therefore, as can 
be seen from figure 5.2, it is apparent that high levels of ABCC1 and ABCC4 were seen in 
protein lysate from HEK293T cells transfected with ABCC1 and ABCC4 plasmid DNA 
respectively as compared to the untreated and the HEK293T cells treated with empty vector 
plasmid DNA. Consequently, the results suggested that at PEI to DNA ratio of 10:1 and after 
96 hours post transfection was the optimal PEI transfection condition as relatively high protein 
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expression levels of ABCC1 and ABCC4 were obtained in protein lysate from HEK293T cells 
transfected with ABCC1 and ABCC4 plasmid DNA respectively. 
 
The optimisation of PEI transfection was also performed in HeLa cells as shown in figure 5.3. 
 
 
 
Figure 5.3. Protein expression levels of ABCC1 and ABCC4 in HeLa cells following PEI 
transfection with ABCC1 and ABCC4 plasmid DNA respectively. HeLa cells were 
transfected with PEI at a ratio of 10:1, 15:1, 20:1 to plasmid DNA (empty vector plasmid, 
ABCC1 plasmid DNA and ABCC4 plasmid DNA). The transfected HeLa cells were incubated 
at specific time points of 48, 72 and 96 hours. At each specific time point, transfected HeLa 
cells were harvested and Western blot analysis was performed. The molecular weight 
standards were loaded in the first lane (Thermo Scientific Prestained Protein Molecular weight 
marker, 20 to 120 kDa) and 12 µl of samples were loaded in each lanes. The PVDF membrane 
blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) 
overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in rabbit 
(1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. 
 
 
 
In the case of PEI transfection in HeLa cells, overexpression of ABCC1 in HeLa was obtained 
after transfection with ABCC1 plasmid DNA at PEI to DNA ratios of 10:1, 15:1 and 20:1 when 
compared to the untreated HeLa cells and the HeLa cells treated with empty vector plasmid 
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DNA (Figure 5.3). However, high protein level of ABCC4 in HeLa cells treated with ABCC4 
plasmid DNA was significant only at PEI to DNA ratio 20:1. Hence, the results suggested that 
at PEI to DNA ratio of 20:1 and after 96 hours post transfection was the optimal PEI 
transfection condition as relatively high protein expression levels of ABCC1 and ABCC4 in 
HeLa transfected cells were obtained. 
 
Due to the high efficiency of PEI transfection in HEK293T and HeLa cells, attempts to optimise 
the transfection of ABCC1 and ABCC4 plasmid DNA in MCF-7 and MDA-MB231 breast cancer 
cells using PEI to try to overexpress the endogenous ABCC1 and ABCC4 were performed 
and results were analysed using Western blot analysis as shown in figures 5.4 and 5.5. 
 
 
 
Figure 5.4. Protein expression levels of ABCC1 and ABCC4 in MCF-7 cells following PEI 
transfection with ABCC1 and ABCC4 plasmid DNA respectively. MCF-7 cells were 
transfected with PEI at a ratio of 10:1, 15:1, 20:1 to plasmid DNA (empty vector plasmid, 
ABCC1 plasmid DNA and ABCC4 plasmid DNA). The transfected MCF-7 cells were incubated 
at specific time points of 48, 72 and 96 hours. At each specific time point, transfected MCF-7 
cells were harvested and Western blot analysis was performed. The molecular weight 
standards were loaded in the first lane (Thermo Scientific Prestained Protein Molecular weight 
marker, 20 to 120 kDa) and 12 µl of samples were loaded in each lanes. The PVDF membrane 
blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) 
overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in rabbit 
(1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
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C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. 
 
 
Figure 5.5. Protein expression levels of ABCC1 and ABCC4 in MDA-MB231 cells 
following PEI transfection with ABCC1 and ABCC4 plasmid DNA respectively. MDA-
MB231 cells were transfected with PEI at a ratio of 10:1, 15:1, 20:1 to plasmid DNA (empty 
vector plasmid, ABCC1 plasmid DNA and ABCC4 plasmid DNA). The transfected MDA-
MB231 cells were incubated at specific time points of 48, 72 and 96 hours. At each specific 
time point, transfected MDA-MB231 cells were harvested and Western blot analysis was 
performed. The molecular weight standards were loaded in the first lane (Thermo Scientific 
Prestained Protein Molecular weight marker, 20 to 120 kDa or 10 to 170 kDA) and 12 µl of 
samples were loaded in each lanes. The PVDF membrane blots for ABCC1 and ABCC4 
proteins were blocked in blocking buffer (5% BSA in TBS-T) overnight and incubated in 
appropriate primary antibodies, anti-ABCC1 derived in rabbit (1:1000 in blocking buffer) and 
anti-ABCC4 derived in rat (1:100 in blocking buffer) respectively. The secondary antibodies 
used were anti-rabbit HRP (1:3000 in TBS-T) and anti-rat HRP (1:5000 in TBS-T). The level 
of protein expressions were detected using the Li-Cor C-Digit blot scanner and the images 
were analysed using Image Studio Lite software imaging system. 
 
 
 
Significant overexpression of ABCC1 in MCF-7 cells was obtained after transfection with 
ABCC1 plasmid DNA at PEI to DNA ratios of 15:1 and 20:1 when compared to the untreated 
MCF-7 cells and the MCF-7 cells treated with empty vector plasmid DNA (Figure 5.4). 
However, protein expression level of ABCC4 in MCF-7 cells treated with ABCC4 plasmid DNA 
was relatively stable at PEI to DNA ratio 10:1, 15:1 and 20:1 when compared to the untreated 
205 
 
and the MCF-7 cells treated with empty vector plasmid DNA. Hence, the results suggested 
that using PEI as a transfection reagent to transfect MCF-7 cells with ABCC4 plasmid DNA 
may not be as effective as when it was used to transfect MCF-7 cells with ABCC1 plasmid 
DNA. Furthermore, PEI transfection in MDA-MB231 cells with ABCC1 and ABCC4 plasmid 
DNAs did not cause any increase in protein expression levels of ABCC1 and ABCC4 in MDA-
MB231 transfected cells when compared to the untreated MDA-MB231 cells and the MDA-
MB231 cells treated with empty vector plasmid DNA at all the transfection condition of PEI to 
DNA ratio 10:1, 15:1 and 20:1 (Figure 5.5).  
 
Therefore, the results suggested that at transfection condition of PEI to DNA ratios of 15:1 and 
20:1 were equally efficient in transfecting MCF-7 cells with ABCC1 plasmid DNA but PEI as a 
transfection reagent was inefficient in transfecting MCF-7 cells with ABCC4 plasmid DNA. 
Moreover, PEI was equally inefficient in transfecting MDA-MB231 cells with ABCC1 and 
ABCC4 plasmid DNAs.  
 
Although, PEI is a very cost effective transfection reagent that produces highly stable 
complexes and reproducible results as well as high transfection efficiency in most cell lines 
and was able to transfect MCF-7 cells with low cell cytotoxicity, PEI has proved to be inefficient 
in transfecting MDA-MB231 cells. Therefore, Lipofectamine 3000® Transfection Reagent, 
which can also produce high transfection efficiency was suggested.  
 
5.4     Optimisation of plasmid DNA transfection conditions using the Lipofectamine® 
3000 reagent as a transfection reagent  
 
The Lipofectamine 3000® Transfection Reagent is a cationic lipid transfection reagent that can 
facilitate the delivery of DNA and siRNA into cells. Cationic lipids are made up of one or two 
hydrocarbon chains attached to a positively charged head group. The charged head group 
promote DNA condensation and mediate the interaction between the phosphate backbone of 
the nucleic acid and the lipid. The positive surface charge of the liposomes facilitate the fusion 
of the liposome / nucleic acid transfection complex with the negatively charged cell membrane 
causing the transfection complex to enter the cell via endocytosis (Gibco Life Technologies, 
2016). 
 
Therefore, because The Lipofectamine 3000® reagent has proven to produce simple and fast 
delivery of plasmid DNA in cells, have a high transection efficiency, works effectively with a 
wide range of cell types and the results produce are consistent (Gibco Life Technologies, 
2016), the Lipofectamine 3000® reagent was selected as an alternative transfection reagent 
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to transfect cells with the plasmid DNAs. Moreover, as MCF-7 cells and in particular MDA-
MB231 cells have proven to be difficult to transfect using PEI, the Lipofectamine 3000® 
reagent, could be a reliable transfection reagent with a higher transfection efficiency with 
improved cell viability in difficult-to-transfect cell types (Gibco Life Technologies, 2016). Like 
with any transfection reagent, optimisation of plasmid DNA transfection condition using The 
Lipofectamine 3000® reagent was performed.  
 
The transfection of plasmid DNA using the Lipofectamine 3000® reagent was performed using 
the Lipofectamine 3000® reagent kit (Invitrogen – Thermofisher Scientific). According to the 
manufacturer’s instructions, the plasmid DNA-lipid complex was made up of either 0.75 μl or 
1.5 μl of the Lipofectamine 3000® reagent as proposed volume for optimisation transfection 
condition, 0.5 μg of total plasmid DNA and 1 μg of P3000® reagent (provided from the 
Lipofectamine 3000® reagent kit) for transfection in 24-well plate. The plasmid DNA-lipid 
complex was incubated at room temperature for 10-15 minutes and after added to the cells. 
To improve cell viability, the cell culture medium was replaced with fresh cell culture medium 
24 hours after transfection. Subsequently, the transfected cells were incubated for two days, 
after which the transfected cells were harvested and the protein expression levels of ABCC1 
and ABCC4 in the MCF-7 and MDA-MB231 transfected cells were analysed in Western blot 
analysis and results are as shown in figures 5.6 and 5.7 respectively.  
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Figure 5.6. Protein expression levels of ABCC1 and ABCC4 in MCF-7 cells following the 
Lipofectamine® 3000 transfection with ABCC1 and ABCC4 plasmid DNA respectively. 
According to the manufacturer’s instructions, MCF-7 cells were seeded a day before the day 
of transfection with the optimal cell seeding density for MCF-7 cells was 1.1 x 105 cells per well 
of 24-well plate so as to reach 70% confluency the day of transfection. Briefly, the plasmid 
DNA-lipid complex for one well was made by mixing one tube containing 25 μl of optiMEM, 
0.5 μg of plasmid DNA and 1 μl of the P3000® Reagent (provided in Lipofectamine 3000® 
reagent kit) with another tube containing 25 μl of optiMEM and either 0.75 μl or 1.5 μl of 
Lipofectamine 3000® reagent for optimisation transfection. The plasmid DNA-lipid complex 
was incubated at room temperature for 10-15 minutes and after added to the cells.  
Subsequently the transfected cells were incubated for two days after which the transfected 
cells were harvested and the protein expression levels of ABCC1 and ABCC4 in the MCF-7 
transfected cells were analysed in Western blot analysis. The molecular weight standards 
were loaded in lanes 1 and 6 (Thermo Scientific Prestained Protein Molecular weight marker, 
20 to 120 kDa) and 20 µl of samples were loaded in each lanes. Samples in lanes 2, 3 and 9 
were treated with 0.75 µl of Lipofectamine 3000® reagent and samples in lanes 5, 8 and 10 
were treated with 1.5 µl of Lipofectamine 3000® reagent.   The PVDF membrane blots for 
ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) overnight 
and incubated in appropriate primary antibodies, anti-ABCC1 derived in rabbit (1:1000 in 
blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) respectively. The 
secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-rat HRP (1:5000 
in TBS-T). The level of protein expressions were detected using the Li-Cor C-Digit blot scanner 
and the images were analysed using Image Studio Lite software imaging system. 
 
 
 
As can be seen from figure 5.6, the Western blot analysis indicated that the Lipofectamine 
3000® reagent efficiently transfected MCF-7 cells with ABCC1 and ABCC4 plasmid DNAs as 
the protein lysate from MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNA respectively 
showed higher protein expression levels than those of the untreated and the MCF-7 cells 
treated with empty vector plasmid DNA. It is to note that MCF-7 cells do express ABCC1 and 
in this case the blot for ABCC1 expression (Figure 5.6) did not show any expression of ABCC1 
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in untreated and in empty vector plasmid DNA treated cells, this may be because the relative 
level of protein expressions were relatively low hence they were not detected with the 
exposure used.   Moreover, using 0.75 µl of Lipofectamine 3000® reagent was able to produce 
relatively higher protein expression levels of ABCC1 and ABCC4 in ABCC1 and ABCC4 
plasmid DNA treated MCF-7 cells than when 1.5 µl of Lipofectamine 3000® reagent was used. 
Hence, the results suggested that the optimal volume of the Lipofectamine 3000® reagent to 
use for one transfection in a well of a 24-well plate was 0.75 µl. Therefore, 0.75 µl of 
Lipofectamine 3000® reagent was used as the optimal volume for overexpression of ABCC1 
and ABCC4 in MCF-7 cells for downward cellular functional assays. 
 
 
Figure 5.7. Protein expression levels of ABCC1 and ABCC4 in MDA-MB231 cells 
following the Lipofectamine® 3000 transfection with ABCC1 and ABCC4 plasmid DNA 
respectively. According to the manufacturer’s instructions, MDA-MB231 cells were seeded a 
day before the day of transfection with the optimal cell seeding density for MDA-MB231 cells 
was 1.5 x 105 cells per well of 24-well plate so as to reach 70% confluency the day of 
transfection. Briefly, the plasmid DNA-lipid complex for one well was made by mixing one tube 
containing 25 μl of optiMEM, 0.5 μg of plasmid DNA and 1 μl of the P3000® Reagent (provided 
in Lipofectamine 3000® reagent kit) with another tube containing 25 μl of optiMEM and either 
0.75 μl or 1.5 μl of Lipofectamine 3000® reagent for optimisation transfection. The plasmid 
DNA-lipid complex was incubated at room temperature for 10-15 minutes and after added to 
the cells.  Subsequently the transfected cells were incubated for two days after which the 
transfected cells were harvested and the protein expression levels of ABCC1 and ABCC4 in 
the MCF-7 transfected cells were analysed in Western blot analysis. The molecular weight 
standards were loaded in lanes 1 and 6 (Thermo Scientific Prestained Protein Molecular 
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weight marker, 20 to 120 kDa) and 20 µl of samples were loaded in each lanes. The PVDF 
membrane blots for ABCC1 and ABCC4 proteins were blocked in blocking buffer (5% BSA in 
TBS-T) overnight and incubated in appropriate primary antibodies, anti-ABCC1 derived in 
rabbit (1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in blocking buffer) 
respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in TBS-T) and anti-
rat HRP (1:5000 in TBS-T). The level of protein expressions were detected using the Li-Cor 
C-Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. 
 
 
 
The Western blot analysis indicated that the use of Lipofectamine 3000® reagent as a 
transfection reagent may not be efficient in transfecting MDA-MB231 cells with ABCC1 and 
ABCC4 plasmid DNAs as the protein lysate from MDA-MB231 cells treated with ABCC1 and 
ABCC4 plasmid DNA alone showed no significant increase in protein expression levels than 
those of the untreated and the MDA-MB231 cells treated with empty vector plasmid DNA 
(Figure 5.7).  However, the protein expression levels of ABCC1 and ABCC4 in the protein 
lysate from ABCC1 and ABCC4 plasmid DNA treated MDA-MB231 cells may indicate a slight 
increase when compared to those from the untreated and the MDA-MB231 cells treated with 
empty vector plasmid DNA. 
 
To further optimised plasmid DNA transfection conditions using Lipofectamine 3000 in MDA-
MB231 cells, MDA-MB231 cells were transfected again with ABCC1 and ABCC4 plasmid 
DNAs respectively using either 0.75 μl, 1.5 μl as well as 2.25 μl of Lipofectamine 3000® 
reagent in one transfection. The use of a higher volume of Lipofectamine 3000® reagent (2.25 
μl) was suggested as assumption that a higher volume may produce higher transfection 
efficiency. The results are as shown in figure 5.8. 
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Figure 5.8. Comparison of the protein expression levels of ABCC1 and ABCC4 in MDA-
MB231 cells following the Lipofectamine® 3000 transfection with ABCC1 and ABCC4 
plasmid DNA respectively. According to the manufacturer’s instructions, MDA-MB231 cells 
were seeded a day before the day of transfection with the optimal cell seeding density for 
MDA-MB231 cells was 1.5 x 105 cells per well of 24-well plate so as to reach 70% confluency 
the day of transfection. Briefly, the plasmid DNA-lipid complex for one well was made by 
mixing one tube containing 25 μl of optiMEM, 0.5 μg of plasmid DNA and 1 μl of the P3000® 
Reagent (provided in Lipofectamine 3000® reagent kit) with another tube containing 25 μl of 
optiMEM and either 0.75 μl, 1.5 μl or 2.25 μl of Lipofectamine 3000® reagent for optimisation 
transfection. The plasmid DNA-lipid complex was incubated at room temperature for 10-15 
minutes and after added to the cells.  Subsequently the transfected cells were incubated for 
two days after which the transfected cells were harvested and the protein expression levels of 
ABCC1 and ABCC4 in the MCF-7 transfected cells were analysed in Western blot analysis. 
The molecular weight standards were loaded in lanes 1 and 6 (Thermo Scientific Prestained 
Protein Molecular weight marker, 20 to 120 kDa) and 16 µl of samples were loaded in each 
lanes. The PVDF membrane blots for ABCC1 and ABCC4 proteins were blocked in blocking 
buffer (5% BSA in TBS-T) overnight and incubated in appropriate primary antibodies, anti-
ABCC1 derived in rabbit (1:1000 in blocking buffer) and anti-ABCC4 derived in rat (1:100 in 
blocking buffer) respectively. The secondary antibodies used were anti-rabbit HRP (1:3000 in 
TBS-T) and anti-rat HRP (1:5000 in TBS-T). The level of protein expressions were detected 
using the Li-Cor C-Digit blot scanner and the images were analysed using Image Studio Lite 
software imaging system. 
 
 
 
As can be seen from figure 5.8, using either 0.75 μl, 1.5 μl or 2.25 μl of Lipofectamine 3000® 
reagent was able to produce relatively higher protein expression levels of ABCC1 in ABCC1 
plasmid DNA treated MDA-MB231 cells when compared to those from the untreated and the 
MDA-MB231 cells treated with empty vector plasmid. As previously shown in figure 5.7, 
transfecting MDA-MB231 cells with ABCC1 and ABCC4 plasmid DNAs may not be efficient 
211 
 
as the protein lysate from MDA-MB231 cells treated with ABCC1 and ABCC4 plasmid DNA 
showed no significant increase in protein expression levels when compared to those of the 
untreated and the MDA-MB231 cells treated with empty vector plasmid DNA. 
 
These results indicate that MDA-MB231 cells may prove to be a difficult to transfect cell type 
that even the use of Lipofectamine 3000® reagent may not give a high transfection efficiency. 
Although the cell viability was not affected during transfection, a lot of factors such as 
experimental parameters, nature of the plasmid and the method of delivery must be 
considered to obtain a more efficient transfection. Furthermore, the transfection in one cell 
batch may varies to another cell batch as using Lipofectamine 3000® reagent produce 
transient transfection. Thus consideration to use a more effective alternative such as viral 
mediated transfection or switch to stable cell lines may solve the problem.    
 
Subsequently as shown in figure 5.7, protein expression level of ABCC4 in the protein lysate 
from ABCC4 plasmid DNA treated MDA-MB231 cells may indicate a slight increase when 
compared to those from the untreated and the MDA-MB231 cells treated with empty vector 
plasmid DNA, we decided to still use Lipofectamine 3000® reagent as a transfection reagent 
to transfect MDA-MB231 cells. Therefore, the volume of the Lipofectamine 3000® reagent 
used to try to obtain ABCC1 and ABCC4 overexpression in MDA-MB231 cells respectively so 
as to use the transfected MDA-MB231 cells for downward cellular functional experiments was 
1.5 μl per well of 24-well plate. 
 
5.5     Effects of single overexpression of ABC transporters on cancer cell colony 
formation 
 
Cells transfected with plasmid DNAs following the Lipofectamine 3000® manufacturers’ 
protocol were seeded for the colony formation assay to assess the ability of a single cell to 
grow in to a colony after ABCC1 and ABCC4 had been overexpressed. Graphs showing the 
number of colonies formed from MCF-7 and MDA-MB231 cell lines are shown in figures 5.9A 
and 5.9B respectively. 
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Figure 5.9. The impact of overexpression of ABCC1 and ABCC4 gene expression in (A) 
MCF-7 and (B) MDA-MB231 cells on colony formation. The MCF-7 and MDA-MB231 
breast cancer cells were transfected with 0.5 μg of plasmid DNA using the Lipofectamine 
3000® reagent and the clonogenic capacity of the breast cancer cells upon overexpression of 
ABCC1 and ABCC4 was assayed after 7 days. The transfected breast cancer cells were fixed 
and stained with PFA and crystal violet respectively. Stained cell colonies were visible and 
were counted manually. The untreated cells are consider the control without any treatment. 
Data are expressed as the mean ± standard error of the mean from at least three independent 
experiments. 
 
 
 
As can be seen in figure 5.9A, the ability of MCF-7 cells to form colonies did increase after 
ABCC1 and ABCC4 overexpression but the increase was not statistically significant when 
compared to that of the untreated MCF-7 cells. In fact, the colonies formed from the MCF-7 
cells treated with empty vector plasmid DNA did also increased when compared to that of the 
untreated MCF-7 cells. In contrary, an opposite effect was seen in MDA-MB231 cells, in that 
the MDA-MB231 cells treated with ABCC1 and ABCC4 plasmid DNA respectively showed no 
significant decrease in the number of cell colonies formed when compared to that of the 
untreated MDA-MB231 cells (Figure 5.9B). MDA-MB231 cells treated with empty vector 
plasmid DNA also showed a small inhibition in clonogenity when compared to that of the 
untreated MDA-MB231 cells. Similarly, MDA-MB231 cells treated with empty vector plasmid 
213 
 
should not affect the clonogenic capacity as in principle, empty vector plasmid DNA should 
not contain any DNA fragment. Therefore, it would suggest that any effects seen may simply 
be caused by the process of transfection.  
 
5.6     Effects of single overexpression of ABC transporters on cancer cell viability 
 
The impact of overexpression of ABCC1 and ABCC4 in breast cancer cells on cell viability 
and cell cytotoxicity was assessed by performing the MTT assay. Subsequently, transfected 
cells were seeded in 24-well plate and after 6, 12, 24, 48 and 72 hours the viability of cells 
was examined (Figures 5.10 and 5.11). 
 
 
 
 
Figure 5.10. Cell viability of MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs 
respectively. The ABCC1 overexpressed MCF-7 cells, the ABCC4 overexpressed MCF-7 
cells and the untreated MCF-7 cells (Control) were seeded in 24-well plates at a seeding 
density of 1.5 x 104 cell/well. An MTT assay was performed. The cell viability was assessed 
after 6, 12, 24, 48 and 72 hours. At each specific time point, 40 µl of MTT (5 mg/ml) was added 
to each well. After an additional one hour of incubation, the cell culture medium was removed 
from each well and 400 µl of DMSO was added. 100 µl of each sample was transferred into a 
96-well plate in triplicates. The absorbance values were read at 570 nm. Data are expressed 
as the mean ± standard error of the mean from at least three independent experiments. 
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Figure 5.11. Cell viability of MDA-MB231 cells treated with ABCC1 and ABCC4 plasmid 
DNAs respectively. The ABCC1 overexpressed MDA-MB231 cells, the ABCC4 
overexpressed MDA-MB231 cells and the untreated MDA-MB231 cells (Control) were seeded 
in 24-well plates at a seeding density of 1.5 x 104 cell/well. An MTT assay was performed. The 
cell viability was assessed after 6, 12, 24, 48 and 72 hours. At each specific time point, 40 µl 
of MTT (5 mg/ml) was added to each well. After an additional one hour of incubation, the cell 
culture medium was removed from each well and 400 µl of DMSO was added. 100 µl of each 
sample was transferred into a 96-well plate in triplicates. The absorbance values were read at 
570 nm. Data are expressed as the mean ± standard error of the mean from at least three 
independent experiments. *P < 0.05, ** P < 0.01 and **** P < 0.0001. P values were derived 
from 2-way ANOVA vs untreated. 
 
 
 
As can be seen from figures 5.10A and 5.10B, the cell viability of MCF-7 cells were not affected 
at any specific time points when they were treated with ABCC1 and ABCC4 plasmid DNAs 
when compared to those of untreated and MCF-7 cells treated with empty vector plasmid 
DNA. Therefore, the overexpression of ABCC1 and ABCC4 in MCF-7 cells did not cause any 
significant increase in cell viability. Similarly, the cell viability of MDA-MB231 cells were also 
not affected at 6, 12 and 24 hour time points when they were treated with ABCC1 or ABCC4 
plasmid DNAs alone when compared to those of untreated and MDA-MB231 cells treated with 
empty vector plasmid (Figure 5.11A). However, an unexpected significant decrease in cell 
viability was seen for the transfected MDA-MB231 cells after 48 and 72 hours (Figure 5.11B). 
This was observed for both ABCC1 and ABCC4 transfections as well as transfection with the 
empty vector. These results may indicate that transfection with ABCC1 or ABCC4 in MDA-
MB231 cells did not increase in cell viability as was seen in MCF-7 cells. However, the 
significant decrease in cell proliferation observed in transfected MDA-MB231 cells at longer 
time scales (48 and 72 hours) may suggest that the plasmids and/or transfection process may 
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cause cell cytotoxicity. Nevertheless, these results suggested that overexpression of ABCC1 
and ABCC4 in MCF-7 and MDA-MB231 cells may not have a direct effect on cell viability.  
 
5.7     Effects of single overexpression of ABC transporters on cancer cell migration 
 
Upon overexpression of ABCC1 and ABCC4 in MCF-7 and MDA-MB231 breast cancer cells 
in 24-well plate with ABCC1 and ABCC4 plasmid DNAs respectively. The transfected cells 
were incubated for 48 hours post transfection according to the Lipofectamine 3000® reagent 
transfection instructions. By 48 hours post transfection, a cell monolayer was formed and a 
scratch assay was performed to monitor cell migration.  
 
The percentage wound closure at 6, 12 and 24 hours for the MCF-7 and MDA-MB231 cells 
are shown in figures 5.12 and 5.13 respectively.  
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Figure 5.12. Percentage wound closure of MCF-7 cells treated with ABCC1 and ABCC4 
plasmid DNAs alone. After transfection of MCF-7 cells with ABCC1 and ABCC4 plasmid 
DNAs alone, the transfected cells were left to incubate for 48 hours. Consequently, a cell 
monolayer was formed and a scratch with a 10 μl pipette tip was made in the cell monolayer. 
The plate was placed in the Cell-IQ where the selected image positions were captured every 
hour for 24 hours. The captured images were analysed in the Cell-IQ analysis software.  Data 
are expressed as the mean ± standard error of the mean from at least three independent 
experiments. 
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Figure 5.13. Percentage wound closure of MDA-MB231 cells treated with ABCC1 and 
ABCC4 plasmid DNAs alone. After transfection of MDA-MB231 cells with ABCC1 and 
ABCC4 plasmid DNAs alone, the transfected cells were left to incubate for 48 hours. 
Consequently, a cell monolayer was formed and a scratch with a 10 μl pipette tip was made 
in the cell monolayer. The plate was placed in the Cell-IQ where the selected image positions 
were captured every hour for 24 hours. The captured images were analysed in the Cell-IQ 
analysis software.  Data are expressed as the mean ± standard error of the mean from at least 
three independent experiments. 
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The transfection of MCF-7 with ABCC1 or ABCC4 plasmid DNA did not significantly affect the 
cell motility when compared to the untreated and the MCF-7 cells treated with empty vector 
plasmid DNA (Figure 5.12A, 5.12B and 5.12C). In contrast, transfection of MDA-MB231 cells 
with ABCC1, ABCC4 or empty vector plasmid DNAs caused a decreased in cell motility 
(Figure 5.13A, 5.13B and 5.13C). Again this is most likely linked to the effect that the 
transfection procedure has on these cells.  
 
5.8     Effects of single gene knockdown of ABC transporters on cancer cell invasion 
 
To determine whether the overexpression of ABCC1 and ABCC4 in MCF-7 and MDA-MB231 
breast cancer cells have an effect on cell invasion, the transwell invasion assay was 
performed.  
 
Similar to the setup for assessing cell invasion of MCF-7 and MDA-MB231 cells treated with 
ABCC1 and ABCC4 siRNAs, 5.0 x 104 cells suspended in 0.5% v/v FBS cell culture medium 
were seeded in each transwell.  The chemoattractant used were 0.5% v/v and 10% v/v FBS 
cell culture medium. The transfected cells were incubated for 24 hours after which the 
transfected cells that migrated across the membranes pores were fixed and stained with 
Differential Quik stain (Polysciences, Inc.) according to manufacturer protocol. The 
percentage cell invasion, was determined by counting the stained migrated cells from 5 
randomly selected fields of view under a light microscope at a magnification of x40. Graphs of 
percentage invasion of MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs alone 
were plotted against the plasmid DNAs as shown in figure 5.14. 
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Figure 5.14. Effect of MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs alone 
on cell invasion across a reconstituted basement membrane in vitro. Upon treatment of 
MCF-7 cells with ABCC1 and ABCC4 plasmid DNAs alone, the cell invasion was assessed by 
performing the transwell invasion assay. The transwells were first coated with Corning Matrigel 
Matrix and a cell suspension of the transfected MCF-7 cells in 0.5% v/v FBS cell culture 
medium were seeded in the transwells. Cell culture medium containing 10% v/v or 0.5% v/v 
FBS were used as the chemoattractant. After 24 hours incubation, invasive cells that have 
crossed the membrane pores were fixed and stained. Stained cells were counted using a light 
microscope (x40) from five different fields of view. Data are expressed as the mean ± standard 
error of the mean from at least three independent experiments.  
 
 
 
Normally, more cells are expected to migrate to 10% v/v FBS cell culture medium compared 
to 0.5% v/v FBS cell culture medium. However, as can be seen from figure 5.14, MCF-7 cells 
treated with ABCC1 and ABCC4 plasmid DNAs alone did not affect cell invasion when 
compared to untreated and MCF-7 cells treated with empty vector plasmid DNA. These results 
may indicate that an overexpression of ABCC1 and ABCC4 may not affect cell invasion. 
 
Furthermore, in the case of MDA-MB231 cells, we did not perform transwell invasion assay 
on these cells because the others assays (Colony formation, MTT and scratch assays) 
indicated a reduction in cell viability when the MDA-MB231 cells were treated with the plasmid 
or the transfection procedure DNAs that may be due to the nature of the plasmid more than to 
do with the transporters.  
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5.9     Analysis of the efficiency of co-overexpression of ABC transporters in breast 
cancer cell lines 
 
5.9.1     Protein expression analysis by Western blot  
 
One of the major factors contributing to failure in chemotherapy is due to multidrug resistance 
that occur because of the overexpression of specific ABC transporters in the cancer cells and 
tumours (Sun et al., 2012). Furthermore, the current finding indicate that these ABC 
transporters may also be implicated in cancer cell proliferation, migration and invasion 
(Adamska et al., 2018). Therefore, the hypothesis is if more than one ABC transporters are 
overexpressed, not only will cause higher multidrug resistance (Mlejnek et al., 2017) but also 
will increase the cancer cell proliferation, migration and invasion more than if just only one 
ABC transporter is being overexpressed.  
 
Therefore, this section looks at whether co-overexpression of ABCC1 and ABCC4 in MCF-7 
breast cancer cells has an effect on cancer cell proliferation, migration and invasion. Only 
MCF-7 cells were included because the transfection of MDA-MB231 cells was not very 
effective in overexpression of the target proteins, and the transfection procedure itself 
appeared to affect the properties of the cells. An analysis of the efficiency of co-overexpression 
of ABCC1 and ABCC4 in the breast cancer cells was performed by Western blot analysis. 
Initially, breast cancer cells were transfected with plasmid DNAs using the Lipofectamine 
3000® reagent.  According to the manufacturer’s instructions, the plasmid DNA-lipid complex 
was made up of either 0.75 μl, 1.5 μl or 2.25 μl of the Lipofectamine 3000® for optimisation 
transfection condition, 0.5 μg of total plasmid DNA (0.25 μg of ABCC1 and ABCC4 plasmid 
DNAs) and 1 μl of P3000® reagent (provided from the Lipofectamine 3000® reagent kit). 
Subsequently, the transfected cells were incubated for two days. The transfected cells were 
harvested and a Western blot analysis was performed to determine the protein expression 
levels of ABCC1 and ABCC4 in the MCF-7 transfected cells (Figures 5.15). 
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Figure 5.15. Western blot analysis of co-overexpression of ABCC1 and ABCC4 in MCF-
7 cells following the Lipofectamine® 3000 transfection with ABCC1 and ABCC4 plasmid 
DNAs in combination. The plasmid DNA-lipid complex for one well was made by mixing one 
tube containing 25 μl of optiMEM, 0.5 μg of total plasmid DNAs and 1 μl of the P3000® Reagent 
(provided in Lipofectamine 3000® reagent kit) with another tube containing 25 μl of optiMEM 
and 0.75 μl of the Lipofectamine 3000® reagent. The transfected cells were incubated for two 
days and were harvested for protein analysis. The molecular weight standards were loaded in 
lanes 1 and 6 (Thermo Scientific Prestained Protein Molecular weight marker, 20 to 120 kDa) 
and 20 µl of samples were loaded in each lanes. The PVDF membrane blots for ABCC1 and 
ABCC4 proteins were blocked in blocking buffer (5% BSA in TBS-T) overnight and incubated 
in appropriate primary antibodies, anti-ABCC1 derived in rabbit (1:1000 in blocking buffer) and 
anti-ABCC4 derived in rat (1:100 in blocking buffer) respectively. The secondary antibodies 
used were anti-rabbit HRP (1:3000 in TBS-T) and anti-rat HRP (1:5000 in TBS-T). The level 
of protein expressions were detected using the Li-Cor C-Digit blot scanner and the images 
were analysed using Image Studio Lite software imaging system. 
 
 
 
Initially, 0.75 μl of Lipofectamine® 3000 reagent was found to give a higher protein expression 
levels in single overexpression of ABCC1 and ABCC4 alone in MCF-7 cells. Therefore, only 
0.75 μl of Lipofectamine® 3000 reagent was used in co-expression of ABCC1 and ABCC4 in 
MCF-7 cells. Therefore, as can be seen from figure 5.15, clearly indicated that co-
overexpression of ABCC1 and ABCC4 was achieved in MCF-7 cells as the protein expression 
levels of ABCC1 and ABCC4 in the protein lysate from MCF-7 cells treated with ABCC1 and 
ABCC4 plasmid DNAs in combination was higher than those of the untreated and the MCF-7 
cells treated with empty vector plasmid DNA. Therefore, similarly, co-overexpression of 
ABCC1 and ABCC4 in MCF-7 cells was performed using 0.75 μl of Lipofectamine® 3000 
reagent for all downward cellular functional experiments. 
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5.10     Effects of co-overexpression of ABC transporters on cancer cell colony 
formation 
 
Initially, MCF-7 breast cancer cells were treated with ABCC1 and ABCC4 plasmid DNAs in 
combination. The colony formation assay was performed to assess the ability of a single cell 
to grow in to a colony after co-overexpression of ABCC1 and ABCC4. The number of colonies 
formed from MCF-7 cell lines are shown in figure 5.16. 
 
 
 
 
 
Figure 5.16. The impact of co-overexpression of ABCC1 and ABCC4 in MCF-7 breast 
cancer cells on colony formation. MCF-7 breast cancer cells were transfected with 0.5 μg 
of total plasmid DNAs using the Lipofectamine 3000® reagent and the clonogenic capacity of 
the breast cancer cells upon co-overexpression of ABCC1 and ABCC4 was assayed after 7 
days. The transfected breast cancer cells were fixed and stained with PFA and crystal violet 
respectively. Stained cell colonies were visible and were counted manually. The untreated 
cells are consider the control without any treatment. Data are expressed as the mean ± 
standard error of the mean from at least three independent experiments. 
 
 
 
As can be seen from figure 5.16, co-overexpression of ABCC1 and ABCC4 in MCF-7 cells did 
not affect colony formation when compared to those of the untreated and the MCF-7 cells 
treated with empty vector plasmid DNA.  
 
5.11     Effects of co-overexpression of ABC transporters on cancer cell viability 
 
MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs in combination was also used to 
assess the effect of co-overexpression of ABCC1 and ABCC4 have on cell viability and cell 
cytotoxicity by performing the MTT assay. Graphs showing the absorbance results are shown 
in figure 5.17. 
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Figure 5.17. Cell viability of MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs 
in combination. Breast cancer cells treated with ABCC1 and ABCC4 plasmid DNAs in 
combination were seeded in 24-well plates at a seeding density of 1.5 x 104 cell/well. An MTT 
assay was performed. The cell viability was assessed after 6, 12, 24, 48 and 72 hours. At each 
specific time point, 40 µl of MTT (5 mg/ml) was added to each well. After an additional 1 hour 
of incubation, the cell culture medium was removed from each well and 400 µl of DMSO was 
added. 100 µl of each sample was transferred into a 96-well plate in triplicates. The 
absorbance values were read at 570 nm. Data are expressed as the mean ± standard error of 
the mean from at least three independent experiments. *P < 0.05 and **** P < 0.0001. P values 
were derived from two-way ANOVA vs untreated. 
 
 
 
As can be seen from figure 5.17, the cell viability of MCF-7 cells treated with ABCC1 and 
ABCC4 plasmid DNAs in combination were not affected at any specific time points when 
compared to those of the untreated and the MCF-7 cells treated with empty vector plasmid 
DNA. Therefore, the co-overexpression of ABCC1 and ABCC4 in MCF-7 cells did not cause 
any significant increase in cell proliferation.  
 
5.12     Effects of co-overexpression of ABC transporters on cancer cell migration 
 
To assess the impact of co-overexpression of ABCC1 and ABCC4 in MCF-7 cells, the scratch 
assay was performed. The percentage wound closure at 6, 12 and 24 hours for the MCF-7 
cells were plotted against the plasmid DNAs as shown in figure 5.18. 
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Figure 5.18. Percentage wound closure of MCF-7 cells treated with ABCC1 and ABCC4 
plasmid DNAs in combination. The transfected MCF-7 cells were left to incubate for 48 
hours. Consequently, a cell monolayer was formed and a scratch using a 10 μl pipette tip was 
made in the cell monolayer. The plate was placed in the Cell-IQ where the selected image 
positions were captured every hour for 24 hours. The captured images were analysed in the 
Cell-IQ analysis software.  Data are expressed as the mean ± standard error of the mean from 
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at least three independent experiments. *P < 0.05. P values were derived from one-way 
ANOVA vs untreated. 
 
 
 
The cell motility of MCF-7 cells transfected with ABCC1 and ABCC4 plasmid DNAs in 
combination were assessed by performing the scratch assay. The co-overexpression of 
ABCC1 and ABCC4 in MCF-7 cells caused a decrease in cell migration after 6 and 24 hours 
incubation when compared to the untreated and the MCF-7 cells treated with empty vector 
plasmid DNA (Figures 5.18A and 5.18C respectively).  
 
5.13     Effects of co-overexpression of ABC transporters on cancer cell invasion 
  
The invasiveness of MCF-7 breast cancer cells treated with ABCC1 and ABCC4 plasmid 
DNAs in combination was investigated by performing the transwell invasion assay. Graph of 
percentage invasion of MCF-7 cells transfected with ABCC1 and ABCC4 in combination is 
shown in figure 5.19. 
 
 
 
 
Figure 5.19. Effect of MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs in 
combination on cell invasion across a reconstituted basement membrane in vitro. Upon 
treatment of MCF-7 cells with ABCC1 and ABCC4 plasmid DNAs in combination, the transwell 
invasion assay was performed to assess cell invasion. The transwells were first coated with 
Corning Matrigel Matrix and a cell suspension of the transfected MCF-7 cells in 0.5% v/v FBS 
cell culture medium were seeded in the transwells. Cell culture medium containing 10% v/v or 
0.5% v/v FBS were used as the chemoattractant. After 24 hours incubation, invasive cells that 
have crossed the membrane pores were fixed and stained. Stained cells were counted using 
a light microscope (x40) from five different fields of view. Data are expressed as the mean ± 
standard error of the mean from at least three independent experiments. ** P < 0.01. P values 
were derived from one-way ANOVA vs 10% v/v FBS untreated. 
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The MCF-7 cells treated with ABCC1 and ABCC4 plasmid DNAs in combination did not affect 
cell invasion when the chemoattractant was 10% v/v FBS cell culture medium (Figure 5.19). 
It seem a bit odd as an increased in cell invasion was expected. Moreover, a significant 
decreased in cell invasion was seen in the ABCC1 and ABCC4 combined transfected MCF-7 
cells when the chemoattractant was 0.5% v/v FBS cell culture medium. Although the possible 
explanation is unknown at the moment, the results may suggest that co-overexpression of 
ABCC1 and ABCC4 may have no effect in cell invasion. 
 
5.14     Summary 
 
 Effective overexpression of both ABCC1 and ABCC4 in HEK293T cells and HeLa cells 
could be effectively achieved by transfection with pcDNA3.1 plasmids containing the 
gene of interest, using the transfection reagent PEI. 
 
 The transfection of ABCC1 and ABCC4 plasmid DNA in MCF-7 and MDA-MB231 cells 
using PEI as a transfection reagent was only achievable in MCF-7 cells at certain PEI 
to DNA ratios (15:1 and 20:1). In contrast, the use of PEI in transfecting MDA-MB231 
cells was not effective and proved to be a challenge, as other factors such as the 
amount of DNA used may be considered. 
 
 Lipofectamine® 3000 transfection reagent was used as an alternative. The transfection 
of MCF-7 cells using the Lipofectamine® 3000 transfection reagent was efficient but 
was not particularly efficient in transfecting MDA-MB231 cells even after optimising the 
volume of the Lipofectamine® 3000 transfection reagent used. 
  
 For MCF-7 cells, the co-expression of ABCC1 and ABCC4 could be achieved using 
the Lipfectamine® 3000 transfection reagent. 
  
 The overexpression of ABCC1 and ABCC4 alone or in combination in MCF-7 cells 
did not have any significant effect on cell colony formation, proliferation, migration 
and cell invasion.  
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 The transfection procedure alone caused a decrease in proliferation of MDA-MB231 
cells. This was not associated with ABCC1 or ABCC4, as the same effect was 
observed with empty vector controls.  
 
 It was hypothesised that an overexpression of ABCC1 and ABCC4 in breast cancer 
cells would cause an increase in cell proliferation, cell migration and cell invasion when 
compared to the untreated and those treated with empty vector plasmid DNA. 
Furthermore, we hypothesised that the co-overexpression of ABCC1 and ABCC4 will 
further increase the effects. However, the results do not indicate this.  
 
 It is important to note that the method of overexpression is transient. Thus the gene 
expression usually returns to normal after 96 to 120 hours after transfection and that 
similar to the siRNA transfection, the efficiency of transfection was not measured in 
terms of the proportion of cells that overexpressed the target proteins in comparison 
to those that were unaffected. In addition, as MDA-MB231 cells may be more difficult 
to transfect than MCF-7 cells, this may be an important consideration. 
 
 The results obtained are preliminary and improvement in the method of transfection 
such as the use of a different plasmid construct, the use of a more efficient delivery 
method such as lentivirus, retrovirus and adenovirus based vectors could be beneficial 
and since a stable expression of the proteins are required, consideration in generating 
a stable cell line might be very useful. 
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Chapter 6 – Analysis of possible mechanisms by which ABCC1 and ABCC4 affect 
cancer cell growth and development  
 
6.1     Objective 
 
Since ABC transporters such as ABCC1 and ABCC4 transport many active signalling 
molecules and hormones as their substrates, it has been suggested that these substrates can 
activate cancer cells as well as regulate the tumour environment so as to help cancer cells to 
grow and develop (Adamska et al., 2018). Therefore mediating the efflux of these substrates 
by ABC transporters may also be important in cancer progression and development (Fletcher 
et al., 2010). 
 
In order to investigate the potential correlation between ABCC1 and/or ABCC4 and their 
bioactive substrates and/or other proteins,  MCF-7 and MDA-MB231 breast cancer cells were 
siRNA transfected with ABCC1- and ABCC4-specific siRNA molecules and the protein 
expression of selected proteins (GPR55, p-ERK and ERK1/2) were determined by Western 
blot.  GPR55 was studied as in previous studies it was found to play an important role in the 
modulation of breast cancer cell migration (Ford et al., 2010) and proliferation (Pineiro et al., 
2011). In addition, GPR55 was also found to be a receptor for l-α-lysophosphatidylinositol 
(LPI) which is also a substrate for ABCC1 (Pineiro et al., 2011; Ruban et al., 2014). The 
extracellular signal-regulated kinase (ERK) signalling pathway is important in mediating a wide 
range of cellular process such as cell differentiation, proliferation, survival, migration and 
metastasis in cancer cells (Roberts et al., 2007). 
 
Secondly, specific ELISAs were used to determine the concentration of cyclic adenosine 
monophosphate (cAMP), prostaglanding E2 (PGE2), sphingosine-1-phosphate (S1P) and 
cysteinyl (Cys) leukotrienes (LTC4, LTD4 and LTE4) produced by cells with or without siRNA 
knockdown of ABCC1 and ABCC4 and cells treated with MK571. ABCC4 has been previously 
shown to export cAMP and cGMP (Wielinga et al., 2003) The cAMP signalling pathway 
controls a diverse range of cellular processes such as cell differentiation, apoptosis and 
proliferation (Cospel et al., 2011). Similarly, PGE2 also was found to promote cancer cell 
survival, migration, angiogenesis, invasion and proliferation (Greenhough et al., 2009), and 
has previously been shown to be a substrate for ABCC4 (Reid et al., 2003b). S1P may also 
be important in promoting cancer cell survival, migration, proliferation and metastasis 
(Maceyka et al., 2012), and is a proposed substrate for both ABCC1 and ABCC4 (Takabe et 
al., 2010; Vogt et al., 2018) In addition Cys LTs control inflammatory responses (Nielsen et 
al., 2005; Mezhybovska et al., 2006) and in cancer, LTD4 was found to affect the expression 
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of many proteins such as β-catenin that helps to promote cell migration, invasion and 
proliferation (Yang et al., 2017). Both ABCC1 and ABCC4 efflux LTC4 (Tian et al., 2005; Rius 
et al., 2008; Chen et al., 2010; Liu et al., 2010; Cole et al., 2014), and ABCC4 has also been 
shown to transport LTB4 (Rius et al., 2008). 
 
6.2     Determining the expression levels of bioactive proteins by Western blot 
 
The expression levels of GPR55, ERK1/2 and p-ERK were determined in HeLa, MCF-7 and 
MDA-MB231 cells by Western blot. Membrane protein samples were obtained by using the 
nitrogen cell cavitation and differential centrifugation, whereas the whole cell lysate samples 
were extracted in lysis buffer containing detergent. Figures 6.1 and 6.2 show the expression 
levels of GPR55 in the membrane protein samples and in the whole cell lysate samples. 
 
 
 
 
Figure 6.1. Western blot analysis of protein expression of GPR55 derived from whole 
cell lysate samples and membrane protein samples from HeLa, MCF-7 and MDA-MB231 
cell lines. 80 μg of total protein was loaded in each well of a 10% v/v SDS gel and α-tubulin 
was used as the loading control. The molecular weight standards were loaded in the first lane 
(Thermo Scientific Prestained Protein Molecular weight marker, 20 to 120 kDa). The PVDF 
membrane blots were blocked in blocking buffer (5% BSA in TBS-T) overnight and incubated 
in appropriate primary antibody, anti-GPR55 derived in rabbit (1:100 in blocking buffer). The 
secondary antibody used was anti-rabbit HRP (1:3000 in TBS-T). The level of protein 
expression of GPR55 was detected using the Li-Cor C-Digit blot scanner and the images were 
analysed using Image Studio Lite software imaging system. Western blot analysis was 
repeated at least three times and similar protein expression levels were obtained. 
 
230 
 
 
 
Figure 6.2. Western blot analysis of protein expression of ERK1/2 and p-ERK derived 
from whole cell lysate samples from HeLa, MCF-7 and MDA-MB231 cell lines. 80 μg of 
total protein was loaded in each well and α-tubulin was used as the loading control. The 
molecular weight standards were loaded in the first lane (Thermo Scientific Prestained Protein 
Molecular weight marker, 20 to 120 kDa). The nitrocellulose membrane blots were blocked in 
blocking buffer (5% BSA in TBS-T) overnight and incubated in appropriate primary antibodies, 
anti-ERK1/2 derived in mouse (1:100 in blocking buffer) and anti-p-ERK derived in mouse 
(1:200 in blocking buffer). The secondary antibody used was anti-mouse HRP (1:4000 in TBS-
T). The level of protein expression of ERK1/2 and p-ERK were detected using the Li-Cor C-
Digit blot scanner and the images were analysed using Image Studio Lite software imaging 
system. Western blot analysis was repeated at least three times and similar protein expression 
levels were obtained. 
 
 
 
The protein expression level of GPR55 was highest in MDA-MB231 cells followed by HeLa 
cells and barely detectable in MCF-7 cells (Figure 6.1). Furthermore, the protein expression 
level of ERK1/2 (Figure 6.2) was highest in MCF-7 cells followed in MDA-MB231 cells then in 
HeLa cells as confirmed by densitometry (Data not shown). Although the Western blot for 
detection of p-ERK may not be clear due to high non-specific background, at the expected 
position on the Western blot clearly shows that the expression level of p-ERK may be equally 
detectable in HeLa and MCF-7 cells but very low expressed in MDA-MB231 cells. Since these 
experiments were looking at native expression levels within cancer cell lines, the relative 
expression of these proteins may be very small and thus hard to detect. However, since the 
results obtained were reproducible, it is suggested that different cancer cell lines express 
different levels of these proteins. 
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6.3     The effect of ABCC1 or ABCC4 knockdown on GPR55 and ERK expression 
 
After MCF-7 and MDA-MB231 cells were siRNA transfected with ABCC1- and ABCC4-specific 
siRNA molecules, the transfected cells were harvested and protein lysates were obtained in 
lysis buffer containing detergent. Since the expression level of GPR55 was barely detectable 
in MCF-7 cells (Figure 6.2), the relative expression levels of GPR55 was only analysed in 
ABCC1 and ABCC4 knockdown MDA-MB231 cells by Western blot as shown in figures  6.3. 
Furthermore the relative expression levels of ERK1/2 and p-ERK in ABCC1 and ABCC4 
knockdown MCF-7 and MDA-MB231 cells were also determine by Western blot analysis as 
shown in figure 6.4.  
 
 
 
Figure 6.3. Western blot analysis of protein expression of GPR55 in ABCC siRNA 
transfected MDA-MB231 cells. 20 μl of protein lysate was loaded in each well of a 10% v/v 
SDS gel and α-tubulin was used as the loading control. The molecular weight standards were 
loaded in the first lane (Thermo Scientific Prestained Protein Molecular weight marker, 20 to 
120 kDa). The PVDF membrane blots were blocked in blocking buffer (5% BSA in TBS-T) 
overnight and incubated in appropriate primary antibody, anti-GPR55 derived in rabbit (1:100 
in blocking buffer). The secondary antibody used was anti-rabbit HRP (1:3000 in TBS-T). The 
level of protein expression of GPR55 was detected using the Li-Cor C-Digit blot scanner and 
the images were analysed using Image Studio Lite software imaging system. Western blot 
analysis was repeated at least three times and similar protein expression levels were obtained. 
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Figure 6.4. Western blot analysis of protein expression of ERK1/2 and p-ERK in ABCC 
siRNA transfected MCF-7 and MDA-MB231 cells. 20 μl of protein lysate was loaded in each 
well and α-tubulin was used as the loading control. The molecular weight standards were 
loaded in the first lane (Thermo Scientific Prestained Protein Molecular weight marker, 20 to 
120 kDa). The nitrocellulose membrane blots were blocked in blocking buffer (5% BSA in TBS-
T) overnight and incubated in appropriate primary antibodies, anti-ERK1/2 derived in mouse 
(1:100 in blocking buffer) and anti-p-ERK derived in mouse (1:200 in blocking buffer). The 
secondary antibody used was anti-mouse HRP (1:4000 in TBS-T). The level of protein 
expression of ERK1/2 and p-ERK were detected using the Li-Cor C-Digit blot scanner and the 
images were analysed using Image Studio Lite software imaging system. Western blot 
analysis was repeated at least three times and similar protein expression levels were obtained. 
 
 
 
As can be seen from figure 6.3, the knockdown of ABCC1 and ABCC4 was achieved in MDA-
MB231 cells. However the knockdown of ABCC1 and ABCC4 did not affect the level of 
expression of GPR55. Similarly, the knockdown of ABCC1 and ABCC4 in MCF-7 and MDA-
MB231 cells did not affect the expression levels of ERK1/2. Past studies have demonstrated 
that ABCC1 is involved in an autocrine loop where by the production of LPI is pumped out of 
cells by ABCC1 and act on GPR55 receptors to initialise a downstream cascade (Pineiro et 
al., 2011; Arifin et al., 2016). Moreover, LPI was also found to activate ERK1/2 (Pineiro et al., 
2011). Detection of p-ERK in the knockdown samples proved tricky with high level of 
background and requires further optimisation. 
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6.4     Determining the concentration of bioactive substrate secreted by ABCC siRNA 
transfected breast cancer cells by ELISA 
 
6.4.1     Cyclic adenosine monophosphate (cAMP) 
 
For measurements of extracellular cAMP in conditioned medium, the transfected and control 
cells were stimulated with 100 µM forskolin for 2 hours at 37 oC (Xie et al., 2011). After 
replacement with fresh cell culture medium (conditioned medium), three wells of non-
transfected cells were treated with 50 µM MK571 and the cells were incubated for 18 hours at 
37 oC. The conditioned media were collected for determination of cAMP by using the cAMP 
ELISA kit (Enzo Life Sciences Inc) which is a competitive immunoassay (Figure 6.5).  
 
 
 
 
 
Figure 6.5. Schematic diagram showing competitive cAMP ELISA. The concentration of 
cAMP produced from the samples were determined by using the cAMP ELISA kit from Enzo 
Life Sciences Inc. Briefly, the cAMP standards (non-acetylated format) and the samples were 
added to the appropriate wells in duplicates followed by the blue conjugate and the yellow 
antibody into the appropriate wells. The plate was then sealed and incubated at room 
temperature of a plate shaker at 500 rpm for 2 hours. After incubation, the contents of the 
wells were discarded and the wells were washed thoroughly three times with the wash buffer 
diluted in distilled water (1:20 dilution). After complete removal of any remaining wash buffer, 
the blue conjugate was added to the appropriate wells followed by the substrate solution to 
each of the wells. The plate was then sealed and incubated for one hour at room temperature. 
After one hour incubation, the stop solution was added to each well and the absorbance was 
measured at 405 nm using multiskan Go microplate reader (ThermoScientific). 
 
 
 
Once the absorbance values were obtained at 405 nm, the mean optical density (OD) of the 
standards and each samples were calculated and subtracted from the mean OD of Blank. The 
data was then input on Graphpad Prism (7.0), a standard curve was generated from a four 
parameter (4PL) logistic fitting curve, as recommended by the manufacturers (Figure 6.6A), 
and the concentration of cAMP from the samples were obtained as shown in figure 6.6B. 
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Figure 6.6. Measurement of extracellular cAMP in conditioned medium. (A) cAMP 
standard curve obtained from cAMP standards OD values. (B) Concentration of extracellular 
cAMP in conditioned medium secreted by ABCC siRNA transfected MDA-MB231 cells and 
MDA-MB231 cells treated with MK571. The absorbance values were read at 405 nm. The 
mean optical density (OD) for each samples were calculated by subtracting the mean OD for 
blank from the mean OD for each samples. Once the cAMP standard curve was generated, 
the concentration of extracellular cAMP from the samples were obtained from extrapolating 
from the cAMP standard curve using a four parameter (4PL) logistic fitting curve analysis. Data 
are expressed as the mean ± standard error of the mean from two independent experiments.  
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Table 6.1. Optical density values from the cAMP ELISA on MCF-7 cell samples. 
Cancer cell line Sample 
  
Mean OD of 
sample 
Mean OD of sample – 
Mean blank OD (0.1611) 
MCF-7 Untreated  0.1660 0.0049 
Negative siRNA 0.1654 0.0043 
siRNA #30 0.1822 0.0211 
siRNA #31 0.1519 -0.0093 
siRNA #34 0.1544 -0.0067 
siRNA #35 0.1871 0.0260 
MK571 50 µM 0.1906 0.0295 
The absorbance values were read at 405 nm. The OD values for the blank were obtained from 
the wells where only p-nitrophenyl phosphate (pNpp) substrate and stop solution were added. 
The mean optical density (OD) for each samples were calculated by subtracting the mean OD 
for blank from the mean OD for each samples. 
 
 
 
The measurement of extracellular cAMP was performed on a 96-well plate coated with affinity 
purified antibody. Since only one plate was provided, fitting all the samples in triplicates was 
not possible on the same plate. Therefore, samples from three independent experiments for 
MCF-7 cells were selected but only two independent experiments for MDA-MB231 cells. The 
standard curve obtained (Figure 6.6A) was as expected according to the product manual 
(Enzo Life Sciences). 
 
The concentration of extracellular cAMP from MDA-MB231 cells are shown in figure 6.6B. 
Treatment with ABCC1 siRNA #31 and ABCC4 siRNA #34 and #35 gave lower extracellular 
cAMP concentrations than the untreated MDA-MB231 cells. This difference was not 
statistically significant, but with further replicates this might change. The decrease was 
statistically significant for MDA-MB231 cells treated with MK571. Since cAMP is a substrate 
of ABCC4 (Russel et al., 2008), the results may indicate that a decrease in cell migration, 
invasion and to a lesser extent cell proliferation was observed when ABCC4 was knocked 
down or inhibited in MDA-MB231 cells, could be caused by less cAMP being pumped out of 
the cells. 
  
In contrast to the results observed for MDA-MB231 cells, as can be seen from table 6.1 the 
mean OD of some samples from MCF-7 cells were negative and some were well below the 
cAMP standard curve (Figure 6.6A), hence the concentrations of extracellular cAMP were not 
able to be extrapolated from the curve. Only one sample treated with siRNA #35 and one 
sample treated with MK571 were able to be extrapolated from the cAMP standard curve (Data 
not shown). Since the ELISA is a competitive immunoassay, this suggests high binding of 
extracellular cAMP to the plate, hence high concentration of extracellular cAMP produced from 
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MCF-7 cells. Consequently, the samples from MCF-7 cells may need to be diluted before 
running another cAMP ELISA. 
 
6.4.2     Prostaglandin E2 (PGE2) 
 
For measurements of PGE2 in conditioned medium, the control and siRNA transfected MCF-
7 and MDA-MB231 cells were stimulated with 10 µg/ml lipopolysaccharides (LPS) for 24 hours 
at 37oC and with 80 nM phorbol 12-myristate 13-acetate (PMA) for one hours at 37oC 
respectively (Kochel et al., 2017). The cell culture medium was then replaced with fresh cell 
culture medium (conditioned medium) and three wells of non-transfected cells were treated 
with 50 µM MK571, and the cells were incubated for 18 hours at 37oC. The conditioned media 
were collected for determination of PGE2 by using the PGE2 competitive ELISA kit (Enzo Life 
Sciences Inc). 
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Figure 6.7. Measurement of Prostaglandin E2 (PGE2) in conditioned medium. (A) PGE2 
standard curve obtained from PGE2 standards OD values. (B) Concentration of PGE2 in 
conditioned medium secreted by ABCC siRNA transfected MCF-7 cells and MCF-7 cells 
treated with MK571. The absorbance values were read at 405 nm. The mean optical density 
(OD) for each samples were calculated by subtracting the mean OD for blank from the mean 
OD for each samples. Once the PGE2 standard curve was generated, the concentration of 
PGE2 from the samples were obtained from extrapolating from the PGE2 standard curve using 
a four parameter (4PL) logistic fitting curve analysis. Data are expressed as the mean ± 
standard error of the mean from two independent experiments. 
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Table 6.2. Optical density values from the PGE2  ELISA using MDA-MB231 cell samples. 
Cancer cell line Sample 
  
Mean OD of 
sample 
Mean OD of sample – 
Mean blank OD (0.1410) 
MDA-MB231 Untreated  0.1375 -0.0035 
Negative siRNA 0.1288 -0.0123 
siRNA #30 0.1338 -0.0072 
siRNA #31 0.1204 -0.0206 
siRNA #34 0.1343 -0.0067 
siRNA #35 0.1298 -0.0112 
MK571 50 µM 0.1355 -0.0055 
The absorbance values were read at 405 nm. The OD values for the blank were obtained from 
the wells where only p-nitrophenyl phosphate (pNpp) substrate and stop solution were added. 
The mean optical density (OD) for each samples were calculated by subtracting the mean OD 
for blank from the mean OD for each samples. 
 
 
 
The standard curved obtained (Figure 6.7A) was similar to what was suggested from the 
product manual (Enzo Life Sciences). 
 
The extracellualar concentration of PGE2 from MCF-7 cells treated with ABCC siRNAs and 
MK571 are shown in figure 6.7B. It can be seen that PGE2 levels were not affected by the 
siRNA knockdown when compared to the concentration of PGE2 from untreated MCF-7 cells. 
Notably there are large error bands, which may be improved by further replicates, but there 
are no suggestions of any effects on extracellular PGE2 levels.  
 
The mean OD of some samples from MDA-MB231 cells (Table 6.2) were negative and some 
were well below the PGE2 standard curve (Figure 6.7A), hence the concentrations of PGE2 
were not able to be extrapolated from the curve. Since the ELISA is a competitive 
immunoassay, the very low OD values of the MDA-MB231 samples may indicate high binding 
of PGE2 from the conditioned medium to the plate, hence suggesting that MDA-MB231 cells 
efflux high amount of PGE2 out of the cells. Therefore in order to determine the concentration 
of PGE2 from the samples from MDA-MB231 cells, these samples may need to be diluted so 
that their OD values fall within the standard curve. 
 
6.4.3     Sphigosine-1-phosphate (S1P) 
 
For measurements of S1P in conditioned medium, the transfected and non-transfected cells 
were incubated in fresh cell culture medium (conditioned medium) with three wells of non-
transfected cells treated with 50 µM MK571 and the cells were incubated for 18 hours at 37oC. 
The conditioned media were collected for determination of S1P by using the S1P ELISA kit 
(Abbexa Ltd) which is a sandwich immunoassay.  
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Figure 6.8. Measurement of S1P in conditioned medium. (A) S1P standard curve obtained 
from S1P standards OD values. (B) Concentration of S1P in conditioned medium secreted by 
ABCC siRNA transfected MCF-7 cells and MCF-7 cells treated with MK571. (C) Concentration 
of S1P in conditioned medium secreted by ABCC siRNA transfected MDA-MB231 cells and 
MDA-MB231 cells treated with MK571. The absorbance values were read at 450 nm. The 
mean optical density (OD) for each samples were calculated by subtracting the mean OD for 
blank from the mean OD for each samples. Once the S1P standard curve was generated, the 
concentration of S1P from the samples were obtained from extrapolating from the S1P 
standard curve using a log-log fitting curve analysis. Data are expressed as the mean ± 
standard error of the mean from two independent experiments for MCF-7 samples and three 
independent experiments for MDA-MB231 samples. * P < 0.05. P values were derived from 
one-way ANOVA vs untreated. 
 
 
 
The S1P standard curve obtained (Figure 6.8A) was as expected according to the product 
manual (Abbexa Ltd). Subsequently, the mean OD of samples from MCF-7 and MDA-MB231 
cells, all fit within the range the S1P standard curve, and hence the concentrations of S1P 
were able to be extrapolated from the curve. The MCF-7 cells gave very low absorbance 
readings, since this ELISA is a sandwich immunoassay the low OD values of the MCF-7 
samples indicate low levels of S1P in the conditioned medium, and suggest that MCF-7 cells 
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efflux low amounts of S1P (Figure 6.8B). The large error bars likely reflect this low signal as 
well as only two replicates. In contrast, MDA-MB231 cells efflux 2-3 – fold more S1P than 
MCF-7 cells (Figure 6.8C). Knockdown of ABCC1 or ABCC4 did not seem to have a significant 
effect on extracellular levels of S1P, however treatment with MK571, which inhibits both 
ABCC1 and ABCC4, caused a significant decrease in efflux of S1P when compared to that of 
the untreated MDA-MB231 cells.  
 
6.4.4     Cysteinyl leukotrienes (LTC4, LTD4 and LTE4) 
 
For measurements of cysteinyl leukotrienes in conditioned medium, the control and siRNA 
transfected cells were stimulated with 10 mM acetylsalicylic acid (Aspirin) for 2 hours at 37oC 
(Mortaz et al., 2007) after which the cell culture medium was replaced with fresh cell culture 
medium (Conditioned medium) and three wells of non-transfected cells were treated with 50 
µM MK571, the cells were incubated for a further 5 hours at 37oC.. The conditioned media 
were collected for determination of cysteinyl leukotrienes by using the cysteinyl leukotrienes 
competitive ELISA kit (Enzo Life Sciences Inc). 
 
 
 
 
Figure 6.9. Cysteinyl leukotrienes standard curve obtained from cysteinyl leukotrienes 
standards OD values. The absorbance values were read at 450 nm. The mean optical 
density (OD) for each standards were calculated by subtracting the mean OD for blank from 
the mean OD for each samples. Once the cysteinyl leukotrienes standard curve was 
generated, the concentration of cysteinyl leukotrienes from the samples were obtained from 
extrapolating from the cysteinyl leukotrienes standard curve using a four parameter (4PL) 
logistic fitting curve analysis.  
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Table 6.3. Optical density values and concentration of the cysteinyl leukotrienes in the 
samples. 
Cancer cell 
line 
Sample 
  
Mean OD of 
sample 
Mean OD of 
sample – Mean 
blank OD (0.1410) 
Concentration of 
LTC4 (pg/ml) 
MCF-7 Untreated  0.6953 0.5798  
Negative siRNA 0.7172 0.6017  
siRNA #30 0.6794 0.5639  
siRNA #31 0.6861 0.5706  
siRNA #34 0.6840 0.5685  
siRNA #35 0.6949 0.5794  
MK571 50 µM 0.2480 0.1325  712.853 
     
MDA-MB231  Untreated 0.7213 0.6058  
Negative siRNA 0.7150 0.5995  
siRNA #30 0.7298 0.6143  
siRNA #31 0.7157 0.6002  
siRNA #34 0.7302 0.6147  
siRNA #35 0.7077 0.5922  
MK571 50 µM 0.2451 0.1296 726.106 
The absorbance values were read at 405 nm. The OD values for the blank were obtained from 
the wells where only p-nitrophenyl phosphate (pNpp) substrate and stop solution were added. 
The mean optical density (OD) for each samples were calculated by subtracting the mean OD 
for blank from the mean OD for each samples. The data was then input on Graphpad Prism 
(7.0) a standard curve was generated from a four parameter (4PL) logistic fitting curve. The 
concentration of the samples were then extrapolated from the standard curve. 
 
 
 
Figure 6.9 shows the standard curve, which was as expected according to the manufacturer’s 
handbook (Enzo Life Sciences). 
 
As can be seen from table 6.3 the mean OD of samples from ABCC siRNA transfected MCF-
7 and MDA-MB231 cells were all higher and over the range of the standard curve, hence the 
concentration of cysteinyl leukotrienes from these samples was not able to be extrapolated 
from the standard curve (Figure 6.9). As the ELISA is a competitive ELISA, higher OD values 
mean less cysteinyl leukotrienes from the conditioned medium, as a result may need to 
incubate the cells in smaller volume of medium to increase the concentration of the cysteinyl 
leukotrienes, if any are present. Furthermore, only samples from cells treated with MK571 
produced mean ODs that fall within the range of the standard curve thus the concentrations 
of cysteinyl leukotrienes were able to extrapolate from the standard curve. However, since the 
conditioned medium contained MK571 and MK571 is a selective leukotriene LTD4 receptor 
antagonist, it may be that MK571 itself is binding to the cysteinyl leukotrienes antibody and 
hence result in high false positive.  
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6.5     Summary   
 
 The protein expression level of GPR55 was highest in MDA-MB231 cells followed by 
HeLa cells and barely expressed in MCF-7 cells. 
 
 The protein expression level of ERK1/2 was highest in MCF-7 cells and may be slightly 
higher in MDA-MB231 cells than in HeLa cells. In addition, in all the cell line the protein 
expression level of ERK1 was lower than that for ERK2. Moreover, the protein 
expression level of p-ERK may be equally expressed in HeLa and MCF-7 cells but not 
in MDA-MB231 cells 
 
 The protein expression levels of GPR55 and ERK1/2 were not affected by the 
knockdown of ABCC1 and ABCC4. Therefore these results suggest that there is no 
correlation between ABCC1 and ABCC4 with GPR55, ERK1/2 and p-ERK. 
 
 Specific ELISA to detect cAMP, PGE2, S1P and cysteinyl leukotrienes in conditioned 
medium from ABCC siRNA transfected MCF-7 and MDA-MB231 cells and those 
treated with MK571 were performed. MCF-7 cells efflux higher levels of cAMP than 
MDA-MB231 cells. However, MCF-7 cells efflux lower levels of both PGE2 and S1P 
than MDA-MB231 cells. 
 
 Since only two separate experiments were performed, the knockdown of ABCC4 in 
MDA-MB231 cells and those treated with MK571 efflux so far may indicated a lower 
amount of cAMP out of the cells when compared to that of the untreated and may 
indicated that neither the knockdown of ABCC1 or ABCC4 or MK571 treatment 
affected the efflux of PGE2 out of MCF-7 cells. Hence, more replicates are need to 
validate these findings.  
 
 The efflux of S1P by MDA-MB231 cells treated with MK571 were significantly reduced 
when compared to that of the untreated. 
 
 Both cells lines efflux low levels of cysteinyl leukotrienes. Large concentration values 
of cysteinyl leukotrienes were obtained from cells treated with MK571. Since MK571 
is a selective leukotriene LTD4 receptor antagonist, it may have a binding affinity for 
the cysteinyl leukotrienes antibody that may result in high false positive.  
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Chapter 7 – Discussion 
 
Breast cancer is one of the most common types of cancer affecting women (Lage, 2003; Scully 
et al., 2012; Martin et al., 2014; Nounou et al., 2015). Breast cancer mortality is mainly due to 
breast cancer metastases to distant organ sites as well as the primary tumour itself (Scully, et 
al., 2012; Ugenskiene, et al., 2012). 
 
Cancer cells can become resistant to the drugs during chemotherapeutic treatment (Leonard 
et al., 2003; Housman et al., 2014). Often due to either drugs becoming inactive, drug efflux, 
changes in drug target and cancer cells acquiring epithelial-mesenchymal transition (EMT), 
becoming resistance to death, acquiring the ability to repair DNA damage, and modification in 
epigenetics (Yasui et al., 2004; Housman et al., 2014; Cree et al., 2017).  
 
The efflux of drugs out of cancer cells is one of the most complex mechanisms of drug 
resistance, and often leads to resistance to more than one drug. A phenomenon known as 
multidrug resistance (MDR) (Leonard et al., 2003; Bozzuto et al., 2010). Several members of 
the ATP-binding cassette (ABC) transporter family of proteins have been found to be 
responsible for the multidrug resistance phenomenon (Bozzuto et al., 2010; Zahreddine et al., 
2013).  
 
Research investigating the role of ABC transporters in multidrug resistance is well established. 
However, recently many studies have suggested that ABC transporters might be implicated 
more generally in the cancer hallmarks (Fletcher et al., 2010 and 2016). To date, little is known 
about their direct contribution to cancer progression and development irrespective of their 
drug-efflux abilities (Fletcher et al., 2010 and 2016; Adamska et al., 2018). Since ABC 
transporters transport many active signalling molecules and hormones as their substrates, it 
has been suggested that these substrates can activate cancer cells as well as regulate the 
tumour environment so as to help cancer cells to grow and develop (Adamska et al., 2018). 
Therefore, mediating the efflux of these substrates may also be important in cancer 
progression and development (Fletcher et al., 2010). 
 
The focus of this thesis was to investigate whether ABCC1 and ABCC4 are implicated in the 
progression and development of breast cancer. As mentioned previously, ABCC1 and ABCC4 
transport a wide variety of bioactive substrates that have been found to mediate various 
signalling pathways that regulates cell proliferation, migration, metastasis, invasion, 
differentiation and apoptosis. Hence, this thesis, looked to address the hypothesis that ABCC1 
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and ABCC4 are involved in breast cancer proliferation, migration and invasion irrespective of 
their drug efflux abilities. 
 
In this thesis, MCF-7 and MDA-MB231 breast cancer cells were treated with ABCC inhibitors, 
the expression of ABCC1 and ABCC4 were knocked down using specific siRNAs as well as 
overexpression by transient transfection with ABCC1- and ABCC4- specific plasmid DNA. The 
treated cells were used in vitro to carry out cellular functional assays such as colony formation 
assay to determine cell proliferation, scratch assay to determine cell migration, MTT assay to 
determine cell viability, transwell invasion assay to determine cell invasion capacity and 
Western blotting and reverse transcription polymerase chain reaction (RT-PCR) to detect 
expression of proteins. 
 
This chapter, looks to discuss and evaluate the results obtained, identify any potential 
limitations and weaknesses encountered during the study and propose any alternative 
methods. Furthermore, the results obtained were further evaluated to see if they are related 
to the literature and how they may agree or disagree with previously published knowledge. 
Subsequently from these findings, future work is proposed that may be undertaken to better 
understand the role of ABCC1 and ABCC4 in breast cancer.  
 
7.1     Different expression levels of ABC transporters in different breast cancer cell 
lines 
 
Multi-drug resistance whether acquired or constitutive in cancer therapy is often attributed to 
a group of proteins known as the ABC transporters which are membrane drug transporters 
which are often overexpressed in different cancer types. Their enhanced expressions often 
correlates with poor prognosis. The ABCB1 (P-glycoprotein), ABCC1 (MRP1) and ABCG2 are 
the most well studied members of the ABC transporters and are involved in multidrug 
resistance in a number of drug resistant tumours (Kovalev, et al., 2013; Begicevic et al., 2017). 
Together with ABCC4, these proteins also transport a variety of physiological, active 
substrates that may be implicated in cancer cell biology (Fletcher et al., 2010; Adamska et al., 
2017). 
 
In our study, the expression of ABCB1, ABCG2, ABCC1 and ABCC4 in HeLa, MCF-7 and 
MDA-MB231 cells were analysed by Western blot. According to our finding, high expression 
of ABCB1 was found in MCF-7 cells followed by HeLa cells and barely detectable in MDA-
MB231 cells. The result indicated that ABCB1 is expressed in MCF-7 cells and may not be 
expressed in MDA-MB231 cells which supports the findings of Mutoh et al., (2006) who found 
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oestrogen mediates the down regulation of ABCB1 in oestrogen positive human breast cancer 
cells. Mutoh et al., (2006) also compared the level of expression of ABCB1 between different 
cancer cell lines and used MDA-MB231 cells as one of the controls since MDA-MB231 cells 
does not express ABCB1. In contrast to our findings another previous study found that the 
expression of ABCB1 was not detectable in drug sensitive MCF-7 cells but when MCF-7 cells 
were exposed to doxorubicin, ABCB1 was overexpressed (Wang et al., 2015). Our results 
clearly show expression of ABCB1 in drug sensitive MCF-7 cells, so perhaps this is simply a 
matter of the sensitivity of the different antibodies and detection systems. 
 
As for the level of expression of ABCG2, it was highly expressed in MCF-7 cells but not 
detectable in HeLa or MDA-MB231 cells. A previous study also found that MCF-7 cells express 
ABCG2 and that its expression is mediated during epithelial-mesenchymal transition (EMT). 
Moreover, the study also found that MDA-MB231 cells do express ABCG2 (Yin et al., 2008). 
 
The expression levels of both ABCC1 and ABCC4 were highest in HeLa cells followed by 
MDA-MB231 cells and lowest in MCF-7 cells. A previous study by Kochel et al., (2017) also 
found that ABCC4 was highly expressed in MDA-MB231 cells but low expression in MCF-7 
cells. The expression level of ABCC1 and ABCC4 was lower in MCF-7 cells than in MDA-
MB231 cells maybe because MDA-MB231 cells are basal cell type compared to MCF-7 cells 
which are luminal cell type. It is possible that MDA-MB231 cell are more invasive due to their 
basal cell type and perhaps this is linked to the expression levels of ABCC1 and ABCC4.  
 
ABCC1 expression has previously been found to be a negative prognostic marker for early 
breast cancer (Munoz et al., 2007) and that there is a strong correlation between the 
expression level of ABCC1 and overall survival and time to relapse (Nooter et al., 1997; Munoz 
et al 2007). In addition, a study found high expression of ABCC1 in breast cancer lymph node 
metastases and suggest that ABCC1 may be implicated in breast cancer metastasis 
(Zochbauer-Muller et al., 2001; Munoz et al., 2007). Moreover, high expression of ABCC1 has 
been found in numerous other cancer types and has been linked to poor clinical outcome such 
as in neuroblastoma (Haber et al., 2006), intrahepatic cholangiocarcinoma (Srimunta et al., 
2012), non-small cell lung cancer (Fang et al., 2018), leukaemia (van der Kolk et al., 2000; 
Beck et al., 2001), oesophageal carcinomas (Nooter et al., 1998), prostate cancer (Sullivan et 
al., 2000). 
 
Similarly, high expression of ABCC4 in some invasive tumours has been associated with poor 
patient survival such as epithelial ovarian carcinoma (Bagnoli et al., 2013; Roundhill et al., 
2015) and neuroblastoma (Norris et al., 2005; Henderson et al., 2011; Huynh et al., 2012; 
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Roundhill et al., 2015), gastric cancer (Zhang et al., 2009), pancreatic cancer (Zhang et al., 
2012). In contrast, a low expression level of ABCC4 in prostate tumours is associated with 
poor event free survival (Ho et al., 2008; Chen et al., 2011; Montani et al., 2013). However, 
the association of ABCC4 to poor prognosis in breast cancer is still not clear but the expression 
of ABCC4 in breast cancer was found to mediate the malignant behaviour in breast cancer 
(Kochel et al., 2015). 
 
Although many studies have been carried out on these transporters, studying them can be a 
challenge as they are expressed in relatively low levels. To effectively study these proteins 
often the cells have been transfected with specific plasmids that express the gene of the 
protein or they have been exposed to high levels of drugs to acquire resistance so that the 
level of the protein is over expressed such as in doxorubicin resistant cancer cell lines and 
etoposide resistant cancer cell lines (Doyle et al., 1998 and 2003; Benderra et al., 2000; 
Alpsoy et al., 2014; Balaji et al., 2016; Gao et al., 2016). However the initial aim of the work in 
this study was to investigate the role of the native expression of these transporters since both 
ABCC1 and ABCC4 expression could be readily detected in MCF-7 and MDA-MB231 cells. 
 
7.2     ABCC1 may be more involved in mediating breast cancer cell proliferation than 
ABCC4 
 
A colony formation assay was done to determine the cell ability to divide (proliferate) from a 
single cell to form a colony.  It was found that Reversan, an ABCC1 and ABCB1 inhibitor 
(Burkhart et al., 2009; Henderson et al., 2011; Tivnan et al., 2015) inhibits colony formation in 
a concentration dependent manner, for all three types of cells HeLa, MCF-7 and MDA-MB231 
cells. Furthermore, MK571, a non-specific ABCC1 inhibitor that can also inhibit ABCC4, 
selectively inhibited colony formation in HeLa and MDA-MB231 cells but not significantly in 
MCF-7 cells. Notably, the level of expression of ABCC1 and ABCC4 were higher in HeLa and 
MDA-MB231 cells than in MCF-7 cells, hence this may suggest a high expression of ABCC1 
and ABCC4 could correlate with an increase in colony formation. Only Reversan but not 
MK571 affected the cell proliferation of MCF-7 cells, which might suggest that ABCC1 is more 
implicated in cell proliferation than ABCC4. However, as Reversan has also been shown to 
inhibit ABCB1 (Tivnan et al., 2015) and MCF-7 cells were the only ones expressing relatively 
high levels of ABCB1, this could be an alternative explanation. A study found that ABCB1 
promotes cell survival in acute myeloblastic leukaemia independent of its drug cytotoxic efflux 
ability and modulate apoptosis (Pallis et al., 2000). Another, important observation was that 
MK571 at 50 µM did not cause any significant inhibition relative to untreated cells as opposed 
to when cells were treated with 100 µM.  Further observations confirmed that Reversan and 
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MK571 not only inhibited the formation of colonies but also reduced the size of colonies thus 
suggesting that the inhibition of ABCC1 (and ABCB1) inhibits cell proliferations (Henderson, 
et al., 2011).  
 
On the other hand, ABCC4 specific inhibitors, Ceefourin 1 and Ceefourin 2 (Cheung, et al., 
2014), did not inhibit colony formation in any of the three types of cell lines indicating that 
inhibition of ABCC4 may not be involved in cell proliferation.  Indomethacin, a non-specific 
inhibitor of ABCC4 (Draper, et al., 1997) also did not affect cell proliferation. Similarly both 
MK571 and Reversan inhibited cell viability. Hence, from these findings, it can be inferred that 
ABCC4 may not have as important a role in cell proliferation as ABCC1 does.  
 
The trypan blue dye exclusion assay was carried out to validate the results obtained from the 
MTT assay. Although it is a straightforward, inexpensive assay, it cannot distinguish between 
healthy viable cells from cells that have an intact membrane but are not healthy. Moreover, 
the cells were counted manually using a hemocytometer that may account for about 10% 
counting error and various factors such as loss of cells in cell suspension and inconsistency 
in the volume of cell suspension when loading the chamber and the density of cell suspension 
may vary between cell samples can give rise to large deviation between counts that eventually 
leads to large error bars (Aslanturk et al., 2018). Nonetheless, the results obtained from the 
trypan blue dye exclusion assay, agree to some extent to the MTT assay, in that it also 
indicated that MK571 and Reversan significantly decrease cell proliferation. This agrees with 
the results of the colony formation assay that ABCC1 may have a larger role in breast cancer 
cell proliferation than ABCC4 does. 
 
As the ABC inhibitors used were not specific and they can inhibit more than one ABC 
transporters in addition to other targets, we decided to knockdown ABCC1 and ABCC4 genes 
using ABCC1- and ABCC4- siRNA specific molecules in both MCF-7 and MDA-MDA breast 
cancer cell lines so as to try to validate the results obtained with ABC inhibitors. 
 
In our findings, the depletion of ABCC1 and ABCC4 did not decrease the number of colonies 
formed in either MCF-7 or MDA-MB231 cells. However combination knockdown of ABCC1 
and ABCC4 genes in MCF-7 cells inhibited the clonogenic capacity of MCF-7 cells to form cell 
colonies. Similar effect of reduction in clonogenic capacity of MDA-MB231 cells was seen with 
one combination of siRNA knockdown (ABCC1 siRNA #30 and ABCC4 siRNA #35). These 
results indicate that ABCC1 and ABCC4, together may mediate breast cancer cell growth and 
that ABCC1 and ABCC4 may have a combined effect affecting the clonogenic capacity of 
breast cancer cells. 
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In a previous study of colony formation by neuroblastoma cells, the knockdown of ABCC1 and 
ABCC4 did cause a decrease in the number of colonies formed and a combined knockdown 
of ABCC1 and ABCC4 decreased the number of colonies formed even more (Henderson et 
al., 2011). Whilst the single knockdowns in our study did not show significant effects, the 
combined knockdown shows similar effects. Reasons for this difference could include differing 
efficiencies of siRNA knockdown and/or different expression levels of ABCC1 and ABCC4 to 
start with. Furthermore, Henderson et al., 2011 also found that the number of neuroblastoma 
colonies formed was reduced after cells were treated with Reversan, which agrees well with 
our findings. 
 
The study of cancer cell viability using MTT assays showed little effect upon ABCC1 or ABCC4 
knockdown, either individually or in combination. This contrasts with the findings by Zhao et 
al., (2014) who found that ABCC4 is required for cell proliferation in non-small cell lung cancer. 
However they used shRNA lentiviral vector to mediate the knockdown in the cells, which may 
have been more efficient and thus may have a significant impact on the results obtained (Zhao 
et al., 2014). Furthermore, another study found that the downregulation of ABCC4 expression 
in Panc-1 and BxPC-3 human pancreatic cancer cell lines using a lentivirus expressing an 
ABCC4 shRNA also significantly decreased colony formation and proliferation in vitro (Zhang 
et al., 2012). In another study, the proliferation of MGC80-3 gastric cancer cells was 
significantly inhibited with lentivirus ABCC4 shRNA (Chen et al., 2014).  
 
In general, the RNAi mechanism of suppression of gene expression is usually transient and 
lasts for 96 to 120 hours after which the gene expression will start to recover (Mocellin et al., 
2004). Originally it was speculated that since the colony formation assay last for 7 days, it is 
suggested that the suppression of ABCC1 and ABCC4 may have recovered. Therefore, a 
shorter incubation period, for example 3 days may be suggested. However, in the 
neuroblastoma study by Henderson et al., (2011), colony formation assays were also carried 
out for 7 days, and in the non-small lung cancer study by zhao et al., (2014) the assays were 
run for 8 days. 
 
Different methods were used for the transfections however, with Henderson et al., (2011) 
using Lipofectamine 2000 as the transfection reagent, whereas INTERFERin was used in the 
current study. Even though the Western blot data did show a knockdown of ABCC1 and 
ABCC4 in both MCF-7 and MDA-MB231 cells when compared to the untreated cells, and 
according to the manufacturers’ recommendation, 1nM siRNA with INTERFERin can provide 
more than 90% silencing efficiency in a wide variety of cells, the percentage or the number of 
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cells that was actually being transfected is not known in each transfection. Further optimisation 
of the knockdown process might be required such as using a different volume of INTERFERin 
or increasing the concentration of siRNA per transfection. Consideration to use other 
transfection reagent such as Lipofectamine 3000, or the use of plasmids which express siRNA, 
or short hairpin RNAs (shRNAs) expressed from plasmids, which can undergo selection to 
obtain stable cell lines with knockdown of the target protein. Alternatively, a more efficient 
delivery method such as lentivirus, retrovirus and adenovirus based vectors could be 
beneficial. Moreover, CRISPR/Cas9 could be trialled to achieve an effective knockout of these 
genes. CRISPR/Cas9 is a gene-editing technology that requires an endonuclease, CRISPR-
associated protein 9 (Cas9) to break a double-stranded DNA hence allowing the genome to 
be modify and for efficiency gene editing, a guide RNA is required to match a desired target 
gene (Redman et al., 2016). 
 
Moreover, the suppression of ABCC1 and ABCC4 may have upregulated other ABC 
transporters as a compensatory effect for the down regulation of ABCC1 and ABCC4. Several 
ABC transporters have overlapping substrate specificity and it is known that they can in certain 
circumstances compensate for each other. A study found that the treatment of vinblastine and 
methotrexate (MTX) with ABCA2 RNAi partially decreased the expression of ABCA2 but at 
the same time increased ABCA3 expression in childhood T-cell acute lymphoblastic 
leukaemia. A similar observation was seen when ABCA3 was suppressed which caused an 
increased in ABCA2 expression (Efferth et al., 2006).  
 
Attempts to overexpress ABCC1 and ABCC4 in MCF-7 and MDA-MB231 cells were a 
challenge especially in MDA-MB231 cells transfection. The Lipofectamine® 3000 transfection 
reagent was used as the transfection reagent and efficient transfection was obtained in MCF-
7 cells but not in MDA-MB231 cells even after optimising the volume of the Lipofectamine® 
3000 transfection reagent used. Again perhaps lentivirus delivered overexpression might be 
a way forward for overexpression studies. 
 
Therefore, according to our findings, single and co-overexpression of ABCC1 and ABCC4 in 
MCF-7 and MDA-MB231 cells did not affect colony formation and cell proliferation when 
compared to untreated. In Henderson et al., (2011) overexpression of both ABCC1 and 
ABCC4 in neuroblastoma cell lines was achieved effectively, and this showed an increase in 
cell migration and colony (Henderson et al., 2011). In our study, the overexpression of ABCC1 
and ABCC4 in MCF-7 and MDA-MB231 cells were expected to cause an increase in colony 
formation but were not the case. Again, this may be the method of transfection was not very 
efficient as Henderson et al., (2011) used a retroviral vector carrying a plasmid with the gene 
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of interest to efficiently transfect the cells.  Moreover, although no cell cytotoxicity was 
observed during transfection, speculation that the size of the plasmid DNA vector might affect 
the efficiency of transfection, as there may be a low percentage of cell that have actually been 
transfected. A study found that the size of plasmid DNA molecules may affect gene transfer 
capacity (Kreiss et al., 1999) and that the introduction of plasmid DNA molecules may impaired 
the cells normal metabolic functioning (Metabolic load) (Glick, 1995). 
 
Finally, the method of overexpression of ABCC1 and ABCC4 in MCF-7 and MDA-MB231 cell 
is transient. Similar to the siRNA transfection, the efficiency of transfection was not measured 
in terms of the proportion of cells that were overexpressed in comparison to those that were 
unaffected. Hence, alternative transfection methods such as to generate a stable cell lines 
expressing the gene of interest may be an important consideration. 
 
7.3     ABCC1 and ABCC4 may be involved in mediating breast cancer cell migration 
 
Another aspect commonly used to assess cancer development is cell migration. In normal 
physiological process, cell migration is a complex process that is important for embryonic 
development, gastrulation (Keller, 2005), nervous system development (Hatten, 1999), 
placental development, and immune cell trafficking (Wilson et al., 2010) and wound healing 
(Kramer, et al., 2013; Valster, et al., 2005). However, cell migration can also contribute to 
pathological processes such as tumour formation and metastasis (Valastyan et al., 2011; 
Pachmayr et al., 2017).  Tumour metastasis is one of the major problem in the treatment of 
cancer and it is associated with low survival of patients and poor prognosis (Kramer, et al., 
2013). Thus, we assessed cell migration using the scratch assay.  
 
Cell migration was monitored using the scratch assay. It should be noted that the results 
obtained from the scratch assay do represent cell migration and not cell proliferation as 
according to the MTT assay, the cell proliferation was not affect by any of the treatments over 
the short periods of time used for the scratch assay. 
 
Only MK571, a non-specific inhibitor of ABCC1 and ABCC4, inhibited cell migration in the 
MDA-MB231 cell line but not in MCF-7 cell line. In contrast, the other inhibitors did not affect 
cell migration as measured by the scratch assay. As MK571 can inhibit both ABCC1 and 
ABCC4, perhaps it is this dual inhibition which has the greatest effect on migration. However, 
as MK571 is also a leukotriene antagonist, it may also inhibit the binding of LTD4 to cysteinyl 
leukotriene receptor 1 (CysLT1) (Gekeler et al., 1995). Hence down regulating β-catenin 
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signalling which is important in promoting cancer cell survival and inhibiting apoptosis (Nielson 
et al., 2005; Mezhybovska et al., 2006; Peters-Golden et al., 2007).   
 
Moreover, ABCC1 suppression and ABCC4 suppression in MCF-7 cells inhibited cell 
migration more than the knockdown of ABCC1 and ABCC4 in MDA-MB231 cells. Analysis of 
the scratch assays with MCF-7 knockdown cells suggested that ABCC4 inhibition may play a 
larger role in breast cancer cell migration than ABCC1. Surprisingly, when both ABCC1 and 
ABCC4 were knocked down in combination, the MCF-7 or MDA-MB231 cell migration were 
not affected. The overexpression of ABCC1 or ABCC4 in MCF-7 and MDA-MB231 cells also 
did not affect cell migration. The reasons for these conflicting results are not totally clear, 
however a more efficient transfection method may help. 
 
Nevertheless, our findings indicate that ABCC1 and ABCC4 may be important in breast cancer 
cell migration as was seen in the ABC inhibitor experiments and that ABCC4 may have a 
greater effect on cell migration than ABCC1 as was seen in MCF-7 cells in the siRNA 
experiments. Our findings contrast to the results obtained with neuroblastoma cells by 
Henderson, et al., 2011 who found that Reversan an ABCC1 inhibitor significantly inhibited 
neuroblastoma cell migration. In addition, the knockdown of ABCC1 significantly decreased 
cell migration in neuroblastoma more than the knockdown of ABCC4 and that an exposure of 
ABCC1- and ABCC4- specific siRNA molecules in combination in neuroblastoma cells caused 
even more significantly decreased in cell migration (Henderson et al., 2011). Interestingly, it 
has been shown that the migration of human dendritic cells are more influenced by ABCC4 
than ABCC1 as a study conducted showed that inhibition of dendritic cell migration by 
sildenafil or by ABCC4 gene knockdown, attenuated their migration from human skin explants 
(van de Ven et al., 2008 and 2009). Therefore, maybe the roles of ABCC1 and ABCC4 are 
different between cells / cancer types.  
 
The scratch assay is a widely used experiment to evaluate cell migration as it is easy to setup, 
analyse and is cheap. In addition, the scratch assay is a convenient assay to study cell-cell 
interaction and cell-matrix interactions on cell migration, which can mimic cell migration in vivo, 
such as the metastases of cancer cells from one region of the body to another (Liang, et al., 
2007; Orimo, 2014). However, one major drawback is that the scratch is unevenly thick as 
usually the scratch is made manually with a pipette tip and variation in gap width is critical.  In 
addition, after wounding, some cells may be left floating in the gap even after washing, often 
these cells reattached to the plate and migrate and proliferate in to the wounded area which 
may lead to unreliable results. Furthermore, wounding in an uncontrolled manner may cause 
cell damage. To ensure invariable wound sizes with defined edges, the electrical cell-substrate 
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impedance sensing (Lo et al., 1995) or laser ablation (Tamada et al., 2007) of the cells in a 
defined area may be useful. However both systems might leave cells in the wounding area 
after the electric ablation (Poujade, et al., 2007). One suggestion that could be used to 
measure cell migration is to monitor the movement of single cells. The single cell motility assay 
could be performed to measure the migration of a single cell on colloidal gold particle coated 
surfaces (Takaishi et al., 1995).  In principle, cells are seeded on cell culture plates coated 
with colloidal gold particles and when the cells move, they phagocytose the gold particles 
leaving a white track that can be photographed and the area that has been cleared by the 
moving cell can be measured, thus allowing the detection of cell pathway in real time and the 
determination of the absolute speed of migration of a single cell (Kramer et al., 2013).This 
assay has been used to monitor the migratory paths of pancreatic cancer cells (Lin et al., 
2005), squamous cell carcinomas of the head and neck (Sommer et al., 2011) as well as in 
breast cancer cells (van Golen et al., 2000). Another way that could be used to measure the 
movement of a single cell is to track the individual cells in time-lapse experiments using a 
videomicroscopy (Jaqaman et al., 2008; Meijering et al., 2012). Essentially, the migration 
paths of the selected cells are recorded and analysed to determine the rate and direction of 
migration at a given time point as well as the total distance move by the cells. Other possible 
approaches to monitor cellular migration could include transwell migration assay (Boyden 
chamber assay), cell exclusion zone assay, spheroid migration assay, fence assay (ring 
assay), capillary chamber migration assays (microfluidic chamber assay) and microcarrier 
bead assay (Kramer, et al., 2013). 
 
7.4     ABCC4 may be involved in mediating breast cancer cell invasion more than 
ABCC1 
 
Approximately 90% of death from cancer are due to cancer metastasis whereby cancerous 
growth occurring at a distant site from where the primary tumour was originally found 
(Valastyan et al., 2011; Gao et al., 2013; Weinberg, 2014; Orimo, 2014; Guan, 2015; 
Pachmayr et al., 2017). Early detection of tumours is essentially in combating cancer and 
stopping metastatic spreading. However, cancers that are metastatic at diagnosis are usually 
highly fatal and incurable (Guan, 2015; Chambers et al., 2015). Therefore, the need for novel 
therapeutic strategies are essential to prevent cancer metastasis. As the metastatic process 
is a multistage process, the mechanism of metastasis is still not clear hence is still a challenge 
to produce anti-metastatic drugs.   
 
Although cancer metastasis is a multistage processes, the initial invasion of cancer cells into 
the surrounding tissue at the primary tumour site is critical. Therefore, understanding the 
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molecular mechanism of cancer cells acquiring an invasive phenotype is essential so as to 
come up with novel cancer metastasis treatment strategies (Kramer et al., 2013). 
 
As cancer invasion is an essential part of cancer development and progression, we decided 
to investigate whether ABCC1 and ABCC4 are implicated in fascilitating cell invasion in breast 
cancer using the transwell invasion assay. Results showed that the suppression of ABCC1 
and ABCC4 in MCF-7 cells decreased cell invasion. 
  
In comparison, only the knockdown of ABCC4 in MDA-MB231 cells decreased cell invasion.  
Since the MDA-MB231 breast cancer cell line is considered to be more invasive than the MCF-
7 breast cancer cell line and the expression level of ABCC1 and ABCC4 are higher in MDA-
MB231 cells than in MCF-7 cells, it is suggested that ABCC4 may be involved in mediating 
breast cancer cell invasion more than ABCC1. However, past studies have found that the 
efflux of sphingosine-1-phosphate (S1P) by ABCC1 also influences cell invasion as well as 
cell proliferation in MCF-7 breast cancer cells (Takabe et al., 2010; Yamada et al., 2018). 
 
Since the transwell invasion assay measures the number of invasive cells that have degraded 
the matrix, moved through the extracellular matrix layer and attached to the underside of the 
membrane inserts (Valster et al., 2005; Kramer et al., 2013; Justus et al., 2014), to determine 
the thickness of the basement membrane extract of the ECM and the cell seeding density are 
very important as they vary between cell lines.  Furthermore, the transwell invasion assay is 
an endpoint assay. In our experiment, the cells that have stayed on top of the membrane were 
initially removed with a cotton swab and the invasive cells at the bottom of the membrane were 
fixed, stained and counted under the microscope. However, the procedure of removal of cells 
that have stayed on top of the membrane is tricky and this can lead to errors. Moreover, 
counting cells under a light microscope can be very tedious as for each well, five areas were 
selected for cell counting and also if invasive cells at the bottom of membrane are overlapping 
and close to each other, made cell counting difficult. As a result, this may account for the large 
variations in the results obtained that leads to large error bars. Therefore, for the results to be 
more reliable, careful removal of cell at the top of the membrane is needed, and once the 
stained invasive cells have been counted, the stained invasive cells can be lysed and 
quantified in a plate reader. 
 
Other alternative invasion assay that may be considered are the platypus invasion assay (No 
platypus in the assay), 3D cell tracking assay, vertical gel invasion assay, spheroid 
confrontation assay, gelatin degradation assay, spheroid gel invasion assay and 
spheroid/monodispersed cell invasion assay (Kramer et al., 2013). 
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7.5     Possible signalling cascade involving ABCC1 and ABCC4 in mediating breast 
cancer progression and development 
 
To date, the direct contribution of ABC transporters in mediating cancer progression and 
development irrespective of their drug-efflux abilities is still not clear (Fletcher et al., 2010 and 
2016; Adamska et al., 2018). Since ABC transporters transport many active signalling 
molecules and hormones as their substrates, it has been suggested that these substrates can 
activate cancer cells as well as regulate the tumour environment hence contributing to cancer 
development and progression (Adamska et al., 2018). In addition, signalling lipid molecules 
such as sphingosine-1-phosphate (S1P), prostaglandins and leukotrienes have a profound 
role in tumour biology and are known to be substrates of certain ABC transporters.  Therefore, 
mediating the efflux of these molecules may also be important in cancer progression and 
development (Fletcher et al., 2010).  
 
GPR55, an orphan G-protein-coupled receptors (GPCR) has been proposed to be involved in 
an autocrine loop that includes ABCC1 exporting lysophosphatidylinositol (LPI), important for 
mediating cancer cell proliferation (Figure 7.1) (Pineiro et al., 2011; Yamashita et al., 2013). 
GPR55 signalling cascade involves ERK (Pineiro et al., 2011), and the activation of ERK has 
also been found to mediate migration of pancreatic carcinoma cells (Stahle et al., 2003).  
 
Initially, the expression levels of GPR55, ERK1/2 and p-ERK were compared in HeLa, MCF-
7 and MDA-MB231 cells by Western blot. The protein expression level of GPR55 was highest 
in MDA-MB231 cells followed by HeLa cells and barely detectable in MCF-7 cells. Our findings 
support the finding of Ford et al., 2010 who performed a quantitative RT-PCR analysis to 
determine the expression of GPR55 in MCF-7 and MDA-MB231 cells. Ford et al., 2010 found 
that the level of expression of GPR55 was around 30-fold higher in MDA-MB231 cells when 
compared to that in MCF-7 cells. 
 
Furthermore, ERK1/2 expression was highest in MCF-7 cells and may be slightly higher in 
MDA-MB231 cells than in HeLa cells. In addition, p-ERK expression may be equally detectable 
in HeLa and MCF-7 cells but very low expressed in MDA-MB231 cells. Similar level of 
expression of ERK1/2 and p-ERK was seen in a study by Choi et al., 2009, who also found 
that the expression of ERK1/2 and p-ERK was higher in MCF-7 than in MDA-MB231 cells. 
However, in contrast another previous study found that the expression of ERK1/2 was higher 
in MDA-MB231 cells but lower in MCF-7 cells. In addition, they also found that MCF-7 cells 
has a higher p-ERK expression than in MDA-MB231 cells (Taherian et al., 2011). Since these 
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experiments were looking at endogenous expression levels of the proteins, the level of 
expression of these proteins may be hard to detect.  
 
Furthermore, ABCC1 and ABCC4 in MCF-7 and MDA-MB231 cells were knocked down and 
the expression level of GPR55 and ERK were assessed by Western blot. However, the protein 
expression levels of GPR55 and ERK1/2 were not affected by the knockdown of ABCC1 and 
ABCC4.  
 
  
 
 
Figure 7.1.  An autocrine loop involving ABCC1, LPI and GPR55 for regulating cancer 
cell proliferation. LPI is synthesised intracellularly by cPLA2. Once LPI is made, it is pump 
out of the cells by ABCC1. LPI can then bind to GPR55 on the cell surface that in turn activate 
downward signalling pathways such as the induction of calcium mobilisation, the activation of 
Akt and ERK1/2 in these cells which are involve in mediating cell proliferation. ABCC1, ATP-
binding cassette transporter C1; LPI, lysophosphatidylinositol; GPR55, G-protein receptor 55; 
cPLA2; cytosolic phospholipases A2; Akt, protein kinase B; ERK1/2, mitogen-activated protein 
kinase 1/2 (Pineiro et al., 2011). 
 
 
 
It is plausible that knockdown of ABCC1 (or ABCC4) should not have a direct effect on the 
expression of GPR55. Knockdown of ABCC1 should decrease levels of LPI exported, but this 
does not mean it will affect the expression of GPR55, just the signalling through it. If the 
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signalling is affected though it might be expected that an effect on downstream ERK signalling 
might be observed. No effect on ERK was observed in our study, however i) GPR55 is able to 
signal via more than one signalling pathway, ii) other GPCRs also utilise ERK and iii) the 
antibody for detecting phosphorylated ERK gave very high background signals making it 
difficult to detect. 
 
To investigate which other substrates of ABCC1 and/or ABCC4 might play a role, the 
extracellular levels of cAMP, PGE2, S1P and cysteinyl leukotrienes were analysed by ELISA. 
 
According to our study, the suppression of ABCC4 in MDA-MB231 cells and those treated with 
MK571, an ABCC1 and ABCC4 inhibitor inhibited the efflux of cAMP out the cells. cAMP is a 
substrate for ABCC4 (Russel et al., 2008) but not ABCC1. cAMP is involved in the regulation 
of differentiation, proliferation and apoptosis (Kim et al., 2001; Guillemin et al., 2002). 
Moreover, a study on acute myeloid leukaemia (AML) found that the intracellular cAMP is 
regulated by ABCC4 which in turn caused inhibition of cell proliferation but promoted cell 
differentiation (Copsel et al., 2011). This cAMP efflux may be an important factor by which 
ABCC4 affects breast cancer development. Our results, also suggested that MDA-MB231 
cells efflux lower levels of cAMP than MCF-7 cells. A prevous study also found that the level 
of activity of cAMP in MCF-7 cells was higher than that in MDA-MB231 cells (Dezong et al., 
2014). 
 
PGE2 has been reported to regulate cell migration and proliferation while inhibiting immune 
surveillance and apoptosis in cancer cells (Dannenberg et al., 2003; Greenhough et al., 2009; 
Knab et al., 2014). A previous study found that high expression of ABCC4 together with low 
level of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and low expression of 
prostaglandin transporter (PGT) promote the accumulation of PGE2 in the tumour 
microenvironment hence stimulate cancer cell proliferation, metastasis and cell survival that 
may contribute to the poor prognosis of triple-negative breast cancer (Kochel et al., 2016 and 
2017).  However, our results from the ELISA indicated that the knockdown of ABCC1 or 
ABCC4 in MCF-7 cells or MK571 treatment had no effect on the efflux of PGE2 out of the cells, 
suggesting PGE2 was not involved. However, it was not possible to measure the effect in 
MDA-MB231 cells since the levels of PGE2 exceeded the standard curve. Therefore, more 
experiments would be needed to explore this further. Moreover, our results also may indicate 
that MCF-7 cells efflux a low concentration of PGE2 than MDA-MB231 cells which agrees with 
a study done by Timoshenko et al., 2003, who investigated the role of prostaglandin E2 
receptors in migration of murine and human breast cancer cells. 
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S1P is a ligand of five specific GPCRs S1P1-5 (S1PRs) and has been found to mediate 
important biological actions including cell migration, differentiation, proliferation and 
cytoskeletal organisation, angiogenesis, lymphocyte trafficking, mast cell function and 
vascular maturation (Saba et al., 2004; Taha et al., 2004; Ishii et al., 2004; Young et al., 2006; 
Alvarez et al., 2007; Strub et al., 2010). ABCC1 has been shown to be a major transporter of 
S1P in mast cells that may influence migration of mast cells to antigen (Mitra et al., 2006; 
Alvarez et al., 2007). ABCC4 has also been implicated in efflux of S1P release from platelets 
(Vogt et al., 2018). In a previous study, using MCF-7 breast cancer cells, it was found that 
estradiol stimulated the production of S1P by sphingosine kinase 1 (SphK1). The export of 
S1P was facilitated by ABCC1 and ABCG2. Once S1P had been effluxed out of the cell, S1P 
bound and activated S1P receptors that increase epidermal growth factor receptor (EGFR) 
transactivation in a matrix metalloprotease-dependent manner and stimulate ERK1/2 to further 
activate downstream signalling cascade that are responsible for breast cancer proliferation, 
invasion and progression (Figure 7.2) (Takabe et al., 2010).  
 
In this current study, the efflux of S1P by MDA-MB231 cells treated with MK571 were 
significantly reduced when compared to that of the untreated MDA-MB231 cells. Although the 
individual knockdowns did not alter S1P levels, MK571 is able to inhibit both ABCC1 and 
ABCC4 and this combined effect may be larger. Further experiments with a more efficient 
method of knockdown will allow this question to be addressed. 
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Figure 7.2. A schematic diagram showing the potential mechanism involving ABCC1 
and S1P in promoting breast cancer proliferation, invasion and progression. Binding of 
E2 to ER-α and not to GPR30 stimulate the production of S1P by SphK1. The export of S1P 
by ABCC1 and ABCG2, binds and activates S1PR that in turn stimulate ERK1/2 signalling 
cascade which is important in mediating breast cancer cell proliferation, invasion and 
progression. ABCC1, ATP-binding cassettes transporter C1; S1P, sphingosine-1-phosphate; 
E2, Estradiol; GPR30, G-protein receptor 30; ER-α, estrogen receptor α; SphK1, sphingosine 
kinase 1; ERK1/2, mitogen-activated protein kinase 1/2 (Takabe et al., 2010). 
 
 
 
In our study, we also found that the MCF-7 samples showed low concentrations of S1P 
exported out of the cells compared to MDA-MB231 cells. This contrasts with Takabe et al., 
2010 who found that MCF-7 cells export relatively high levels of S1P into the cell culture 
medium, more than MDA-MB231 cells. Furthermore, another study have confirmed that the 
export of S1P by ABCC1 activates SphK1 and the accumulation of S1P in the tumour 
microenvironment in breast cancer have enhanced important biological processes involved in 
cancer progression (Yamada et al., 2018).  
 
According to our ELISA results, large concentration of cysteinyl leukotrienes were obtained 
from cells treated with MK571. Since MK571 is a selective leukotriene LTD4 receptor 
antagonist, it may have a binding affinity for the cysteinyl leukotrienes antibody that may result 
in high false positive. Alternatively, it could be that inhibiting the LTD4 receptor results in some 
kind of feedback loop to increase the production of cysteinyl leukotrienes. Many other ABCC 
subfamily of transporters including ABCC2, ABCC3, ABCC10 and ABCC11 are able to efflux 
LTC4 (Cui et al., 1999; Rius et al., 2008; Chen et al., 2005 and 2010).  ABCC4 is able to efflux 
both LTC4 and LTB4 which are important mediators of inflammation (Cui et al., 1999; Rius et 
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al., 2008; Chen et al., 2005 and 2010). Since in our study, only ABCC1 and ABCC4 were 
being knocked down, other ABCC transporters may still be capable in exporting Cysteinyl 
leukotrienes, thus the concentration of cysteinyl leukotrienes in the conditioned medium may 
not be affected by the knock down of ABCC1 and ABCC4 as indicated in our results. Moreover, 
in pancreatic cancer cells, LTB4 was found to induce ERK1/2 phosphorylation that in turn 
activate cell proliferation (Tong et al., 2002; Knab et al., 2014). 
 
Although the ELISA is a straightforward assay that is easy to follow and requires little hands-
on-time, each step is very critical and involved careful pipetting of small volumes of a number 
of reagents to the plate at different times, thus the degree of errors and contaminations 
between reagents are very high hence may lead to large degree of variation in data resulting 
in large error bars as this may be the case in our experiments. Some of our data fall outside 
the standard curve so was difficult to extrapolate the concentration, therefore, the samples 
might need to be diluted or concentrated. Moreover, since the ELISA was done only one time, 
a repeat might be useful to validate the results obtained thus far. 
 
7.6     Future work 
 
 Use flow cytometry to analyse the percentage of cells that have been transfected with 
ABCC1- and ABCC4-specific siRNA molecules in a cell population. The results will 
determine the efficiency of transfection and allow optimisation or use a different 
transfection reagent or methods.  
 
 Consider generating stable cell lines for knockdown and/or overexpression of ABCC1 
and ABCC4. 
 
 Perform immunofluorescence staining on cell lines to determine the level of expression 
of specific proteins of interest and their location in the cell. 
 
 Repeat ELISA analysis, including dilution/concentration of samples so that all signals 
lie within the standard curves. 
 
7.7     Overall conclusion 
 
This thesis demonstrate that the expression levels of ABC transporters varies between breast 
cancer cell lines. The involvement of ABCC1 and ABCC4 in mediating breast cancer cell 
proliferation, migration and invasion were investigated. Our results suggested that ABCC1 
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may be more involved in mediating breast cancer cell proliferation than ABCC4 and in contrast 
ABCC4 may be involved in mediating breast cancer cell invasion more than ABCC1. 
Furthermore, our findings also indicate that breast cancer cell migration may be influenced by 
the expression of ABCC1 and ABCC4. 
 
Subsequently, understanding the mechanism by which ABCC1 and ABCC4 are involved in 
breast cancer development and progression is very important. Since ABC transporters 
transport many active signalling molecules and hormones that are also implicated in cancer 
progression, studying these molecules would be very useful in determining any possible 
mechanism. Although in this thesis, only cAMP, PGE2, S1P and cysteinyl leukotrienes were 
being examined, results looks promising and further investigation in to these molecules may 
be required to obtain a clear correlation with ABCC1 and ABCC4. 
 
Taken together our findings have shown that ABCC1 and ABCC4 may be implicated in breast 
cancer development and progression. However, further investigations are need to validate our 
current results. Nevertheless, our results suggest that ABCC1 and ABCC4 could be a potential 
therapeutic target for breast cancer.  
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